The development of viral vectors for targeted gene delivery to atherosclerotic plaques by White, Katie
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
Theses digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
The Development of Viral Vectors for Targeted Gene 
Delivery to Atherosclerotic Plaques,
By
Katie White
This being a thesis submitted for the degree of Doctor of 
Philosophy in the Faculty of Medicine, University of Glasgow
Division of Cardiovascular and Medical Science
© K. White 
January 2007
ProQuest Number: 10390525
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10390525
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW 1  
UNlVEFr ”vlysMu.....;
Summary
Cardiovascular disease is one o f the leading causes o f death in the W estern world. One 
of the most common causes is the rupture o f unstable atherosclerotic plaques, which can 
lead to thrombus formation, occlusion o f the artery and myocardial infarction. Therefore 
there is a need for treatments that stabilise vulnerable plaques. Gene therapy has the 
potential to provide a novel treatm ent for this. To maximise therapeutic gene expression 
and minimise any potential adverse effects due to unwanted transgene expression in non­
target tissues, a gene delivery vector specifically targeted to areas o f atherosclerotic 
vasculature is required. The vector is also required to efficiently infect cells to produce 
relatively long term transgene expression, be stable in blood, non-toxic, non- 
immunogenic and producible at high titres. Viral vectors, particularly those based on 
adenovirus (Ad) and adeno-associated virus (AAV) have many o f the desired features, 
but transduce vascular cells relatively inefficiently and in a non-selective manner. 
Methods o f altering their tropism have been established and could be utilised to develop 
vectors with a high degree o f selectivity for atherosclerotic plaques. Detargeting of 
vectors can be achieved by mutating regions o f the virus caps id that are thought to bind 
the native cellular receptors and retargeting to novel cell types is achieved by inserting 
peptide ligands into the virus capsid. The aim o f this study was to develop 
atherosclerotic plaque targeted vectors and to characterise Ad and AAV vector platforms 
in this regard. Two approaches were taken. In the first approach three previously 
identified plaque targeting peptides were tested for their ability to target viral vectors to 
atherosclerotic plaques. The second approach involved performing phage display in a 
mouse model o f plaque rupture to identify novel peptides that specifically target unstable 
plaques. Further work was carried out to characterise and develop methods for using an 
AAV2 based peptide library as a novel tool for biopanning.
The atherosclerotic plaque targeting peptides CAPGPSKSC, CNHRYMQMC and 
CQEPTRLKC were incorporated into the fiber capsid protein o f the Ad5 based vector 
A dK O l, which contains mutations that block binding to the primary receptor, the 
coxsackie and adenovirus receptor (CAR). In vitro, the peptide-modified AdKOl
vectors produced higher levels o f transduction o f several endothelial cell lines, compared 
to unmodified A dK O l, suggesting the vectors target vascular cells, but further testing 
was required in vivo. It has previously been demonstrated that following systemic 
administration A dK O l vectors are not efficiently detargeted from the liver, so the 
peptides were incorporated into alternative vector platforms. The A dK O lS* vector 
platform contains mutations that block binding to CAR and the putative co-receptor 
heparin sulphate proteoglycans (HSPG) and it has been shown to be detargeted in vivo. 
However, all the peptide-modified A dK O lS* vectors were found to be non-infective. 
Pseudotyping o f Ad vectors involves replacing the fiber o f one serotype with that of 
another, to produce a vector with a novel tropism. The plaque targeting peptides were 
inserted into an Ad5 vector pseudotyped with the A dl9p  fiber (Ad5/19p). Although the 
peptide-modified Ad5/19p vectors transduced vascular cells more efficiently than 
unmodified Ad5/19p, the increased transduction was not specific to vascular cells. 
Therefore, in this study, none o f the Ad vectors tested provided a suitable platform. The 
CAPGPSKSC and CNHRYM QM C peptides were also incorporated into the receptor 
binding site o f the AAV2 capsid. Promising results were achieved both in vitro and in- 
vivo. In an ApoE-/- mouse model o f atherosclerosis the peptide-modified AAV2 vectors 
were found to be targeted to the brachiocephalic artery and aorta (sites where plaques are 
Imown to develop) and detargeted from all other tissues examined, which suggests that 
the vectors are retargeted to areas o f  atherosclerotic vasculature with a high degree o f 
selectivity. Further testing o f  these vectors is required to determine if they are plaque 
specific or specific for vascular cells.
Currently there are no effective ways to diagnose and locate the presence o f unstable 
plaques and there are no treatments aimed specifically at inducing stabilisation or 
regression o f unstable plaques. In parallel with the testing o f the previously identified 
plaque targeting peptides, biopanning with phage display libraries was performed in a 
mouse model o f atherosclerotic plaque rupture that has been shown to reproduce unstable 
plaques. Targeted pools o f peptides were identified and BLAST searching identified 
many peptides with homology to proteins known to be associated with atherosclerosis
and plaque rupture. Further testing o f the individual candidate peptides is now required 
to analyse their targeting capacity.
HSPG is known to be the primary receptor for AAV2. Insertion o f targeting peptides into 
the HSPG binding site on the AAV2 capsid has been shown to be an effective way of 
detargeting and retargeting the vector with some peptides, but for other peptides the 
vector maintains the ability to bind HSPG. Characterisation o f an AAV2 library with 
random 7-mer peptides inserted into the HSPG binding site has shown that in general 
positively charged peptides enable AAV to retain the capacity to bind HSPG. This is 
thought to be because AAV2 binds HSPG through an electrostatic interaction between 
negatively charged HSPG and the positive charge o f the binding site. This interaction is 
blocked by insertion o f negative or neutral peptides but can be maintained by the 
insertion o f positively charged peptides. This information can be used for the 
development o f AAV2 based vectors using peptides identified by phage display. In vitro 
biopanning with the AAV library was also used to identify endothelial cell targeted 
peptides that are thought to infect cells independently o f an interaction with HSPG. 
Methods were also developed to use the library for in vivo biopanning.
This study has made progress towards the development o f atherosclerotic plaque targeted 
vectors by identifying and characterising peptides that have the potential to target vectors 
specifically to areas o f atherosclerosis. These vectors could potentially be developed as 
tools to enable gene delivery selectively to atherosclerotic plaques or could be utilised 
with imaging agents to detect plaques. This work has also provided further 
characterisation o f Ad and AAV platform vectors that may be utilised in the development 
o f vectors with a highly selective tropism.
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Chapter 1: 
Introduction
1.1 Cardiovascular disease
The term cardiovascular disease (CVD) is used to describe all diseases o f the heart and 
circulatory system. It encompasses monogenic disorders such as familial 
hypercholesterolemia and more complex conditions such as hypertension and coronary 
heart disease (CHD), which are caused by a combination o f multiple genetic and 
environmental factors. CVD is the leading cause o f death in both men and women in the 
majority o f Western countries and by 2020 it is predicted to be the main cause o f death 
worldwide (Murray and Lopez, 1997). In the UK more than a third o f people now die 
from CVD and over 20% o f the population is thought to have some form of CVD 
(www.heartstats.org). N early half o f all CVD related deaths are caused by CHD and a 
further 28% of deaths are due to stroke (caused by atherosclerosis in the cerebral artery) 
(www.heartstats.org). CHD caused by atherosclerosis in the coronary artery, leads to 
narrowing and obstruction o f the artery, resulting in angina or myocardial infarction. 
Atherosclerosis is therefore a major health concern as it is one o f the leading causes of 
death worldwide.
1.2 Atherosclerosis
Atherosclerosis is caused by the deposition o f cholesterol in the artery wall in 
combination with an inflammatory immune response. Atherogenesis (the process by 
which atherosclerosis develops) is a complex process that normally begins at an early age 
and remains asymptomatic for decades.
The arterial wall consists o f 3 layers, the intima, the media and the adventitia (Figure 
1.1). The intima is the inner most layer o f the vessel surrounding the vessel lumen. On 
the lumenal side is a layer o f endothelial cells (EC) that are involved in regulating 
haemostatic processes in the lumen and anti-inflammatory, mitogenic and contractile 
processes in the vessel wall. The media is made up o f layers o f smooth muscle cells 
(SMC) and extracellular matrix proteins (mainly elastin). The adventitia mainly consists 
of connective tissue and fibroblasts.
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Damage to the endothelium and endothelial dysfunction are thought to initiate 
atherogenesis. Endothelial dysfunction, a situation in which ECs no longer carry out 
their normal biochemical processes can be caused by many factors including 
hypertension, hypercholesterolemia, diabetes, toxins found in tobacco smoke and 
disturbances in blood flow (Nerem, 1992, Fuster et a l ,  2005). Endothelial dysfunction 
causes a decrease in nitric oxide (NO) synthesis, an increase in oxidation and uptake of 
circulating lipoproteins, monocyte entry into the vessel wall, SMC proliferation, 
extracellular matrix deposition and vasoconstriction (Fuster et a l ,  2005). NO availability 
is important for maintaining the vessel as it is involved in vasodilation, inhibition of 
vascular SMC proliferation and migration and down-regulation .o f inflammatory and 
adhesion molecules (Gewaltig and Kojda, 2002). Reactive oxygen species (ROS) 
decrease NO bioavailability and upregulate the transcription o f many pro-inflammatory 
genes, chemokines, adhesion molecules and pro-thrombotic factors in the endothelium, 
causing endothelial dysfunction (Melo et a l ,  2004).
One o f the main determinants o f where atherosclerosis develops is the haemodynamic 
strain caused by blood flow. Atherosclerosis most commonly occurs at points where 
blood flow causes low average shear stress but high oscillatory shear stress e.g. vessel 
bifurcation points (Dai et a l ,  2004, Malek et a l ,  1999). Endothelial dysfunction and 
shear stress caused by changes in blood flow can cause inflammatory activation o f ECs, 
which stimulates them to express leukocyte adhesion molecules such as P-selectin, E- 
selectin, intracellular adhesion molecules (ICAMs), vascular cell adhesion molecule-1 
(VCAM-1), and integrins. Leukocytes loosely adhere to selectins before forming stable 
attachments to adhesion molecules (Blakenberg et a l ,  2003). In response to chemokines 
such as monocyte-chemoattractant protein-1 (MCP-1), monocytes and T-cells migrate 
into the intima (Boring et al., 1998, Gu et a l ,  1998). In the intima monocytes 
differentiate into macrophages in response to macrophage colony stimulating factor (M- 
CSF) (Ishibashi et al, 1990, Clinton et a l ,  1992). Oxidised low density lipoprotein 
(oxLDL) is produced by LDL cholesterol reacting with free radicals produced by 
macrophages, SMC and EC. Modified lipoproteins such as oxLDL cannot bind to the 
normal LDL receptor, but as part o f the innate immune response, macrophages express
scavenger receptors that bind to and take up modified lipoproteins, and apoptotic cell 
fragments. This causes them to develop into foam cells (Hansson, 2001). At this stage 
fatty streaks are said to have formed.
Foam cells and lymphocytes within the vessel wall secrete cytokines that stimulate SMC 
proliferation, extracellular matrix production (Libby, 2002) and enhance the 
inflammatory process. SMC proliferation and migration from the media into the intima 
in conjunction with increased uptake o f lipoproteins and inflammatory cells and 
production o f extracellular matrix proteins leads to the formation o f a fibrous cap 
covering a lipid rich core, resulting in the production o f an atherosclerotic plaque (Figure 
1.2A).
The fibrous cap consisting o f SMC and extracellular matrix proteins has an important 
protective role in maintaining plaque stability and preventing the pro-thrombotic 
molecules in the lipid core coming into contact with the blood (Stary, 1990). Plaques 
continue to develop, with changes occurring in their size and cellular and molecular 
composition. Activated T-cells in the intima produce inflammatory cytokines such as 
interferon-y (INF-y), that further stimulate macrophages. Foam cells produce more pro- 
inflammatory cytokines and reactive oxygen species, propagating the inflammatory 
response and signaling macrophages to die by apoptosis. This leads to the formation of a 
necrotic core within the plaque. In established plaques tissue factors, proinfiammatory 
cytokines and matrix metalloproteinases (MMPs) are secreted. MMPs degrade the 
extracellular matrix, weakening the fibrous cap and as the lipid core continues to grow an 
unstable plaque forms.
Plaque growth and remodeling can cause narrowing o f the lumen or outward growth. 
Plaque growth into the lumen is associated with the formation o f large stable plaques that 
cause angina, whereas outward remodeling is more commonly a feature o f unstable 
plaques (Schoenhagen et a l ,  2000).
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1.2.1 Plaque rupture
Until recently it was thought that the risk o f death due to atherosclerosis was increased by 
the extent o f stenosis and lumenal narrowing. However in the last 15 years it has been 
noted that the major risk factor is actually plaque rupture, which leads to clot formation 
(thrombus) and blockage o f arteries (Falk et a l ,  1995, Davies, 1996). Approximately 
70% o f all fatal myocardial infarctions are caused by plaque rupture (Falk et a l ,  1995) 
and the remaining 30% are due to plaque erosion, where the endothelial cells are 
removed (Virmani et a l ,  2000, Farb et a l ,  1996). The cause o f plaque erosion is poorly 
understood but eroded plaques generally have lower macrophage infiltration, less 
calcification (Farb et a l ,  1996) and contain higher levels o f mast cells than rupture prone 
plaques (Kovanen et a l ,  1995). It has been proposed that mast cells produce proteases 
that disrupt endothelial cell adhesions, which leads to plaque erosion (Mayranpaa et a l ,  
2006). M ore is known about what causes plaques to become unstable and prone to 
rupture. Unstable plaques are generally described as those that have a thin fibrous cap 
and a large lipid core. Autopsy studies have been used to define their features more 
precisely (Table 1.1). Although unstable plaques are relatively well classified the final 
trigger that causes plaque rupture to occur is not normally known, although its probable 
that external factors acting on the plaque such as an increase in blood pressure can act as 
the trigger.
Plaque rupture enables contact between blood and the thrombogenic and pro-coagulant 
proteins from the plaque such as tissue factor from apoptosed macrophages (Mallat and 
Tedgui, 2000) and oxidized lipids (Toschi et a l ,  1997, Fernândez-Ortiz et a l ,  1994) 
(Figure 1.2B). This results in thrombus formation that can occlude the vessel and is a 
common cause o f myocardial infarction (Virmani et a l ,  2000). However, not all ruptures 
result in occlusion o f arteries, many are asymptomatic and result in the formation o f 
smaller clots that are then incorporated into the plaque following repair by collagen 
synthesis. This tends to accelerate plaque progression and increase plaque instability 
(Mann and Davies, 1999). The extent o f thrombus formation following plaque rupture is 
dependent on a number o f factors including composition o f the plaque, rate o f blood flow
Feature Comment Reference
Plaque size Large plaques are generally more stable and 
cause angina, whereas plaques that cause less 
than 50% narrowing o f the lumen are unstable. 
Outward remodeling and medial atrophy that 
does not decrease the lumen size are more 
commonly associated with unstable plaques.
(Schoenhagen et 
a l ,  2000, 
Ambrose et a l , 
1988, Rao et a l ,  
2005)
Large lipid core Plaques with a lipid rich core that takes up more 
than 50% of the plaque volume are more 
unstable.
(Davies, 1996, 
Rao et a l ,  2005)
Thin fibrous cap Plaques with thin fibrous caps (less than 65pm 
thick) depleted in collagen and SMC are defined 
as unstable.
(Burke et a l , 
1997)
Cholesterol
levels
A high total/HDL cholesterol ratio is associated 
with plaque instability. HDL cholesterol is 
protective as it promotes reverse cholesterol 
transport from tissues to the liver. LDL 
cholesterol is pro atherogenic as it mediates 
uptake o f cholesterol into macrophages.
(Burke et a l ,  
1997, Barter, 
2004)
Red blood cell 
accumulation
Neo-vascularisation and intra-plaque 
hemorrhages increase plaque vulnerability as red 
blood cells enhance necrotic core expansion and 
increase the immune response.
(Kolodgie et a l ,  
2003, Rao et a l ,  
2005, Mann and 
Davies, 1999)
Table 1.1 Characteristics o f unstable plaques.
in the area and systemic procoagulant activity (Fuster et a l ,  2005). Lipid-rich plaques 
are the most thrombogenic and high levels o f tissue factor found in macrophage rich 
areas o f the plaque also contribute to thrombus formation (Toschi et a l ,  1997) 
(Fernândez-Ortiz et a l ,  1994). Factors which increase systemic procoagulant activity 
include high levels o f plasm a LDL cholesterol, smoking and hyperglycemia in diabetics 
(Rauch et a l ,  2001).
1.2.2 Current treatments to reduce risk factors for atherosclerosis
There are a number o f ways o f  treating atherosclerosis depending on the underlying cause 
o f the condition. The majority o f treatments focus on reducing risk factors that are known 
to contribute to the progression o f atherosclerosis and major cardiovascular events. 
Lifestyle changes such as ceasing smoking, increasing exercise, improving diet and 
weight loss are recommended to reduce environmental risk factors. M anagement o f other 
conditions associated with an increased risk o f atherosclerosis, such as diabetes and 
hypertension is also important.
The main focus o f the current treatment for atherosclerosis is to try and reduce the 
incidence o f plaque rupture and thrombus formation by controlling the risk factors 
involved. Therefore drugs focus on reducing hypertension, reducing the total/FIDL 
cholesterol ratio and administering anticoagulants to prevent thrombus formation 
occurring. There are many anti-hypertensive drugs, for example beta-blockers that can 
be used to slow down the heart rate and lower blood pressure. Angiotensin converting 
enzyme (ACE) inhibitors lower blood pressure by reducing the generation o f angiotensin 
II and can also reduce inflammation caused by macrophages secreting interleukin-6 (IL- 
6) (Schieffer et a l ,  2000). Reducing blood pressure can reduce the stress exerted on 
plaques and therefore reduce the likelihood of plaque rupture occurring. Aspirin can also 
be prescribed to reduce platelet aggregation, thrombus formation and it has an anti­
inflammatory effect.
The development o f statins was a major advance in the treatment o f atherosclerosis. 
Their main mechanism o f action is to lower cholesterol by inhibiting 3-hydroxy-3
methylglutaryl coenzyme A (HMG-CoA) reductase, the key regulatory enzyme in the 
production o f cholesterol. However, patients with normal serum cholesterol levels also 
benefit from them, probably due to their anti-inflammatory action as they have been 
shown to down regulate T-cell activation o f macrophages (Sposito and Chapman, 2002) 
and inhibit the expression o f the pro-inflammatory CD40/CD40L (Semb et a l ,  2003) and 
MCP-1 (Morikawa et a l ,  2002). There is also evidence from both humans and animal 
models, that statins down regulate tissue factor and MMP expression in plaque 
macrophages (Aikawa et a l ,  2001, Cortellaro et a l ,  2002). Additionally some statins are 
thought to stabilise plaques (Kennedy et a l ,  2005) by increasing expression o f tissue 
inhibitors o f matrix metalloproteinases (TIMPs), which results in an increase in plaque 
collagen content (Crisby et a l ,  2001).
There are many different types o f statins available, which have slightly different 
properties, but despite their wide ranging mode o f action, not everyone responds to or can 
tolerate statins so other forms o f treatment are required (Oka and Chan, 2005). Other 
drugs that can improve the lipoprotein balance include niacin (Vitamin B3), drugs that 
inhibit the absorption o f  dietary cholesterol such as ezetimibe and fibrates that increase 
HDL levels, and lower LDL cholesterol. Although there is now evidence that some 
statins might mediate some plaque regression, there are no treatments aimed directly at 
altering the plaque composition.
In advanced cases o f atherosclerosis, surgical procedures such as angioplasty and 
coronary artery bypass grafting (CABG) are used. Percutaneous transluminal coronary 
angioplasty (PTCA) is a technique that involves the insertion o f a balloon into the artery 
at the site o f the plaque. Inflating the balloon breaks up the plaque and stretches the 
artery. However, surgical manipulation o f the artery results in damage to the 
endothelium that causes inflammation, smooth muscle cell proliferation and thrombus 
formation. This results in neointimai hyperplasia and narrowing o f the vessel. A stent (a 
hollow metal mesh) can be deployed into the artery to provide support and reduce the 
subsequent narrowing o f  the vessel. However stents themselves can be proinfiammatory 
and this can result in tissue growth around the stent and instent restenosis. This occurs in
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30-60% of patients with complex lesions that receive a bare metal stent (Fattori and Piva, 
2003). To reduce the rate o f instent restenosis stents can be coated in drugs that have an 
immunosuppressive, anti-proliferative, anti-inflammatory, anti-thrombotic and/or 
prohealing effect. For example, the first drug eluting stents were coated in sirolimus 
(rapamycin), which blocks cell cycle progression, reducing SMC, T-cell and B-cell 
proliferation and so reduces tissue growth and the immune response (McKeage ei a l ,  
2003). Even with the use o f drug eluting stents restenosis remains a problem (Brasen et 
a l ,  2001) and additionally they have been associated with an increase in late stent 
thrombosis (occurring more than 12 months after procedure) (McFadden et a l ,  2004). 
Further long-term studies are required but it seems that even with recent advances in stent 
development the procedure still has some limitations.
CABG involves taking an artery or vein from another anatomical site o f the patient and 
grafting it from the aorta to the coronary artery to bypass the narrow section o f the artery 
to improve blood flow. Damage caused to the vessel during the operation can cause 
neointima formation due to smooth muscle cell migration, proliferation and extracellular 
matrix production. This results in occlusion o f the bypass vessel. Where possible, 
arteries such as the internal mammary or radial artery are used for the graft as they have 
lower rates o f failure than vein grafts, due to the anatomical differences between veins 
and arteries (Nezic et a l ,  2006). However, for patients that require multiple vessel grafts 
veins are commonly used. Vein graft failure due to neointima formation occurs in about 
50% o f patients between 5-10 years after the procedure (Tsui and Dashwood, 2002).
1.2.3 Plaque stabilisation and regression
Atherosclerosis has traditionally been thought o f as a progressive and irreversible 
disease; however there is now evidence from both animal models and clinical trials that 
shows that plaque stabilisation and regression is possible by reducing lipid content and 
inflammation in the plaque. Lipid lowering is thought to decrease macrophage 
accumulation, reduce inflammation and increase collagen content, resulting in 
remodeling o f the arterial wall and plaque stabilisation (Libby and Aikawa, 2002). For 
example, transplantation o f a section o f atherosclerotic aorta from apolipoprotein E
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Imockout (ApoE-/-) mice into healthy C57/BL6 mice caused a reduction in the size of 
lesions by about 50% in just 3 weeks (Reis et a l ,  2001). This dramatic regression was 
thought to be due to a 90% decrease in plasma cholesterol levels (Reis et a l ,  2001). The 
number o f foam cells was also significantly reduced, as they migrated from the lesions to 
the draining lymph node (Llodra et a l ,  2004). Aikawa et a l  (Aikawa et a l ,  1998) have 
also shown that lowering plasma cholesterol levels can increase plaque stability. Rabbits 
were fed a high fat diet and had plaque formation induced by balloon injury to the carotid 
artery. H alf were then fed a normal diet and half were maintained on the high fat diet. 
16 months later lesions o f animals that were fed a normal diet contained fewer 
macrophages, had decreased MMP activity and contained more collagen (Aikawa et a l ,  
1998), suggesting they were more stable. A similar study in rabbits showed that after 6 
months o f cholesterol withdrawal the plaques contained fewer macrophages, less 
apoptotic cells and more collagen, however the size o f plaques were unaffected by 
cholesterol lowering (Kockx et a l ,  1998). Pravastatin is thought to cause plaque 
stabilisation in humans by decreasing plaque lipid content, lipid oxidation and 
inflammation and increasing TIM Pl and collagen content (Crisby et a l ,  2001). It has 
recently been shown to have a similar effect in ApoEV- mice without affecting plasma 
cholesterol levels (Johnson et a l ,  2005b). A recent clinical trial (A Study to Evaluate the 
Effect o f Rouvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden, 
ASTEROID) has shown that high doses o f rouvastatin can cause plaque regression after 2 
years o f treatment (Nissen et a l ,  2006). A mean reduction in LDL cholesterol of 53% 
was achieved in combination with a significant increase in HDL cholesterol (Nissen et 
a l ,  2006). This resulted in an average decrease in plaque volume o f 6.8% and is the first 
trial in humans that has been able to show that a decrease in plaque volume can be 
achieved. However the trial design was not sufficiently powered to show significance at 
the level o f plaque regression, so further studies are in progress (Nissen et a l ,  2006).
1.2.4 Future forms of treatment
Due to the high incidence o f cardiovascular disease it has been suggested that everyone 
over the age o f 55 should be treated prophylactically with a combination o f drugs that has 
become known as the Polypill (Wald and Law, 2003). The Polypill would consist o f a
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statin, blood pressure lowering drugs (e.g. a Beta-blocker, an ACE inhibitor and a 
thiazide (a diuretic)), folic acid and aspirin (Wald and Law, 2003). It is predicted that 
this would reduce the incidence o f CVD events by more than 80% (Wald and Law, 
2003). However there are likely to be problems with patient compliance o f seemingly 
healthy people.
There are also many novel treatments for CHD that are under investigation. Many of 
these focus on reducing the immune response that occurs. For example, the pro- 
inflammatory cytokine tumour necrosis factor a  (TN Fa) has been implicated in plaque 
development as ApoE-/- and TN Fa-/- double knock-out mice develop smaller lesions 
that express significantly lower amounts o f other inflammatory molecules including 
ICAM-1, VCAM-1 and MCP-1 compared to ApoE-/- mice (Ohta et a l ,  2005). Also their 
macrophages have a lower expression level o f scavenger receptor so take up less oxLDL, 
(Ohta et a l ,  2005). In ApoE-/- mice inhibition o f TNF with a TNF-antagonist also 
decreased plaque formation (Laurat et a l ,  2001). Inhibition o f other cytokines implicated 
in plaque development, such as INF-y {Whitman, 2000 #6081}, could also be o f benefit.
Another approach has investigated vaccinating with oxLDL, or heat shock protein 60. In 
animal models this has reduced atherosclerosis development, possibly by activating a 
protective B- or T-cell response (Palinski et a l ,  1995, Zhou et a l ,  2001, Maron et a l ,  
2002).
Other ways o f improving the HDL/total cholesterol ratio by increasing the amount of 
circulating HDL are being developed. HDL is required for reverse lipid transport to 
remove cholesterol from peripheral tissues including the artery wall and take it to the 
liver for excretion. HDL also has anti-oxidative, anti-inflammatory and anti-thrombotic 
properties (Shah and Chyu, 2005). The first evidence that HDL has a protective effect 
was from cholesterol fed rabbits that were given purified HDL, which caused a decrease 
in atherosclerosis (Badmion et a l ,  1990). Evidence suggests that increasing HDL 
cholesterol has a higher atheroprotective effect than a decrease in LDL cholesterol (Lee 
and Choudhury, 2006). There are several methods o f increasing HDL levels that are
13
currently undergoing pre-clinical and clinical trials. Some promising results have been 
achieved using ApoA-I Milano, a rare naturally occurring mutant o f  the ApoA-I protein. 
ApoA-I is the major protein component o f HDL cholesterol. The mutant contains a 
single amino acid substitution that provides increased resistance to the development of 
atherosclerosis (Franceschini et a l ,  1980). A small proof o f concept trial demonstrated a 
significant regression in plaques in patients receiving recombinant ApoA-I Milano 
(Nissen et a l ,  2003). But weekly injections were required so it may be more effective to 
use gene transfer techniques to enable the patient to synthesise the protein. Wang et al. 
(Wang et a l ,  2006a) recently reported some success with ex vivo gene therapy using a 
retroviral vector expressing ApoA-I from a macrophage specific promoter. Infected bone 
marrow cells were transplanted into ApoE, ApoA-I double knock-out mice. After 24 
weeks o f fat feeding the degree o f aortic atherosclerosis was reduced by 65% (Wang et 
a l ,  2006a). Gene therapy therefore has the potential to treat CHD.
1.3 Animal models o f atherosclerosis
To develop new treatments for atherosclerosis an accurate animal model o f the human 
disease is required. Many different animal models o f atherosclerosis have been 
developed, but it has proven very difficult to reproduce many o f the features o f the 
human condition to produce a model that accurately reflects the molecular and 
phenotypic changes that occur in the development o f unstable plaques. There are several 
models which use artificial methods to cause plaque rupture, such as inflating balloon 
catheters in plaques (Rekhter et a l ,  1998a), using forceps to damage mouse aortas 
(Reddick et a l ,  1998) and administration o f Russell viper venom (a procoagulant and 
endothelial toxin) and histamine to cholesterol fed rabbits (Abela et a l ,  1995). However 
for this study these models are unsuitable as they do not reflect the natural molecular 
changes that occur in unstable plaques.
Another study produced plaques in the mouse carotid artery by placing a silastic collar 
around the artery (der Thu sen et a l ,  2002). Luminal overexpression o f p53 from an 
adenovirus (Ad) vector caused apoptosis, which led to cap thinning (der Thu sen et a l ,  
2002). 3/16 animals showed evidence o f plaque rupture 14 days after Ad administration.
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To increase the occurrence o f this, mice were treated with phenylephrine to make them 
hypertensive, resulting in plaque rupture in 40% o f  the animals, (der Thusen et a l ,  2002). 
A recent study with ApoE-/- fed a normal diet used carotid artery ligation to induce 
plaque formation, before a cuff was placed around the artery to cause cracks in the plaque 
cap (Sasaki et a l ,  2006). Four days after cuff insertion, cracks in the neointima and 
thrombus formation were consistently observed and by 7 days occlusive thrombi were 
found in all mice (Sasaki et a l ,  2006). This provides a fast and reliable method of 
inducing plaque development and rupture that lead to the formation o f occlusive thrombi, 
which are not commonly seen in many other models. Flowever, these models require a 
lot o f manipulation o f the plaque to induce rupture, so they provide relatively limited 
information about the natural progression o f unstable plaques and plaque rupture. The 
main advantage o f these models is the short time period required for plaque development 
and rupture and that the tim ing o f plaque rupture can be controlled.
Recently a new approach has been taken to developing a mouse model o f plaque rupture. 
ApoE-/- transgenic mice with vascular SMC that express the human diphtheria toxin 
receptor (SM 22a-hD TR ApoE-/-) were created (Clarke et a l ,  2006). M ice were fat fed 
for 12 weeks from the age o f six weeks and then were given diphtheria toxin, which 
induced vascular SMC apoptosis. Although this had no effect on plaque size it caused 
thinning o f the plaque cap, with a loss o f SMC and extracellular matrix proteins and an 
increase in necrotic core size (Clarke et a l ,  2006). Treatment with diphtheria toxin also 
caused a significant increase in the amount o f macrophages and the proinfiammatory 
cytokine IL-6 (Clarke et a l ,  2006). Although these plaques had many o f  the features of 
unstable plaques no thrombus formation was detected (Clarke et a l ,  2006). However, the 
mice were culled 3 weeks after diphtheria toxin administration, so if  this was extended 
plaque rupture may occur. This method may provide a rapid and reliable model for 
generating unstable plaques with many features o f human plaques, in a relatively short 
time period.
One o f the first reports o f spontaneous plaque rupture was seen in 42-60 week old ApoE- 
/- mice that developed lesions in their brachiocephalic artery (BCA) which showed
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evidence o f intraplaque hemorrhages possibly due to plaque rupture (Rosenfeld et a i ,
2000). The mice had layered lesions suggesting that multiple throm botic events could 
have occurred (Rosenfeld et a l ,  2000). This had not been noticed previously as most 
studies focused on the aorta and did not examine the vasculature at these longer time 
points. The BCA (or innominate artery) is a small artery that connects the aortic arch to 
the right subclavian and right carotid artery (Figure 1.3). The occurrence o f plaque 
rupture specifically in the BCA has been proposed to be due to a particularly high degree 
of tension in the wall o f this artery. Another study using ApoE and LDL receptor 
(LDLR) knockout mice provided evidence o f a low level (3 o f 82 cholesterol fed mice) of 
plaque rupture in mice monitored for up to 12 months (Calara et a l ,  2001).
A reliable model o f plaque rupture seems to have been developed in C57/B16/129SvJ 
ApoE-/- mice by feeding a diet o f 21% beef lard and 0.15% cholesterol (Johnson and 
Jackson, 2001, W illiams et a l ,  2002). After 14 months o f fat feeding many mice had 
plaque rupture events with associated thrombus formation in the BCA. Analysis o f the 
lesions showed many similarities with unstable human plaques including a thin fibrous 
cap with reduced amounts o f SMC and elastin overlying a lipid rich core. Many of the 
plaques had a layered appearance, which has also been seen in human plaques and was 
proposed to be due to previous silent ruptures (Burke et a l ,  2001). Alternatively it could 
be due to periods o f rapid plaque growth, but either way it is further evidence that the 
plaques produced in this model have a similar phenotype to those seen in humans. It was 
thought that 79% o f plaques analysed had features consistent with earlier plaque ruptures 
having occurred. O f 98 mice, 51 showed evidence o f plaque rupture in the BCA. This 
level o f plaque rupture had not previously been reported in ApoE-/- mice, and it may be 
due to the strain background used in this case as 129Sv mice absorb cholesterol more 
effectively than C57/B16 (Jolley et a l ,  1999). Also, C57/B16 mice express a higher level 
o f transforming growth factor (31 (TG F-pl) than 129Sv mice, which may decrease 
inflammation within the plaque and so have a protective role (W illiams et a l ,  2002). 
Other studies have also shown the strain background is important, for example, C57/B16 
mice develop 7-9 fold more atherosclerosis than FVB mice that have higher plasma 
cholesterol levels. The main problems with both this and the study by R osenfeld  et a l
16
oc cc 02 <■
CQ
ûû w
O  WCJÛ .£5
QQ
.g
S-u01
■s
"8
§
3
Oif
C3I00
<UflQuJ3
OO01o
m
g
&
C/3
S<4-,O
I3I
U
e
têI
1&<u02
£
17
(Rosenfeld ei a l ,  2000) is the length o f time required to develop the phenotype and the 
fact that plaque rupture did not cause the development o f fibrin-rich platelet clots that can 
occlude the artery after plaque rupture, which is commonly seen in humans.
Further work using this model has shown that these mice can develop unstable plaques 
after only 8 weeks o f fat feeding (Johnson et a l ,  2005b). After just 4 weeks o f fat 
feeding, fatty streaks were visible in the BCA and by 6 weeks plaques had developed 
(Johnson et a l ,  2005b). After 8 weeks these were complex lesions with a layered 
appearance and in 62% o f 173 mice plaque rupture was seen (Johnson et a l ,  2005b). 
Pravastatin, which is thought to stabilise atherosclerotic plaques in hum ans (Crisby et a l ,
2001), was administered to these mice in conjunction with fat feeding. After 9 weeks this 
was found to have no affect on the incidence o f plaque rupture, however when the study 
was extended to 40 weeks, mice treated with pravastatin had a lower incidence of plaque 
rupture (Johnson et a l ,  2005b). At both time points control animals had a significantly 
higher incidence o f buried fibrous layers indicative o f previous plaque ruptures (Johnson 
et a l ,  2005b). Treatment with pravastatin also reduced the occurrence o f sudden death 
(Johnson et a l ,  2005b). When treatment was delayed until after the plaques had 
developed, the incidence o f plaque rupture was decreased probably due to a stabilising 
effect o f pravastatin (Johnson et a l ,  2005b). These results suggest that this provides a 
relatively quick and reliable model o f atherosclerotic plaque rupture. However, the 
presence o f fibrous layers and buried caps within the plaques cannot be assumed to be 
due to previous plaque rupture, but may be due to intraplaque haemorrhages from plaque 
microvessels (Lutgens et a l ,  2003), but no neovascularization has been seen in over 700 
ApoE-/- mice (Johnson et a l ,  2005b). Therefore this model is one o f the most reliable 
models o f  spontaneous plaque rupture that has many o f  the features o f the human disease 
and the disease state is achieved in a relatively short period o f  time.
1,4 Gene therapy
Gene therapy can simply be defined as the delivery o f a gene to host cells to express a 
protein that has a therapeutic effect. The gene can replace a missing or defective gene, 
produce a protein that inhibits the undesirable effects o f another protein, or introduce a
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new cellular function such as a protein with metabolic, structural or signaling functions 
(Dzau et a l ,  2003). Initially it was proposed as a form o f treatm ent for monogenic 
disorders such as cystic fibrosis and Duchenne’s muscular dystrophy, where supplying 
the correct form o f the gene should cure the condition, but gene therapy treatments are 
now being developed for a wide range o f diseases, including highly complex conditions 
such as CHD and cancer.
1.4.1 Current status o f gene therapy
In 1990 the first gene therapy clinical trial was approved for treating adenosine 
deaminase deficiency using a retrovirus vector (Kohn et al., 1998), since then over 1000 
gene therapy trials have been carried out. About 2/3 o f these are for cancers and less than 
10% are for vascular disorders (http://www.wiley.co.ul</wileychi/genmed/clinical/). The 
majority o f these focused on inducing angiogenesis to treat ischemia (Melo et a l ,  2005). 
As yet no serious side effects have been reported in any cardiovascular gene therapy 
clinical trials.
The first government approved gene therapy treatment was Gendicine (SiBono, Shenzen, 
China), which was approved in 2004 in China for treatment o f head and neck squamous 
cell carcinomas. It is a replication deficient Ad vector that expresses tum our suppressor 
p53 from a Rous Sarcoma Virus (RSV) promoter. In over 2500 patients no significant 
side effects have been seen and the vector seems to be well tolerated (Peng, 2005). In 
combination with radiotherapy, Gendicine caused complete regression o f cancers in 64% 
of patients and partial regression in 29% o f patients in clinical trials for head and neck 
squamous cell carcinomas (Peng, 2005). Gendicine has also been shown to have a 
beneficial affect in the treatm ent o f advanced liver and lung cancers (Peng, 2005). There 
have currently been over 50 cancer clinical trials using Ad vectors expressing p53 (Peng,
2005). These have been carried out for a range o f cancers including bladder (Pagliaro et 
a l ,  2003) and lung cancers (Swisher et a l ,  2003). No serious side effects have been seen 
but some patients suffer from minor problems such as pain at the site o f injection, fatigue 
and fever (Peng, 2005).
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Currently one o f the main challenges o f gene therapy research is the development of 
vectors that can be administered systemically and deliver the therapeutic genes 
selectively to the target tissue and cell type so that the gene is expressed at a high enough 
level to have a therapeutic effect without either the vector or the gene product causing 
any significant side effects.
1.5 Gene therapy vectors
The requirements o f an efficient gene delivery vector vary depending on the disease to be 
treated, but generally they are required to be selective for the target cell type or organ, 
non-toxic, non-immunogenic, stable in vivo and producible on a large scale. Due to 
differences in the mode o f delivery, target cell type and required duration o f transgene 
expression, many gene therapy treatments are likely to require the development o f a 
unique vector tailored for that application. Therefore there are many different types of 
vectors being researched, but these can broadly be divided into non-viral and viral 
vectors.
1.5.1 Non-viral vectors
Non-viral vectors are less immunogenic and easier to produce than viral vectors, but the 
level o f transgene expression they can provide is significantly lower than can be achieved 
with viral vectors. Several strategies are being developed to try and overcome this 
deficiency.
The simplest form o f vector is naked plasmid DNA. When in contact with the cell 
membrane, a small amount is taken up by the cell resulting in a very low level of 
transduction. To improve the efficiency o f cellular uptake, plasmid DNA can be 
incorporated into cationic liposomes or cationic proteins e.g. poly-lysine (McKenzie et 
a l ,  2000). Alternatively, histones can be used to compact the DNA into complexes 
which enable cellular entry via an interaction with sulphated membrane bound 
proteoglycans (Mislick and Baldeschwieler, 1996). In vitro these vectors do produce 
some improvement in transduction, but in vivo transgene expression levels remain low 
due to their poor transfection efficiency, and because they are rapidly cleared from
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plasma (Filon and Phillips, 1997, Johnson-Saliba and Jans, 2001). Although liposomes 
improve cellular uptake o f the DNA, once inside the cell the majority o f the DNA 
remains in the cytoplasm where it is degraded as the vectors are inefficient in escaping 
the liposome/endosome complex, avoiding degradation in the cytoplasm, trafficking to 
the nucleus and crossing the nuclear membrane (Johnson-Saliba and Jans, 2001, Jans et 
a l ,  2000). Plasmids that reach the nucleus remain extrachromosomal and are rapidly 
degraded so they provide only transient gene expression (Niidome and Huang, 2002). To 
try and overcome these deficiencies, proteins that enable receptor-mediated endocytosis, 
endosomal disruption, and nuclear import sequences have been incorporated into the 
vector complex (Glover et a l ,  2005, Cartier and Reszka, 2002). For example a novel 
vector known as GD5 contains the DNA-binding domain o f the yeast transcription factor 
GAL4 (to form the complex with the DNA), an antibody that binds the tumour-associated 
cell surface protein ErbB2 (to target the vector), and the diphtheria toxin translocation 
domain to disrupt the endosome (Uherek et a l ,  1998). To overcome the transient nature 
of the gene expression, site-specific recombinases commonly found in viruses that infect 
prokaryotes are being incorporated into vectors to mediate recombination into the host 
genome (Glover et a l ,  2005).
In an attempt to target liposomes to specific cell types and increase their cellular uptake, a 
system has been developed to form a complex o f a liposome (Lipofectin), an integrin 
targeting peptide and plasmid DNA (LID system) (Hart et a l ,  1998). This has been used 
to increase transduction o f vascular EC and SMC in vitro, but transgene levels remain far 
lower than that achieved with Ad vectors (Parkes et a l ,  2002). Recently it has also been 
used in vivo in a rat carotid angioplasty model (Meng et a l ,  2006). A LID vector 
expressing TIM Pl was applied to the adventia o f balloon injured carotid arteries. 28 
days later the intima to media ratio was 46% lower in treated arteries compared to 
controls, suggesting the vector produced therapeutic levels o f transgene expression. This 
demonstrates that the LID system can be used to enhance non-viral gene delivery.
Many physical methods o f gene delivery have also been developed to improve the 
efficiency o f  non-viral gene therapy. Hydrodynamic pressure created by injecting large
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volumes o f DNA can be used to force more o f the plasmid from the blood into tissues. 
This has been shown to be particularly effective in improving gene transfer to 
hepatocytes, following tail vein injection in mice (Niidome and Huang, 2002). 
However, it has limited application in patients as it can only be used in tissues where it is 
possible to create high pressure e.g. by using a blood pressure cuff on limbs (Glover et 
n/.,2005).
Electroporation is commonly used for in vitro transfection, as it increases the efficiency 
with which DNA passes through the cell membrane. It has also been shown to function 
in vivo in many tissues including skin, lung, liver, kidney, heart, brain, muscle and 
tumours (Magin-Lachmann et a l ,  2004, Somiari et a l ,  2000, Wells, 2004). However the 
technique has many disadvantages as it requires a highly invasive procedure, is limited to 
accessible tissues, causes considerable cell death and the level o f gene expression 
achieved is still lower than that from viral vectors (Li and Huang, 2000). Another 
method known as the gene gun involves firing gold particles coated with DNA at the 
target tissue. This enables delivery o f the DNA directly into the cytoplasm. Due to its 
limited tissue penetration it has mainly been used for gene delivery to skin. Little success 
has been achieved with this technique, for example in a mouse tumour model, delivery of 
cytokines was found to have no affect on tumour development (Kitagawa et a l ,  2003).
One o f the more successful methods for increasing the efficiency o f non-viral gene 
delivery is to apply ultrasound to the target tissue at the time o f injection. This increases 
the permeability o f the cell membrane and therefore increases uptake o f DNA. Gas filled 
microbubbles can be used as a contrast agent to increase the efficiency o f  the technique 
(Niidome and Huang, 2002). It has been shown to increase transduction o f vascular cells 
about 300-fold compared to naked DNA alone (Lawrie et a l ,  1999). In vivo it has been 
demonstrated to increase plasmid uptake into the carotid artery o f rabbits and rats 
following intra luminal delivery (Huber et a l ,  2003, Taniyama et a l ,  2002). A 
therapeutic effect o f ultrasound enhanced gene delivery was demonstrated in a porcine 
model o f saphenous vein grafting (Akowuah et al., 2005). Veins were transfected ex vivo 
with a plasmid expressing TIMP3. 28 days after grafting the luminal area was
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significantly larger than controls (Akowuah et al., 2005). Unlike the other techniques 
described, ultrasound is less invasive and can be focused on inaccessible tissues deep 
within the body and it can be used to increase the selectivity o f  a vector as the ultrasound 
can be focused on a specific tissue (Newman et al., 2001). The use o f ultrasound in other 
procedures has shown it has a good clinical safety profile, so it is a promising technique 
for improving non-viral gene delivery to the vasculature.
Although these technologies can improve transgene expression, they still remain in 
general, less efficient than viral vectors.
1.5.2 Viral vectors
There are many different types o f viruses that are being investigated as potential vectors 
for gene therapy. The type o f viral vector used for a particular gene therapy depends on 
the cell type to be targeted and whether transient or long-term transgene expression is 
required. The important features o f the main types o f viral vectors compared to non-viral 
vectors are summarised in Table 1.2. Historically, the most commonly used are 
retroviruses and adenoviruses. This is highlighted by clinical trial data (Figure 1.4) that 
show that these are used in 50% o f all clinical trials. Although there are disadvantages 
associated with each type o f vector, our understanding o f virus biology enables them to 
be altered to create a vector with the desired properties that expresses the transgene in the 
target tissue type. The work in this study focuses on the development o f adenovirus and 
adeno-associated virus vectors (AAV), which are described in detail in sections 1.6 and 
1.7.
1.5.2.1 Retroviral vectors
Retroviruses are enveloped viruses with an RNA genome. They can be used to 
efficiently infect proliferating cells to provide long term transgene expression as their 
RNA genome is reverse transcribed and integrated into the host DNA (Daly and 
Chernajivski, 2000). However, they cannot infect non-dividing cells as they cannot cross 
the nuclear membrane, so infection can only occur in cells undergoing mitosis as the 
nuclear envelope is broken down (Miller et a l ,  1990, Lewis and Emerman, 1994). This
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is a particular problem for vascular gene therapy as most vascular cells are quiescent at 
the time of gene delivery. Unlike other retroviruses, lentiviruses (a subclass of 
retroviruses) can transduce both dividing and non-dividing cells and have been shown to 
efficiently transduce both EC and SMC (Dishart et a l ,  2003).
To use retroviruses as gene therapy vectors, all viral genes are removed leaving the long 
terminal repeats, which are required for reverse transcription, integration and virus 
packaging (Young et a l ,  2006). This enables the production o f virus that can carry 
expression cassettes o f up to 8 kb and prevents the occurrence o f  an immune response 
against viral gene products. It also improves the safety o f these vectors as it prevents 
recombination with wild type virus occurring (Dull et a l ,  1998).
There are also concerns about the safety o f using retroviruses as integration into host 
DNA is potentially oncogenic. The site o f integration does not seem to be sequence- 
specific but it does seem to occur more frequently in gene rich regions (Wu et a l ,  2003b) 
(Schroder et a l ,  2002). This problem has been highlighted by recent data from a clinical 
trial for X-linked severe combined immune deficiency (X-SCID) that used ex vivo gene 
transfer o f an oncoretroviral vector expressing the common cytokine receptor gamma 
chain (yc) into autologous bone marrow cells. Although a sustained clinical benefit was 
seen in nearly all patients (Hacein-Bey-Abina et a l ,  2002, Cavazzana-Calvo et a l ,  2005), 
three children have developed leukemia within three years o f the initial treatment due to 
insertional mutagenesis o f the vector causing up-regulation o f expression o f the proto­
oncogene L M 02 (Marshall, 2002, Hacein-Bey-Abina et a l ,  2003a, Hacein-Bey-Abina et 
a l ,  2003b, Cavazzana-Calvo et a l ,  2005). This has been fatal in one o f the cases. These 
trials have highlighted both the exceptional potential o f gene therapy and the associated 
safety concerns.
Recently a major advance was made in the safety o f lentivirus vectors by the production 
of non-integrating vectors that provide stable transgene expression in vivo (Philippe et a l ,  
2006, Yanez-M unoz et a l ,  2006). Previously non-integrating lentiviruses have been 
shown to provide prolonged transgene expression in a range o f non-dividing cell types in
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vitro (Sanez et a i ,  2004, Lu et a l ,  2004, Vargas Jr. et a l ,  2004). Two studies have now 
produced HIV based vectors with a mutated integrase gene, that produce transient gene 
expression in dividing cells and long-term gene expression in quiescent cells, as the viral 
genome remains episomal (Philippe et a l ,  2006, Yanez-Munoz et a l ,  2006). One study 
showed transgene expression in the mouse eye lasted at least 9 months and the level of 
expression achieved was equivalent to that seen with integrating vectors (Yanez-Munoz 
et a l ,  2006). In both a mouse and rat model o f retinitis pigmentosa, the level of 
therapeutic gene expression achieved following subretinal injection caused a significant 
improvement in the condition o f the rodents (Yanez-Munoz et a l ,  2006). Another study 
demonstrated stable gene expression lasting at least 6 months in the dog eye following 
subretinal injection o f the vector (Philippe et a l ,  2006). It was estimated that vector 
integration occurred 500-1250 times less than with unmodified viruses (Philippe et a l ,  
2006), suggesting that the mutated virus would have a greatly improved safety profile. 
However the mutation affected transgene expression, causing an approximately 10-fold 
decrease in expression possibly due to the integrase mutation affecting another stage o f 
gene expression such as virion maturation, uncoating or nuclear import (Philippe et a l ,
2006). With further improvements in the expression cassette it may be possible to 
enhance this. These vectors therefore have great potential for gene therapy with less 
safety concerns.
1.5,2.2 Other types of viral vectors
Herpes Simplex V irus-1 (HSV-1) has also been investigated for use as a gene therapy 
vector. It is a large, double stranded DNA virus with a broad host cell range that includes 
non-dividing cells. As it is particularly efficient at transducing neuronal cells and 
hepatocytes it has been tested for treating gliomas (tumours o f glial cells in the central 
nervous system), with some encouraging results from initial clinical trials 
(PapanastassioLi et a l ,  2002, Brown, 2005).
For cancer gene therapy there are several other oncolytic viruses such as vaccinia virus 
(Zeh and Bartlett, 2002), polio virus (Gromeier et a l ,  2000) and measles virus (Hallak et 
a l ,  2005), which are being investigated. For example, a measles virus targeted to oivp]
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integrin on activated endothelial cells has been shown to cause regression o f myeloma 
tumours in a mouse model (Hallak et al., 2005).
1.6 Adenovirus
Ad based vectors are now the most commonly used type o f vector in clinical trials 
(Figure 1.4) and they are the most widely used agent for vascular gene transfer. This is 
because Ads have many characteristics that can be exploited to develop highly efficient 
gene delivery vectors. As they are one o f the more established gene therapy vectors their 
natural biology has been more extensively studied than most, which has enabled the 
development o f efficient methods for modifying the virus capsid and genome to produce 
replication deficient, tropism-modified vectors at relatively high titres. They can have a 
large packaging capacity for expression cassettes (up to 36 kb) so they can be produced 
to contain a wide range o f expression cassettes and transgenes. They efficiently 
transduce both non-dividing and actively dividing cells without incorporation o f viral 
genes into the host genome, so there are fewer concerns about the oncogenicity o f Ad 
mediated gene transfer. However, the virus does provoke an immune response that limits 
the transgene expression and can causes problems with vector-induced toxicity (See 
section 1.6.7).
1.6.1 Ad Serotypes
Currently 51 different human Ad serotypes and many more from chimps, pigs, mice and 
birds have been identified. The human Ad serotypes have been classified into groups A- 
F (Figure 1.5) based on their ability to agglutinate red blood cells, DNA sequence 
homology, genomic organisation, and their oncogenicity in rodents (Shenk, 1996). There 
is also some correlation between subgroup and tissue trop ism (Table 1.3). Group B 
viruses were previously subdivided into 2 groups (B1 and B2) based on genetic 
differences. Group B1 (Ad3, Ad7, Ad 16, Ad21 and Ad50) are mainly associated with 
acute respiratory infections and group B2 (A di Ip, Ad34 and Ad35) have mainly been 
associated with kidney and urinary tract infections. CD46 is the receptor for the majority 
o f group B viruses (Gaggar et a l ,  2003) with the exception o f possibly Ad3 and Ad7 
(Martilia et a l ,  2005). A recent study has suggested a new classification system for the
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Group Serotypes Associated
Infections
(Zhang and 
Bergelson, 2005)
Main Receptor
A Ad 12, Ad 18, Ad31 Respiratory Bind CAR but not known if it is 
the primary receptor (Freimuth, 
1999, Bewley et a l ,  1999)
B I Ad35, Ad50 Respiratory, kidney 
and urinary tract
CD46 (Gaggar et a l ,  2003, 
Tuve et a l ,  2006)
B II Ad3, Ad7p, A d l4 Respiratory, kidney 
and urinary tract
Receptor X (an unidentified 
glycoprotein) (Tuve et a l ,  2006)
B i l l Ad lip Respiratory, kidney 
and urinary tract
CD46 and receptor X (Tuve et 
a l ,  2006)
C Adi ,  Ad2, Ad5, 
Ad6
Respiratory CAR (Bergelson et a l ,  1997, 
Tomko et a l ,  1997).
D AdS, Ad9, Ad 10, 
A dl3 , A d l5 , Ad 17, 
Ad 19, Ad20, Ad22, 
Ad23, Ad24, Ad25, 
Ad26, Ad27, Ad28, 
Ad29, Ad30, Ad32, 
Ad33, Ad36, Ad37, 
Ad38, Ad39
Epidermic 
keratoconj uctivitis
Some e.g. Ad37, 19a and 8 use 
sialic acid as their primary 
receptor (Arnberg et a l ,  2000, 
Arnberg et a l ,  2002, Burmeister 
et a l ,  2004). CD46 might also 
be a primary receptor (Wu et a l ,  
2004, Trauger et a l ,  2004, 
Zhang and Bergelson, 2005).
E Ad4 Respiratory Bind CAR (Roelvink et a l ,  
1998) but not known if it is the 
primary receptor
F Ad40, Ad41 Gastroenteritis Express 2 fibers. The long fiber 
binds CAR, the short fiber has 
no known receptor (Roelvink et 
a l ,  1998, Nakam ura et a l ,  
2003).
Table 1.3 Adenovirus subgroups. The most common primary cellular receptor for each 
group is shown, but this has not been determined for all Ad serotypes and there is some 
variation seen within subgroups.
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group B viruses based on the identification o f a novel receptor (called receptor X) for 
some of the serotypes (Table 1.3) (Tuve et a l ,  2006).
1.6.2 Structure o f adenoviruses
Adenoviruses are non-enveloped viruses with an icosahedral capsid consisting o f 3 main 
structural proteins, hexon, fiber and penton base and several minor capsid proteins. 
Structural images o f all 3 capsid components (Rux et a l ,  2003, van Raaij et a l ,  1999, 
Zubieta et a l ,  2005) and the complete capsid (Stewart, 1993, Fabry, 2005) have been 
produced. The capsid consists o f 240 trimeric hexon capsomeres (the main structural 
component o f the capsid) and 12 pentameric penton bases (Figure 1.6A). The trimeric 
fiber protein protrudes from the penton base at each o f the 12 vertices o f the capsid 
(Figure 1.6A). Minor capsid proteins, protein Ilia (pllla), pVl, PV lll and plX have roles 
in joining the hexon and penton subunits together (Fabry, 2005).
The fiber dictates haem agiuttination and its main function is to mediate binding to the 
host cell receptor to tether the virus to the cells. All serotypes have the same basic fiber 
structure consisting o f an N-terminal tail which binds to the penton base, a central shaft 
consisting o f a repeated sequence and a C-terminal globular knob domain that provides a 
large surface area for interactions with the cellular receptor. The knob domain o f the 
fiber is the most poorly conserved region between serotypes as it contains the receptor 
binding domains, typically on surface exposed loops. The N-terminal tail is highly 
conserved between serotypes, with normally more than 50% o f residues identical to that 
of Ad5 (Nicklin et a l ,  2005). The crystal structure o f Ad2 in complex with the fiber 
demonstrated that 11 residues from the N-terminal tail make contact with the penton by 
inserting between 2 penton monomers. The fiber shaft contains a variable number of 
(3 repeats, ranging from 5.5 in Ad35 to 22.5 in A d l2  (Nicklin et a l ,  2005). Each repeat is 
approximately 13Â long and consists o f 15-20 amino acids that form 2 anti-parallel 13- 
strands connected by a (3-turn. These repeats join to form a very rigid and stable structure 
(van Raaij et a l ,  1999). Although it might not be directly involved in receptor binding, 
the shaft can affect interactions with cellular receptors, as the longer fibers potentially 
cause less steric hindrance between the receptor and capsid. Furthermore the ability of
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the fiber to bend also seems to affect virus transduction. Electron microscopy has shown 
hinges in the fiber shaft o f several group C viruses (Chroboczek et a l ,  1995, Ruigrok et 
a l ,  1990) that are thought to be caused by a 2-4 residue insertion in the P-turn in the 3“^*^ 
p-repeat in several serotypes. Kinks in the fiber may reduce steric hindrance by allowing 
the fiber to bend, altering its orientation relative to the capsid (Wu et a l ,  2003a),
Although there is a high degree o f homology between fibers o f different serotypes, there 
is some variation between the primary receptors they use. This is due to differences in 
primary amino acid sequence, the shaft length and rigidity and net charge o f the fiber 
knob. It is only in the last 10 years that the cellular receptors have begun to be identified, 
so for many serotypes the cellular receptors are not yet accurately defined (Table 1.3).
1.6.3 The adenovirus genome and vector development
The Ad genome is a linear double-stranded genome o f approximately 36 kb. It encodes 
early genes that are involved in regulating replication (Figure 1.7) and the late genes that 
mainly encode structural proteins. The genes are encoded on both strands in a series of 
overlapping transcription units (Figure 1.7). At either end o f the genome is an inverted 
terminal repeat (ITR) o f  100-140bp.
There have been many advances in vector production that now enable Ads to be produced 
with the majority o f the viral genome removed. The viruses are produced in cell lines 
that express the required viral genes or by co-infection o f viruses that have the necessary 
genes for replication but lack the packaging signal, so the wild type genome cannot be 
packaged. Deletion o f  unrequired virus genes reduces the immune response caused by 
the virus and enables larger expression cassettes to be incorporated into the virus.
First generation Ads commonly have E l and part or all o f the E3 gene deleted. E l A is 
essential for virus replication so this produces replication defective viruses. It enables the
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incorporation o f expression cassettes o f up to 8.2 kb (Bett et a l ,  1993). The vectors still 
stimulate an immune response against transduced cells, possibly due to a low level o f 
virus replication (Yang et a l ,  1994, Yang et a l ,  1995, Dai et a l ,  1995). This results in 
transient gene expression that lasts about 2-3 weeks (Yang et a l ,  1995). Despite this first 
generation vectors are still the most commonly used.
Second generation vectors also have E2 and E4 genes removed, which increases their 
packaging capacity. In some cell types this can increase the duration o f transgene 
expression (Hu et a l ,  1999, Engelhardt et a l ,  1994). However second generation vectors 
do not provide longer-term transgene expression in vascular cells (Wen et a l ,  2000). 
Second generation vectors are rarely used.
Helper-dependent or gutted viruses have all viral genes deleted leaving the 2 ITRs and 
the packaging signal required for DNA replication and packaging (Mitani et a l ,  1995, 
Kochanek, 1999). This produces a virus with a packaging capacity o f approximately 36 
kb. In vivo studies suggest significantly longer transgene expression can be achieved 
with these vectors, although they still cause an innate immune response (Dellorusso et a l ,  
2002, Ehrhardt and Kay, 2002, Muruve et a l ,  2004, Pastore et a l ,  2004, Chen et a l ,  
1997, Oka et a l ,  2001), probably because the vectors are still sequestered by Kupffer 
cells (macrophages found in the liver) (Schiedner et a l ,  2003).
1.6.4 Mechanism of adenovirus infection
For the development o f gene therapy vectors it is important that the natural mechanism of 
cell infection is understood as all stages o f the infection process and not ju st the initial 
cell-binding event affect vector tropism.
Ad5 is the most extensively studied adenovirus and is the most commonly used as a gene 
therapy vector. Although there is some variation in the mechanism o f Ad5 infection in 
different cell types in vitro, the general mechanism has been well characterised. For other 
serotypes a similar mechanism o f infection is probably used but this has not been 
characterised. Ad5 binds to the host cell through an interaction between the fiber knob
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and the cellular receptor, coxsackie and adenovirus receptor (CAR) (Bergelson et a l ,  
1997, Tomko et a l ,  1997). This tethers the virus to the cell surface and brings the capsid 
close to integrins; no CAR mediated signal is actually required for internalisation 
(Shayakhmetov et a l ,  2005a). The ROD m otif in the penton base binds to oty integrins to 
activate virus internalisation by causing rearrangements in the actin cytoskeleton 
(Wickham et a l ,  1993, W ickham, 1994, Huang et a l ,  1995, Li et a l ,  2001, Huang et a l ,  
1996, S alone et a l ,  2003). The need for Ad to bind both CAR and integrins at the same 
time means the fibers are required to be long (Shayakhmetov and Lieber, 2000) and 
flexible (Wu et a l ,  2003a). An interaction between the fiber shaft and heparan sulphate 
proteoglycans (HSPGs) has also been implicated in mediating infection (Dechecchi et a l ,  
2000, Dechecchi et a l ,  2001), but there is no direct evidence that binding occurs (Smith 
et a l ,  2003a, Nicol et a l ,  2004, Smith et a l ,  2003b, Bayo-Puxan et a l ,  2006)(A. Kritz, in 
press).
After receptor binding the virus is internalised into an endosome via a clathrin coated pit. 
(Varga et a l ,  1991, Wang et a l ,  1998). As the endosome becomes more acidic, virus 
disassembly occurs as the penton undergoes a conformational change. This exposes 
minor protein VI, which triggers a further pH drop and disruption o f the membrane 
leading to virus escape from the endosome (Greber et a l ,  1993, W iethoff, 1998). Ad 
protease in the capsid also becomes exposed and this enhances virus release (Medina- 
Kauwe, 2003). Lysis o f the endosome and release o f the virion into the cytoplasm 
enables it to evade degradation by lysosomal enzymes. The virus then translocates to the 
nucleus via microtubules (Suomalainen et a l ,  1999). At the nuclear membrane, complete 
virus disassembly occurs and the genome is released into the nucleus. Ad2 has been 
shown to do this by docking with the nuclear pore complex CAN/Nup214 and histone HI 
(Trotman et a l ,  2001). In the nucleus E l A is the first gene to be expressed. It 
transactivates the expression o f the other early transcription units (E lB , E2, E3 and E4) 
and induces the cell to enter S phase, which provides the optimal environment for viral 
replication (Berk, 1986). This is followed by expression o f the late genes. E lB  is 
involved in the transport o f late mRNAs into the cytoplasm where they are translated. 
The L4 protein associates with the hexon in the cytoplasm soon after translocation and
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mediates hexon trimérisation, (Cepko, 1983), Hexon trimers are transported back to the 
nucleus (Woodrich, 2003), where they associate with the penton and minor capsid 
proteins to form the protein capsid. DNA encapsidation then occurs and Ad protease 
cleaves a subset o f structural proteins into their mature form to produce fully infectious 
virions. Cell lysis and virus release then occurs, about 30 hours after the original 
infection (McConnell and Impériale, 2004).
1.6.5 AdS tropism
CAR, a member o f the immunoglobulin superfamily, is a cell membrane protein that is 
made up o f a short leader sequence, an extracellular domain containing 2 
immunoglobulin domains, a single membrane spanning domain and an intracellular 
domain (Bergelson et a l ,  1997). The first immunoglobulin domain is sufficient for Ad 
binding (Bewley et a l ,  1999, Freimuth, 1999). The exact expression profile o f CAR has 
not been determined, but CAR mRNA has been detected in heart, brain, pancreas, 
intestine, lung, liver and kidney (Tomko et a l ,  1997, Fechner et a l ,  1999, Howitt, 2003). 
CAR is localised to the basolateral surface o f polarised epithelial cells, specifically 
concentrated at the end o f the lateral plasma membrane, a site associated with tight 
junctions and adherence junctions (Cohen et a l ,  2001, Walters et a l ,  2002). Its precise 
function is not known; however it has a role in homotypic cell-to-cell fusion (Flonda,
2000). Cells that do not express CAR include many advanced tumours, skeletal muscle 
cells, SMC, haematopoietic stem cells and dendritic cells. M ost tissues o f transgenic 
animals that broadly over-express CAR, are more readily transduced by Ad (Tallone et 
a l ,  2001), and in transgenic animals tissue-specific CAR expression has been shown to 
increase transduction o f skeletal muscle (Nalbantoglu et a l ,  2001) and lymphocytes 
(Schmidt et a l ,  2000, Wan et a l ,  2000) which are normally refractory to infection.
After systemic administration o f Ad5 to rodents and non-human primates, about 95% of 
measurable transduction is found in liver hepatocytes (Huard et a l ,  1995, Sullivan el: al ,  
1997, Alemany and Curiel, 2001, Mizuguchi et a l ,  2002, Smith et a l ,  2002, Leissner et 
a l ,  2001). However, the majority o f the virus injected does not successfully transduce 
any cells as it is rapidly cleared from the blood, with a half-life o f  less than 3 minutes in
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mice (Alemany et a l ,  2000, Koizumi et a l ,  2003, Sakurai et a l ,  2003). This is probably 
due to the virus being taken up very efficiently by Kupffer cells, where it is then 
inactivated and degraded (Lieber et a l ,  1997, W olff et al., 1997, W orgall et a l ,  1997a). 
Activated Kupffer cells stimulate an innate immune response by release of 
pro inflammatory cytokines and chemokines (Liu and Muruve, 2003).
If Ad is delivered locally e.g. into a tumour, then vector dissemination to the blood and 
liver occurs (Mizuguchi et a l ,  2002, Okada et a l ,  2003, Hiltunen et a l ,  2000).
The broad tropism o f Ad and the high degree o f transgene expression in the liver 
following systemic transduction are undesirable for many gene therapy applications, so 
studies have been carried out to produce Ad based vectors with altered tropism.
1.6.6 Ad-mediated cardiovascular transduction
Systemic delivery o f Ad5 results in a very low level o f transduction o f vascular cells. 
However unmodified Ad can produce a high level o f transgene expression in endothelial 
cells and some expression in SMC in vessels if the virus is applied locally and a high 
dose is used (Lemarchand et a l ,  1993, Lee et a l ,  1993, M errick et a l ,  1996). For 
example, in intact human vessels ex vivo transduction with an Ad vector can result in 
transduction o f virtually all EC but transduction o f intimai SMCs is low (1.3-3.8%) as the 
virus cannot cross the endothelium (Rekhter et a l ,  1998b). If the endothelium is 
damaged then Ad can penetrate the elastic lamina and infect SMC (George et a l ,  1998, 
Gruchala et a l ,  2004). Ad infection causes an inflammatory response in the vessel wall 
that limits transgene expression to only 1-2 weeks (Newman et a l ,  1995, Channon et a l ,  
1998).
It has been reported that Ad5 more efficiently transduces atherosclerotic vessels 
compared to healthy vessels (Ooboshi et a l ,  1997, Rekhter et a l ,  1998b), possibly 
because o f an increase in VCAM-1 expression. VCAM-1 and CAR are both members o f 
the immunoglobulin superfamily and have 43% homology in the region o f CAR known 
to bind A d5 (Chu et a l ,  2001). This led to the proposal that VCAM-1 might act as a
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receptor for Ad5 and it has been shown that Ad5 transduction was 5-10 fold higher in 
VCAM-1 expressing cells (Chu et a l ,  2001).
1.6.7 Immune response to Ad vectors
One o f the main disadvantages o f Ad vectors is that they provoke a strong immune 
response. Within minutes o f virus administration the innate immune response is 
triggered and this can result in inflammation, loss o f transduced cells and systemic 
toxicity (McConnell and Impériale, 2004). It causes 80-90% of first generation Ads to be 
removed from the liver within 24 hours o f vector administration (W orgall et a l ,  1997a). 
It is caused by the uptake o f Ad by the reticuloendothelial system (RES), mainly by 
Kupffer cells. Although they lack CAR, uptake o f virus is highly efficient and results in 
vector clearance from the blood and activates the inflammatory and adaptive immune 
response.
The adaptive cellular immune response is initiated by Kupffer cells and other antigen 
presenting cells, leading to presentation o f virus and transgene proteins in the major 
histocompatability complex (MHC) class I. This activates cytotoxic T lymphocytes 
(CTLs) against both the virus and transgene. To aetivate T-cells viral gene expression is 
also required (Muruve et a l ,  2004). Although first generation E l deleted Ads cannot 
replicate, some viral gene expression remains and this is sufficient to activate the cellular 
immune response mediated by CTLs. (Yang et a l ,  1994). This leads to the death of 
transduced cells and therefore the loss o f transgene expression. Due to the removal o f the 
majority o f the virus genome, HdAds do not activate the cellular immune response so 
produce longer-term transgene expression than first generation Ads (Schiedner et a l ,  
1998).
The humoral response to Ad is activated by binding o f the virus to immunoglobulins on 
the surface o f B-cells. This results in the activation o f B-cells and the production o f anti- 
Ad antibodies, which prevent cellular entry and promotes uptake o f the virus by 
macrophages, thereby limiting transgene expression. If the transgene is a foreign protein
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then this can also provoke a humoral response that can reduce the action of the 
therapeutic protein.
Immunity that develops after receiving a dose o f gene therapy can also prevent successful 
readministration o f the same vector, but this depends on the dose and route of 
administration used. For example, intra-muscular administration o f a low dose o f Ad5 
produced detectable transgene expression and did not affect a repeated intra-muscular 
injection, but intra-venous readministration failed to produce transgene expression (Chen 
et a l ,  2000a). As the humoral and innate immune responses are mediated directly by the 
virus capsid they do not differ for first generation and HdAds (Alba et a l ,  2005). The 
affect o f anti-Ad antibodies ean be reduced by using alternative serotypes (Kass-Eisler et 
al ,  1996, M ack et a l ,  1997), coating the virus with polyethylene glycol (PEG) 
(O'Riordan et a l ,  1999, Croyle et a l ,  2001, Croyle et a l ,  2005), or co-admi ni storing 
immunosuppressive drugs (Smith et a l ,  1996, Fang et a l ,  1995).
A further issue relating to the immune response to Ad is that about 80% o f the population 
have pre-existing anti-Ad 5 antibodies due to natural infection (Chirmule et a l ,  1999, 
Vigne et a l ,  2003). These can inhibit the effectiveness o f gene therapy treatments 
(Varnavski et a l ,  2005, Chirmule et a l ,  1999, Chen et a l ,  2000b, Varnavski et a l ,  2002) 
and in mouse models pre-existing immunity has been shown to increase mortality rates 
(Varnavski et a l ,  2005, Vlachaki et a l ,  2002).
The host immune response to Ad vectors has also been implicated in causing serious 
adverse effects. In a pilot clinical trial for the monogenic disorder ornithine 
transcarbamylase (OTC) deficiency, a patient died because o f the immune response to the 
treatment. Patients were given replication-defective Ad with the OTC trans gene via the 
hepatic artery at increasing doses (Raper et a l ,  2002). In one o f two patients given the 
highest dose o f the vector (6 x lO” particles/kg), it caused a strong systemic 
inflammatory response that led to multiple organ failure and death 98 hours after 
injection o f the vector (Raper et a l ,  2003). The other patient given the same dose and 
patients given lower doses suffered from mild fevers, suggesting there is significant
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patient variability in response to the same vector (Raper et a l ,  2002). This is a critical 
issue in the translation o f Ad based vectors to the clinic.
If  targeted Ad vectors with a high level o f cellular specificity can be produced, then this 
should in theory reduce virus dissemination and the dose required, and thereby minimise 
and localise the immune response against the treatment (Schoggins et a l ,  2005).
1.7 Adeno-associated virus
AAV is classified as a Dependovirus  in the Parvoviridae family as it usually requires co- 
infection with a helper virus (such as Ad or HSV) for it to undergo productive 
replication. AAV has many attributes that make it a promising vector for gene therapy. 
One o f the main features o f AAV based vectors is that they have been shown to produce 
stable transgene expression in a number o f animal models (Snyder et a l ,  1999, Herzog et 
a l ,  1999, Flotte et a l ,  1993, Xiao et a l ,  1996, Woo et a l ,  2005). AAV also have a 
relatively broad tropism, can infect both dividing and non-dividing cells (Monahan and 
Samulski, 2000b), are non-pathogenic in humans and are significantly less immunogenic 
than adenovirus vectors (Chirmule et a l ,  1999, Chirmule et a l ,  2000, Xiao et a l ,  2000, 
Beck et a l ,  1999). AAV2 is the most commonly used serotype for gene therapy vectors.
1.7.1 Structure of AAV
AAV is a small non-enveloped virus with an icosahedral capsid. It has a linear single­
stranded DNA genome o f  approximately 4.7 kb, which encodes 2 genes rep (replication) 
and cap (capsid) flanked by ITRs. The ITRs are required for viral DNA replication. The 
rep gene encodes the non-structural proteins Rep78, Rep68, Rep52 and Rep40, which are 
involved in regulating gene expression. The cap gene encodes the 3 structural proteins 
that form the AAV capsid. It is transcribed to produce mRNA that is alternatively spliced 
to produce two transcripts. The largest transcript encodes virion protein 1 (V Pl) and the 
shorter transcript encodes VP2 and VP3 by translation from 2 start codons. All 3 
transcripts use the same stop codon, therefore VP2 (72 kDa) and VP3 (60 kDa) are 
truncated forms o f V Pl (90 kDa), identical in the C-terminus. The capsid is formed from 
60 subunits with a molar ratio o f V P l, VP2 and VP3 o f approximately 1:1:20
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(Rabinowitz and Samulski, 2000). It has 12 five-fold axes o f symmetry and at each one is 
a narrow pore, which is important for both viral infectivity and genome packaging 
(Bleker et a l ,  2005). The most prominent feature o f the AAV2 capsid surface is the 
three-fold-proximal peaks, which are formed by the interaction o f two subunits (Xie et 
a l ,  2002) (Figure 1.8A). The unique N-terminal region o f VPl contains a phospholipase 
A 2 domain (PLA2) (Zadori et a l ,  2001) that is thought to be required for virus 
translocation to the nucleus and initiation o f viral gene expression (Girod et a l ,  2002). 
The VP3 region found in all 3 capsid proteins contains the areas o f the capsid that 
mediate cell receptor binding. The function o f VP2 has not been elucidated and it has in 
fact been shown that viruses lacking VP2 can be produced (W arrington et a l ,  2004, 
Grieger and Samulski, 2005). Each o f the 60 capsid subunits has a |3-barrel core structure 
whieh is commonly found in parvoviruses (Xie et al., 2002). Long loops between the 13- 
strands o f the barrel are poorly conserved between parvoviruses and it is these loops 
which are displayed on the capsid surface and mediate interactions with cell surface 
receptors and antibodies (Xie et a l ,  2002).
1.7.2 AAV serotypes
Over the last few years the number o f  AAV serotypes and genetic variants isolated has 
increased rapidly. The main reason for this is the development o f a polymerase chain 
reaction (PCR) screening technique that has been used to detect AAV variants in non­
human primates (Gao et a l ,  2003). PCR screening o f the hypervariable regions o f the 
AAV capsid from primate tissues has demonstrated that AAV has undergone rapid 
molecular evolution in non-human primates (Gao et a l ,  2003). Currently there are 
eleven different AAV serotypes (A A V l-11) and over 100 different variant capsid 
sequences have been identified (Gao et a l ,  2004). By definition a serotype is a newly 
isolated virus that does not cross-react with neutralising sera for other serotypes. The 
serology o f the variants has not yet been fully investigated therefore they are not yet 
classified as serotypes. Serotypes 1-6 were isolated as live viruses whereas AAV7-11 
were identified by PCR screening o f hypervariable region 3 o f the AAV capsid in primate 
tissues (Gao et a l ,  2003). As many o f the serotypes have only recently been identified 
work is ongoing to fully characterise these viruses and determine their primary receptors
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Figure 1.8 Structure of AAV2 A. Structure o f  the AAV2 capsid with a threefold 
peak region marked (Xie et al., 2002). B. Side view o f  a VP timer with the positions o f  
amino acids involved in HSPG binding indicated (Kern et al., 2003). C. Structure o f  
A AV2 V P l subunit (Image courtesy o f  Luca Perabo).
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(Table 1.4). The novelty o f some serotypes is under question as AAV6, 10 and 11 might 
not be true serotypes. AAV6 is almost serologically identical to A A V l and it is thought 
to have formed due to a recombination event between AA Vl and 2 as the left ITR and p5 
promoter region are almost identical to AAV2 and the rest o f  the genome is almost 
identical to A A V l (Rutledge et a l ,  1998, Xiao et a l ,  1999). AAV 10 and 11 are not yet 
fully characterised but do not cross react with anti-A A V2 antibodies (Zhijian et a l ,  2006, 
Mori et a l ,  2004).
1.7.3 AAV2 receptor binding and infection pathway
The most extensively studied serotype and the most commonly used as a gene therapy 
vector is AAV2. The primary receptor for AAV2 is HSPG (Summerford and Samulski,
1998), which is expressed on many different cell types, so the virus has a very broad 
tropism. It uses ayps integrin (Summerford et a l ,  1999), fibroblast growth factor 
receptor type 1 (FG FR l) (Qing et a l ,  1999), hepatocyte growth factor receptor c-Met 
(Kashiwakura et a l ,  2005) or laminin receptor (Akache et a l ,  2006) as co-receptors to 
enable internalisation. The exact mechanism by which AAV2 enters the cell and traffics 
to the nucleus is still not fully understood.
Before the crystal structure o f AAV2 was solved insertional mutagenesis studies 
identified residues that mediate binding o f AAV2 to HSPG (Section 1.13,2 for more 
detail). Alignment o f AAV2 capsid sequence with that o f A A V l and AAV3 that both 
bind HSPG and AAV4 and AAV5 that do not bind HSPG, identified 15 different residues 
that could be involved in HSPG binding (Wu et a l ,  2000). The solving o f the crystal 
structure in 2002 (Xie et a l ,  2002) supported the results o f mutational studies as it 
showed that the basic amino acids R484, R487, R585, R588 and H509 clustered around 
the 3-fold proximal peak and are critical for forming the HSPG binding site (Figure 1.8B) 
(Xie et a l ,  2002). The primary amino acid sequence around these residues 
R484QQRVSK490 and R 585GNR5S9 form motifs typical o f sequences known to bind 
heparin (Xie et a l ,  2002). Importantly, the 3D conformation o f the amino acids in this 
region o f the capsid resembles a heparin binding site, which is commonly a flat pocket 
with a positive charge (Hileman et a l ,  1998).
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Serotype Prim aiy Receptor Species origin
AA V l Sialic acid (Chen et a l ,  2005) Human or non-human primates
AAV2 HSPG (Summerford and Samulski, 
1998)
Human
AAV3 HSPG (Rabinowitz et a l ,  2001, 
Handa et a l , 2000)
Human
AAV 4 0-1 inked sialic acid (Kaludov et a l ,  
2001)
Non-human primates
AAV5 N-linked sialic acid (Kaludov et a l ,  
2001, Walters et al., 2001)
PDGF receptor (Di Pasquale et a l ,  
2003).
Human
AAV6 Sialic acid (Zhijian et a l ,  2006) Human
AAV7 Unknown Rhesus monkey
AAV8 Laminin receptor (Akache et a l ,  
2006)
Rhesus monkey
AAV9 Laminin receptor (Akache et a l ,  
2006)
Rhesus monkey
AAVIO Unknown Cynomolgus monkey (Mori et 
a l ,  2004)
AA V l I Unknown Cynomolgus monkey (Mori et 
a l ,  2004)
Table 1.4 AAV serotypes.
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Further mutational studies found that substitutions R585A and R588A caused the greatest 
reduction in HSPG binding, whereas making conservative substitutions to lysine caused 
no reduction in heparin binding or infectivity o f the virus (Kern et a l ,  2003, Opie et a l ,
2003). Substitution o f residues R484, R487 and R532 also caused reduction in heparin 
binding and infectivity, but to the extent seen with R585 and R588 substitutions (Opie et 
aï., 2003, Kern et a l ,  2003). These experiments identified both the residues involved in 
HSPG binding and the importance o f the positive charge o f the residues.
The regions o f the AAV2 capsid that bind to the co-receptors are yet to be identified. A 
recent mutational study has identified a region known as the ‘dead zone’ that lies adjacent 
to the heparin binding site (Lochrie et a l ,  2006). This is not involved in heparin binding, 
but is required for transduction (Lochrie et a l ,  2006). A model has been produced 
showing this ‘dead zone’ could potentially be the binding site for the co-receptor FGFRl 
(Lochrie et a l ,  2006). Although the areas o f the capsid responsible for co-receptor 
binding are yet to be identified, it has still been possible to produce viruses with 
significantly altered trop ism s.
Following receptor binding, the principal mechanism of entry into cells is via receptor- 
mediated endocytosis in clathrin-coated pits (Duan et a l ,  1999, Bartlett et a l ,  2000). 
Single virus tracing (SVT) has shown that a single AAV particle is transported in an 
endosome towards the nucleus by a mechanism likely to involve active transport via 
microtubules (Seisenberger et a l ,  2001). AAV is released from the late endosome when 
it is at a low pH (Douar et a l ,  2001, Bartlett et a l ,  2000, Hansen et a l ,  2001a). After 
release from the endosome, AAV2 trafficking is poorly understood and probably varies 
in different cell types and possibly even within the same cell. For example, in polarised 
human epithelial cells virus entry from the basolateral side results in efficient 
transduction, but from the apical side the ubiquitin-proteasome pathway inhibits it (Duan 
el a l ,  2000b).
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How the virus enters the nucleus is also yet to be determined, but it is thought to be 
accelerated by the presence o f helper virus (Xiao et a l ,  2002). It was originally thought 
that AAV2 enters the nucleus via nuclear pore complexes, but agents that block this do 
not effect transduction (Hansen et a l ,  2001b). It is also not known whether the virus 
uncoats before or after entry into the nucleus. However, it is thought that a highly 
conserved basic region (amino acids 166-172) found within the VP2 region o f all 11 
AAV serotypes is required for the virus genome to enter the nucleus (Grieger et al ,  
2006). Confocal microscopy has shown that mutation o f this region causes the virus to 
accumulate at the surface o f the nucleus but no viral genomes were detected inside the 
nucleus (Grieger et a l ,  2006).
Once inside the nucleus the presence or absence o f helper virus determines whether 
AAV2 enters either the lytic pathway or becomes latent. In the absence o f  a helper virus, 
AAV becomes latent and integrates into a specific region o f human chromosome 19 
known as A A V Sl (Kotin et a l ,  1990, Kotin et a l ,  1991). This region o f the genome is 
the only area that contains the necessary features for AAV2 integration, a Rep binding 
site, a terminal resolution site and a spacer sequence (Meneses et a l ,  2000). The 
mechanism by which this highly specific integration occurs is unknown, although it does 
require virus proteins Rep78 and Rep68 and the ITRs (Weitzman et a l ,  1994, Huttner et 
al., 2003). In the presence o f helper virus or an agent such as UV irradiation or genotoxic 
compounds that cause DNA damage (Yakinoglu et a l ,  1988), the single stranded genome 
is converted to double stranded DNA. This can occur by second strand synthesis or the 
annealing o f a plus and minus strand from two separate virions that have infected the 
same cell (Figure 1.9A and 1.9B) (Ferrari et a l ,  1996, Fisher et a l ,  1996, Nakai et a l ,  
2000, Hauck et a l ,  2004). DNA synthesis requires Rep78 and Rep68.
The first stage o f virus assembly is the formation o f empty caps ids in the nucleus. A 
basic region in VP3 (amino acids 307-312) has been shown to be essential for capsid 
assembly to occur (Grieger et at., 2006). The 4 Rep proteins then form a complex on the 
capsid surface. Sequence specific binding o f the AAV genome to the large Rep proteins 
mediates translocation o f the genome into the capsid (King et a l ,  2001).
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A. DNA  
synthesis
B. Co- 
infection
C. Intramolecular 
hybridisation
2.3kb4.6kb
Intermolecular
hybridisation
4.6kb
Protein Expression
Figure 1.9 M echanism s o f transgene expression from AAV vectors. A. single stranded 
DNA genome is converted to double stranded DNA by DNA synthesis. B. Co-infection o f  2 
viruses enables positive and negative strand annealing to produce double stranded DNA. C. 
Intramolecular hybridisation o f  a se lf complementary genome produces double stranded 
DNA.
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1.7.4 AAV2 tropism
AAV2 has a relatively broad tropism and can transduce a wide range o f  tissues in vivo 
including muscle, lung, the retina and the central nervous system (Acland et a l ,  2001). 
However, following systemic administration the vast majority o f virus is found in the 
liver (Nathwani et a l ,  2001, Miao et a l ,  2000).
1.7.5 AAV and vascular transduction
AAV2 poorly transduces vascular endothelial cells in vitro and in vivo (Gnatenko et a l ,  
1997, M aeda et a l ,  1997, Richter et a l ,  2000, Nicklin et a l ,  2001a, Dishart et a l ,  2003, 
Pajusola et a l ,  2002, Vassalli et a l ,  2003). This is despite ECs expressing HSPG and the 
virus CO-receptors p 5 integrin and FGF receptor-1 (Pajusola et a l ,  2002). This may be 
due to sequestration o f the virus in the extracellular matrix by binding to HSPG (Pajusola 
et a l ,  2002) and/or proteasomal degradation o f the virus during the trafficking process 
(Duan et a l ,  2000b, Nicklin et a l ,  2001a, Denby et a l ,  2005). The effect o f the 
proteasome on AAV2 transduction seems to vary in different cell types as transduction 
enhancement varies when proteasome inhibitors are used (Yan et a l ,  2002, Douar et a l ,
2001). The mechanism by which the proteasome can block transduction is not fully 
understood as it may not be that the proteasome actually degrades the virion (Duan et a l ,  
2000b, Yan et a l ,  2002), but somehow reduces nuclear uptake o f the virus (Duan et a l ,  
2000b, Yan et a /,2 0 0 4 ) .
When an intact blood vessel is exposed to AAV2 the majority o f transduction is observed 
in smooth muscle cells and not the overlying endothelial cells (Richter et a l ,  2000, 
Pajusola et a l ,  2002), in complete contrast to Ad5 (Lemarchand et al,, 1993). Higher 
levels o f transduction o f SMC than EC have also been seen in vitro (Mohuczy et a l ,
1999). This could be due to expression o f the virus receptor or differences in efficiencies 
in the later steps o f the transduction pathway in each cell type.
Comparing AAV2 and A d5 transduction o f mouse carotid arteries showed that both 
produced very low levels o f transduction and transduction levels with AAV were 8-fold 
lower than Ad. However transgene expression from the AAV vector lasted up to 8 weeks
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whereas with Ad a maximum o f 2 weeks expression was seen (Vassalli et a l ,  2003). 
Another study compared the transduction o f rabbit arteries following intraluminal 
injection o f AAV2 or Ad5 vectors (Gruchala et a l ,  2004). AAV2 mainly transduced 
SMC and produced transgene expression for at least 100 days where as Ad transduced 
EC and transgene expression was undetectable after just 14 days (Gruchala et a l ,  2004). 
Ad also caused a significant inflammatory response whereas that caused by AAV2 was 
not much greater than that seen with control infections (Gruchala et a l ,  2004). These 
studies highlight major differences between the 2 vector types and suggest that they may 
be utilised for different conditions. For example AAV may be more suitable for treating 
chronic conditions such as atherosclerosis where sustained transgene expression will 
probably be required, whereas Ad may be more appropriate for inhibiting SMC 
proliferation after acute vascular injury where high levels o f short term gene expression 
may be adequate (George et a l ,  2000).
1.7.6 Advances in the development of AAV based vectors
One o f the major limitations o f using AAV as a gene therapy vector is the small 
packaging capacity o f the virus, which has an optimum range o f  4.1-4.9 kb (Dong et al., 
1996). Attempts to package larger expression cassettes have shown that up to 5.6 kb can 
be packaged, but the resulting viruses have decreased transduction efficiency (Grieger 
and Samulski, 2005, Hermonat et a l ,  1997). Several methods are being developed to 
overcome this limitation.
A split-gene strategy where 2 vectors are used each expressing half o f  the gene with a 
splice donor and splice acceptor site incorporated, makes use o f the fact that AAV 
genomes can naturally recombine. The 2 vectors are required to infect the same cell and 
form head to tail heterodimers from which the ITRs are then spliced out o f the mRNA 
transcript to join the two halves o f the transcript together (Duan et a l ,  2003). Another 
method relies on homologous recombination to join the 2 halves o f the transgene (Duan 
et a l ,  2000a). However these processes produce much lower transgene expression than 
single vector constructs because o f the added complexity involved and the requirement
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for the 2 different vectors to infect the same cell (Reich et a l ,  2003, Sun et a l ,  2000, 
Duan et al,20Çt\).
Another limitation o f AAV vectors is the slow rate o f conversion o f the single stranded 
genome to double stranded DNA, which is required for transgene expression (Ferrari el 
a l ,  1996, Fisher et a l ,  1996). The development o f self-complementary AAV (scAAV) 
vectors that contain a double stranded genome to overcome the rate-limiting step of 
second strand synthesis (McCarty et a l ,  2001) has been shown to produce a higher level 
o f gene expression more rapidly than vectors with a single stranded genome (McCarty et 
al ,  2003, Wang et a l ,  2003, Ren et a l ,  2005) (Figure 1.9). However this reduces the 
size o f the expression cassette that can be used to only 2.3 kb.
1.7.7 Immune responses to AAV
There is virtually no innate immune response to AAV compared to that produced by Ad 
(Zaiss et a l ,  2002). AAVs also induce a weaker cell-mediated immune response than 
Ads, probably because they less efficiently infect antigen presenting cells (Bessis et a l ,  
2004). However recent evidence suggests the activation o f T-cells may be more o f a 
problem than originally thought. Activation o f T-cells has been implicated in liver 
toxicity seen in a clinical trial for haemophilia B (Manno et a l ,  2006). It has also 
recently been shown that in both mice and non-human primates, intramuscular 
administration o f AAV2 activated T-cells against the AAV2 capsid, where as AAV7 and 
AAV8 produced little T-cell activation (Vandenberghe et a l ,  2006). Further work 
showed the T-cell activation was due to the heparin binding m otif RGNR (residues 585- 
588), so it was proposed that HSPG-mediated uptake o f AAV2 into dendritic cells (DC) 
leads to the activation o f  T-cells (Vandenberghe et a l ,  2006). This was supported by 
evidence that showed vectors with a heparin binding m otif bind DCs but those without 
the m otif do not (Vandenberghe et a l ,  2006). This suggests that vectors with peptides 
inserted after residue 587 can have both altered tropism and activate a reduced immune 
response compared to wild type AAV2, but this is peptide dependent.
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The humoral response to AAV is also a problem. Between 50-96% o f people have anti- 
AAV2 antibodies (Blacklow et a l ,  1968), with 18-67.5% of these being neutralising 
(Chirmule et a l ,  1999, Erl es et a l ,  1999, Moskalenko et a l ,  2000). The effect o f these on 
transgene expression from AAV vectors is under investigation. Repeated re­
administration o f AAV2 to rabbit lungs generated increasing levels o f anti-AAV2 
neutralising antibodies, which by the third dose reduced the level o f transgene expression 
(Beck et a l ,  1999). When a vector pseudotyped with AAV3 was used for the third dose 
transgene expression remained unchanged (Beck et a l ,  1999). The same pattern o f 
results was seen in a similar experiment in mice (Halbert et a l ,  2000). It has been shown 
that if the animal is immunosuppressed at the time of the first delivery, then the same 
vector can be successfully readministered (Halbert et a l ,  1998, M anning et a l ,  1998).
Data from cystic fibrosis clinical trials has also shown that pre-existing anti-A A V2 
antibody levels did not correlate with the amount o f gene transfer produced (Aitken et a l ,  
2001, W agner et a l ,  2002). However, after receiving the AAV2-CFTR vector patients 
had higher levels o f these antibodies and they prevented efficient transduction from 
subsequent administration o f AAV2 (Peden et a l ,  2004).
Capsid modifications that reduce the effect o f neutralising antibodies have been 
identified. Peptide insertion into exposed loop regions o f the capsid identified 
immunogenic domains around amino acids 534 and 573 and found that transduction o f a 
virus with a peptide inserted at residue 587 was unaffected by the presence o f human sera 
containing anti-AAV2 neutralising antibodies (Huttner, 2003). A recent study also 
showed that 2 mutants (R471A and N587A) were resistant to all human sera tested and 
identified other mutants that were resistant to some o f the sera. From this 3 antigenic 
epitopes have been proposed, one at the heparin binding site including residue 587, 
another involving E548 and T550 (and possibly R471) at the side o f the spike and a third 
involving residues N705 and V708 (Lochrie et a l ,  2006). Two other antigenic regions 
involving amino acids 261 and 447 have previously been identified (Moskalenko et a l ,  
2000). As human sera contains a diverse range o f antibodies against many different 
regions o f the AAV2 capsid (Lochrie et a l ,  2006), it is unlikely that just disrupting one
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epitope will be sufficient to produce an antibody resistant virus suitable for use in the 
general population.
1.7.8 Safety concerns associated with AAV vectors
The potential for AAV vectors to mediate germ-line transmission has become a concern 
since the discovery o f vector DNA in the semen of patients involved in a haemophilia 
clinical trial, (High et a l ,  2004). However this was only detected transiently (High et al ,  
2004) and in a previous study vector DNA was not detected in patient semen (Kay et a l ,
2000). Animal studies in rats, rabbits and mice have detected AAV in the gonads 
following either myocardial, intramuscular or intravenous delivery o f  the vector (Pachori 
et a l ,  2004b, Jakob et a l ,  2005, Arruda et a l ,  2001). However, no vector DNA was 
detected in sperm o f their offspring (Arruda et a l ,  2001, Jakob et a l ,  2005) suggesting 
germ-line transmission was not occurring. Another study in mice has also shown that 
direct exposure o f sperm to AAV does not result in germ-line transmission (Couto et a l ,
2004). Therefore these studies suggest that the risk o f germ-line transmission is low but 
will still require careful monitoring in clinical trials.
There are also concerns about the ability o f AAV to integrate into the host cell genome. 
Although wild type AAV only integrates at a specific locus in the human genome, in 
some cases vectors have been found to integrate randomly due to the removal o f Rep78 
and Rep68 genes. However, more commonly the vector genome remains episomal 
(Nakai et a l ,  2001, Schnepp et a l ,  2003, Nakai et a l ,  2003). Although this integration is 
a safety concern, studies have shown that it occurs only at a relatively low rate in the liver 
(Nakai et a l ,  2001) and in skeletal muscle no integration could be detected (Schnepp et 
a l ,  2003). Unlike retroviruses, integration o f  AAV vectors requires non-homologous end 
joining at existing chromosome break points (Miller et a l ,  2004, M iller et a l ,  2002) so it 
is less likely to occur. Recently a large-scale study looked for tumours in the livers of 
695 mice that received AAV2 vectors and found only one tumor (Bell et a l ,  2005) 
suggesting that AAV does not cause tumours, but vector integration will still require 
careful monitoring in clinical trials.
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Currently over 20 phase I and II clinical trials have been performed using AAV vectors 
for treating diseases such as Parkinson’s disease, Canavan’s disease, a l  anti-trypsin 
deficiency, cystic fibrosis and hemophilia B (Carter, 2005). They have shown AAV to 
have a good safety profile as in more than 200 patients no serious side effects have yet 
been seen (Carter, 2005).
1.8 Targeting of viral vectors
One o f  the major challenges o f gene therapy is the development o f vectors that deliver 
the transgene to the target tissue type with a high degree of specificity. This is required to 
improve the efficiency o f the vector when transduction o f less permissive cell types is 
required, to prevent unwanted transgene in non-target tissues, to optimise the minimal 
dose required and therefore maximise the safety profile o f the vector. Targeting can be 
achieved at the level o f transduction, transcription or ideally both.
1.8.1 Transcriptional targeting
The most commonly used promoters in gene therapy vectors are based on the constitutive 
viral promoters from cytomegalovirus (CMV) and Rous sarcoma virus (RSV). They are 
active in a wide range o f cell types so they are not ideal for producing tissue-specific 
transgene activity. Also, there are problems with transcriptional silencing o f virus- 
based promoters, which limits the duration o f transgene expression. For vascular-targeted 
gene therapy, several studies have shown that CMV and RSV promoters are relatively 
inefficient in vascular cells (Richter et aL, 2000, Gruchala et a l ,  2004, Nitta et a l ,  2005, 
C le sham et a l ,  1996). It is also possible that transcriptional silencing o f the CMV 
promoter may occur relatively quickly in the vasculature. A study comparing AAV 
transduction o f the heart and the coronary artery in mice using a CM V promoter showed 
transgene expression was still relatively high in the heart 1 year after vector 
administration, but it was barely detectable in the artery after just 8 weeks, with gene 
expression having peaked after just 2 weeks compared to 8-26 weeks in cardiomyocytes 
(Vassalli et a l ,  2003). Therefore other promoters may be more suitable for vascular- 
targeted gene therapy.
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Several different promoters that are thought to possess endothelial specificity have been 
tested, including promoter sequences from fms-like tyrosine kinase-1 (Flt-1) (a receptor 
for VEGF), vascular endothelial growth factor receptor 1 (VEGFR-1), intracellular 
adhesion molecule (ICAM-2), von Willebrand factor (vWF), Tie 2, E-selectin and 
thrombomodulin (Melo et a l ,  2004, Minami et a l ,  2002, Aird et a l ,  1995, Weller- 
Guettler et a l ,  1996, Cowan et a l ,  1996, Cowan et a l ,  1998). Nicklin et a l  (Nicklin et 
a l ,  2001b) compared the activity o f Flt-1, lCAM -2 and vWF promoters in Ad vectors in 
ECs. Flt-1 and 1C AM-2 produced expression levels equivalent to a CMV promoter but 
analysis in other cell types showed Flt-1 has a higher degree o f EC specificity than the 
lCAM-2 promoter (Nicklin et al., 2001b). After systemic administration in mice the Flt- 
1 promoter produced a substantially lower level o f transgene expression in the liver 
compared to the CMV promoter (Nicklin et a l ,  2001b). A larger fragment o f the Flt-1 
promoter has also been shown to be upregulated by hypoxia, suggesting that under 
disease conditions its activity may be enhanced (Gerber et a l ,  1997)
Gory et al. (Gory et a l ,  1999) investigated using a 2.5 kb region o f the promoter from 
VE-Cadherin and found it produced EC selective gene expression in vivo. However in 
some EC beds only a low level o f expression is achieved. The efficiency o f this 
promoter has been significantly improved by incorporating 4 kb o f the 5’ end o f the first 
intron into the promoter system (ITisatsune et a l ,  2005).
As many eukaryotic promoters provide weaker transgene expression than viral 
promoters, another approach has been to use endothelial specific enhancer elements in 
combination with the murine leukemia virus promoter sequence. Enhancers from the 
promoters o f preendothelin-1, E-selectin, lCAM-2, Flt-1 and vW F have produced 
enhanced specificity for EC in this system (Jaggar et a l ,  1997, M avria et a l ,  2000, 
Richardson et a l ,  2004).
There have also been some studies focusing on the development o f vascular SMC 
specific promoters. The SM -22a promoter has been shown to be active in arterial but 
not venous SMC in mice The human vascular smooth muscle cell a-actin  promoter is
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active in vascular smooth muscle, cardiac and skeletal muscle when incorporated into a 
plasmid (Keogh et a l ,  1999) or an Ad vector (Wills et a l ,  2001). Another study 
combined the major immediate early murine cytomegalovirus enhancer/promoter 
(MIEmCMV), the W oodchuck hepatitis virus post-transcriptional regulatory element 
(WERE) and fragments o f  the rabbit smooth muscle myosin heavy chain (SMMHC) 
promoter in an adenovirus vector (Appleby et a l ,  2003). Compared to M IEmCMV alone 
the promoter increased transgene expression o f SMC in vitro 90-fold and porcine 
coronary arteries in vivo 40-fold (Appleby et a l ,  2003).
To produce disease-effective transcriptional control, vectors are being developed to 
produce gene expression regulated by conditions such as hypoxia, inflammation or 
increased shear-stress by combining a tissue specific promoter with regulated enhancer 
elements (Modlich et a l ,  2000, Houston et a l ,  1999). A retroviral vector with an 
expression cassette containing hypoxia response elements and endothelial cell specific 
enhancer elements from the kinase domain region (Flk-1) promoter increased transgene 
expression in endothelial cells in response to hypoxic conditions (Modlich et a l ,  2000). 
A shear stress response element increased transgene expression in vitro and in vivo in 
response to shear-stress (Houston et a l ,  1999). Studies focusing on treating ischemia 
have developed vectors which contain hypoxic response elements so transgene 
expression is more specifically localised to ischemic tissue (Su et a l ,  2004, Pachori et a l ,  
2004a). These promoter systems may be utilised to target gene expression to only 
diseased areas o f the vasculature to reduce potential side effects o f unwanted gene 
expression in healthy tissue.
1,8.2 Transdiictional targeting
Three basic methods have been developed to target the transduction o f viral vectors 
(Figure 1.10).
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1.8.2.1 Non-genetic targeting
Non-genetic modification o f viruses provides the simplest way of altering vector tropism. 
It involves coating the virus in a bispecific molecule that binds to both the virus capsid 
and the novel receptor. M ethods have been developed to utilise bispecific antibodies, 
antibody fragments and bispecific fusion proteins for re-targeting. One o f the main 
advantages o f using bispecific conjugates is that in most cases the natural tropism of the 
virus is eliminated due to steric hindrance.
Another modification strategy involves coating the virus with inert polymers such as 
polyethylene glycol (PEG) or poly[N-(2-hydroxy-propyl)methylacrylamide] (pEIPMA). 
Ad vectors modified in this way have been found to have reduced toxicity, cause a 
reduced cell-mediated and humoral immune response (O'Riordan et a l ,  1999, Croyle et 
a l ,  2001, Croyle et a l ,  2005) and have a longer plasma circulation time than unmodified 
Ad (Fisher et a l ,  2001, Green ei a l ,  2004). However it also significantly reduces the 
efficiency o f transduction due to steric hindrance, for example, PEGylation reduced Ad5 
transduction o f A549 cells (human lung carcinoma cells) 200-fold (Eto et a l ,  2005). 
Conjugating a targeting ligand to the PEG can increase transduction and enables targeting 
o f the vector (Romanczuk et a l ,  1999, Fisher et al., 2001). For example, a PEG and 
FGF2 coated Ad has been shown to infect cells via FGF2 receptor in a CAR independent 
manner, to increase transduction o f tumour cells in a model o f ovarian cancer and reduce 
transduction o f non-target cells in other organs (Lanciotti et a l ,  2003). Also, an E~ 
selectin specific antibody combined with PEG has been used to target activated 
endothelial cells both in vitro and in vivo (Ogawara et a l ,  2004).
One o f the problems with non-genetic targeting is that it can be difficult to produce 
clinical grade uniform preparations o f the complex without batch variation. Genetic 
retargeting may therefore provide a more reliable and attractive vector from a regulatory 
standpoint.
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1.8.2.2 Pseudotyping
As different serotypes have slightly different caspids and therefore different cellular 
trop isms it is possible to exploit these differences to develop gene therapy vectors 
targeted to different cell types. Pseudotyping involves replacing part or all o f the capsid 
o f one serotype with that o f another serotype to produce a vector with a novel tropism. 
For enveloped viruses pseudotyping is achieved by incorporating alternative envelope 
glycoproteins into the envelope.
1.8.2.3 Genetic targeting o f viral vectors
Genetic modification o f the virus capsid can be used to both detarget the virus from its 
native tropism and retarget it to a different cell type. Detargeting can be achieved by 
mutating residues in the capsid that are known to be involved in the virus binding to 
native receptors. Retargeting can be achieved by inserting peptides that bind to 
alternative cellular receptors into the capsid o f viral vectors to alter their tropism. To be 
successful, the peptide needs to be incorporated into an exposed region o f the capsid so 
that it is accessible for cellular binding and it needs to be in a locale that has no 
detrimental affect on capsid assembly or function. This requires both detailed knowledge 
o f the capsid structure and the identification o f efficient targeting peptides.
1.9 Phage display
Phage display is the most common method used to identify targeting peptides when there 
is no known suitable ligand. The technique was first used by Smith et al. (Smith, 1985) 
to identify peptides that bound to a specific monoclonal antibody, since then it has been 
developed to have a wide range o f applications. For example, it can be used to identify 
peptides that bind to a specific target molecule, cell or tissue in vitro or in vivo. Phage 
display (also known as biopanning) involves screening large numbers o f random peptides 
(known as libraries) expressed on the surface o f bacteriophage to identify peptides that 
have a high binding affinity for a specific target. It is a very powerful technique as the 
libraries used can have a very high diversity (dependent on peptide length), with as many 
as 10  ^different peptides being displayed (Scott and Smith, 1990).
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1.9.1 In vitro phage display
The basic method o f in vitro biopanning involves incubating the phage library with the 
target (either a protein or a cell type), then the target is washed to remove any unbound 
phage. Phage that remain bound to the target are eluted and amplified before being 
reapplied to the target. This is repeated for several cycles to produce a pool o f phage 
enriched in peptides that bind to the target with a high affinity. Sequencing o f the phage 
genome is used to identify the targeting peptide motifs.
One o f the most successful in vitro biopanning experiments identified the integrin 
binding peptide ACDCRGDCRCG (RGD4C) (Koivunen et a l ,  1995). This peptide 
forms 2 disulphide bonds and was shown to have a 200-fold higher affinity for integrins 
than other linear RGD containing peptides that bind integrins (Koivunen et a l ,  1995). It 
has subsequently been used in several in vivo studies. After intravenous administration 
into a mouse model o f  breast cancer the peptide was found to target the tumour cells 
more efficiently than the brain or the kidney (Pasqualini et a l ,  1997). Coupling the 
peptide to the chemotherapeutic drug doxorubicin was found to increase the potency o f 
the drug in a mouse model o f breast cancer (Arap et a l ,  1998). The peptide has also been 
used to target a number o f viral and non-viral vectors to tumours (Seki et a l ,  2002, Mitra 
et a l ,  2005, Yamamoto et a l ,  2006, Line et a l ,  2005, Stachler and Bartlett, 2006) and 
SMC (W ork e /a /., 2004b).
Although in vitro phage display has been used to identify some useful molecular markers, 
it has several disadvantages. In vitro many tissue specific markers are no longer 
expressed so the cultured cell phenotype is not the same as in vivo (Borsum et a l ,  1982). 
It has been shown that 40% o f rat lung endothelial cell surface proteins cannot be 
detected when the cells are grown in vitro (Durr et a l ,  2004). Also, some molecules that 
might not normally be accessible from the bloodstream may be bound during in vitro 
phage display.
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1.9.2 In vivo phage display
In vivo phage display can be used to overcome some of the problems described for in 
vitro phage display. It ensures the identified binding region o f the target receptor is 
accessible to the circulation and it combines a form of negative selection as phage with a 
higher specificity for other targets (e.g. ubiquitously expressed receptors) will bind 
preferentially to them. It also ensures that the phage selected is stable in the blood and 
not rapidly degraded. As well as identifying targeting peptides, phage display has also 
been used to better characterise protein expression on the endothelium.
The basic in vivo phage display method was developed by Pasqualini and Ruoslahti 
(Pasqualini and Ruoslahti, 1996) (Figure 1.11). The library was injected intravenously 
into the animal and the phage left to circulate for approximately 5 minutes before animals 
were perfused. Perfusion is an important step as it removes phage that are bound non- 
specifically or with only a weak affinity for the target and removes phage that remain in 
the blood (Rajotte et a l ,  1998). Tissues o f interest are removed and phage are extracted 
for analysis. With longer circulation times, phage that internalise into cells can be 
specifically identified (Barry et a l ,  1996). Repeated rounds o f  biopanning produce a 
restricted library with a high degree o f  selectivity for the target tissue.
This basic method can be modified to include additional steps, such as an initial ex vivo 
step involving biopanning on cells from the target tissue to produce an enriched library 
for in vivo screening (Hoffman et a l ,  2004). This pre-selection can reduce the number of 
in vivo rounds required and also seems to identify peptides which are more efficiently 
internalised into the target cells (Ruoslahti, 2004). Also, the delivery o f  non-infectious 
phage before delivery o f the library can be used to saturate binding sites in the reticulo­
endothelial system to prevent non-specific uptake o f phage (Hoffman et a l ,  2004).
The first described example o f in vivo phage display was carried out in mice (Pasqualini 
and Ruoslahti, 1996). After 3 rounds o f biopanning peptides that were selective for the 
brain and the kidney endothelium were isolated (Pasqualini and Ruoslahti, 1996). This 
suggested that the endothelium o f different vascular beds expressed unique molecular
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markers and that these could be exploited for tissue-specific targeting. Further in vivo 
biopanning in mice has identified unique molecular markers on the endothelium of the 
lung, pancreas, intestine, uterus, adrenal gland, retina (Rajotte et a l ,  1998) and muscle 
(Samoylova and Smith, 1999). These tissue specific molecular markers have become 
known as the ‘vascular address system’ (or ZIP code) as they can be exploited to target 
vectors to specific tissues with a high level o f selectivity, EC gene expression varies 
between different vascular beds as in different tissues the EC are exposed to different 
environments e.g. varying oxygen concentrations in the blood and are required to carry 
out different functions depending on their location (Minami and Aird, 2005, Lacorre et 
a l ,  2004, Aird, 2004).
The vasculature o f diseased tissues also expresses unique molecular markers. 
Biopanning has now been performed to identify peptides that bind to several types of 
cancers including nasopharyngeal cancer (Lee et a l ,  2004b), prostate cancer (Arap et a l ,  
2002a) and breast cancer (Essler and Ruoslahti, 2002). It has also been used to identify 
peptides that target pancreatic and skin tumour cells at different stages o f the tumour 
development (Hoffman et a l ,  2003), demonstrating that malignant and pre-malignant 
tissues express different m olecular markers. This highlights the high level o f selectivity 
that can be achieved using biopanning.
However, there are also disadvantages to in vivo phage display. Using animal models can 
result in the identification o f  peptides that bind to a receptor that is not well conserved 
between species so might not bind to the human form of the protein. Or, if the disease 
model used is not accurate the receptor may not actually be expressed in the human 
disease state. For example, pro state-sped fie membrane antigen is expressed in human 
prostate cancer and human tumour vasculature but in the mouse it is normally expressed 
in the brain and kidney (Arap et a l ,  2002b). So it is essential that an accurate animal 
model is used and the peptides are tested across a range o f  species wherever possible. 
However species-specific peptides do not seem to be a common occurrence (Ruoslahti, 
2002).
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In vivo phage display has been carried out in humans (Arap et a l ,  2002a). The first 
example o f this was in a patient with a B cell tumour that had been pronounced brainstem 
dead. 4716 peptide motifs were isolated from different organs and analysed to identify 
tri-peptide motifs that were commonly found in each organ (Arap et a l ,  2002a). 
However, due to the diversity o f the human population, one round o f biopanning in one 
person is not sufficient to draw many conclusions and there are obvious ethical problems 
in expanding this kind o f  study. Recently a phage display study in 8 patients with breast, 
melanoma and pancreatic cancers was carried out to isolate tumour-targeting phage (Krag 
et a l ,  2006). In 3 o f the patients 2-3 rounds o f biopanning were possible (Krag et a l ,  
2006). Repeated peptides and some consensus motifs within peptides were identified, 
some of which were found to have homology to known human proteins that have been 
associated with cancer (Krag et a l ,  2006). Some of the phage identified were tested to 
see if they bound to corresponding cancer cell lines, but in most cases no binding or 
reduced binding was seen compared to cells from the original tumour (Krag et a l ,  2006). 
Therefore it is important that these peptides are tested further to check that they are not 
patient-specific.
To try and reduce the numbers o f both animals and humans required for in vivo 
biopanning Ko Ion in et a l  (Kolonin et a l ,  2006) have developed a technique where by 
one animal can be used to identify phage that target several tissues. The method involved 
statistical analysis o f large numbers o f peptides to identify tripeptide motifs (Kolonin et 
a l ,  2006). To overcome ethical problems with performing phage display in humans, 
biopanning has also been carried out on human tissues transplanted into mice. For 
example, this has been successfully performed with synovial tissue from arthritis patients 
(Lee et a l ,  2002).
1.10 Targeting of leiitivirus vectors
Lentivirus vectors used for gene therapy are commonly based on human 
immunodeficiency virus (HIV), which has a natural tropism for CD4+ expressing T-cells. 
To broaden the range o f cells that can be infected by the vector, pseudotyped viruses with
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the vesicular stomatis virus glycoprotein (VSV-G) incorporated into the virus envelope 
have been produced (Cronin et a l ,  2005).
Several studies have compared the level o f transduction o f vascular cells achieved by 
lentiviral and other viral vectors. Dishart et a l  (Dishart et a l ,  2003) showed an HIV-1 
vector pseudotyped with VSV-G produced better transduction o f  human saphenous vein 
SMC and EC than AAV serotypes 2, 3, 4, 5 and 6. Comparing this vector to Ad5 vector 
showed that both human coronary artery ECs and human coronary artery SMCs were also 
more efficiently transduced by the lentivirus (Cefai et a l ,  2005). Although these results 
seem promising for producing vascular-targeted vectors, due to the broad tropism of 
VSV-G modified vectors (Follenzi et a l ,  2002), following systemic delivery in vivo they 
are unlikely to produce selective transduction o f the vasculature, but may be utilised for 
local delivery.
To increase the selectivity o f these vectors for ECs the use o f different promoters has 
been investigated. Comparing promoter sequences from T ie l, Tie2, Flk-1, VE-Cadherin 
and ICAM-2 genes in a VSV-G modified vectors showed that the Tie2 promoter and 
enhancer sequences provided the best specificity for endothelial cells in vitro and tumour 
endothelial cells in vivo in a mouse model (De Palma et a l ,  2003). This demonstrated 
that transcriptional targeting could be used to increase the selectivity o f VSV-G modified 
lentiviruses administered systemically.
Another study has investigated the transduction o f  endothelial cells with a lentivirus 
vector containing a Hantavirus glycoprotein (HTNV-pseudotyped lentivirus)(Qian et a l ,  
2006). In vivo studies in balloon injured carotid arteries o f rabbits showed that the 
HNTV-pseudotyped lentivirus produced significantly higher levels o f reporter transgene 
expression than either VSV-G pseudotyped lentivirus or adenoviral vectors following 
local administration (Qian et al., 2006). When HTNV-pseudotyped lentivirus expressing 
human extracellular superoxide dismutase (EC-SOD) was administered to rabbits with 
balloon injured carotid arteries a significant reduction in the intimal/media ratio was seen 
6 weeks after administration, indicating a reduction in stenosis (Qian et a l ,  2006). These
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studies suggest that target Ientiviruses may be developed into vectors that can be used for 
cardiovascular gene therapy.
1.11 Targeting Ad vectors
1.11.1 Non- genetic retargeting of Ad
There are many studies that have used non-genetic targeting techniques to successfully 
modify the tropism o f Ad5 in vitro. The first proof o f concept used an anti-knob 
neutralising antibody fragment (Fab) conjugated to folate to retarget the vector to a folate 
receptor over-expressed on cancer cells (Douglas et a l ,  1996). Similar methods have 
been used to target other molecules including FGF receptor on K aposi’s sarcoma cells 
(Goldman et a l ,  1997), epidermal growth factor (EOF) receptor (Miller et a l ,  1998) and 
CD40 on dendritic cells (Tillman et a l ,  1999). Another system has used soluble CAR 
protein fused to an anti-CD40 antibody or EGF to retarget the virus to CD40 (Pereboev et 
a l ,  2002) and EGF receptor respectively (Dmitriev et a l ,  2000).
There are several examples o f non-genetic targeting o f Ad to vascular cells. A single 
chain variable fragment (scFv, a fusion o f the variable regions o f the heavy and light 
chains o f an antibody) has been used to target Ad5 to endothelial cells by creating a 
fusion protein o f an EC targeting peptide SIGYPLP (identified by phage display) with an 
anti-Ad scFv (Nicklin et a l ,  2000). This increased transduction o f ECs by about 15-fold 
compared to unmodified Ad (Nicklin et a l ,  2000). Wickham et a l  (Wickham et a l ,  
1996) used a bi-specific antibody that binds to the Ad penton base and ay integrins to 
increase Ad5 transduction o f both vascular EC and SMC and Harari et a l  (Harari et a l ,
1999) used the a bi-specific antibody to target Ad5 to E-selectin to generate a vector 
which targeted activated ECs. Although these studies have demonstrated the production 
o f vectors with altered tropism in vitro, in vivo testing is required to fully validate these 
systems.
One o f the first examples o f using this technology in vivo used the 9B9 antibody that 
binds to the Ad5 knob and angiotensin converting enzyme (ACE) to target Ad vectors to 
the pulmonary endothelium in vivo following i.v. delivery (Reynolds et a l ,  2000). This
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produced 20-fold higher transgene expression in the lung compared to untargeted vector 
but levels o f virus in the liver remained relatively high (Reynolds et a l ,  2000). To 
increase the specificity o f the vector the viral promoter was replaced with the Flt-1 
promoter. This resulted in a 15-fold increase in transgene expression in the lung and a 
67% reduction in liver expression, and demonstrated that transcriptional and 
transductional targeting can be combined to have a synergistic effect on transgene 
expression in vivo (Reynolds et a l ,  2001). The efficiency o f the vector carrying 
endothelial nitric oxide synthase (eNOS) transgene was tested in stroke-prone 
spontaneously hypertensive rats (SHRSP) to determine if the level o f targeting achieved 
was sufficient to have a therapeutic effect. Following systemic administration o f the 
vector, gene expression was predominantly observed in the lung vasculature, and this had 
a significant hypotensive effect whereas an untargeted Ad5 produced no change in blood 
pressure (Miller et a l ,  2005). This was the first study to demonstrate a therapeutic effect
achieved using a targeted viral vector in vivo.
1.11.2 Genetic retargeting o f Ad
The HI loop is an exposed region on the surface o f the fiber knob o f  Ad5 (Figure 1.6B 
and 1.6C). It consists mainly o f hydrophilic amino acids that connect p-strands H and I 
(Xia et a l ,  1994). This loop region is not involved in any intramolecular interactions 
within the knob so insertion o f additional amino acids into this region was thought to be 
feasible without affecting fiber trimérisation. Insertion into the HI loop results in the
incorporation o f 36 copies o f the peptide into each virion.
One o f the first examples o f genetically retargeting Ad was performed by Wickham et al 
(Wickham et a l ,  1997). Several targeting peptides (including an RGD peptide for 
integrin binding and KKKKKKK (K?) for heparin binding) were inserted at the C 
terminus o f the knob to expand the tropism o f the virus (W ickham et a l ,  1997). The 
RGD modified virus produced higher levels o f transduction o f EC and SMC and the K? 
modified virus produced between 5-550 fold increase in transduction o f several cell lines 
including EC, SMC, macrophages and fibroblasts (Wickham et a l ,  1997). Dmitriev et a l  
(Dmitriev et a l ,  1998) inserted an RGD peptide into the HI loop o f Ad5 and showed this
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increased transduction o f  human umbilical vein ECs and human ovarian cancer cells 
independently o f CAR. Since these first studies were published many different targeting 
peptides have been inserted into the Ell loop (commonly after residue T542) to expand 
the tropism o f Ad vectors and enable enhanced transduction o f a range o f cells. It has 
since been shown that insertions o f  up to 100 amino acids can be tolerated in this position 
(Belousova et a i ,  2002).
This technology has also been used in vivo. For example, local administration into the 
tumours o f a B 16 mouse melanoma model o f a vector with RGD inserted into the HI loop 
produced a 40-fold increase in transgene expression in the tumour and an 8-fold decrease 
in expression in the liver (Mizuguchi and Hayakawa, 2002). However, due to the broad 
expression o f integrins this vector would be unsuitable for systemic delivery to produce 
highly selective transgene expression, but it may have applications for ex vivo gene 
therapy. For example Hay et al. (Hay et a l ,  2001) showed that insertion o f an RGD 
peptide into the HI loop o f Ad5 increased transduction o f EC in rabbit jugular veins ex 
vivo to produce a 4-fold increase in gene expression.
Although the majority o f studies use the HI loop for peptide insertion other sites have 
been investigated. Hexon is the most abundant capsid protein, so peptide insertion into it 
results in display o f the highest number o f copies o f peptide (720); therefore it could 
enable highly efficient retargeting. Hexon is highly conserved between Ad serotypes but 
there are hypervariable loop regions that extend from the surface o f the virus. Insertion 
o f an 11-mer RGD containing peptide into hypervariable region 5 o f the Ad5 hexon 
resulted in a 30% increase in transduction o f vascular SMC using 10-fold less virus 
(Vigne et a l ,  1999). This demonstrated that hexon can tolerate peptide insertion and that 
it can be used to alter the virus tropism.
Eighty trimers o f the m inor capsid protein pIX are incorporated into the capsid to 
stabilise hexon-hexon interactions (Vellinga et a l ,  2005). It is possible to insert 
relatively large peptides into the surface exposed C-terminus o f pIX (Dmitriev et a l ,  
2002, M eulenbroek et a l ,  2004). To extend the peptide away from the virus surface so
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that it is more exposed, an a  helical spacer is incorporated with the peptide (Vellinga et 
al., 2004). However, as this position is less well exposed than the HI loop it is unlikely to 
provide such efficient targeting.
Although these studies have demonstrated that it is possible to genetically alter the 
tropism o f Ad vectors in vitro, for many gene therapy vectors a highly specific gene 
therapy vector is required. Therefore, as well as expanding the tropism o f the virus to 
target the vector to a novel cell type, ablation o f the natural vector tropism is also 
required. Targeting o f Ad vectors could enable tissue specific transgene expression 
following systemic administration o f the vector, could reduce vector dissemination and 
toxicity and enable the use o f lower doses o f vector. In addition to this, fiber modified 
viruses do not provoke as strong as immune response as unmodified vectors (Schoggins 
et a l ,  2005).
1.11.3 Detargeting Ad vectors
Early attempts at ablating CAR binding to reduce the natural tropism o f Ad5 involved the 
replacement o f the fiber knob with a trimérisation domain to enable fiber formation and 
targeting ligands such as a the myc epitope, a 6-His tag or RGD peptide (van Beusechem 
et a l ,  2000, M agnusson et a l ,  2001). Kransyth et al. (Krasnykh et a l ,  2001) deleted the 
entire fiber knob and shaft except the N-terminal 2 amino acids and replaced it with a 
truncated form o f bacteriophage T4 fibritin protein linked to a 6-His tag. This vector no 
longer interacted with CAR and produced a 100-fold increase in transduction o f cells 
expressing a 6-His receptor (Krasnykh et a l ,  2001).
The residues in the knob domain that mediate binding to CAR were identified by 
alignment o f sequences from 14 Ad serotypes that bind CAR to find conserved residues 
(Roelvink et a l ,  1999). Site directed mutagenesis and transduction studies in A549 cells 
(that express CAR) were used to identify the critical CAR binding residues (Roelvink et 
a l ,  1999). It was concluded that the main CAR binding site consists o f residues in the 
AB loop (S408, P409, K417), the B p sheet (K420) and the DE loop (Y447), and that 
residues in the EG loop (mainly Y491) are indirectly involved (Roelvink et a l ,  1999).
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The results o f this, other mutational studies (Kirby et aL, 1999, Kirby et a l ,  2000) and 
the solving o f the crystal structure o f Ad 12 bound to CAR (Bewley et a l ,  1999) 
confirmed these residues were important residues for CAR binding. This led to the 
development o f CAR-binding ablated forms o f Ad5, such as AdK Ol that has the point 
mutations S408E and P409A. These have been shown to reduce viral infectivity by about 
99% in vitro (Jakubczak et a l ,  2001).
By combining genetic retargeting strategies with the CAR ablating mutations it is 
possible to generate vectors with novel, highly specific tropisms. Nicklin et a/.(Nicklin et 
a l ,  2001c) generated a modified virus that was both CAR binding ablated and retargeted 
by combining the KOI mutations with insertion o f the EC targeting peptide into the HI 
loop (Figure 1.6). This virus transduced human umbilical vein EC and human saphenous 
vein EC but not vascular SMC more efficiently than A dK O l, showing that the virus had 
some selectivity for ECs (Nicklin et a l ,  2001c).
In a similar study 2 12-mer peptides identified by phage display performed on human 
umbilical vein ECs were inserted into the HI loop o f Ad5 in combination with the KOI 
mutations. The vectors were found to be selective for human umbilical vein ECs but not 
human aortic ECs, human saphenous vein SMCs or human fibroblasts showing that the 
cellular selectivity o f the peptides was maintained after the peptides were inserted into 
the HI loop (Nicklin et a l ,  2004). But following systemic administration, both viruses 
produced high levels o f transgene expression in the liver even though the in vitro trop ism 
had been shown to be independent o f CAR binding (Nicklin et a l ,  2004). Despite the 
high level o f liver transduction the viruses were still found to be selective for venous ECs 
compared arterial ECs (Nicklin et a l ,  2004), so they may be useful for local gene 
delivery e.g. to vein grafts.
1.11.4 In vivo modification of Ad tropism
As demonstrated by the previous example, attempts to modify the tropism o f Ad vectors 
have shown that although binding to CAR can have an important role in Ad transduction 
in vitro, in vivo its role is less certain. Several studies that have tried to ablate the natural
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tropism of Ad by mutating CAR binding residues have shown that in vivo this does not 
have a great affect on reducing hepatotropism (Table 1.5). Therefore to produce a truly 
retargeted virus with a highly selective tropism in vivo, additional mutations are required.
Mutation o f the ROD m otif in the penton base that is involved in integrin binding shows 
it is not vital for infection in vitro, although it does cause virus internalisation to occur at 
a much slower rate (Bai et a l ,  1993), and it reduces the efficiency o f  endosomal escape 
(Shayakhmetov ei a l ,  2005a). It is not known whether the mutated virus uses an integrin 
independent method o f internalisation or if a different part o f the capsid is able to interact 
with the integrin. It has also been shown that blocking virus interaction with HSPGs can 
significantly reduce transduction in vitro (Dechecchi et a l ,  2000, Dechecchi ei a l ,  2001). 
As a result o f  these studies, combinations o f mutations that block interactions with CAR, 
integrins and HSPGs have been tested in a number o f in vivo studies.
Einfield et al. (Einfeld et a l ,  2001) found that combining CAR binding mutations and 
mutation o f the RGD m otif caused a 700-fold decrease in liver tropism in mice, whereas 
mutating CAR or RGD alone caused only 10- and 20-fold decreases in liver transduction, 
respectively. In rats mutation o f RGD was found to cause a 30% decrease in transduction 
and in combination with the CAR mutation caused a 99% decrease in transduction (Nicol 
et a l ,  2004). However, in primates mutation o f RGD alone had no affect on liver 
transduction, although transduction o f all other tissues tested was significantly decreased 
(Smith et a l ,  2003a). These studies have shown that combining mutations to block 
binding to both CAR and integrins synergistically reduced transduction, but the extent of 
this varies in different species.
Investigating the effect o f  blocking HSPG interaction in vivo showed that mutation o f the 
putative binding domain KKTK (residues 91-94 in the 3'^ '^  repeat o f the fiber shaft) to 
GGAG (known as the S* mutation) (Figure 1.6) caused a 15-fold decrease in liver 
transduction following systemic administration in mice (Smith et a l ,  2003b). Combining 
the heparin binding mutation with the CAR binding mutation (K O I) reduced liver 
transduction 1000-fold (Smith et a l ,  2003b). A similar study compared the
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Mutation Tropism compared to unmodified AdS 
following intravenous injection
Reference
Y477A mutation in 
DE loop
There was no difference in vector 
biodistribution in mice.
(Alemany and 
Curiel, 2001)
S408E mutation in 
AB loop
There was no difference in vector 
biodistribution in mice.
(Leissner et a l ,  
2001)
Mutation o f TAYT 
in the FG loop
There was no difference in vector 
biodistribution in mice.
(Mizuguchi et a l ,  
2002)
S408E and P409A in 
AB loop
No decrease in liver transduction in non­
human primates.
(Smith et a l ,  2003a)
S408E and P409A in 
AB loop
In rats there was no decrease in liver 
transduction.
(Nicol et a l ,  2004)
R412S, A425G, 
E416G and K417G 
in AB loop
10-fold decrease in liver transduction in 
mice.
(Einfeld et a l ,  2001)
K420A in B f3 sheet 
o f the fiber knob
9-fold decrease in liver transduction in 
mice.
(Yun et a l ,  2005)
P409B and K417A 
in AB loop, in 
combination with 
mutation o f RGD in 
the penton base
There was no difference in vector 
biodistribution in mice.
(Martin et a l ,  2003)
S408E and P409A in 
AB loop
In mice there was no decrease in liver 
transduction.
(Smith et a l ,  2002, 
Smith et a l ,  2003b)
Table 1.5 The affect o f CAR ablating mutations on in vivo tropism of Ad5.
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biodistribution profiles o f A dK O l, AdS* and A dK O l S* after systemic administration to 
cynomolgus monkey (Smith et a i ,  2003a). Only the AdS* and A dK O l S* vectors 
showed reduced accumulation in the liver compared to unmodified Ad5, and they also 
showed reduced amount o f virus in all other tissues tested including the spleen, lung, 
kidney and heart. A similar study in rats supported this work as it showed that the KO IS* 
mutations caused a 95-fold decrease in liver transduction although the S* mutation alone 
caused ju st a 2-fold decrease in liver transduction (Nicol et a l ,  2004).
These studies confirmed that in vivo CAR binding is not a significant factor in mediating 
Ad transduction, but that by combining CAR ablating mutations with mutation o f the 
KKTK or RGD m otif does significantly reduce Ad infectivity.
Koizumi et al. (Koizumi et a l ,  2003) used a slightly different approach to produce a 
detargeted virus by combining a CAR ablated Ad5 knob with, the shorter fiber shaft of 
Ad35 (that has no KKTK motif) and a mutant A d5 penton base without an RGD motif. 
The double mutant virus was found to produce a 270-fold decrease in liver transduction 
following systemic administration in mice, however in combination with the Ad35 fiber 
this caused a 300,000-fold decrease in liver transduction (Koizumi et a l ,  2003). 
However, both vectors were cleared from the blood very rapidly (Koizumi et a l ,  2003), 
so the lack o f transgene expression was likely to be due to degradation o f the vectors. 
No retargeting o f this vector has been demonstrated.
Due to discrepancies in CAR expression levels and virus biodistribution profiles (Fechner 
et a l ,  1999), and the lack o f effect seen on in vivo tropism by mutating CAR, the 
mechanism o f Ad transduction in vivo is currently under debate and the role o f CAR 
binding is being questioned. Recent studies have proposed that an interaction between 
Ad and blood coagulation factors might have a more significant role in determining Ad 
tropism. Shaykhmetov et al. (Shayakhmetov et a l ,  2005b) showed that coagulation 
factor IX (FIX) and complement component C4-binding protein (C4BP) bind to the virus 
and to cellular HSPG and LDL receptor related protein (LRP) to act as a bridge between 
the virus and cell, mediating virus uptake into hepatocytes and Kupffer cells. A virus
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unable to bind CAR, C4BP and FIX (with knob mutations Y447A, deletion o f TAYT in 
the FG loop and insertion o f a 12 amino acid peptide in the HI loop at position 547) was 
found at a 50-fold lower level in the liver o f intravenously injected mice compared to 
unmodified Ad5 (Shayaldimetov et a l ,  2005b). Another recent study showed that Ad5 
hepatocyte transduction both in vitro and in vivo is enhanced by virus binding to the 
vitamin K-dependent coagulation factors FX, protein C, FVII and FIX (Parker et a l ,  
2006). In vivo warfarin was used to down-regulate the coagulation factors and this 
resulted in significantly reduced liver transduction that could be restored by injection of 
FX (Parker et a l ,  2006). Direct binding o f FX to both unmodified Ad5 and AdKOl was 
also demonstrated (Parker et a l ,  2006). These studies have provided important 
information about alternative mechanisms of Ad transduction in vivo that can be used to 
further develop more selective Ad vectors. By blocking coagulation factor binding and 
therefore uptake into Kupffer cells, the immune response to Ad vectors should be reduced 
and the selectivity o f targeted vectors could be improved.
Although there are many examples o f vector modifications that increase transgene 
expression in the target tissue, as yet there have no been no examples o f peptide targeted 
Ads that have also been successfully detargeted from the liver following systemic 
administration. To improve the degree o f detargeting it is likely that additional 
detargeting mutations will be required e.g. to block binding to coagulation factors. It 
may also be improved by incorporating targeting peptides with a stronger affinity for 
their receptor and peptides that also enhance virus internalisation and/or trafficking.
1.11.5 Pseudotypiiig Ad
Pseudotyping o f Ad most commonly involves replacing the entire fiber or part o f the 
fiber o f one Ad serotype with that o f another. Normally A d5 is used as the basis o f the 
vector as it is the best characterised and can be produced efficiently. The technique was 
first described by Kransyth et al. (Krasnykh et a l ,  1996) who produced an Ad5 vector 
with the knob o f Ad3.
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Several studies have analysed vascular cell transduction mediated by pseudotyped vectors 
(Table 1.6). Although many o f these studies have identified pseudotyped viruses that 
more efficiently infect vascular cells than Ad5, in vivo many o f the viruses have a broad 
tropism therefore would require further modifications to be developed into highly 
selective vectors.
Generally, subgroup B viruses transduce primate vascular cells more efficiently than 
Ad5, but there seem to be species-specific factors that suggest they are less efficient in rat 
and pig cells (Havenga et al., 2001). CD46, the receptor for most group B viruses
(Gaggar et a l ,  2003) is not expressed in mice except in the testes so they are unlikely to 
provide a good platform for developing vascular targeted gene delivery vectors in animal 
models. Also CD46 is a membrane bound protein involved in complement regulation 
and is expressed on all nucleated human cells, so is therefore unlikely to provide the 
required level o f selectivity. For example, although Ad5/35 and A d 5 /ll have been 
shown to transduce ECs more efficiently than Ad5 (Havenga et a l ,  2001), following 
intravenous injection into baboons the viruses were detectable in all major organs 
including liver, spleen, heart, brain and bone marrow (Ni et a l ,  2005).
As yet, no pseudotyped viruses that selectively transduce vascular cells have been 
produced, but one o f the more promising vectors is Ad5 pseudotyped with A dl9p, which 
has been shown to have a reduced tropism for rat liver in vivo and mouse, rat and human 
hepatocytes in vitro (Denby et a l ,  2004). It also transduces human endothelial cells and 
smooth muscle cells at least as efficiently as Ad5 (Denby et a l ,  2004). With additional 
genetic modifications to improve its selectivity it may be possible to develop it into a 
highly efficient vascular-targeted vector.
One o f the main problems with pseudotyping is that it can reduce the titre o f vector 
achieved (Kreppel et a l ,  2005). However it has the advantage o f producing vectors to 
which the population has a lower level o f pre-existing antibodies. Although 
administration o f Ad5/35 and other pseudotyped vectors have been shown to induce anti-
75
Vector Result Reference
A d5 with the A d3 fiber 
(Ad5/3)
Increased transduction o f human 
vascular SMC .
(Su et al., 
2001)
Ad5, 5/12, 5/16, 5/28, 
5/40L (groups C, A, B, D, F 
respectively)
Ad5/16 produced the highest level o f 
transduction (10-100 fold higher than 
Ad5) o f SMC from human umbilical 
vein, iliac artery, left interior mammary 
artery, aorta and saphenous vein. 
However in rat and pig SMC Ad5 
transduction was 100 and 5-10 fold 
higher than Ad5/16, showing species 
specificity. Ad5/16 produced higher 
levels o f transduction than Ad5 in 
human vessels ex vivo.
(Havenga et 
#7 ,2001)
Ad5 pseudotyped with 
group B viruses 11, 35 and 
41
Pseudotypes transduced human ECs 
more efficiently than A d5.
(Havenga et 
#7 ,2001)
Ad2 pseudotyped with 
Ad 17 fiber
More efficient transduction o f human 
umbilical vein ECs than Ad2.
(Chilion et a l ,  
1999)
A d ll  (group B), 4 (group 
E), 41 (group F)
Infect human microvascular ECs more 
efficiently than A d5
(Zhang et a l ,  
2003)
Ad5 pseudotyped with 
Ad37 or Ad 19p (group D)
Do not transduce human, mouse or rat 
hepatocytes as efficiently as A d5 but 
transduce human EC and SMC at least 
as efficiently as Ad5.
(Denby et a l ,  
2004)
Table 1.6 Transduction of pseudotyped Ads in vascular cells.
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Ads antibodies (Ophorst et a l ,  2004, Gall et a l ,  1996) as both hexon and fiber are targets 
for neutralising antibodies (Siimida et a l ,  2005, Vigne et a l ,  2003).
1.12 Targeting AAV
1.12.1 Targeting AAV using bi-specific molecules
Bi-specific antibodies, which bind to both the AAV2 capsid and an alternative receptor 
on the target cell surface, have been used to retarget AAV2 vectors. Bartlett et al. 
(Bartlett et a l ,  1999) carried out the first proof o f concept using a bi-specific antibody 
that targeted the virus to integrins. In vitro, this was shown to expand the tropism of 
AAV2 as it did not inhibit the natural tropism of the virus and it enabled infection of 
normally non-permissive human megakaryocytic cells (Bartlett et a l ,  1999).
A more advanced strategy involved insertion o f an IgG binding domain into the capsid of 
AAV2 at residue 587 to create a vector that could be used to test the targeting capacity of 
different ligands (Ried et a l ,  2002). Antibodies against a l  integrin, c-kit stem cell 
receptor and CXCR4 were used to target the virus to M-07e, Jurkat and M ecl cells with a 
high degree o f selectivity, although the level o f transduction remained lower than that 
seen with AAV2 (Ried et a l ,  2002). The low efficiency o f the vectors may have been 
due to the insertion o f a relatively large peptide (34 amino acids) into the capsid.
An alternative non-genetic targeting strategy involved producing biotinylated AAV2 
which was then conjugated to streptavidin linked EGF. The vector produced enhanced 
transduction o f ovarian cancer cells expressing EGF receptor but also retained the native 
AAV2 tropism (Ponnazhagan et a l ,  2002). These studies provide proof-of-concept of 
non-genetic targeting o f AAV2 in vitro but their stability in vivo and large-scale 
production needs further examination and the specificity o f the retargeting may be 
compromised if the native tropism o f the vector is retained.
1.12.2 Genetic targeting o f AAV
The first example o f genetic targeting o f AAV2 was performed by Girod et al. (Girod et 
a l ,  1999) before the crystal structure o f AAV2 was solved. By comparing the AAV2
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amino acid sequence with the crystal structure o f canine parvovirus, 6 possible positions 
were identified that were predicted to be in a surface exposed position that could tolerate 
peptide insertion (Girod et a l ,  1999). A 14 amino acid RGD containing peptide (L I4) 
was inserted at these sites. The most affective insertion was after residue 587. This 
produced a virus that transduced an integrin expressing cell line, B16F10 that is normally 
non-permissive to AAV2. Transduction could be inhibited by synthetic RGD peptide and 
in cell lines normally permissive to AAV2, soluble heparin reduced but did not ablate 
transduction (Girod et a l ,  1999). This suggests that transduction was mediated by the 
RGD peptide binding to integrins, but that the virus was not completely detargeted from 
FISPG. Subsequent publication o f the AAV2 capsid structure showed that amino acid 
587 is located in the three-fold symmetry axis o f the capsid, protruding from the external 
surface o f the virus and facing the inside o f the crown like structure that forms the 
heparin binding site (Xie et a l ,  2002) (Figure 1.8).
Several other groups have also carried out insertional mutagenesis studies to identify 
other regions o f the capsid that can tolerate peptide insertion. Variable success has been 
achieved as peptide insertion has been shown to produce a number o f different outcomes. 
It can either prevent virus assembly, reduce the titre o f the resulting virus, reduce virus 
infectivity by either preventing cell binding or inhibition o f a later stage o f the 
transduction process or it can produce a virus with expanded or altered tropism (Figure 
1.12). Due to the organisation o f the AAV2 genome it is difficult to modify any o f the VP 
proteins individually other than the unique 137 residues at the N-terminal o f V P l. The 
N-terminal region o f V P l is highly conserved among the different AAV serotypes (Gao 
et a l ,  2003) and contains the phospholipase domain, so there are few sites suitable for 
peptide insertion. Residue 34 has been used as an insertion site for a serpin receptor 
targeting peptide to produce a vector that infects the normally unpermissive cell line IB3, 
but heparin binding was still required for infectivity (Wu et al,, 2000). The N-terminus 
o f VP2 contains a hypervariable region that has been shown to tolerate some peptide 
insertions. Insertion o f peptides after residue 138 is well tolerated and the peptide is 
displayed on the capsid surface (Wu et a l ,  2000). Several different peptides have been 
successfully incorporated at this position to expand the tropism of the virus by enabling it
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to use an additional receptor for cell binding, but the vectors are still able to bind heparin 
(Wu et a l ,  2000, Shi et a l ,  2001, Shi and Bartlett, 2003, Loiler et a l ,  2003). For 
example, insertion o f a lutenizing hormone receptor targeting peptide at residue 138 was 
shown to enhance transduction o f OVCAR-3 cells even in the presence o f soluble 
heparin, even though the vector could still bind heparin (Shi et a l ,  2001). Eleven o f the 
twelve hypervariable regions o f the capsid lie within the VP3 region o f the proteins and 
encode surface exposed loops between the critical structural domains o f the capsid. The 
majority o f successful peptide insertions are in the VP3 region which results in the 
incorporation o f 60 copies o f the peptide into the capsid. Recently a double mutant 
vector has been produced with the targeting peptide RGD4C inserted after both residues 
520 and 584 (Shi et a l ,  2006). Previously insertion o f peptides at residue 520 has been 
shown to produce vectors which had very low titres due to instability and an inability to 
efficiently package the genome (Shi et a l ,  2001) and insertion o f RGD4C peptide after 
residue 584 alone retains some heparin binding ability (Shi et a l ,  2006). But these 
deficiencies are overcome in the double mutant which is unable to bind heparin and was 
shown to infect several cells by integrin binding mediated by the inserted peptide (Shi et 
a l ,  2006).
Despite the identification o f some other possible peptide insertion sites amino acid 587 
remains the favoured position with which most success in producing viruses with 
modified tropisms have been achieved. There have been several examples o f vascular 
targeting peptides incorporated in this position (Table 1.7). Despite the insertion of 
targeting peptides into the heparin binding site o f the capsid, in some cases the vector 
retains the ability to bind HSPG.
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Peptide inserted Target Results Reference
NGRAHA Sarcoma ceils. 
Peptide binds CD 13, 
which is expressed by 
angiogenic
vasculature and many 
tumour cell lines.
Transduced tumour 
vasculature but still bound 
heparin to some degree.
(Grifman et 
#7,2001)
SIGYPLP Endothelial cells Selective for ECs. Low 
transduction o f SMCs and 
hepatocytes. Heparin 
independent transduction.
(Nicklin el #7, 
2001a)
RGD-4C peptide ay integrin Vector bound ay integrin and 
enhanced transduction o f 
cells expressing av integrin 
up to 40-fold, independently 
o f HSPG binding. Also 
targeted tumour cells in a 
murine model o f ovarian 
cancer, providing the first 
evidence o f genetic 
retargeting o f AAV2 in vivo.
(Shi and 
Bartlett, 2003)
EYHHYNK SMC Up to 70-fold increase in 
human SMC trasnsduction.
(Work et #7, 
2004a)
M TPFPTSNEANL Venous EC Higher transduction o f 
venous EC but not arterial 
EC in vitro and in vivo. 
Heparin independent 
transduction.
(White et a l ,  
2004)
QPEHSST Brain
microvasculature
Higher transgene expression 
seen in rat brain compared to 
rAAV. No difference in 
liver transduction. Heparin 
independent transduction.
(Work et a l ,  
2006)
VNTANST Pulmonary
endothelium
Higher transgene expression 
seen in rat lungs compared to 
unmodified AAV. No 
difference in liver 
transduction. Heparin 
independent transduction.
(Work et a l ,  
2006)
Table 1.7 Examples o f peptide-modified AAV2 vectors targeted to the vasculature.
Peptides were inserted into the capsid after residue 587.
1.12.3 Alternative AAV serotypes and pseudotyping
Pseudotyping is being used to exploit the natural variation o f the AAV serotypes to 
produce vectors targeted to different tissues. The similar structural organisation o f the 
genome and capsid o f the different AAVs makes produetion o f pseudotyped vectors 
relatively easy. The majority o f pseudotyped AAVs utilise an AAV2 transgene 
expression cassette in combination with the capsid o f another serotype. Many studies in 
animals have been carried out to determine the tropism of vectors pseudotyped with the 
alternative capsids (Table 1.8). Due to the different tropisms o f these viruses, different 
pseudotypes have the potential to be developed for different forms o f gene therapy. For 
example AAV5 efficiently transduces airway epithelial cells (Sumner-Jones et al., 2006) 
so may be useful for cystic fibrosis gene therapy. Whereas AAV6 efficiently transduces 
skeletal muscle (Blankinship et a l ,  2004) so could potentially be used to treat muscular 
dystrophies. AAV8 has a strong hepatic tropism so is being developed for treating 
haemophilia by mediating hepatic expression o f FIX (Davidoff et a l ,  2005, Nath wan i ét­
a l ,  2 ^ 5 ) .
Several AAV pseudotypes are thought to be particularly efficient for cardiac targeted 
gene therapy. A A V l, AAV6, AAV8 and AAV9 have been shown to efficiently 
transduce skeletal and cardiac muscle (Blankinship et a l ,  2004) (Wang et a l ,  2005, 
Gregorevic et a l ,  2004, Inagaki et a l ,  2006, Pacak et a l ,  2006, Du et a l ,  2004, Su et a l ,  
2006, Kawamoto et a l ,  2005). These vectors may be utilised for treating myocardial 
ischemia following myocardial infarction. For example, an A A V l vector with a hypoxia 
induced promoter (comprising o f hypoxia-response elements and the promoter o f myosin 
light chain2v) expressing VEGF was injected intramyocardially into mice following 
ligation o f the coronary artery (Su et a l ,  2006). It caused a significant increase in 
neovascularisation and improved cardiac function (Su et a l ,  2006).
Although the serotypes do have different tropisms, they generally have a broad tropism 
following systemic administration, and produce higher levels o f transgene expression 
than AAV2 in most tissues (Muller et a l ,  2006, Grimm et a l ,  2003). Therefore they are
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Serotype Tropism R ef
AAV2 W ide tissue tropism including liver, spleen, 
muscle, CNS and lung.
(Nathwani et al., 2001)
AA Vl Higher transduction o f skeletal muscle than 
AAV2, and lower transduction o f the liver. 
Higher transduction o f the CNS than 
AAV2.
(Xiao et a l ,  1999, Burger 
et al., 2004)
AAV4 Strong tropism for ependymal cells in CNS. (Davidson et a l ,  2000)
AAV5 Higher transduction o f skeletal muscle, 
retinal and airway epithelia and CNS 
compared to AAV2.
(Hildinger et a l ,  2001, 
Zabner et a l ,  2000, 
Davidson et a l ,  2000, 
Burger et a l ,  2004, 
Rabinowitz et a l ,  2001)
AAV6 Higher transduction o f airway epithelia than 
AAV2.
Efficient cardiac gene transfer.
Efficient skeletal muscle transduction. 
Transduces liver more efficiently than 
A A V l and AAV2.
(Halbert et a l ,  2001, 
Gregorevic et a l ,  2004, 
Blankinship et a l ,  2004, 
Grimm et a l ,  2003)
AAV7 Transduction o f skeletal muscle equivalent 
to AAV 1.
(Gao et a l ,  2002)
AAV8 10-100 fold higher transduction o f mouse 
liver compared to any other AAV serotype. 
Efficient transduction o f the heart and 
skeletal muscle following systemic 
administration.
(Gao et a l ,  2002, Wang 
et a l ,  2005, Nakai ei a l ,  
2005)
AAV9 Broad tropism, produces higher 
transduction than most serotypes in most 
tissues.
Transduces myocardium more efficiently 
than AAV 2 and AAV2/1 following 
intravenous administration.
5-10 fold higher transduction o f the 
myocardium than AAV8.
(M uzyczka and 
W arrington, 2005, 
Inagaki et a l ,  2006, 
Pacak et a l ,  2006)
AAV 10 Broad tropism - 6 weeks after systemic 
administration in mice transduction o f liver, 
heart, muscle, lung, kidney and uterus was 
detectable.
(Mori et a l , 2004)
AAV 11 Broad tropism - 6 weeks after systemic 
administration in mice transduction o f 
muscle, kidney, spleen, lung, heart and 
stomach was detectable. Unlike most 
serotypes, liver transduction is poor.
(Mori et a l ,  2004)
T able 1.8 T rop ism  of pseudotyped AAV vectors. Pseudotypes contained the AAV2 
ITRs and the capsid o f the serotype indicated.
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unlikely to provide the high specificity o f infection required for some gene therapy 
treatments, but they might provide a better platform vector to which further modifications 
could be made to enable the creation o f a vector with the desired tissue selectivity. As 
yet, there are few examples o f genetic modifications being made to the capsid o f any 
serotype other than AAV2. One example is the insertion o f the RGD4C peptide at 
residue 590 o f A A V l (Stachler and Bartlett, 2006). Unmodified A A V l transduces 
vascular endothelial cells more efficiently than AAV2 (Chen et a l ,  2005) and A A V l- 
RGD4C transduces human umbilical vein EC and human saphenous vein EC better than 
AA V l in vitro (Stachler and Bartlett, 2006). However due to the wide range o f cells that 
express the target integrin reeeptor, this virus would have low selectivity in vivo.
Recently AAV serotypes 2-5 and AAV2 pseudotyped with AAV 1-5 capsids were tested 
to compare their transduction o f human and rat aortic ECs (Chen et a l ,  2005). At 7 days 
post infection AA V l gave the highest level o f transduction in both cell lines, however at 
days 14 and 21 AAV5 was producing higher levels o f transgene expression despite the 
expression from A A V l remaining stable (Chen et a l ,  2005). In vivo A A V l and AAV5 
produced more transgene expression than AAV2 in rat aortic endothelial and smooth 
muscle cells (Chen et a l ,  2005). A previous study carried out by Dishart et a l  (Dishart 
et a l ,  2003) comparing AAV2-6 transduction o f human umbilical vein EC and human 
saphenous vein EC showed they were all inefficient vectors but that AAV2 produced the 
highest transduction at day 5, but later time points were not investigated (Dishart et a l ,  
2003). Denby et a l  (Denby et a l ,  2005) compared the transduction o f AAV2, AAV7 
and AAV8, in EC and SMC, but found that neither were more effective than AAV2 and 
all three serotypes were affected by proteasomal degradation.
Differences in tropism may not just be due to binding o f different cellular receptors. 
Despite AAV2 and 8 having 83% amino acid similarity, AAV8 produces a 20-fold higher 
level o f transduction o f  mouse liver than AAV2 (Nakai et a l ,  2005). It is thought that 
this increase may be due to more efficient virus uncoating rather than cellular binding 
(Thomas et a l ,  2004). Although AAV3 has been shown to bind HSPG, it has a different 
tropism from AAV2, possibly due to the use o f different co-receptors. For example,
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AAV3 can transduce haematopoietic ceils that cannot be transduced by AAV2 (Handa et 
a l ,  2000).
In addition to producing a virus with a novel tropism AAV pseudotyped vectors may be 
more efficient than AAV2 as studies have shown that a smaller percentage of the 
population have pre-existing antibodies to the alternative serotypes. Although people 
have been found to have existing neutralising antibodies against serotypes 1 ,3,  4, 5, 6 
and 8, they occur at a lower rate than for AAV2 (Lochrie et al., 2006, Erles et a l ,  1999, 
Hildinger et a l ,  2001, Xiao et a l ,  1999, Halbert et a l ,  2006). Also, many of the novel 
serotypes and variants are from non-human sources so the existing immunity to these 
may be relatively low. Existing anti-A A V2 antibodies have no detrimental effect on the 
transduction o f AAV5 (Hildinger et a l ,  2001, Peden et a l ,  2004), AAV6 (Halbert et a l ,
2000), AAV7 (Gao et a l ,  2002), AAV8 (Gao et a l ,  2002) or AAV4 (Kok et a l ,  2005).
1.12.4 Hybrid vectors
The production o f hybrid vectors that combine the high efficiency o f infection o f Ad with 
the longevity o f expression o f AAV2 are under investigation. The AAV ITR flanked 
expression cassette is packaged into the Ad capsid to combine the most desirable 
properties o f the 2 vectors. This has been tested in a mouse model o f glycogen storage 
disease type II, using an AAV2 expression cassette in an Ad5 capsid to express human 
acid a-glucosidase in acid a-glucosidase knock out mice (Sun et a l ,  2003). Transgene 
expression was measured for 6 months and was shown to have a therapeutic effect (Sun 
et a l ,  2003). Hybrid vectors have also been produced with serotyped Ad fibers. The 
Ad35 fiber was pseudotyped onto Ad5 capsid and combined with an AAV2 expression 
cassette. It provided stable transgene expression in  human haematopoietic cells 
(Shayakhmetov et a l ,  2002). This study shows the versatility o f  the different 
components o f viral vectors and that by combining different virus components a more 
appropriate vector with the desired features can be produced.
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1.13 Gene therapy for atherosclerosis
As atherosclerosis is a multifactorial disease there are many different ways in which gene 
therapy might be used to treat the condition. It could be used to prevent plaque 
development, cause plaque regression or plaque stabilisation to prevent plaque rupture. 
Plaque regression is likely to be harder to achieve than inhibiting plaque development 
and is also more difficult to prove experimentally, so there are fewer published examples 
o f gene therapy to treat existing atheroselerotic plaques. M ost groups have focused on 
reducing plasma cholesterol levels to try and increase plaque stability, but delivery of 
genes to control dislipidemia, the inflammatory response, SMC regulation and 
extracellular matrix production/degradation may all be advantageous.
1.13.1 Endothelial dysfunction
Therapeutics that reduce oxidative stress and increase NO bioavailability will improve 
endothelial function and reduce inflammation, so overexpression o f anti-oxidant enzymes 
such as superoxide dismutase (SOD) and NOS in the endothelium should reduce ROS 
and have a vasoprotective effect. For example, local delivery o f an Ad vector expressing 
eNOS to the carotid artery o f hyperlipidémie rabbits resulted in a reduction in 
inflammatory cell infiltration and lipid accumulation after just 3 days (Qian and 
Neplioueva, 1999). Another study using local delivery o f a first generation Ad5 vector to 
the carotid artery o f ApoE-/- mice resulted in the development o f smaller plaques 
containing fewer macrophages 5 weeks after treatment (M ujynya-Ludunge et a l ,  2005). 
Delivery o f an Ad vector expressing manganese SOD into the carotid artery of 
hypercholesterolemic rabbits has been shown to improve endothelial dysfunction 4 days 
post delivery (Zanetti et al., 2001). Longer-term studies are required to determine if any 
o f these treatments could have a significant therapeutic effect.
Intra-ventricular administration o f an Ad5 vector expressing heme-oxygenase 1 (HO-1) 
into ApoE-/- mice was found to significantly reduce lesion formation in the aorta 6 weeks 
after vector administration (Juan et a l ,  2001). When the same vector was delivered by 
tail vein injection it had no affect on the size o f plaques that developed (Juan et a l .
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2001), showing that localised transgene expression was required in this case. If systemic 
administration is necessary then a vascular targeted vector will need to be utilised. The 
mechanism by which HO-1 is atheroprotective is not fully understood, although it is 
known to prevent oxidative injury and is anti-proliferative and anti-inflammatory (Juan et 
a l ,  2001, Morita, 2005).
These treatments all require a highly invasive procedure, so the development of EC 
specific vectors that could be delivered systemically would reduce the need for surgery.
1.13.2 Inflammation
Systemic approaches to reducing the inflammatory component o f plaque development 
have been shown to have some success in animal models. Interleukin 10 (IE 10) is an 
anti-inflammatory cytokine that is thought to have anti-atherogenic effects as it reduces 
the production o f pro-inflammatory cytokines, chemokines and endothelial adhesion 
molecules (Pinderski Oslund et a l ,  1999). Intramuscular administration o f an AAV5 
expressing IE 10 into 4 week old ApoE-/- caused mice to develop smaller lesions with 
reduced MCP-1 expression and the mice had lower total serum cholesterol levels 
(Yoshioka et a l ,  2004). The reduction in cholesterol was thought to be caused by 
inhibition o f cholesterol synthesis (Yoshioka et al., 2004). Another study in LDLR-/- 
mice using intravenous injection o f AAV2 expressing IE 10 demonstrated the protein was 
detectable in plasm a up to 10 weeks after administration and showed the animals 
developed less atherosclerosis than controls or animals that received a vector expressing 
the pro-inflammatory cytokine granulocyte macrophage-colony stimulating factor 
(GMCSF) {U u e t  #7 ,2005).
TGFp is a cytokine that is found in healthy vessels and a decrease in its expression results 
in an accumulation o f inflammatory molecules within the vessel wall (Gamble et a l ,  
1993). TGFPi^*^^, an active mutant form o f the protein was expressed from an AAV2 
vector system ically administered to EDER-/- mice fed a high fat diet (Ei et a l ,  2006). 
Trans gene expression could be detected 18 weeks after administration and treated
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animals had lower levels o f markers o f oxidative stress and less lipid accumulation in 
their aortas, suggesting TGFp may have an atheroprotective role (Li et a l ,  2006).
Although these studies have shown therapeutic effects by over expressing genes involved 
in controlling inflammation, if  these therapies were to progress to humans it is likely that 
specific plaque localised gene expression will be required as systemic changes to the 
immune system may be detrimental to the patients ability to respond to infection.
1.13.3 Lipid Balance
It is thought that gene delivery o f ApoAI-M ilano is likely to improve dyslipidemia (See 
section 1.2.4). Intravenous delivery o f an A A V l, 2 or 5 vector with the ApoAl-M ilano 
transgene into ApoA-I deficient mice resulted in sustained transgene expression for at 
least 24 weeks, with the highest levels achieved by the A A V l vector (Sharif et a l ,  
2005). Whether the levels achieved are high enough to have a therapeutic effect needs 
further investigation. In another study a second generation Ad vector expressing ApoA-1 
was found to cause a 70% reduction o f existing fatty streaks in LDLR-/- mice just 4 
weeks after administration (Tangirala et a l ,  1999). Another group used a FIdAd vector to 
deliver human ApoAI to LDLR-/- mice with advanced lesions (Belalcazar et a l ,  2003). 
24 weeks after treatm ent a 50% reduction in lesion progression was measured and the 
plaques had a more stable phenotype (Belalcazar et a l ,  2003). Long-term expression 
o f ApoAI-M ilano seems to provide a promising treatment for preventing plaque 
progression.
There have also been several studies investigating the effect o f ApoE delivery. One 
study using HdAds to deliver ApoE to ApoE-/- mice showed a single administration 
caused a lifetime correction (2.5 years) o f hypercholesterolemia and prevented plaque 
development (Kim et a l ,  2001). This study demonstrated the sustained transgene 
expression that can be achieved using HdAds (Kim et a l ,  2001). It also showed that 
readministration o f the same vector is ineffective due to neutralising antibodies against 
the capsid, but if a different serotype is used readministration can be successful (Kim et 
a l ,  2001). Several other groups have also used Ad vectors to deliver ApoE to ApoE
deficient mice to cause regression o f fatty streaks (Tsukamoto et a l ,  1999, Desiirmont et 
a l ,  2000) and advanced lesions (Harris et a l ,  2002, Tangirala et a l ,  2001). In a long­
term study ApoE-/-mice were fed a high cholesterol diet for 30 weeks before 
administration o f an HdAd expressing ApoE3. 36 weeks later no plaque regression had 
occurred, but plaque progression was significantly reduced compared to untreated 
animals (Oka and Chan, 2005),
Other studies have focused on lowering LDL cholesterol levels by delivery o f LDL 
receptors (Ishibashi et a l ,  1993, Kozarsky et a l ,  1994) or very low density lipoprotein 
receptor (VLDLR) (Oka et a l ,  2001). Use o f first generation Ads to deliver LDLR to 
LDLR deficient mice (Ishibashi et a l ,  1993) and Watanabe heritable hyperlipidémie 
rabbits (Kozarsky et a l ,  1994) was unsuccessful as it resulted in only transient lowering 
o f plasma cholesterol probably due to an immune response against the LDLR and vector 
used (Kozarsky et a l ,  1994). In a similar study where LDLR-/- mice received a HdAd 
expressing LDLR, mice that received a lower dose (5 x lO’  ^ vp/kg) maintained low 
cholesterol levels for at least 108 weeks and developed significantly less atherosclerosis 
than control animals (Nomura et a l ,  2004). No immune response against the vector were 
detected in these mice, but 2/10 mice that received a higher dose (1.5 x lO'^ vp/kg) 
developed anti-LDLR antibodies (Nomura et a l ,  2004).
The lipid lowering proteins described above do not just act by reducing lipoprotein 
concentration. ApoA-I elevates HDL cholesterol, which has anti-inflammatory and anti- 
oxidative properties as well as promoting reverse cholesterol transport. ApoE has an 
anti-atherogenic affect via many mechanisms including, an anti-oxidant effect, inhibition 
o f T cell proliferation, inhibition o f SMC proliferation and migration, inhibition of 
reverse cholesterol transport and inhibition o f platelet aggregation (Davignon, 2005 #58. 
Gene therapy vectors that alter the lipoprotein balance are produced some of the most 
successful studies in animal models and could be developed into successful therapeutics.
Another approach investigated was the delivery o f a soluble form o f the macrophage 
scavenger receptor (sMSR) to reduce oxLDL uptake into macrophages and so reduce
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plaque development. An AAV2 vector expressing sMSR was delivered to LDLR-/- mice 
by tail vein injection at the same time as fat feeding was begun (Jalkanen, 2003 #5633}. 
sMSR could be detected in serum up to 6 months after administration and this resulted in 
a 21% reduction in the size o f lesions that developed in the aorta (Jalkanen et a l ,  2003).
1.13.4 M atrix remodeling
TIMPs have an important role in the regulation o f MMP activity and extracellular matrix 
remodeling which occurs during plaque progression. Tail vein injection o f an HdAd 
expressing TIM Pl or TIMP2 into ApoE-/- mice fed a high fat diet showed that TIMP2 
expression in plasma reduced development o f lesions whereas TIM Pl expression had no 
effect (Johnson et a l ,  2006). The plaques that did develop in mice that received TIMP2 
had a more stable phenotype, containing more SMC and less macrophages (Johnson et 
a l,  2006). This was proposed to be due to TIMP2 inhibiting the migration of 
macrophages and inhibiting smooth muscle cell apoptosis (Johnson et a l ,  2006). TIMP2 
may therefore be a good candidate gene for a treatment aiming to stabilise vulnerable 
plaques.
Another study used tail vein injection o f ApoE-/- mice o f an Ad5 vector for systemic 
expression o f decorin, a matrix proteoglycan that regulates cell proliferation, migration 
and growth factor activity (Zen et a l ,  2005). Decorin could be detected in plasma for up 
to 4 weeks after vector administration and resulted in a significant reduction in 
atherosclerosis (Zen et a l ,  2005).
1.13.5 Thrombus formation
There are also several studies that have investigated the use o f gene therapy to prevent 
thrombus formation. For example Waugh et al. (Waugh et a l ,  1999a) have produced an 
Ad vector that expresses tissue plasminogen activator (tPA), which catalyses the rate 
limiting step in fibrinolysis. The vector was administered into rabbit arteries 3 days 
before thrombus formation was induced (Waugh et a l ,  1999a). It inhibited thrombus 
formation without having any affect on systemic coagulation factors (Waugh et a l ,
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1999a). Similar results were achieved using an Ad vector expressing the anticoagulant 
protein thrombomodulin in the same model (Waugh et a l ,  1999b).
Tissue factor pathway inhibitor (TFPI) inhibits the coagulation cascade and therefore 
blocks thrombus formation. Local gene delivery o f an Ad vector expressing TFPI to 
rabbit carotid arteries inhibited subsequent induced thrombus formation (Nishida et al., 
1999). Another study has also shown a protective role o f TFPI in preventing thrombus 
formation (Zoldhelyi et a l ,  2000). Gene delivery o f other genes including hirudin (Rade 
et a l ,  1996) and cyclo-oxygenase (Zoldhelyi et a l ,  1996) have also shown some 
inhibition o f thrombus formation in animal models. It is important that anti-coagulants 
such as TFPI are only active at the site o f unstable plaques, so they are good candidates 
for therapeutic genes delivered using vectors targeted specifically to unstable plaques.
All the examples described above have used either local delivery to the vessels or 
systemic expression o f proteins to try and reduce atherosclerosis. There are no published 
examples o f the use o f vectors targeted specifically to established atherosclerotic plaques. 
Ideally this is what is required, so a non-invasive procedure can be used to deliver a 
highly selective vector. The majority o f studies have also focused on preventing plaque 
development rather than the targeting o f existing plaques, the likely clinical scenario. 
Also, the majority o f the animal studies described only short-term transgene expression, 
but validation o f both short and long term gene expression is required. So, there is a need 
for the development o f vectors that can be used to specifically target gene expression to 
areas o f atherosclerosis to either stabilise or cause regression o f existing plaques.
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Chapter 2; 
Materials and Methods
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2.1 Chemicals
All chemicals unless otherwise stated were obtained from Sigma Chemical Company 
(Poole, UK) and were o f the highest grade obtainable. All oligonucleotides were 
obtained from M W G-Biotech (Edersberg, Germany).
2.2 Tissue culture
All tissue culture work was performed under containment level 2, in sterile conditions 
using a vertical laminar flow hood. Table 2.1 describes the cell types used in this study.
2.2.1 M aintenance o f cell lines
Cell lines were maintained in the appropriate cell culture media (Table 2.1) and incubated 
at 37°C in a 5% CO2 atmosphere. Confluent cultures o f cells were passaged using 
trypsin-ethylendiamine tetra-acetic acid (trypsin-EDTA). Briefly, cells were washed 
twice in phosphate buffered saline (PBS) (Biowhittakers, Berkshire, UK) and incubated 
in a minimal volume of trypsin-EDTA (Gibco, Invitrogen, Paisley, UK) for 
approximately 5 minutes, until the majority o f cells had detached. The action o f trypsin- 
EDTA was blocked by the addition o f 8 ml media. Cells were harvested by 
centrifugation at 480 x g and resuspended in fresh media for passaging or plating. For 
plating cells were counted in a haemocytometer to enable them to be seeded at the j
required density.
2.2.2 Cryo-preservation of cell lines I
Cells were harvested as described in section 2.2.1 and re-suspended at a density o f |
approximately 1-2 x 10^ cells/ml in complete cell culture media supplemented with 10% |
dimethyl sulphoxide (DMSO). Cell suspensions were aliquoted into sterile 2 ml cryo- 
preservation vials and cooled at a constant -UC/m inute to -80®C using isopropanol.
Vials were then transferred to liquid nitrogen and stored indefinitely.
For recovery o f cryo-preserved cells, vials were removed from liquid nitrogen and 
warmed in a 37°C water bath until the cells were completely thawed. Cells were then
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transferred to a T-25 flask containing 5 ml o f pre-warmed cell culture media and 
incubated overnight at 37°C. The following day they were placed in fresh media.
2.2.3 Isolation of human saphenous vein EC (HSVEC)
Saphenous veins were obtained from patients undergoing coronary artery bypass graft 
surgery. Ethical permission was obtained; reference number 04/161 (1) and 
03CA022VRW.
HSVEC were isolated by collagenase digestion. Veins were washed in RPMI (Roswell 
Park Memorial Institute) media supplemented with 100 lU/ml penicillin, 100 pg/ml 
streptomycin. One end o f the vein was clamped with a surgical clip to seal it and enable 
the vein to be filled with collagenase solution (2 mg/ml in PBS). The vein was then 
sealed and incubated at 37°C for 15 minutes. The collagenase solution was collected 
from the vein, then the process was repeated with fresh collagenase solution. The vein 
was washed with RPMI and the solution collected and pooled with the collagenase 
fractions. Cells were harvested by centrifugation at 200 x g for 10 minutes. Cells were 
re-suspended in cell culture media and placed in a T-25 flask. Cells were maintained for 
up to 7 passages.
2.3 Animal models
8 week old C57B16/129SvJ ApoE-/- mice were maintained on a diet o f 21% beef lard 
supplemented with 0.15% cholesterol (Special Diets Services, Witham, Essex, UK) for 
10 weeks (maintained by Bristol University Biological Services Staff). C57B16 ApoE-/- 
mice were obtained from Charles River Laboratories (Manston, Kent, UK) to set up a 
breeding colony maintained by University o f Glasgow Biological Services Staff. For in 
vivo studies these mice were maintained on a diet o f 21% beef lard supplemented with 
0.15% cholesterol for 12 weeks from the age o f 6 weeks. C57/B16 mice obtained from 
(Harlan, Oxfordshire, UK) were maintained on a standard rodent chow diet.
All animals were housed under controlled environmental conditions. Temperature was 
maintained at ambient temperature with 12 hour light/dark cycles. Food and water were
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provided ad  libitum. All work was performed in accordance with the Animals and 
Scientific Procedures Act 1986 under project licenses 60/3011 held by Professor A. 
Baker and 30/2151 held by Dr C. Jackson.
2.4 Plaque histology
Mice were anesthetised by intra-peritoneal injection o f Euthatal (Pentobarbital Sodium 
200 mg/ml) (Merial Animal Health, Essex, UK) before perfusion with PBS. The BCAs 
were removed and fixed overnight in 10% formalin then transferred to PBS. Histological 
analysis was performed by Dr R. McDonald (University o f Bristol). BCA sections were 
stained with haematoxylin and eosin stain (H and E) to show the plaque structure and 
Elastic von Gieson (EVG) stain to determine the elastin content o f the plaque.
2.5 Production of viruses
2.5.1 Production of recom binant Ad5
High titre stocks o f  recombinant Ad5 were produced by large-scale amplification o f a 
plaque pure stock o f Ad5 in 293 cells. Low passage 293 cells were grown to 80% 
confluency then infected with a multiplicity o f infection (MOI) o f approximately 1 
plaque forming unit (pfu)/cell. The media was changed every 3 days until the cytopathic 
effect o f the Ad caused the cells to detach from the flask. Cells were then fed by adding 
10 ml media to each flask until the majority o f cells had detached. Cells were harvested 
by centrifugation at 850 x g for 10 minutes at room temperature. The pellet was 
resuspended in 10 ml o f PBS and an equal volume o f ArkloneP 
(Trichlorotrifluoroethane). The tube was inverted for 10 seconds then gently shaken for 5 
seconds so the solutions were mixed without vigorous shaking (as this results in stripping 
o f the Ad fiber from the capsid). The mixing was repeated. The suspension was 
centrifuged at 850 x g for 15 minutes at room temperature. The upper aqueous layer 
containing the virus was removed. An additional 10 ml o f  PBS was added to the 
remaining solvent layers and the process was repeated. The aqueous layers were pooled 
and stored a t-8 0 °C  until purified on a CsCl gradient.
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2.5.2 Production of fiber gene deleted Ad with the lac Z  transgene (Ad5.lacZ.AF)
633 cells were maintained in selective media (Table 2.1) until they were expanded into 
20 T-150 flasks, where they were cultured in MEM supplemented with 10% (v/v) fetal 
calf serum (PCS), 100 lU/ml penicillin, 100 pg/ml streptomycin and 2 mM  L-glutamine. 
24 hours before cells were infected 0.3 pM  dexamethasone was added to the media. 
Cells were infected with fiber gene deleted Ad5 (MOI 2000 virus particles (vp)/cell) 
when they were approximately 80% confluent. When the cytopathic effect had caused 
the majority o f cells to detach, the cells were harvested by centrifugation at 850 x g for 10 
minutes at room temperature. The pellet was resuspended in 10 ml o f PBS. Cell lysis 
was caused by freezing the suspension in liquid nitrogen and thawing it in a 37°C 
water bath, three times. The suspension was centrifuged at 850 x g for 15 minutes at 
room temperature. The supernatant was stored at -80°C until it was purified on a CsCl 
gradient.
2.5.3 Production of fiber modified Ad viruses
Peptide modified viruses were produced using the previously developed 
transfection/infection protocol where the modified fiber gene is supplied by a plasmid 
(Von Seggern et a l ,  1998, Jakubczak et a l ,  2001, Nicklin et a l ,  2001c). Table 2.2 
describes the plasmids used to produce each o f the Ad platform vectors. All the plasmids 
express the Ad fiber gene from a CMV promoter.
2.5.3.1 Cloning of peptides into the Ad fiber gene
Overlapping oligonucleotides encoding the peptides flanked by the BspEl restriction site 
(Table 2.3) (not required for A d l9p  fiber as blunt ligation was used) were obtained from 
M W G-Biotech (Edersberg, Germany). Oligos were annealed by mixing 1 pM  of each 
oligo (in 100 pi deionised water), heating to 98°C for 10 minutes and then leaving them 
to cool to room temperature. Oligos were electrophoresed on a 16% polyacrylamide gel 
to confirm annealing had occurred.
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Plasmids were digested overnight at 37°C with BspEl (New England BioLabs, Hitch in, 
UK) or Eco47\\\ (Promega, Southampton, UK) in the reactions shown below:
Plasmid (50 pg) 50 pi
BspEl lO U /pl 10 pi
Buffer 3 10 pi
Water 30 pi
Plasmid (50 pg) 50 pi
E coA llll 5 U/pl 10 pi
Buffer D 10 pi
Water 30 pi
1 pg o f digested plasmid was dephosphorylated using 5 U Shrimp Alkaline Phosphatase 
(SAP) (Promega, Southampton, UK) by incubation at 37°C for 15 minutes, followed by 
incubation at 65°C for 15 minutes to deactivate the phosphatase.
Dephosphorylated plasmid and oligo duplexes were ligated using Quick T4 ligase (New 
England BioLabs, Hitchin, UK). 50 ng vector, 5 pmoles oligo, 1 pi ligase and 10 pi of 
the supplied buffer were mixed in a total volume o f 20 pi and incubated at room 
temperature for 5 minutes. Ligated plasmids were then transformed into JM109 
competent E. coli (Promega, Southampton, UK) using a standard heat shock protocol. 
Briefly, 10 pi o f the ligation reaction was incubated with 50 pi competent cells on ice for 
30 minutes. The reaction was placed in a 42°C water bath for 30 seconds and then placed 
back on ice for 2 minutes. 450 pi o f warmed SOC media (20 g/L bactotryptone, 5 g/L 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 20 mM glucose) was added to the tube, which 
was then placed in an orbital shaker for 1 hour at 37°C and 180 rpm shaking. 100 pi was 
plated onto Luria Broth (LB) agar plates (10 g/L bactotryptone, 5 g/L bactoyeast extract,
100
5 g/L NaCl, 15 g/L agar, pH 7.5) supplemented with 100 pg/ml o f amp ici 11 in. Plates 
were incubated overnight at 37°C.
Colonies were amplified and the plasmid was isolated by performing small-scale plasmid 
DMA preparations using the Qiagen plasmid mini preparation kit (QIAGEN Ltd., 
Crawley, UK) as per m anufacturer’s instructions. Restriction digestion o f individual 
clones was performed to determine which plasmids contained a single copy of the 
inserted oligonucleotide duplex. Clones were sequenced to confirm they contained a 
single copy o f the insertion in the correct orientation. Sequencing reactions contained 
250 ng plasmid DNA, 3.2 pmoles primer (primer for A dK O l plasmids 5’- 
CACTTGAGTTGTGTCTCCTCC ACC-3 ’, primer for AdKOlS* plasmids 5’- 
AAGTGTAACAGGATGTGG-3’ and primer for Ad5/19p plasmids 5’- 
TCTTTGATTGTGGTCGCAGG-3’), 0.5 pi v3.1 Ready Reaction mix (Applied 
Biosystems, MA, USA) and 4 pi v3.1 sequencing buffer (Applied Biosystems, MA, 
USA) in a 20 pi reaction. The cycle conditions were denaturing at 96°C for 45 seconds, 
annealing at 50“C for 25 seconds and extension at 60°C for 4 minutes, for 25 cycles. 
Sequencing products were cleaned using CleanSEQ (Agencourt Bioscience Corporation, 
MA, USA) as per m anufacturer’s instructions. Results were analysed on the ABI 3730 
automated sequencer and using SeqScape v2.0.
Large-scale plasmid preparations o f correctly sequenced plasmids were performed using 
the Qiagen plasmid maxi preparation kit (QIAGEN Ltd, Crawley, UK) following the 
m anufacturer’s instructions. Briefly, a 200 ml culture was grown overnight in a 2 litre 
flask in an orbital shaker at 180 rpm and 37"C. Bacteria were harvested by centrifugation 
at 6000 X g for 15 minutes at 4°C. The cells were lysed by alkaline lysis and centrifuged 
at 20000 X g for 30 minutes at 4°C to remove cell debris. The supernatant was removed 
and centrifugation repeated for 15 minutes. The supernatant was applied to a QIAGEN 
tip to bind the DNA. A medium salt wash (1.0 M NaCl, 50 mM MOPS, pH 7, 15% v/v 
isopropanol) was used to remove RNA, proteins and low molecular weight impurities 
DNA was eluted in a high salt buffer (1.25 M NaCl, 50 mM Tris.Cl, pH 8.5, 15% v/v 
isopropanol). Isopropanol precipitation was used to purify and concentrate the DNA.
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The plasmid was resuspended in TE buffer (pH 8.0, 10 mM Tris.Cl, pH 8.5) and stored at 
-20°C. Glycerol stocks o f positive colonies were produced by mixing 150 pi sterile 
glycerol with 850 pi o f culture and these were stored at -80°C.
2.5.3.2 Production of fiber-modified and pseudotyped Ads
Ad vectors with genetically modified fibers were produced in 293-T cells that express the 
adenovirus E l gene, which is essential for virus replication. Twenty 10 cm tissue culture 
Petri dishes (Nunc, W iesbaden, Germany) o f 70% confluent 293T cells (maintained in 
MEM supplemented with 10% (v/v) PCS, 100 lU/ml penicillin, 100 pg/ml streptomycin 
and 2 mM L-glutamine) were transfected with plasmid expressing the modified fiber 
gene using a calcium chloride differential pH method. Briefly cells were washed twice in 
PBS, then placed in 4.5 ml DMEM supplemented with 10% (v/v) PCS, 25 mM HEPES 
pH 7.9. A solution containing 960 pi media (DMEM supplemented with 25 mM HEPES 
pH 7.1), 48 pi 1 M CaClz, 21 pg plasmid DNA per plate was made up. This was added 
dropwise while the plate was gently rocked. As a positive control one plate was 
transfected with an eGFP expressing plasmid. Pollowing overnight incubation at 37°C 
the cells were washed in PBS then placed in 10 ml o f the standard cell culture media. 
The transfection efficiency was assessed using the eGPP transfected plate. If 70-80% of 
cells were positive then cells were infected with 2000 vp/cell Ad5.1acZ.AF (an E l, E3 
and fiber deleted first generation virus). When the cytopathic effect had caused the 
majority o f cells to detach, the cells were harvested by centrifugation at 850 x g for 10 
minutes at room temperature. The pellet was resuspended in 10 ml o f PBS. Cells were 
lysed by freeze/thawing three times in liquid nitrogen and at 37°C. The suspension was 
centrifuged at 850 x g for 15 minutes at room temperature. The supernatant was stored at 
-80°C until purified on a CsCl gradient.
2.5.4 Adenovirus purification using a CsCl gradient
To purify and concentrate the crude Ad stocks, centrifugation on CsCl density gradients 
was used. Fourteen ml cellulose-nitrate ultra-clear centrifuge tubes (Beckman Coulter 
(UK) Ltd, Buckinghamshire, UK) were sterilised with 70% ethanol and then washed with 
sterile water. A CsCl gradient was produced by sequentially layering 2 ml o f CsCl with a
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density o f 1.45, 3 ml o f CsCl with a density o f 1.32 and 2 ml 40% glycerol. The crude 
Ad supernatant was overlayed and the tube filled with PBS. The tube was then loaded 
into a Sorvall Discovery 90 rotor container, placed in the rotor (RPS40T-859) and 
centrifuged at 90,000 x g for 1.5 hours at 4°C with maximum acceleration and free 
deceleration. Following centrifugation a band containing complete virus can be seen 
(Figure 2.1). This was removed by piercing the tube below the virus band with a 22 GA 
needle and drawing o ff the band in the minimum volume without disrupting the other 
bands.
Extracted virus was transferred to a Slide-A-Lyzer Dialysis Cassette (MW cut o f 10,000) 
(Perbio Science UK Ltd., Northumberland, UK) for dialysis. The virus was dialysed 
against 2 L o f 0.01 M Tris pH 8 / 0.001 M EDTA for approximately 2 hours then buffer 
was replaced and the dialysis repeated overnight. The buffer was changed and 
supplemented with 10% (v/v) glycerol and dialysis was continued for a further 2 hours. 
The virus was carefully removed from the cassette, aliquoted and stored at -80°C.
2.5.5 Titration of adenovirus by end-point dilution
Unmodified viruses were titred using the end-point dilution method (Nicklin and Baker, 
1999). Briefly, 293 cells were passaged into 8 rows o f 10 wells in a 96 well plate, so that 
they would be 50-60% confluent the following day. Serial dilutions (from 10"'’-1 0 '")  of 
the viral stock were made in media. The media in each row was replaced with 100 pi o f 
the correct adenoviral dilution (10 wells/dilution). Cells were incubated for 18 hours at 
37°C and then the virus containing media was replaced with 200 pi fresh media. This 
media was then replaced every 2-3 days until a cytopathic effect was seen. After 8 days, 
the number o f wells containing plaques was counted and the titre was calculated in 
pfu/ml using the equation:
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The proportionate distance =
% positive above 50% -50%
% positive above 50%-50% positive below 50%
and log ID50 (infectivity dose) =
log dilution above 50% + (proportionate distance x dilution factor)
For example: titration gives: @ 10""^  all wells positive [10/10]
@ 10-'’ [ 10/ 10]
@ iO ’ [10/10]
@ 1 0  " [9/10]
@ 10-’ [3/10]
@ 10'"' [0/ 10]
@ 10-" [0/10]
The proportionate distance = 90-50 = 0.67
90-30
log ID50 = -8 + (0.67 X -1) = -8.67 
1050= 10-®'*^
TCID 50 (tissue culture infectivity dose 50) = 1
I q-8.67
TC1D5o /1 0 0 |x1 =  10®*’
X dilution factor (=10) 
TCIDso/ml = 1 0 ’ *’
= 4 .6 7 x  lO’ TCIDso/ml
1 TCID5o= 0.7 pfii
Final titre = 3.27 x lO’ pfu/ml
104
< Cell and protein debris
 Em pty virus capsids w ith
no genom e
<-----—  Com plete virus
y
Figure 2.1 CsCl purification o f  Ad virus. V iruses w ere layered on a CsCl gradient 
and centrifuged at 90,000 x  g for 1.5 hours a t 4°C to produce separation o f com plete 
virus particles from em pty capsids and cell debris.
105
2.5.6 Determ ining Ad virus particle titres
As fiber modified Ads do not infect 293 cells with the same efficiency, the end-point 
dilution method cannot be used to determine the virus titre. Instead the particle titre is 
calculated based on the protein content o f the virus stock using the Micro BCA 
(bicinchoininc acid) assay kit (Pierce, Rockford, IL, USA). Briefly, 8 bovine serum 
albumin (BSA) standards ranging from 200 pg/ml to 0.5 pg/ml were prepared and 150 pi 
o f each was pipetted in duplicate into a 96 well plate. 1, 3 and 5 pi o f virus made up to 
150 pi in PBS were also used in duplicate. 150 pi o f BCA working reagent was added to 
each well then incubated at 37°C for 2 h. The absorbance at 570 nm was measured using 
a Wallac Victor^ plate reader. Background absorbance was subtracted from the samples 
and standards and the amount o f protein present in each virus was then calculated from 
the standard curve. The virus particle titre was then calculated using the established 
formula:
1 pg protein = 1 x 1 0 ^  viral particles (Von Seggern et ctl, 1998)
2.5.7 W estern Blotting
Before using a new virus stock it was important to confirm that the virus capsids had the 
fiber protein incorporated. To achieve this SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) and western blots were performed using the 
monoclonal anti-fiber antibody 4D2 (Neomarkers Fremont, CA, USA).
To detect fiber monomers reducing conditions and a 12% polyacrylamide gel (containing 
40% (v/v) polyacrylam ide (30%), 11.25 mM Tris pH 8.8, 0.1% (v/v) SDS, 300 pi 
ammonium persulphate (APS) and 30 pi TEMED) were used. To detect fiber trimer non­
reducing conditions and a 7.5% gel (containing 25% (v/v) polyacrylamide (30%), 11.25 
mM Tris pH 8.8, 0.1% (v/v) SDS 300 pi APS and 30 pi TEM ED) were used. A 4% 
stacking gel containing 13.3% (v/v) polacrylamide (30%), 3.75 mM Tris pH 6.8, 0.1% 
SDS 300 pi APS and 30 pi TEM ED) was used with each gel.
2x10*° vp were mixed with an equal volume o f reducing loading dye (125 mM Tris pH 
6.8, 4% (v/v) SDS, 10% (v/v) glycerol, 0.006% (v/v) bromophenol blue, 2% (v/v) (3-
1 0 6
mercaptoethanol) or non-reducing loading dye (125 mM Tris pH 6.8, 4% (v/v) SDS, 
10% (v/v) glycerol, 0.006% (v/v) bromophenol blue). For reduced conditions virus was 
heated to 95°C for 5 minutes before the gel was loaded. Samples were electrophoresed at 
200 V in running buffer (0.025 M Tris-HCl, 0.2 M glycine, 0.001 M SDS) for 
approximately 2 hours.
Proteins were transferred onto Hybond-P membrane (Amersham Bioscience UK Limited, 
Buckinghamshire, UK) overnight at 30 V in transfer buffer (0.025 M Tris, 0.2 M glycine, 
20% (v/v) methanol, 0.01% (v/v) SDS). The membranes were then blocked in TBS-T 
(150 mM NaCl, 50 mM Tris, 0.1% (v/v) Tween-20) + 10 % (w/v) fat-free milk powder 
(blocking buffer) for 2 hours with shaking. The membrane was incubated for 1 hour at 
37°C with the anti-fiber antibody diluted to 1:1000 in blocking buffer. The membrane 
was washed twice in blocking buffer at room temperature for 5 minute. The secondary 
antibody, rabbit anti-mouse horseradish peroxidase (HRP) (Neomarkers Fremont, CA, 
USA) was diluted 1:2000 in blocking buffer and ineubated with the membrane at room 
temperature for 1 hour. The membrane was then washed four times in blocking buffer 
for 15 minutes at room temperature. An additional three washes o f 5 minutes in TBS-T 
were performed.
Proteins were visualised using the ECL detection system (Amersham Biosciences UK 
Limited, Buckinghamshire, UK) as per m anufacturer’s instructions.
2.5.8 P roduction  o f AAV vectors
All AAV vectors were produeed, purified and titred by Dr. H. Buening (University of 
Cologne, Germany) using a previously described method (Girod et a l ,  1999, Nicklin et 
a l ,  2001a). Briefly, oligonucleotides encoding the peptides CAPGPSKSC (CAP) and 
CNHRYMQMC (CNH) were annealed and ligated into the hdlul-Ascl site o f the plasmid 
pRC’99 to produce plasmids pRCcap and pRCcnh. pRC’99 encodes the AAV wild type 
capsid, so oligonucleotide insertion results in the incorporation o f the peptides after 
amino acid 587 o f the capsid protein (Figure 1.8).
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Viruses were produced using a transfection protocol. Fifteen plate o f 293 cells at 80% 
confluence were cotransfected with 37.5 pg o f the plasmid expressing the virus capsid 
(pRC), pZnL and pXX6 at a 1:1:1 ratio. pXX6 provides the adenovirus genes required 
for helper function. pZnL encodes the AAV ITRs flanking the LacZ  reporter gene and a 
CMV promoter (Girod et a l ,  1999). 48 hours after transfection cells were harvested by 
centrifugation and the cell pellet was re-suspended in 150 mM NaCl, 50 mM Tris-HCl 
pH 8.5. This was freeze-thawed several times to lyse cells and treated with Benzonase 
(50 U/ml) for 30 m inutes at 37°C to remove cellular DNA and RNA. Cell debris was 
removed by centrifugation and the supernatant was then purified on an iodixanol 
gradient. Genomic titres o f the vector were determined by real-time PCR.
Viruses encoding the self-complementary eGFP gene were produced using the same 
method but the plasmid pscAGFPFG2 (which contains the eGFP flanked by AAV2 ITRs) 
was used instead o f pZnL.
2.6 AAV heparin column binding
Heparin column binding was performed by Dr. H. Buening (University o f Cologne, 
Germany). Virus was loaded onto HiTrap Heparin HP (Amersham Bioscience, 
Buckinghamshire, UK), and the initial flow through was collected. The column was 
washed twice with PBS containing 1 niM M gC f, 2.5 mM KCl and then bound virus was 
eluted by applying two 5 ml aliquots o f PBS containing 1 mM M gCb, 2.5 mM KCl, 1 M 
NaCI. The virus content o f each o f the fractions was analysed by real time PCR.
2.7 In vitro infections
2.7.1 In vitro infection with adenovirus
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Viruses were diluted to the desired concentration in PBS. Wells were 
infected with the required multiplicity o f infection (MOI) o f  virus and incubated for 3 
hours at 37°C. Cells were washed in PBS then placed in fresh media and incubated at 
37°C for 48 hours before transgene expression was measured.
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2.7.2 In vitro infection with adenovirus in the presence of anti-CAR antibody
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Cells were pre-incubated on ice for 30 minutes in serum free media, media 
eontaining control rabbit serum or anti-CAR antibody diluted 1 in 200 in serum free 
media (a gift from J. Bergelson, University o f Pennsylvania School o f Medicine, 
Philadelphia, USA). Cells were infected with an MOI of 10000 for 3 hours, washed and 
ineubated in fresh media for 48 hours.
2.7.3 In vitro infections with AAV
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Viruses were diluted to the desired concentration in PBS. Wells were 
infected in triplicate with the required MOI of virus and incubated for 24 hours at 37°C. 
Cells were washed in PBS then placed in fresh media and incubated for a further 72 hours 
at 37 °C.
2.7.4 In vitro infections with AAV in the presence of heparin
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Cells were infected with an MOI of 1000 for 24 hours in the presence or 
absence o f  1 U o f heparin per 1 x 10^ gp. Cells were washed in PBS then incubated in 
fresh media for 48 hours.
2.7.5 In vitro infections with AAV in the presence o f proteasome inhibitors
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Cells were infected with an MOI of 1000 for 24 hours in the presence or 
absence o f proteasome inhibitors 40 pM  LnLL (Calbiochem , M erck Biosciences Ltd., 
Nottingham, UK) or 4 pM  MG 132 (Calbiochem, Merck Biosciences Ltd., Nottingham, 
UK). Cells were washed in PBS then incubated in fresh media for 48 hours.
2.7.6 In vitro peptide competition assay
Cells were seeded in 96-well plates and incubated overnight at 37°C to produce 70-80% 
confluence. Cells were washed in PBS then placed in media containing the required
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concentration o f the peptide (Jerini Peptide Technologies GmbH, Berlin, Germany). 
Virus was then added to each well. AAV (MOI of 1000) was incubated with the cells for 
24 hours before they were washed and placed in fresh media for a further 48 hours. Cell 
lysate was used in the P-gal assay.
2.8 Visualisation of P-galactosidlase (P-gal) expression in infected cells
Following infection cells were washed in PBS then fixed in 50 pi 2% paraformaldehyde 
by incubation on ice for 20 minutes. Cells were then washed in PBS and 100 pi X-gal 
stain (77 mM Na2HPÜ4 , 23 mM NaH 2P0 4 , 1.3 mM MgCfl, 3 mM K4pe(CN)6 , 0.05% 
(v/v) 20 mg/ml X-gal dissolved in dimethyl formamide) was added to each well and 
incubated overnight at 37°C. Cells were washed in PBS and placed in fresh PBS.
2.9 Quantification of p-gal expression in cell lysates
To quantify p-gal expression the Tropix Galacto-Light Plus system (Applied Biosystems, 
MA, USA) was used. Briefly, infected cells were washed in PBS then lysed in 80 pi of 
Lysis Solution (0.2% (v/v) Triton X-100 in PBS). 20 pi o f each sample was transferred 
to a white 96-well plate. Standard curves o f recombinant p-galactosidase protein ranging 
from 0-20 ng and 0-20 pg were produced in duplicate. Galacton Plus chemiluminescent 
substrate was diluted 1:100 in reaction buffer (100 mM sodium phosphate pH 8, 1 mM 
M gCb). 70 pi was then added to each well and incubated for 1 hour at room temperature. 
100 pi o f light emission accelerator was added to each well. Luminescence was 
measured using a W allac Victor^ plate reader, p-galactosidase activity was then 
normalised to protein content o f samples to give relative light units per mg protein 
(RLU/mg protein).
2.10 Determination of protein concentration in cell lysates
The amount o f protein in cell lysates was determined using the BCA assay kit (Pierce, 
Rockford, USA) as per m anufacturer’s instructions. A standard curve was generated 
using dilutions o f BSA ranging from 2000 pg/ml to 25 pg/ml. 200 pi o f BCA working 
reagent was added to 25 pi o f cell lysate or standard, in duplicate in a 96 well plate. The
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plate was incubated at 37°C for 30 minutes. The absorbance was measured at 570 nm on 
the Wallac Victor^ plate reader.
2.11 In vivo virus biodistribution profiles
Mice received the required dose o f virus via tail vein injection. After the required 
duration mice were anesthetised by intra-peritoneal injection o f Euthatal (Merial Animal 
Health, Essex, UK), blood samples were taken by cardiac puncture and then the mice 
were perfused with PBS. For real-time PCR tissues were removed and snap frozen in 
liquid nitrogen. For immunohistochemistry (IHC) tissues were dissected and fixed 
overnight in 10% formalin then transferred to PBS.
2.11.1 Real time PCR
Real-time PCR (Taqman, UK) was used to quantify the number o f virus genome particles 
in tissue extracts.
DNA was isolated from tissue samples using the QlAamp DNA mini kit (Qiagen, CA, 
USA) as per m anufacturer’s instructions. Briefly, approximately 25 mg tissue (up to 10 
mg for spleen) was placed in 200 pi SDS-containing lysis buffer with proteinase K and 
incubated overnight at 56°C. A further 200 pi o f buffer was added to the samples that 
were then heated to 70°C for 10 minutes. For blood samples, 200 pi o f blood was mixed 
with 200 pi o f buffer and incubated at 56‘^ C for 10 minutes. The same protocol was then 
followed for both sample types. 200 pi ethanol was added to the samples, mixed and 
then they were loaded onto a QIAamp Spin Column. Samples were centrifuged for 1 
minute at 6000 x g to adsorb the DNA onto the silica-gel membrane o f the spin column. 
The spin column was washed with 2 buffers and then DNA was eluted in 100 pi 
deionised water by centrifugation at 6000 x g for 1 minute.
The concentration o f DNA in each sample was measured using the NDIOOO 
Spectrophotometer (Nanodrop, DE, USA). All samples were then diluted to 20 ng/pl, 
and 100 ng DNA was used in each reaction. A standard curve was produced from serial 
dilutions o f the virus. All samples and standards were analysed in duplicate.
I l l
For detection o f viruses with the eGFP transgene the SYBR green PCR kit (Applied 
Biosystems, MA, USA) was used with 300 nM forward (5’- 
CTCGATGTTGTGGCGGAT-3’) and reverse primers (5 '-GCGCCGAGGTGAAGTT- 
3’). The cycle conditions used were, step 1 dénaturation, 95°C for 10 minutes, step 2 
amplification and annealing, 95“C for 15 seconds, 60°C for 1 minute repeated for 50 
cycles, step 3, melting point analysis 95°C for 15 seconds, 60 °C for 15 seconds and 95 °C 
for 15 seconds. Results were analysed using Taqman data analysis software (Applied 
Biosystems, MA, USA).
For detection o f viruses with the Lac Z  transgene or AAV library particles with the rep 
gene, Taqman Universal PCR Master Mix, No AmpErase UNG was used (Applied 
Biosystems, MA, USA) with gene specific primer and probe sets. Probes were labeled 5 ’ 
with a FAM fluorophore (6-carboxyfluorescein) and 3 ’ with a TAMRA fluorescence 
quencher (6-carboxytetramethylrhodamine). TAMRA quenches the fluorescence of 
FAM until the probe hybridises to the target sequence and is cleaved by the 5 ’ 
exonuclease activity o f  the polymerase. For the rep gene, 300 nM o f  the forward primer 
(5’-CCGCAGATGTCAACACACAAG-3’) and reverse primer (5’- 
CCCCTGAAGGTACACATCTCTGT-3’) were used in combination with 200 nM of the 
probe (5’-CGTTCTTCCAGGCATGGTCTGGCA-3’). Cycle eonditions were Step 1, 
50”C for 2 minutes, 95 °C for 10 minutes. Step 2, 95 °C for 15 seconds, 60 °C for 1 
minute, repeated for 50 cyeles.
For the lac Z  gene reactions contained 200 nM sense (5'- 
TACTGTCGTCGTCCCCTCAAA-3') and antisense (5'-
TAACAACCCGTCGGATTCTCC-3') LacZ  primers and 300 nM probe (5’- 
TATCCCATTACGGTCAATCCGCCG-3’) (Senoo et a l ,  2000). Cycle eonditions were. 
Step 1, 50”C for 2 minutes, 95°C for 10 minutes. Step 2, 95°C for 30 seconds, 59°C for 30 
seconds, 72°C for 30 seconds, repeated for 50 cycles.
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2.11.2 Imm unohistochem istry
Formalin fixed tissues were embedded in paraffin, then 6 pm sections were cut and 
placed on silane coated slides. Slides were baked for 3 hours at 65°C for 3 hours, then 
40°C overnight. Paraffin was removed from the sections by 2 x 7 minute washes in 
Histoclear (Fisher Seientific, Leicestershire, UK). Sections were rehydrated by passing 
them through an aleohol gradient o f 100%, 95%, 70% ethanol for 7 minutes each. Slides 
were then washed in deionised water for 7 minutes. Endogenous peroxidase activity was 
quenched by incubating slides for 30 minutes in 0.3% (v/v) methanol-hydrogen peroxide 
at room temperature. The slides were then washed twice in water for 10 minutes. IHC 
was performed using Vectastain ABC rabbit IgG kit (Vector Laboratories, Peterborough, 
UK). Briefly, sections were placed in blocking solution (goat serum) and incubated for 1 
hour at room temperature in a humidified chamber to prevent sections from drying out. 
The primary antibody, rabbit anti-(3-gal (MP Biomedicals, Ohio, USA) and the negative 
control antibody rabbit IgG (DakoCytomation, Glostrup, Denmark) were diluted to 6.3 
pg/ml in blocking solution. Antibodies were ineubated on the sections overnight at room 
temperature in a humidified tray. Slides were washed 3 times in PBS, for 5 minutes each. 
The secondary antibody biotinylated goat anti-rabbit IgG (Vector Laboratories, 
Peterborough, UK) was diluted 1:200 in blocking solution and incubated on the slides for 
30 minutes at room temperature. Slides were washed in PBS 3 times, for 5 minutes each. 
The avidin and biotinylated horseradish peroxidase complex (ABC) (Vector Laboratories, 
Peterborough, UK) was then incubated on the slides for 30 minutes at room temperature. 
This was followed by 3 further 5 minute washes in PBS. Slides were then incubated for 
5 minutes in DAB chromogen solution (3,3’ diaminobenzidine, hydrogen peroxide, and 
nickel solution diluted in water) (Vector Laboratories, Peterborough, UK). Slides were 
washed in water for 5 minutes, then nuclei were counter-stained by incubation in 
haematoxylin for 30 seconds. Slides were washed for 5 minutes in running water. 
Seetions were dehydrated by incubation in 70% ethanol, 95% ethanol, 100% ethanol then 
Histoclear for 7 minutes each. Sections were mounted using Histom ount (National 
Diagnostics, Georgia, USA). Nuclei o f p -gal positive cells appeared dark brown/black.
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2.12 Phage methods
2.12.1 Phage libraries
All phage experiments were carried out using the T7Select 10-3b phage display system 
(Novagen, EMD Biosciences, Darmstadt, Germany). In this system phage express 5-15 
copies o f the inserted peptide in the capsid protein lOB. A constrained and a linear 8-mer 
library and non-recombinant control phage (with no peptide insertion) were obtained as 
packaged libraries that required amplification before use (gift from E. Ruoslahti, 
Burnham Institute, USA). All phage amplification and titering was performed using 
BLT5615 E.coli (Novagen, EMD Biosciences, Darmstadt, Germany), which carry an 
ampicillin resistance gene. Expression o f the capsid protein lOA requires addition of 
IPTG (isopropyl-beta-D-thiogalactopyranoside) as the lacUV5 promoter drives its 
expression.
2.12.2 Amplification of phage libraries
Phage were amplified using the liquid lysate amplification protocol as described in the 
Novagen T7 select system manual. Briefly, a single BLT5615 colony was picked from a 
freshly streaked plate and amplified overnight in 50 ml LB, supplemented with 50 pg/ml 
ampicillin, in an orbital shaker at 37°C and 180 rpm. 5 ml o f overnight culture was 
added to 500 ml LB supplemented with 50 pg/ml ampicillin in a 2 L flask, and incubated 
for approximately 2.5 hours at 37°C in an orbital shaker at 180 rpm. The absorbance at 
600 nm was read at intervals. When it reached approximately 0.5, 5 ml 100 mM IPTG 
was added to the flask and the incubation was continued for a further 30 minutes. The 
number o f cells in the culture was calculated using the formula:
Number o f cells = OD^nn x (2x 10  ^cells/mB x culture volume
0.5 ODgoo
Stock phage was added at an MOI o f 0.005. The culture was incubated with shaking at 
37°C for between 1-3 hours, until cell lysis occurred. This was determined visually when 
the solution appeared el ear but contained long thin strands and was also eonfirmed by a 
decrease in the GDôoq. Ten percent (v/v) 5 M NaCl was added to the culture, which was
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then centrifuged at 8000 x g for 10 minutes to remove cell debris. The supernatant was 
transferred to a sterile bottle for PEG precipitation.
2.12.3 Purification of phage
1/6 volume o f 50% (v/v) PEG-8000 was added to the supernatant and thoroughly mixed 
before ineubating at 4°C overnight. The supernatant was then centrifuged at 3185 x g for 
30 minutes at 4°C. The pellet was resuspended in 5 ml precipitation buffer (1 M NaCl, 
10 mM Tris-PICl, pPl 8.0, I mM EDTA), transferred to micro centrifuge tubes and 
vortexed vigorously. This was centrifuged for 10 minutes at 12600 x g. The supernatant 
was removed to a fresh microeentrifuge tube and the pellet was washed in another 2 ml 
precipitation buffer. The supernatants were pooled and titred. For short-term storage, 
phage were kept at 4°C. For longer term storage 10% (v/v) sterile 80% (v/v) glycerol 
was added to the phage, which was stored at -80°C.
2.12.4 Titering o f phage
A single BLT5615 colony was picked from a freshly streaked plate and amplified 
overnight in 25 ml LB, supplemented with 50 pg/ml ampicillin, 5 ml M9 salts (20 g/L 
NH 4CI, 60 g/L KH2PO4 , 120 g/L NaH 2P 0 4 .7 H 2 0 ), 2 ml 20% (v/v) glucose, 0.1 ml 1 M 
M gS0 4 , in an orbital shaker at 37°C and 180 rpm. The culture was diluted to an ODgoo 
o f approximately 1.
LB plates supplemented with 50 pg/ml ampicillin were pre-warmed in a 37°C incubator. 
Serial dilutions o f phage were made in LB. Agar tops (10 g/L bacto-tryptone, 5 g/L yeast 
extract, 1 g/L Mg Cl.gFLO, 7 g/L agarose) was melted and 3 ml aliquots were made and 
placed in a 50°C waterbath. 120 pi 100 mM IPTG was added to each aliquot. 200 pi o f 
BLT5615 culture were added to 100 pi o f each dilution o f phage. This was then added to 
an aliquot o f agar top and poured onto an LB plate. Once set, plates were inverted and 
placed in a 37°C incubator for 3 hours or at room temperature overnight. The number o f 
plaques present at each dilution was counted and used to calculate an average titre for the 
phage stoek using the formula:
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Phage titre (pfu)/ml) = Number o f plaques x dilution factor x 10
2.12.5 Sequencing of phage peptides
Individual plaques were picked from the agar using a glass pipette. Each plaque was 
placed in 250 pi BLT5615 liquid culture grown overnight (as for phage amplification). 
This was incubated in an orbital shaker at 37°C with shaking at 180 rpm for 
approximately 3 hours, until bacterial lysis occurred, 5 pi o f the lysate was used as a 
template for PCR o f the peptide insertion region o f the lOB gene using the primers T7 
Super Up (5 ’ -AGCGGACCAGATTATCOCTA-3 ’) and T7 down (5’- 
AACCCCTCAAGACCCGTTTA-3’). Eaeh PCR contained 200 pM each dNTP 
(Promega, Southampton, UK.), 1.25 U Taq DNA polymerase (Promega, Southampton, 
UK.) and 0.125 pM  each prim er in 2.5 mM MgCE, 50 mM KCl, 10 mM Tris-HCl (pH 
9.0) and 0.1% Triton X-100. The reactions were subjected to 40 cycles o f denaturing at 
94°C for 1 minute, annealing at 52°C for 1 minute and extension at 72°C for 1 minute. 
PCR products were analysed by agarose gel electrophoresis. PCR produces were cleaned 
using AmpPure (Agencourt Bioscience Corporation, MA, USA) as per manufacturer’s 
instructions. Purified PCR products were resuspended in 40 pi water and 10 pi o f this 
was used in the sequencing reaction. Sequencing reactions contained 3.2 pmoles primer, 
0.5 pi v3.1 Ready Reaction mix (Applied Biosystems, MA, USA), 4 pi v3.1 sequencing 
buffer (Applied Biosystems, MA, USA) in a 20 pi reaction. The cycle conditions were 
denaturing at 96°C for 50 seconds, annealing at 50°C for 20 seconds and extension at 
60°C for 3 minutes, for 25 cycles. Sequencing products were cleaned using CleanSEQ 
(Agencourt Bioscience Corporation, MA, USA) as per m anufacturer’s instructions. 
Results were analysed on the ABI 3730 automated sequencer using SeqScape v2.0.
2.12.6 UV irradiation of phage
Phage were titred and then diluted to the required concentration in precipitation buffer. 
Phage were irradiated using the Stratalinker UV Crosslinker (Stratagene, CA, USA). UV 
irradiation was performed for 9 hours at 4°C using 120 mJ UV irradiation. Following 
irradiation the phage were re-plated to confirm their inactivation through a lack o f plaque 
formation. Non-irradiated phage was used as a positive control.
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2.12.7.1 In vivo phage display
In vivo phage display was performed in 18 week old C57B16/129SvJ ApoE-/- mice that 
had been maintained on a diet o f 21% beef lard supplemented with 0.15% cholesterol for 
10 weeks. Mice were anesthetised by i.p injection o f 0.125 ml/10 g o f 5% (v/v) Rompon 
(PANTEX, De Hoeve, Holland) 10% (v/v) Ketaset (Fort Dodge Laboratories Inc., Iowa, 
USA) diluted in PBS. W here a predose was required it was injected via the tail vein and 
left to circulate for 15 minutes, before injection o f phage libraries. All animals received 
phage library via tail vein injection and it was left to circulate for 15 minutes. Mice were 
further anesthetised by intraperitoneal injection o f approximately 0.1 ml Euthatal (Merial 
Animal Health, Essex, UK). Blood samples were taken by cardiac puncture before mice 
were perfused with PBS until all organs appeared clear o f blood (approximately 5 
minutes). Tissue samples were taken and snap frozen in liquid nitrogen then stored at - 
80°C.
2.12.7.2 Extraction of phage from tissues
Phage were extracted from the entire BCA, carotid artery and aorta or approximately 100 
mg o f the other tissues. Tissues were placed in a fast RNA green biopulveriser lysis 
matrix tube (Qbiogene, CA, USA) containing 500 pi ice cold DM EM -PI (DMEM 
supplemented with 1% (w/v) BSA, 1 mM PMSF, 1 pg/ml leupeptin, 2 pg/ml aprotinin). 
The tissues were homogenised in a Fastprep system (Qbiogene) by performing six 45 sec 
runs at a speed o f 5.5. Samples were placed on ice every two runs to prevent 
overheating. The homogenate was removed and an additional 500 pi DMEM-PI was 
added to the tube. An additional 2 runs were performed, and then the buffer was pooled 
with the first aliquot. A further 2 runs were performed with another 500 pi buffer. To 
each homogenate 100 pi 1% non-idet P40 (NP40) was added and incubated on ice for 5 
minutes. This was followed by the addition o f 30 ml 1% sodium azide. Samples were 
stored at 4°C for up to 5 days before titering was performed.
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2.12.7.3 Bulk amplification of phage from tissue homogenates
The same protocol was used as for the initial amplification o f the libraries (section 
2.12.2) but instead o f calculating the amount o f phage to add to the liquid culture, all the 
remaining tissue homogenate from the animals in the group was added to the culture.
2.12.7.4 Amplification o f individual phage
The standard amplification protocol was followed (section 2.12.2) but 5 ml cultures were 
used and 100 pi o f the small-scale phage amplification used for PCR was added to the 
culture. Once lysed the cultures were pooled for purification.
2.13 AAV Library M ethods
2.13.1 Production of AAV library
The AAV libraries were produced by Dr L. Perabo, University o f Cologne, Germany 
(Perabo et a l ,  2003). Briefly, a library o f AAV plasmids (p587Lib7) was synthesised by 
inserting olignucleotides encoding 7 amino acids into Ascl and Not\ restriction sites in the 
cap gene, so that the peptides would be expressed after residue 587 (Figure 2.2). The 
plasmid library was transformed into D H 5a E.Coli and amplified. Viruses were 
produced by co-transfection o f the library plasmids and pXX6, using a protocol similar to 
that used to make peptide-modified AAVs (Section 2.5.8). Virions were purified on an 
iodixanol gradient and titred by dot blot analysis.
2.13.2.1 In vitro biopanning with the AAV library
Cells were seeded in T25 flasks and incubated overnight at 37°C to produce 70-80% 
confluence. RGB cells were co-infected with wild type Ad at MOI 500 and AAV library 
at MOI 20000 for 24 hours before the cells were washed in PBS and placed in fresh 
media. HeLa cells were co-infected with wild type Ad at MOI 10 and AAV library at 
MOI 20000 for 2 hours and then washed and placed in fresh media. 5 days after 
infection, cells were washed in PBS and resuspended in 500 pi AAV lysis buffer (150 
mM NaCl, 50 mM Tris-HCl, pH 8.5). Cells were lysed by freeze/thawing three times in 
liquid nitrogen and a 37°C waterbath. The supernatant was removed and the cell pellet 
was re-suspended in 200 pi PBS. 400 pi o f supernatant was used to infect cells for the
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next round o f biopanning and the remaining 100 pi was used for real time PCR and 
sequencing.
2.13.2.2 PCR and sequencing analysis o f eel! fractions from AAV library biopanning
DNA was extracted from biopanning cell media, pellet and supernatant samples using the 
QlAamp DNA Mini Kit (Qiagen, CA, USA) as per m anufacturer's instructions. PCR was 
performed using primers (AAVF 5 ' -AAGCCAC AAGGACGAT G AAGA-3 ' and A AYR 
5’-ATGTCCGTCCGTGTGTGGAAT-3') to amplify a 330 bp region o f the cap gene that 
contains the peptide insertion. Reactions contained 5 pi o f template DNA, 200 pM  each 
dNTP (Promega, Southampton, UK.), 2.5 U Taq DNA polymerase (Promega, 
Southampton, UK.) and 0.25 pM  each primer in 2.5 mM M gCb, 50 mM KCl, 10 inM 
Tris-HCI (pPI 9.0) and 0.1% Triton X-100. The reactions were subjected to 40 cycles of 
denaturing at 95°C for 1 minute, annealing at 56°C for 1 minute and extension at 72°C 
for 1 minute. PCR products were analysed by agarose gel electrophoresis. The PCR 
products were gel extracted using QIAquick Gel extraction kit (Qiagen, CA, USA) as per 
m anufacturer’s instructions. Briefly, the band was cut from the gel and placed in buffer 
at 50°C for 10 minutes to dissolve the gel. The solution was applied to a spin column and 
centrifuged to adsorb the DNA onto the membrane. The column was washed and then 
DNA was eluted in deionised water.
To sequence peptides from individual virions, the PCR product was TA cloned using 
Invitrogen TA cloning kit (Paisley, UK) as per manufacturer’s instructions. Briefly, the 
purified PCR product was ligated to the plasmid pC R 2.1 using T4 DNA ligase. The 
plasmid was then transformed into TOPIO competent E.coli by heat shock. Blue/white 
screening was used to identify positive colonies, as colonies containing a ligated PCR 
product appeared white on X-gal plates. Each white colony was picked into 400 pi LB 
supplemented with 100 pg/ml ampicillin and grown in an orbital shaker at 37°C with 
shaking at 180 rpm for 4 hours. 1 pi o f each culture was used as a template for PCR 
using M l3 forward and reverse primers (5’-GTAAAACGACGGCCAG-3’ and 5’- 
CAGGAAACAGCTATGAC-3 ’ which anneal to pCR2.1 either side o f  the cloning site. 
Reactions contained 1 pi o f template, 200 pM  each dNTP (Promega, Southampton, UK.),
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1.25 U Taq DNA polymerase (Promega, Southampton, UK.) and 0.25 pM  each primer in
2.5 mM M gC f, 50 mM KCl, 10 mM Tris-HCl (pH 9.0) and 0.1% Triton X-100. The 
reactions were subjected to 40 cycles o f denaturing at 95°C for 1 minute, annealing at 
50°C for 1 minute and extension at 72°C for 1 minute. PCR products were analysed by 
agarose gel electrophoresis and cleaned using AmpPure (Agencourt Bioscience 
Corporation, MA, USA) as per m anufacturer’s instructions. Purified PCR products were 
re-suspended in 40 pi water and 10 pi o f this was used in the sequencing reaction. 
Sequencing reactions contained 3.2 pmoles o f AAVF primer, 0.5 pi v3.1 Ready Reaction 
mix (Applied Biosystems, MA, USA), 4 pi v3.1 sequencing buffer (Applied Biosystems, 
MA, USA) in a 20 pi reaction. The cycle conditions were denaturing at 96°C for 45 
seconds, annealing at 50°C for 25 seconds and extension at 60°C for 4 minutes, for 25 
cycles. Sequencing products were cleaned using CleanSEQ (Agencourt Bioscience 
Corporation, MA, USA) as per m anufacturer’s instructions. Results were analysed on the 
ABI 3730 automated sequencer using SeqScape v2.0.
2.13.2.3 Analysis o f AAV library peptide composition
Peptide composition was analysed using receptor ligands contact (RELIC) programs 
(http ://rel ic.bio.anl. gov/rel icPeptides. aspx).
2.13.3 Production of heparin binding and non-binding AAV libraries
The AAV library was split into heparin binding and non-binding pools based on affinity 
for a heparin column as described in section 2.6. This was performed by Dr L. Perabo, 
University o f Cologne, Germany (Perabo et a l ,  2006b).
2.13.4 In vitro biopanning with the heparin non-binding AAV library
Cells were seeded in 10 cm^ tissue culture dishes (Nunc W iesbaden, Germany) and 
incubated overnight at 37°C to produce 70-80% confluence. Cells were co-infected with 
wild type Ad at MOI 10 and AAV library at MOI 20000 for either 3 or 24 hours before 
the cells were washed in PBS and placed in fresh media. Seventy-two hours after 
infection, cells were washed in PBS and resuspended in 1.5 ml AAV lysis buffer (150 
mM NaCl, 50 mM Tris-FICl, pFI 8.5). Cells were lysed by freeze thawing three times in
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liquid nitrogen and a 37°C waterbath. The supernatant was removed and the cell pellet 
was resuspended in 500 |li1 PBS. 1 ml o f supernatant was used to infect ceils for the next 
round o f biopanning and the remaining supernatant was used for real tim e PCR and 
sequencing.
2.13.5 In vivo biodistribiition studies with the AAV library
18 week old C57B16 ApoE-/- mice maintained on a diet o f 21% beef lard supplemented
with 0.15% cholesterol, for 12 weeks received 4 x 10’° gp AAV library or AAV control 
via tail vein injection. Twenty-four hours after injection, blood samples were taken by 
cardiac puncture, then mice were perfused with PBS. Tissues were removed and snap 
frozen in liquid nitrogen. DNA was extracted from tissues using the QIAamp DNA mini 
kit (Qiagen, CA, USA). This was used as a template for PCR and sequencing or real­
time PCR for biodistribution analysis.
To produce a restricted library for the second round, the peptide containing region o f 
virions extracted from the target tissue had to be amplified by PCR, cloned into p587Lib7 
and used to synthesise a new pool o f the library. PCR was carried out using primers 5’- 
GTAGCCATGGA A ACTAGATA AGAA AG AATACG-3 ’ and 5 ’ -
TACCAGCTCCCGTACGTCCTCGGC-3’ which amplifies a 1.3 kb region o f the
genome which can be ligated into the plasmid using restriction sites SnaB\  and BsiWl. 
PCRs contained 5 pi o f tissue extracted DNA as the template, 200 pM  each dNTP 
(Promega, Southampton, UK.), 1.25 U Taq DNA polymerase (Promega, Southampton, 
UK.) and 0.25 pM  each primer in 2.5 mM M gC f, 50 mM KCl, 10 mM Tris-HCl (pH
9.0) and 0.1% Triton X-100. The reactions were subjected to 40 cycles o f denaturing at 
95°C for 40 seconds, annealing at 59°C for 40 seconds and extension at 68°C for 2 
minutes. PCR products were analysed by agarose gel electrophoresis and cleaned using 
AmpPure (Agencourt Bioscience Corporation, MA, USA) as per m anufacturer’s 
instructions.
Cloning o f the PCR products was carried out by Dr. H. Buening (University o f Cologne, 
Germany) using the original protocol for producing the library (Section 2.13.1).
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For the second round o f  biopanning the same method was used, but each mouse received 
2 X lO'^ gp as the titre o f the virus pools were lower than that o f the original library.
2.13.6 In vivo biodistribution of heparin non-binding and binding AAV libraries
C57/B16 mice received 4 x 10^ gp o f A3, non-binding library, AAV-RC or binding library 
via tail vein injection. 24 hours after injection, blood samples were taken by cardiac 
puncture, then mice were perfused with PBS. Tissues were removed and snap frozen in 
liquid nitrogen. DNA was extracted from tissues using the QIAamp DNA mini kit 
(Qiagen, CA, USA) and used as a template for real-time PCR to analyse the 
biodistribution profiles o f the viruses.
2.14 Surface plasmoii resonance analysis
Surface plasmon resonance experiments were carried out by Dr J. M cVey (Imperial 
Collage London) using a Biacore X instrument (Biacore, Stevenage, UK). Human M T l- 
MMP was immobilised onto a CM5 biosensor chip according to the manufacturer’s 
instructions. Virus was passed over the chip at a flow rate o f 20 pl/min.
2.15 Statistical analysis
All in vitro experiments were carried out in triplicate on three independent occasions. 
Results shown are representative and values are mean ± standard error o f the mean 
(SEM). Student’s unpaired t-test was used to analyse the results, which were considered 
significant when p<0.05.
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Chapter 3:
Production and Characterisation 
of Atherosclerotic Plaque 
Targeted Viral Vectors
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3.1 Introduction
Genetic interventions aim ing to prevent rupture o f  unstable atherosclerotic plaques are 
likely to be m ost effective using a vector that can provide transgene expression 
specifically in the plaque follow ing intravenous injection. This is due to the need for 
an adequate dose o f  therapeutic agent to be provided locally to act on the appropriate 
target cells. D evelopm ent o f  a vector w ith target tissue selectivity is required to 
prevent unw anted transgene expression in other tissues, to reduce the chance o f 
possible side effects and enable the use o f  a lower dose to reduce potential vector 
toxicity. Therefore the ideal vector needs to be amenable to engineering to install 
targeting, stable in blood, non-toxic, efficient at cell internalisation and producing 
transgene expression and producible at high titres. Viral vectors m ay provide the 
best tool for achieving this as they provide a highly efficient and adaptable gene 
delivery system. However, as yet no vectors that selectively target atherosclerotic 
plaques have been identified, although m ethods o f  targeting vectors are now well 
established and m ay be applied to overcom e this problem.
Healthy vasculature and atherosclerotic plaques are clearly very different at the 
cellular and m olecular level (Ross, 1993). M olecules that are selectively upregulated 
on the surface o f  plaques could potentially function as receptors for gene therapy 
vectors. I f  peptides that target these m olecules can be identified, it should be possible 
to exploit these differences to target viral vectors to plaques w ith a high degree o f 
specificity. Liu et al. (Liu et a l ,  2003) perform ed biopanning w ith an M l3 phage 
library in an ApoE-/- m ouse m odel o f atherosclerosis to investigate molecular 
differences betw een atherosclerotic and healthy vasculature. The biopaiming 
identified 103 plaque-targeting peptides, 3 o f  w hich have been used in this study.
3.1.1 CAPG PSK SC (CAP) peptide
The m ost com m only occurring peptide m otif ('Vq^/yPSVrSC) was found at a 
frequency o f 9.7%  and is contained w ithin the CAPGPSKSC (CAP) peptide. Further 
w ork showed that this peptide was unable to bind the aortic endothelium  o f  healthy 
mice, but did bind to hum an arterial atherosclerotic lesions ex vivo, suggesting that the 
peptide has a plaque-specific targeting capacity (Liu et a l ,  2003). It also suggests 
that the disease m odel m aybe a reliable reflection o f atherosclerosis in hum ans in this
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context, as it dem onstrated that the peptide was not species or m odel specific. 
BLAST (Basic local alignm ent search tool) searching showed the CAP peptide has 
hom ology to Chym ase I, a serine protease that is involved in angiotensin II 
generation. Affinity clirom atography followed by m ass spectrom etry identified 
glucose-regulated protein 78 (Grp78) (also Imown as BiP) as the putative receptor for 
this peptide (Liu et a l ,  2003). Grp78, a m em ber o f the hsp70 family, was originally 
identified as an endoplasm ic reticulum  (ER) chaperone protein where it has a role in 
the unfolded protein response defense m echanism  (Kaufman, 1999, Lee, 2001, Reddy 
et a l ,  2003). It is constitutively expressed in the ER o f alm ost all cell types (Kim et 
a l ,  2006) and has been shown to be expressed on the surface o f  cells under stress 
(Delpino and Castelli, 2002). Its expression is upregulated in m any cells under 
pathological conditions including cancer cells (Shin et a l ,  2003, A splin et a l ,  2000), 
rheum atoid fibroblasts (M isra et a l ,  1997), cardiom yocytes follow ing myocardial 
infarction (Thurerauf et a l ,  2006) and ischem ia (Szegezdi et a l ,  2006) and in 
atherosclerotic plaques (Bhattacharjee et a l ,  2005). This upregulation is thought to 
be caused by conditions such as ischem ia, hypoxia and glucose deprivation, which 
often occur in these disease states. H igher cellular levels o f  Grp78 expression result 
in its increased localisation to the cell m em brane (Delpino et a l ,  1988).
In atherosclerosis G rp78 is expressed on the endothelium  o f  plaques and on the 
surface o f m onocytes and foam  cells w ithin plaques (Bhattacharjee et a l ,  2005) 
(Outinen et a l ,  1999). A t the cell surface it can associate w ith the low-density 
lipoprotein receptor-related protein (M isra et a l ,  2002), which is also upregulated 
during plaque progression (Llorente-Cortes et a l ,  2004). There are several 
m echanism s that m ay cause an increase in Grp78 expression in plaques. The ER 
stress/unfolded protein response pathw ay that increases expression o f  Grp78 is active 
at all stages o f  developm ent o f atherosclerosis (Zhou et al., 2005). Peroxynitrate, an 
oxidant (generated by N O  reacting w ith superoxide) that causes ER  stress and is 
associated w ith progression o f  atherosclerosis can upregulate Grp78 in hum an ECs 
(Diclchout et a l ,  2005). Hyperhoniocysteinem ia a Imown risk factor for 
atherosclerosis (W ald et a l ,  2002) is also thought to cause an increase in Grp78 
expression, as it has been show n that stim ulating hum an um bilical vein ECs with 
hom ocysteine causes an upregulation in Grp78 expression (Kokam e et a l ,  1998). 
Inducing hyperhoniocysteinem ia in ApoE-/- mice has also been shown to increase
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expression o f Grp78 in advanced plaques, and it was found to be m ainly localised to 
the plaque cap (Zhou et a l ,  2004).
The role o f  Grp78 in atherosclerotic plaques is still unclear. It m ay have a protective 
role in inhibiting atherosclerosis by decreasing the procoagulant activity o f tissue 
factor, through direct binding o f  tissue factor in the cell m em brane (W atson et a l ,  
2003, Bhattacharjee et a l ,  2005). It m ay also be involved in inliibiting hom ocysteine- 
induced gene expression (W erstuck et a l ,  2001). It is speculated that hom ocysteine 
causes cellular stress as it reduces N O  bioavailability (Outinen et a l ,  1999). This 
alters the intracellular redox potential and produces reactive oxygen species, which 
results in the accum ulation o f  unfolded proteins in the ER. G rp7 8 may have a 
protective role in overcom ing this (Kokame et a l ,  1998, Eikelboom  and Lonn, 1999). 
H om ocysteine also prom otes SM C growth, which may contribute to the development 
o f atherosclerosis (Tsai et a l ,  1994).
Interestingly Grp78 has been proposed to act as a native receptor for some viruses. It 
can associate w ith class 1 m ajor histocom patability protein (M HC class I) on the cell 
surface and this com plex has been shown to act as a co-receptor for coxsackie virus 
A9 (CAV9) in com bination w ith the receptor avPa integrin (Triantafilou et al., 2002). 
It has also been proposed to act as a receptor for dengue virus serotype 2 
(Jindadanirongwech et a l ,  2004). As other viruses use Grp78 as a receptor, this 
shows that it m ust be accessible for virus binding and can enable vector 
internalisation, w hich is an im portant requirem ent for successful gene delivery.
Other phage display studies have identified Grp78 as a potential receptor for peptides. 
Biopanning on a hum an m etastatic m elanom a cell line identified the peptide 
CTVALPGG YV RVC that uses G rp78 as a receptor (Kim  et a l ,  2006). Phage display 
for antibody fingerprinting (phage display on im m obilised patient imm unoglobulins) 
identified G rp78 as a potential receptor for targeting tum ours (M intz et a l ,  2003). In 
another phage display study im m obilised Grp78 was used as the target and this 
identified the targeting peptides W IFW IQL and W DLA W M FRLPV G (Blond- 
Elguindi et a l ,  1993), w hich target tumour cells in breast and prostate cancer models 
and hum an prostate cancers ex vivo (Arap et a l ,  2004). These studies demonstrate
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that Grp78 expression m ay be upregulated in several cancers and verified that Grp78 
can act as a m olecular target. N one o f the Grp78 targeting peptides share any 
com m on m otifs, im plying that they bind to different regions o f the protein.
3.1.2 CQ EPTRLK C (CQE) peptide
The second m ost com m only occurring m otif from the biopaim ing was 
(E*Vg^/tRVa^'"/hC), which occurred in 4.9%  o f peptides and is found in the peptide 
CQEPTRLKC (CQE) (Liu et a l ,  2003). BLAST studies identified hom ology with a 
novel protein described as an interferon-induced protein (Liu et a l ,  2003). N o further 
experim ents were carried out to provide any inform ation about the possible receptor 
for the peptide.
3.1.3 CN H R YM Q M C (CNH ) peptide
A nother m otif (CN^/hR^/yM Q M SC) that occurred at a relatively high frequency 
(1.8%) was contained in the peptide CNHRYM QM C (CNH). This peptide is o f 
particular interest as BLA ST scanning showed it has hom ology to tissue inhibitor o f 
m atrix m etalloproteinases 2 (TIM P2) (Liu et a l ,  2003). TIM Ps are naturally 
occurring inhibitors o f  m atrix m etalloproteinases (M M Ps), a group o f  24 structurally 
related zinc proteases that degrade extracellular m atrix proteins. M any M M Ps are 
Imown to be expressed in atherosclerotic plaques where they have a role in vascular 
rem odeling, SMC m igration, neointim a formation, angiogenesis and plaque disruption 
(Rajavashisth et a l ,  1999, Brown et a l ,  1995, Galls et a l ,  1994, Li et a l ,  1996, 
Henney et a l ,  1991, N ikkari et a l ,  1995, Southgate et a l ,  1996, Jolmson et a l ,  
2005a). There are four m em bers o f the TIM P family, TIM Ps -1, -2, -3 and -4, which 
vary in their tissue distribution, transcriptional regulation and m etalloproteinase 
specificity, although there is some overlap (Lafleur et a l ,  2003). For example, TIM Ps 
2-4 inliibit m em brane type 1 m atrix m etalloproteinase (M T l-M M P) whereas TIM Pl 
has no effect (Nagase et a l ,  2006).
TIM P2 has 2 functions, it is required for the activation o f M M P2 and it acts as an 
inhibitor o f  proteases activated by M Tl-M M P. A ctivation o f  pro-M M P2 occurs when 
TIM P2, pro-M M P2 and 2 M T l-M M P  m olecules form a com plex in the cell 
m em brane (Strongin et a l ,  1995) (Butler et a l ,  1998). M T l-M M P  then cleaves pro- 
M M P2 to produce the active form  o f the protein. This process is dependent on the
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TIM P2 concentration. A n excess o f TIM P2 prevents the second M T l-M M P 
m olecule from  binding so inliibits M M P2 activation (Hernandez-Barrantes et a l ,  
2001). H igh levels o f  TIM Ps -3 and - 4  also inhibit pro-M M P2 activation (Hernandez- 
Barrantes et a l ,  2001). However, in the absence o f  TIM P2, M T l-M M P  undergoes 
autolytic proteolysis to an inactive form, so TIM P-2 has both a positive and negative 
affect on M T l-M M P  activity (H ernandez-Barrantes et a l ,  2000).
As TIM P2 is know n to interact w ith M T l-M M P at the cell surface, it is possible that 
the TIM P2 hom ologous peptide CNH may also bind to M T l-M M P. TIM P2 
com petitively inhibited the binding o f  the CNH peptide to hum an um bilical vein 
endothelial cells (HUV EC), suggesting that the peptide does bind to a TIM P2 receptor 
(Liu et a l ,  2003). How ever, the region o f TIM P2 hom ologous to the peptide differs 
from the regions o f  TIM P2 known to be involved in contact w ith M T l-M M P 
(Fernandez-Catalan et a l ,  1998) so it has been proposed that it m ay be binding to an 
alternative previously unrecognised TIM P2 receptor (Liu et a l ,  2003, Chester et a l ,  
1995, Corcoran and Stetler-Stevenson, 1995).
Relatively high levels o f  TIM P2 expression have been detected in atherosclerotic 
plaques (Rajavashisth et a l ,  1999), where its m etalloproteinase activity m ight limit 
plaque progression (George, 2000). M T l-M M P is expressed in both normal and 
atherosclerotic hum an arteries and has been localised to m acrophages and SMC 
within plaques (Rajavashisth et a l ,  1999, Galis et a l ,  1994). In the presence o f 
inflam m atory m olecules such as oxLDL, IE -la , and T N F a, sm ooth muscle cell 
expression o f  M T l-M M P  is upregulated (Rajavashisth et a l ,  1999). Therefore 
expression levels are higher in atherosclerotic plaques than healthy vasculature. This 
suggests M T l-M M P  m ay be a prom ising target for a gene delivery system  selective 
for atherosclerotic plaques. M T l-M M P is a 64 kD a protein, and is one o f six MMPs 
that have a single transm em brane domain. The catalytic dom ain is displayed on the 
exterior o f  the cell (Sato et a l ,  1994). It is involved in activation o f M M P2 and 
degradation o f m any extracellular m atrix proteins including gelatin, fibronectin, 
proteoglycans, aggrecan and type I, II and III collagens (Pei and W eiss, 1996, Ohuchi 
et a l ,  1997, d'Ortho et a l ,  1997). Recently M T l-M M P has also been shown to be
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involved in m onocyte m igration and transm igration through activated endothelial 
cells (M atias-Rom an et a l ,  2005).
The tliree peptides CAP, CNH and CQE are therefore prom ising candidate peptides 
for targeting vectors to atherosclerotic plaques, so it is necessary to test their targeting 
capacity in a range o f  vector platform s.
3.1.4 V iral vector platform s
The m ost com m only used viral vectors for cardiovascular disease gene therapy are 
based on Ad5. How ever, following system ic adm inistration, Ad5 does not transduce 
the vasculature, as it is highly efficient at infecting other organs, particularly the liver 
and spleen. Strategies used for producing genetically targeted Ads with altered 
tropism  are now well established (See section 1.11.2). Insertion o f  targeting peptides 
into the HI loop o f  the virus fiber has proven to be an efficient way o f  expanding viral 
tropism  by enabling the virus to bind a novel receptor (Km snykli et a l ,  1998) 
(Dm itriev et a l ,  1998, N icklin  et a l ,  2001c). To produce a virus w ith a high level o f 
cellular specificity it is also necessary to detarget the virus from  its native receptors. 
M utations that ablate A d5 binding to its receptors CAR (Roelvink et a l ,  1999, 
Jakubczak et a l ,  2001), integrins (W ickliam et a l ,  1993, W ickliam, 1994, Huang et 
a l ,  1995) and HSPG (Sm ith et a l ,  2003a, Sm ith et a l ,  2003b, N icol et a l ,  2004) 
have been identified and shown to reduce the natural tropism  o f  the virus. By 
combining the detargeting m utations w ith the plaque targeting peptides it should be 
possible to produce a highly selective vector.
Ad5 can also be pseudotyped to produce vectors with altered tropism . As yet, no 
pseudotypes w ith a high degree o f  selectivity for vascular cells have been identified 
but there are some prom ising pseudotypes that m ight provide a useful platform  for the 
developm ent o f  a plaque-targeted vector. Ad5 pseudotyped with the fiber o f  A d l9p , a 
subgroup D virus, has been show n to have a reduced tropism  for rat liver m  vivo and 
mouse, rat and hum an hepatocytes in viti^o (Denby et a l ,  2004). It also transduces 
hum an endothelial cells and sm ooth m uscle cells at least as efficiently as Ad5 (Denby 
et a l ,  2004). A d l9 p  also has a favourable safety profile as it has only been isolated 
once (in 1955 in Saudi Arabia) and unlike m ost A d serotypes it is not associated with 
any disease (Arnberg et a l ,  1997). In the general population neutralising antibodies
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to A d l9 p  occur at a m uch lower frequency com pared to Ad5 neutralising antibodies, 
as they have been found in less than 20%  and 80% o f  people respectively (Vigne et 
a l ,  2003). Therefore although the A d l9 p  receptor has not yet been identified, it has 
m any features that suggest it m ay be a useful serotype for providing a vector naturally 
detargeted from  the liver w hich can be m odified to be retargeted to the vasculature.
AAY2 has m any features that suggest it could be developed into an effective plaque 
targeted vector. It has been shown to produce sustained transgene expression, it is not 
thought to be associated w ith any hum an pathology and it is less im m unogenic than 
Ad vectors (M onahan and Sam ulski, 2000a). However, following systemic 
adm inistration o f  A A V2 a very low  level o f  transduction o f  vascular cells is achieved 
(Wliite et a l ,  2004, W ork et a l ,  2006) and the m ajority o f  the virus is found in the 
liver and spleen (Nathw ani et a l ,  2001, Koeberl et a l ,  1997). Insertion o f  targeting 
peptides into the HSPG binding site o f the virus capsid has been shown to reduce its 
natural tropism  and retarget it to alternative cell types (Girod et a l ,  1999). For 
example, peptide insertion has been shown to enable targeting to endothelial cells 
(Nicklin et a l ,  2001a, W liite et a l ,  2004), sm ooth m uscle cells (W ork et a l ,  2004a) 
and the vasculature o f  the lung and brain (W ork et a l ,  2006). Therefore if  plaque- 
targeting peptides can be identified and incorporated into the AAV2 capsid it may 
result in a highly efficient gene delivery vector.
3.1.5 Aims
The aims o f  this chapter are:
• To produce Ad and AA V vectors with the 3 plaque targeting peptide 
CA PGPSKSC, CN HRYM QC and CQEPTRLKC displayed on the capsid 
surface.
• To investigate the tropism  o f  these vectors by perform ing in vitro transduction 
assays in a range o f vascular and non-vascular cell types.
• To determ ine the biodistribution profile o f selected vectors in a mouse model 
o f atherosclerosis to investigate whether the vectors selectively target areas o f 
atherosclerotic vasculature.
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3.2 Results
3.2.1 ApoE-/- m ouse m odel o f atherosclerosis and plaque stability
One o f  the m ost reliable and established animal m odels o f  atherosclerosis uses ApoE- 
/- m ice on a C57/B16 background. M aintaining these m ice on a high fat diet 
supplem ented w ith cholesterol causes the developm ent o f com plex atherosclerotic 
lesions in the brachiocephalic artery (BCA) after a relatively short period o f time 
(Jolmson and Jackson, 2001). A new  colony o f mice was established for this study, so 
histology was perform ed to confirm  that mice developed advanced lesions. From the 
age o f 8 weeks mice were fed a high fat diet for 10 or 12 weeks before histological 
analysis was perform ed on the BCAs. Anim als m aintained on a normal chow diet 
showed no signs o f  atherosclerosis (13.2A), whereas mice fed a high fat diet for 10 
weeks developed large stable lesions w ith thick fibrous caps (Figure 3 .IB ). M ice fed 
a high fat diet for 12 w eeks generally developed more advanced lesions (Figure 3.1C). 
To further the developm ent o f advanced plaques w ith an unstable phenotype, mice 
received the high fat diet from 6 weeks old (Figure 3 .ID). One m ouse (from 3 
examined) had a plaque w ith a buried fibrous cap indicative o f  an earlier plaque 
rupture and another animal had a very large alm ost totally occlusive plaque. 
Although a very small sam ple num ber has been used in this study, it suggests the mice 
consistently developed advanced plaques, but not plaque ruptures, therefore this 
model can be used for developm ent o f  vectors that target advanced plaques.
The m ajority o f  anim als used in this w ork were fed a high fat diet for 12 weeks from 
the age o f 6 weeks and had visible lesions in the BCA at the tim e o f  dissection. 
Wliere stated, age m atched m ice m aintained on a normal chow diet were used.
3.2.2.1 Production and in vitro characterisation of plaque targeted vectors based 
on the CAR binding m utant A d K O l
To initially test the ability o f the peptides CAP, CNH and CQE to alter the in vitro 
tropism  o f  Ad5, the peptides were inserted into the FII loop o f  the A dK O l vector, 
which has previously been shown not to bind CAR due to the loiob m utations S408E 
and P409A (Nicklin et a l ,  2001c, Jakubczak et a l ,  2001). The A dK O l vector 
provides a sim ple system  in which the in vitro targeting capacity o f  the peptides can 
be assessed in the context o f  the A d vector. The resulting virus particle titres (Table
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A.
B.
C.
D.
Adventitial
inflammation
Fatty streak
Medial hypertrophy
Fibrous cap
Buried fibrous cap
Figure 3.1 Example cross sections of BCAs from ApoE-/- mice stained with H 
and E or EVG. Mice were maintained on A. a normal chow diet B. a Western 
diet o f  o f  21% beef lard supplemented with 0.15% cholesterol for 10 weeks from 
the age o f  8 weeks C. a Western diet for 12 weeks from the age o f  8 weeks. D. a 
Western diet for 12 weeks from the age o f  6 weeks.
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3.1) were all in the expected range, suggesting peptide insertion did not have a 
detrim ental affect on capsid form ation. W estern blot analysis o f  the purified virus 
was able to detect the recom binant m onom er fiber (60 IdDa) under denatured 
conditions and fiber trim ers (180 kDa) under sem i-native conditions, indicating that 
peptide insertion did not affect capsid form ation (Figure 3.2).
To exam ine the effects o f  the capsid m odifications on virus infectivity, infections o f 
several vascular cell lines were perform ed with the A dK O l-C A P, A dK O l-C N FI and 
A dK O l-C Q E. In all the vascular cell types tested all 3 peptide-m odified viruses 
(except A dK O l-C A P in SVEC 4-10) produced signiEcantly higher transduction than 
the parental A dK O l virus (p<0.05) (Figure 3.3). As a control, infections were also 
carried out in a non-target cell line, HeLa. H eLa cells were chosen since they are a 
non-vascular cell line and do not express the putative receptors for the CAP peptide 
(Grp78) (Chae et al^  2004) and CNH peptide (M T l-M M P) (Zhai et a l ,  2005). There 
was no significant difference in transduction betw een any o f  the peptide-m odified 
viruses and the A dK O l virus (Figure 3.3). These results suggest that all 3 peptide- 
m odified A dK O l viruses have an increased tropism  for vascular cells.
3.2.2.2 Infection o f A d K O l viruses in the presenee o f anti-CA R antibody
To test w hether the peptide-m odified vectors still require binding to CA R to infect 
cells, or whether the peptide insertion enables them  to use an alternative receptor, 
infection o f  the m ouse endothelial cells was repeated in the presence o f a CAR- 
neutralising antibody that is known to reduce AdCTL infectivity (Cohen et a l ,  2001) 
or control rabbit serum  (Figure 3.4). Com pared to cells incubated w ith control serum, 
only the transduction o f  A dC TL was significantly reduced (p<0.05) by the presence 
o f the anti-CA R antibody w hereas A dK O l, A dK O l-C A P , A dK O l-C N H  and 
A dK O l-C Q E  transduction was unaffected, suggesting that the A dK O l viruses do not 
use CA R for cellular attachm ent.
3.2.3 Production and in vitro characterisation of A dK O lS* viruses
The in vitro results using the A dK O l viruses indicate the CAP, CNH and CQE 
peptides may efficiently target the vectors to cells o f the vasculature, but it is 
im portant to determ ine w hether this vascular transduction can be replicated in vivo 
following system ic injection o f  the viruses. However, it is well laiow n that the
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Virus Particle titre (vp/ml)
: AdCTL 3 .7 5 x l0 > 2
: AdKO l 3 .7 5 x l0 ‘2
! AdKO l-CAP 5 .0 3 x l 0 ‘2
: AdK O l-CN H  4.59x10*2
' AdKO l-CQ E 2 .32x10*2
Table 3.1 Example partiele titres of genetically engineered Ad vectors.
135
A.
B.
I
.§CO I IICQ <Uh<
Py w XGx z
V Y Y
o o o
T3 T3< < <
0
1
160 kDa 
50 kDa
30 kDa
250 kDa 
160 kDa
75 kDa
30 kDa
fiber
monomers
fiber
trimers
fiber
monomers
Figure 3.2 Western blot of fiber-modified Ad vectors. 2 x 10^ ® vp o f  each virus 
was used in western blotting to detect the virus fiber A. under reducing conditions B. 
under non-reducing conditions. Full range rainbow marker (Amersham Biosciences, 
Bucks, UK) was used to determine the size o f  proteins detected. Fiber monomer =  
60 kDa. Fiber trimer = 180 kDa.
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0
®  Media 
O  Serum
anti CAR antibody
AdCTL AdKOl A dK O l-
CAP
AdKOl
CNH
AdKOl
CQE
B.
AdCTL AdKOl A dK O l- A dK O l- AdKOl- 
CAP CNH CQE
Figure 3.4 Infection o f  A d K O l vectors in m ouse endothelial cells in the 
presence o f  an anti-C A R  antibody. A. IP-IB cells B. SVEC 4-10 cells. Ceils were 
pre-incubated on ice for 30 minutes in serum free media, media containing control 
serum or anti-CAR antibody diluted 1 in 200 in serum free media. Cells were 
infected with an MOI o f  10,000 for 3 hours, washed and incubated in fresh media for 
48 hours. Cell lysate was used in a p-gal assay to quantify the transgene expression, 
which was normalised to the total protein content o f  the sample. p <0.05 vs serum.
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A dK O l m utation alone is insufficient for detargeting Ad5 from  the liver (Smith ei a i ,  
2003b, Einfeld et a l ,  2001, Leissner et a l ,  2001, Smith ei a l ,  2002, Nicol et a l ,  
2004). A previous study w ith peptide-m odified A dK O l viruses targeted to ECs 
showed that although the viruses were effective in vitro they failed to have any 
retargeting effect in vivo (N icklin et a l ,  2004). The CAP, CNH and CQE peptides 
were therefore incorporated into the fiber o f A dK O lS* w hich has been shown to 
produce an approxim ately 1000-fold decrease in liver transduction compared to 
AdCTL follow ing system ic adm inistration in rats, m ice and non-hum an primates 
(Nicol et a l ,  2004, Sm ith et a l ,  2003b, Smith et a l ,  2003a). Therefore A dK O lS* 
may provide a potentially useful platform  for in vivo retargeting.
The A dK O l S'*' vectors were generated using the same transient transfection/infection 
method as the A dK O l viruses. All particle titres were in a sim ilar range (between 1.5 
X 10^  ^vp/ml and 9 x  lO’  ^vp/m l) suggesting the capsid m odifications had not affected 
virus formation.
Initially, the A dK O lS*  viruses were tested in vitro using the same m ethod as for the 
A dK O l viruses. This show ed that in all cell lines tested (RGE, IP -IB , SVEC 4-10, 
HSVEC, hum an coronary artery endothelial cells (HCAEC), H eLa cells and mouse 
hepatocytes the am ount o f transgene expression was never significantly higher than 
the background levels m easured in uninfected cells (data not shown). Staining o f 
cells infected w ith M OI 10000 confirmed the lack o f transgene expression (data not 
shown). We therefore sought an alternative vector platform  for in vivo testing o f  the 
peptides.
3.2.4 Production and in vitro characterisation o f Ad5/19p viruses
Due to the lack o f  infectivity o f  the A dK O l S* viruses, it was decided to investigate 
using Ad5 pseudotyped w ith the A d l9 p  fiber (Ad5/19p) as an alternative platform  
(Denby et a l ,  2004). The 3 plaque targeting peptides were inserted into the HI loop 
o f Ad5/19p and pseudo typed viruses were produced using the transient 
transfection/infection m ethod (Jakubczak et a l ,  2001, N icklin el a l ,  2001c). Viruses 
were titred using the BC A  particle titre m ethod (Von Seggern et a l ,  1998) (Table 3.2) 
and confirm ed by Taqm an analysis (Figure 3.5). W estern blotting was used to 
confirm  that the viruses had fibers (data not shown).
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Virus
Ad5/19p
Ad5/19p-CAP
Ad5/19p-CNH
Ad5/19p-CQE
Titre vp/ml
3.45 X 10*2 
4.22 X 10*2 
3.05 X 10*2 
1.7 X 10*2
Table 3.2 Partiele titres of the Ad5/Adl9p viruses.
45
40
35
30
e t
value 20 
15 
10 
5 
0
Ad5/19p
Ad5/19p-CAP
Ad5/19p-CNH
Ad5/19p-CQE
1x10* 1x102 1x10^ lxl(X* 1x10^ 1x10^ 1x102 i^lO»
Virus particles
Figure 3.5 Taqman real time PCR to confirm the partiele titres of the Ad5/19p 
viruses. Serial dilutions o f  the viruses based on the particle titre were used as a template 
for Taqman PCR using primers that bind the lac Z  transgene.
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In vitro infections were perform ed in the vascular cell lines and H eLa cells. In all the 
cell lines tested, the 3 peptide-m odified viruses produced significantly higher levels o f 
infection com pared to Ad5/19p. (Figure 3.6) Flowever, unm odified Ad5/19p only 
infected RGE, HSVECs and HCAECs at a low  level and did not infect any o f the 
other cell types tested. In all the cell lines and w ith all 3 peptide-m odified viruses a 
dose response was seen and in all cases (except Ad5/19p-CNH M OI 1000 in IP-IB  
and SVEC 4-10, A d5/19p-CQ E M OI 10000 in HSVECs) significantly higher levels 
(p<0.05) o f  transduction com pared to unm odified Ad5/19p were m easured. X-gal 
staining o f  cells infected w ith 10000 vp/cell shows the same pattern o f  results as the 
(3-gal assay (Figure 3.7). This suggests that peptide insertion enables a non-specific 
interaction betw een the vectors and cells, which results in cellular uptake o f the 
vectors.
3.2.5.1 Production and in vitro characterisation of peptide-m odified AAV2 
vectors
In parallel w ith the adenovirus studies, the CAP and CNH peptides were incorporated 
into the capsid o f  AAV2 after residue 587, as described previously (Girod el a l ,  1999, 
Nicklin et a l ,  2001a). A lthough both the CAP and CNH peptides could be 
incorporated into the capsid to produce functional viruses, A A V 2-CN H  was difficult 
to produce at titres equivalent to AA V2-RC and AAV2-CA P, w ith the titres o f 
preparations being approxim ately 10 fold lower.
Initial in vitro experim ents were carried out w ith the plaque targeted AAV2 vectors to 
determine if  the transduction profiles were sim ilar to that seen w ith the A dK O l 
vectors. As w ith the A dK O l based viruses, the peptide-m odified A A  Vs did not 
produce significantly higher transduction o f non-vascular HeLa cells com pared to the 
control virus, in fact AA V2-CA P transduction was significantly lower than control 
virus. In the m ouse, hum an and rat endothelial cell lines, A A V 2-CN H  produced 
significantly higher levels o f  transduction (Figure 3.8). How ever, AA V2-CA P only 
produced a significantly higher level o f  transduction in RGE cells (Figure 3.8).
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Figure 3.6 In vitro infection of peptide-modified Ad5/19p viruses. A. IP-IB, B.
SVEC 4-10, C. RGE, D. HCAEC, E. HSVEC, F. HeLa. Cells were infected with the 
MOI stated for 3 hours, then washed and incubated in fresh media for 48 hours. (3-gal 
activity in the cell lysates was quantified and levels were normalised to the total 
protein content. * p <0.05 vs Ad5/19p.
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Figure 3.8 Infection of pcptide-m odiBed AAV2 vectors. Cells were infected with an 
MOI o f  1000 for 24 hours, then washed and incubated in fresh media for 48 hours. Cell 
lysate was used in a p-gal assay to m easuie the amount o f  transgene which was 
normalised to the total protein content o f  the sample. * p <0.05 vs AAV2-RC,
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3.2.5.2 H eparin binding o f peptide-m odified AAV2 based vectors
To determ ine whether insertion o f  the peptides into the capsid o f  AAV2 affects the 
ability o f  the virus to bind HSPG, binding to the receptor analogue heparin was 
evaluated. The viruses were loaded onto a heparin column, which was then washed 
before bound virus was eluted in a high salt solution. Quantitative PCR o f the 
resulting fractions was used to analyse the extent o f  heparin binding (Perform ed by H, 
Buening). Both peptide-m odified viruses and control AAV2 bound to the colum n and 
were eluted in the first elution w ith 1 M NaCl (Figure 3.9), suggesting both modified 
vectors still bind heparin. H ow ever the m ajority o f AAV2-CAP and AA V2-CN H was 
not detected in any o f  the fractions whereas 100% o f AA V2-RC was recovered. This 
m ay be due to the rem aining virus still being bound to the colunni and requiring a 
higher concentration o f  salt solution to elute it.
To determ ine w hether this interaction with heparin affects infectivity o f  the viruses, 
infection o f  the m ouse endothelial cell lines was repeated in the presence o f soluble 
heparin (Figure 3.10), In both cell lines both peptide-m odified viruses and AAV2-RC 
showed reduced levels o f  infection in the presence o f  heparin, suggesting both AAV2- 
CAP and AAV2-CNFI m aintain the ability to bind HSPG.
3.2.5.3 Affect o f proteasom e inhibitors on AAV2 transduction
The low level o f  transduction o f  endothelial cells by AAV2 is thought to be due to 
both the sequestration o f the vector in the extracellular m atrix caused by HSPG 
binding (Pajusola et a l ,  2002) and due to degradation o f internalised virions by the 
proteasom e (N icklin et a l ,  2001a, Denby et a l ,  2005). It has previously been 
dem onstrated that the peptide aldehyde proteasom e inhibitors N-acetyl-L-leucyl-L- 
leucyl-norleucine (LnLL) and M G132 can enliance transduction o f wild type AAV2 
but can have little affect on some peptide-m odified AAV2 vectors (peptide 
dependent) as they are thought to traffic to the nucleus via an alternative m echanism  
(W ork et a l ,  2004a, N icklin et a l ,  2001a). To determine w hether this pathway 
affects AA V 2-CA P and AA V2-CNH, infections o f SVEC 4-10 and IP -IB  cells were 
perform ed in the presence o f the proteasom e inhibitors M G 132 and LnLL (Figure 
3.11). Both A A V2-RC and AA V2-CA P transduction was significantly enlianced by 
both proteasom e inhibitors in both cell lines, whereas A A V 2-CN H  transduction was 
only significantly increased by M G132 in SVEC 4-10 cells.
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Figure 3.9 B inding o f AAV2 vectors to a heparin colum n. The viruses w ere applied 
to a heparin column, w hich w as washed w ith  1 m M  M gCl2 , 2.5 m M  KCl and then 
heparin bound virus w as eluted in Im M  M gCl2 , 2.5 m M  KCl, IM  N aC .l. Collected 
fractions were analysed by quantitative PC R  and the percentage o f  to tal virus loaded 
onto the colum n w as calculated for each fraction.
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Figure 3.10 H eparin com petition experim ent. A. IP-IB B. SVEC 4-10. Cells w ere 
infected w ith  an MOI o f  1000 for 24 hours in the presence or absence o f 1 lU  o f  
heparin per 1 x 10^ gp, then w ashed and incubated in fresh m edia for 48 hours. Cell 
lysate w as used in  [3-gal assay to m easure the am ount o f  transgene and norm alised to the 
total protein content o f  the sample. * p <0.05 vs no heparin.
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Figure 3.11 A ffect o f proteasom e inhibitors on transduction o f  AAV2 vectors. A.
IP -IB  B. SVEC 4-10 cells w ere infected w ith an M OI o f  1000 for 24 hours in the 
presence or absence o f  proteasom e inhibitors LnLL (40 pM ) or M G  132 (4 pM ), then 
w ashed and incubated in Resh m edia for 48 hours. Cell lysate w as used in a  (3-gal 
assay to m easure the am ount o f  transgene expression, w hich w as norm alised to the 
total protein content o f  the sample. *p<0.05 vs m edia only.
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3.2,6 Peptide com petition assay
To attempt to assess w hether the viruses infect cells via interactions between the 
inserted peptide and a novel receptor, peptide com petition assays were performed 
with the AAV2 based vectors. The infection o f SVEC 4-10 cells was repeated in the 
presence o f  soluble peptides w ith the same sequence as the inserted peptide or a 
different peptide as a control (Figure 3.12). There was no significant affect on 
transduction o f  either A A V 2-CA P or AA V2-CN H with either the m atched or control 
non-specific peptide.
3.2.7.1 M T l-M M P  may act as the receptor for CNH peptide
BLAST searching the CNH peptide showed it had significant sequence hom ology to 
TIM P2 and it was shown that the binding o f  this peptide to endothelial cells could be 
inliibited by T1MP2 (Liu et a l ,  2003). As TIM P2 forms a com plex w ith M T l-M M P 
at the cell m em brane, it is possible that the CNH peptide m ay target M Tl-M M P. To 
determine if  CNH uses M T l-M M P  as a receptor, infections o f  AA V2-CN H were 
carried out in the hum an fibrosarcom a cell line HT 1080 stably transfected with M T l- 
M M P and control untransfected cells that express a low level o f  M T l-M M P  (Green et 
a l ,  1994). AAV2-CNF1 produced significantly higher transduction o f  the cells 
transfected with M T l-M M P , whereas there was no significant difference in the 
transduction o f the control vector AAV2-RC (Figure 3.13A), This suggests that 
AAV2-CNFI uses M T l-M M P  as a receptor. To provide further evidence that the 
increase in transduction was due to the CNH peptide interacting w ith M T l-M M P the 
experim ent was perform ed w ith the A dK O l-C N H  and A d5/19p-CN H  vectors. A 
similar pattern o f  results was seen with A dK O l-C N H , as transduction o f  the M T l- 
M M P expressing cells was 17-fold higher than the untransfected cell line (Figure 
3.13B). However, transduction o f Ad5/19p-CNH was not significantly higher in the 
M T l-M M P expressing cell line com pared to untransfected HT 1080 cells, although in 
both cell lines A d5/19p-CN H  produced significantly higher levels o f  transduction 
than the unm odified virus (Figure 3.13C). This supports the earlier results with the 
Ad5/19p peptide-m odified vectors, which suggested that peptide insertion mediates 
non-specific uptake o f  the virus.
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Figure 3.13 Infection o f  H T1080 cells expressing M T l-M M P . A. Cells w ere infected 
w ith AA V vectors M OI 1000 for 24 hours, then w ashed and incubated in Ifesh m edia for 48 
hours. B. Cells were infected w ith  A dK O l viruses, M O I for 3 hours, then w ashed
and incubated in fresh m edia for 48 hours. C. Cells w ere infected w ith A d5/19p viruses, 
M OI 100,00 for 3 hours, then w ashed and incubated in fresh m edia for 48 hour s. Cell lysate 
w as used in a P~gal assay to m easure the am ount o f  transgene expression, w hich w as 
norm alised to the total protein content o f  the sam ple. *p < 0.05 v HT1080 cells.
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3.2.7.2 Surface plasm on resonance (SPR)
Although the above experim ents suggest that the CNH m odified viruses are 
interacting w ith M T l-M M P , due to the com plexity o f  the virus:cell interaction this 
needs to be confirm ed by utilising an alternative technique. Hence, the interaction 
was tested by surface plasm on resonance (SPR) experim ents using a Biacore system. 
Biacore is a cell free system  that investigates the direct interaction betw een a protein 
and another m olecule and can provide inform ation on their rate o f  association, 
dissociation and affinity, in real time. M T l-M M P was im m obilised on a biosensor 
chip and TIM P2, AA V 2-RC, AA V2-CNH, Ad5/19p or A d5/19p-CN H  were injected 
over the chip (perform ed by Dr J. M cVey) (Figure 3.14). A dose-dependent 
interaction w ith A A V 2-CN H  was observed but none o f the other viruses tested bound 
to M T l-M M P, suggesting that AA V2-CN H can bind to M T l-M M P. The positive 
control TIM P2 was also show n to bind M T l-M M P (Figure 3.14). This supports the 
previous evidence that suggests that the CNH peptide binds to M T l-M M P  and that 
the AAV2 vector provides an optim al platform  for this interaction to occur.
3.2.8 In vivo characterisation of Ad5/19p vectors in ApoE-/- m ice m aintained on 
a high fat diet
The A d5/19p vectors were tested in vivo to determine if  the viruses had any tissue 
specificity. B iodistribution profiles were produced by Taqm an analysis (Figure 
3.15A) and im m unohistochem istry was used to detect transgene expression. Taqm an 
analysis detected higher levels o f the unm odified Ad5/19p in all tissues exeept the 
BCA, spleen and m uscle o f  m ice that received Ad5/19p-CAP. (Figure 3.15B)
Im m unohistochem istry for the lacZ  transgene w as carried out on sections o f  the BCA, 
aorta and liver. LacZ  expression could only be detected in the liver o f  mice that 
received Ad5/19p (Figure 3.16). These results suggest that in the context o f the 
Ad5/19p fiber, the 3 plaque-targeting peptides do not produce retargeting to areas o f 
atherosclerosis.
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Figure 3.14 SPR using an M T l-M M P  coated chip. A. TIM P2 (1.3 pM ) B. Ad5/19p. 
C. Ad5/19p-CNH . D. AA V2-RC. E . A A V 2-CN H  were injected over the chip for the 
tim efram e m arked by the arrows. F. D ose response o f  AAV2-CNH.
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Figure 3.15 Biodistribution of peptide-modified Ad5/19p viruses in ApoE-/- mice fed 
a high fat diet. 1 x 10'* vp were injected into the tail vein o f  mice. M ice were sacrificed 
1 hour later. A. DNA was extracted from tissues and used as a template for real time 
PCR using primers that detect the lac Z  transgene. B. Fold change in the amount o f  
virus detected compared to Ad5/19p. n=3 per group. *p<0.05 vs Ad5/19p.
154
1-1 <UOQ
uX 1)
<L> O >
ï |Z  -ë
' 'I
t
W) 
eS
2 Î
n<. Ic ou
a<
«yIf
5 - s
oe01
sI
"3o
"O
<u
sII
>
(S'
11I
couÜ00
i  Go e9E S
OQ
-gil
K 
a IN
<
:55
I a #  K a a
.
^  -  ■ J%
ÎS<
. . . . . .
p f *
# # '%
‘:i\
#a %  r
m
/ #
g , # -
«5
4€m , . 
#
OQ
ÿ < SCJ oJ OQ <
156
3.2.9 B iodistribution profiles o f the AAV2 based vectors in ApoE-/- mice 
m aintained on a high fat diet
As the in vitro results w ith the peptide m odified AAV2 vectors were encouraging, the 
tropism  o f  the vectors was analysed in vivo in ApoE-/- mice. 6 x 10^ gp o f  the AAV2 
vectors was injected into the tail vein o f  the mice. 28 days later DN A was extracted 
from tissues and used as a tem plate for real-tim e PCR to produce biodistribution 
profiles o f  the viruses (Figure 3.17). The results showed that for both AAV2-CAP and 
AAV2-CNH there was a 10-100 fold increase in the amount o f  vector detected in the 
BCA and aorta com pared to the am ount o f unm odified AAV2 detected (Figure 17B). 
In addition to this retargeting, both m odified vectors were detected at a lower level 
than control virus in all other tissues examined, suggesting that the peptides also have 
a detargeting affect on the natural tropism  o f  the virus.
3.2.10 Biodistribution profiles o f the AAV2 based vectors in ApoE-/- mice 
m aintained on a norm al rodent chow diet
The biodistribution profiles o f  AA V2-RC and AA V2-CAP were analysd in ApoE-/- 
mice fed a norm al rodent chow  diet, which have been show n not to develop 
atherosclerosis by the age o f  18 weeks (See section 3.2,1). The protocol was identical 
to that used w ith the m ice fed a high fat diet. The results show  that unlike in the fat 
fed mice, AA V2-CA P was not detected at a higher level than A A V 2-RC in the BCA 
or aorta o f  healthy m ice (Figure 3.18A and 3.18B). Com pared to A A V2-RC there 
was a slightly higher level o f AAV2-CAP detected in the spleen and brain o f  mice 
m aintained on a healthy diet, but the results suggest that in healthy m ice AAV2-CAP 
is not efficiently targeted to any o f  the tissues investigated (Figure 3.18A and 3.18B). 
Com paring the biodistribution profiles o f AA V2-CAP in healthy and fat fed mice 
showed that there was over a 100-fold decrease in the am ount o f vector detected in 
the BCA and aorta o f  healthy mice (Figure 3.18C). There was also a relatively large 
decrease in the am ount o f  vector detected in the kidney (Figure 3.18C), a com m on site 
for atherosclerosis in hum ans (Ki'umme and Donauer, 2006). These results suggest 
that AA V2-CAP m ay be targeted to areas o f  atherosclerotic vasculature and not to 
healthy vasculature.
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Figure 3,17 Biodistribution of peptide-modified AAV2 viruses in ApoE-/- mice fed 
a high fat diet. 6 x 10  ^gp were injected into the tail vein o f  mice, that were sacrificed 
28 days later. A. DNA was extracted from tissues and used as a template for real time 
PCR with primers that bind the eGFP transgene. B. Fold change in number o f  gp/100 
ng DNA compared to AAV2-RC. n=3 per group
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Figure 3.18 Biodistribution of AAV2 vectors in ApoE-/- mice fed a normal chow diet.
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bind the eGFP transgene. B. Fold change in number o f  gp/100 ng DNA compared to 
AAV2-RC. C. Comparison o f  AAV2-CAP biodistribution in mice fed a normal diet and 
mice fed a high fat diet. n=4 per group for normal diet, n=3 per group for high fat diet
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3.3 Discussion
This chapter describes the production and characterisation o f viral vectors containing 
atherosclerotic plaque targeting peptides that were identified by phage display (Liu et 
a l ,  2003). The peptides were successfully incorporated into A dK O l, A dK O lS*, 
Ad5/19p and AAV2 vector platform s to identify the optim um  system  for exposure o f 
the peptides. In vitro the peptide-m odified A dK O l, Ad5/19p and AAV2 vectors 
generally produced higher levels o f  transduction o f  endothelial cells com pared to the 
control viruses. How ever the A dK O lS* viruses failed to efficiently transduce any o f 
the cell types tested. In vivo the m ost prom ising results were achieved with the 
A A V 2“based vectors, as com pared to control virus higher levels o f AAV2-CAP and 
AA V2-CN H were found in the BCA  and aorta o f atherosclerotic mice. A decrease in 
the am ount o f  the peptide-m odified viruses was found in all other tissues suggesting 
that the vectors had been detargeted from  their native tropism  and retargeted to areas 
o f atherosclerotic vasculature. No retargeting o f AAV2-CAP was detected in healthy 
mice, supporting the hypothesis that the vector is targeted specifically to 
atherosclerotic plaques and not healthy vasculature.
3.3.1 Production o f peptide-m odified viruses
All 3 plaque targeting peptides (CAP, CQE and CNH) were successfully inserted into 
the capsid o f  A dK O l, A dK O l S* and Ad5/19p vectors. The CAP and CNH peptides 
were incorporated into the capsid o f  AAV2 to produce functional viruses, however 
AAV2-CNH was difficult to produce at titres equivalent to A A V 2-RC and AAV2- 
CAP, suggesting that the CNH peptide m ay have some affect on the efficiency o f 
AAV2 capsid assem bly and packaging. The CNH peptide contains a tyrosine residue, 
w hich as a large amino acid m ight cause a greater alteration in capsid structure and 
therefore could affect the efficiency o f capsid form ation (see chapter 5). Also, 
peptides containing m ultiple cysteine residues that can form  a constrained 
conform ation have in some cases been shown to be less well tolerated by the AAV2 
capsid during packaging (Grifm an et a l ,  2001).
3.3.2. Analysis o f the targeting capacity of the peptides in vitro
The basic transduction profiles o f  the A dK O l and AAV2 peptide-m odified vectors 
suggest that the peptide insertions are targeting the viruses to endothelial cells, as in
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the m ajority o f  cases the peptide-m odified viruses gave significantly higher levels o f 
transduction than the appropriate control virus. A lthough the peptides were identified 
in a m ouse m odel, these results suggest the viruses are not species-specific. 
Therefore, in the A dK O l and AAV2 platform s the peptides are exposed on the vector 
surface in a location and conform ation that enables binding to a receptor expressed on 
the surface o f the vascular cell types investigated. However, in the Ad5/19p and 
A dK O lS* platform s, the peptides did not target the vectors to vascular cells. 
Therefore, the results suggest that the CAP, CNPI and CQE peptides are able to target 
vectors to vascular cells, but the efficiency o f  this is dependent on the vector platform. 
The differences seen m ay be due to differences in platform  vector tropism , the degree 
o f surface exposure o f  the peptide or influences o f  the capsid on the peptide structure, 
as surrounding amino acids in the virus capsid m ay affect the conform ation o f the 
peptide.
3.3.3 C om parison of the vector platform s
3.3.3.1 A d K O l based vectors
Unlike the other vector backgrounds the transduction profiles produced by the 
A dK O l viruses show  that all 3 peptide-m odified viruses and unm odified A dK O l 
have sim ilar transduction profiles as they all gave the highest level o f transduction in 
RGE cells and low est in IP -IB  cells. Im portantly all 3 peptides enhanced the 
transduction o f A dK O l in vascular cells. Although the in vitro results were 
promising, the A dK O l vectors were not tested in vivo as previous studies have shown 
the vector platform  is not sufficiently detargeted from the liver (Sm ith et al. , 2003b, 
E infeld et a l ,  2001, Leissner et a l ,  2001, Sm ith et a l ,  2002, N icol et a l ,  2004, 
N icklin et a l ,  2004).
3.3.3.2 A d K O l S* based vectors
In vitt^o testing show ed that unm odified A dK O lS* and the peptide-m odified 
A dK O lS* viruses inefficiently infected all cell lines tested. This is despite the 
peptides being inserted into the capsid in the same position as in the A dK O l vectors, 
suggesting that incorrect peptide exposure m ay not be the cause o f  the reduced level 
o f infectivity. The lack o f  infectivity is likely to be due to the A dK O lS* mutations 
reducing virus infectivity and not the inability o f  the peptides to retarget the virus. To
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determ ine if  this is the case, cell-binding assays could be carried out in vitro to 
examine whether the viruses still binds target cells but are unable to infect them.
The S* m utation was originally proposed to block fiber binding to the putative Ad5 
CO-receptor HSPG (Dechecchi et a l , 2000, Dechecchi et a l , 2001, Smith et al., 
2003b) but a direct interaction has not been demonstrated. So it could be affecting 
other properties o f  the shaft such as fiber flexibility, or intracellular trafficking o f the 
virus. Since this w ork was begun, other studies have also been perform ed with 
peptide-m odified A dK O lS* viruses (A. Kritz, in  press) (Bayo-Puxan et a l , 2006). 
The integrin targeting peptide CDCRGDCFC (RGD4C) (Pasqualini et a l , 1995) that 
has previously been show n to enhance transduction o f both A dK O l and AAV2 based 
vectors (Reynolds et a l , 1999, Shi and Bartlett, 2003) was inserted into the HI loop o f 
the A dK O lS* vector. This vector was shown to produce no significant increase in 
transduction o f  integrin expressing cells such as HSVECs, although it was 
dem onstrated to bind to cells at a significantly higher level than unmodified 
A dK O lS* (A. Kritz, in press) suggesting that the m utation inhibits cellular entry. 
Brain and lung targeting peptides that have been used to retarget AAV2 (W ork et a l ,  
2006) were also tested in the A dK O lS* virus in vitro and in vivo and no retargeting 
was seen com pared to unm odified A dK O IS* (A. K iitz, in press). A sim ilar study that 
com bined m utating the fiber shaft 91KK92 to GA and the insertion o f  an ROD 
containing peptide in the HI loop also reported reduced transduction levels and lack o f 
retargeting both in vitro and in vivo, although efficient detargeting was achieved 
(Bayo-Puxan et a l , 2006). This suggests that the lack o f retargeting and transduction 
o f the plaque targeted A dK O l S* vectors is not unique to the plaque targeting peptides 
but has so far been show n w ith all peptides tested. Also, m utational ablation o f  HSPG 
binding has been show n to cause a greater reduction in transduction than the presence 
o f soluble heparin, so it has been suggested that the HSPG m utation m ust be having 
additional affects on the virus:cell interaction (Bayo-Puxan et a l , 2006). Together 
these results indicate that the A dK O lS* m utation m ay actually be inhibiting a later 
stage in the transduction pathw ay follow ing receptor binding, such as virus 
internalisation, endosom e disruption or nuclear trafficking.
The 91KK TK 94 m otif that is substituted for GAGA in the S"' virus is located in a linker 
region o f the 3'^ repeat o f the fiber shaft, and is ju st 3 residues away from  a 4 amino
1 6 2
acid sequence that is thought to enable the fiber to bend (Chiu et a l ,  2001, 
Chroboczek et a l ,  1995). This fiber flexibility is thought to have an im portant role in 
m ediating cell entry as w hen the flexible 3*^  ^ repeat o f Ad5 was exchanged for the 
rigid 3"^  ^ repeat o f Ad37, a significant decrease in receptor binding and infection was 
seen (W u et a l ,  2000). It is thought the fiber bend enables the virus to bind to co­
receptors such as integrins by allowing the virus capsid close proxim ity to the cell 
surface whilst avoiding steric hindrances betw een the cell and virus (Chiu et a l ,  2001, 
Wu, 2004). It m ay also be required to orientate the virus so it can contact multiple 
receptors sim ultaneously (W u, 2004). It has also been proposed that the fiber bend 
could serve to expose the K K TK m otif to enable interactions w ith HSPG (Smith et 
a l ,  2003b). However, only subgroup C viruses have the K K TK  m otif but other 
viruses such as Ad 12 in subgroup A have a flexible fiber (Chiu et a l ,  1999), so at 
least in these viruses the bend m ust have an alternative function. A lthough the KKTK 
m otif does not directly produce the flexibility in the fiber, the substitution o f  it may 
affect the fiber flexibility due to structural changes (van Raaij et a l ,  1999) in such 
close proxim ity to the fiber bend. This could restrict interaction betw een the ROD 
sequence in the penton base and ay inte grins and so reduce virus internalisation. To 
determine the exact role o f  the K K TK  m otif further work is required to determine the 
structural and functional affect o f  m utating it.
3 3 .3 .3  A d5/19p based vectors
The in vitro results show  unm odified A d5/19p only infects RGE, HSVECs and 
HCAECs at a low level and does not infect either o f the m ouse endothelial cell lines, 
suggesting they do not express the receptor for A d l9p , which is yet to be identified, 
although soluble A d l9 p  knob has been shown to bind sialic acid (Burm eister et a l ,
2004) so this m ay be involved in the virus:cell interaction.
A lthough the in vitro results show  the peptide-m odified A d5/19p vectors transduce 
vascular cells m ore efficiently than Ad5/19p, they also produce significantly higher 
levels o f  transduction o f  the non-target H eLa cells that do not express the putative 
receptors for the CAP and CNH peptides. Wlien com paring the transduction o f the 
vascular cells w ith non-target H eLa cells, only transduction o f  RGE cells was 
significantly higher (p<0,05). There was also no difference in the transduction o f
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Ad5/19p-CNH in HT1080 and HT1080 M T l-M M P expressing cells. These results 
suggest that the incorporation o f  the peptides m ay be enabling non-specific uptake o f 
the viruses into cells, how ever to fully test this transduction o f  a w ider range o f cells, 
including m ore prim ary cells needs to be investigated.
Taqm an results from  the in vivo study detected reduced levels o f  A d5/19p-CN H  and 
Ad5/19p-CQE in all tissues com pared to Ad5/19p, suggesting that peptide insertion 
has had a detargeting affect on the virus, but no retargeting effect. Ad5/19p-CAP 
does show some enhancem ent in transduction o f BCA, spleen and m uscle, suggesting 
that to some extent retargeting to areas o f atherosclerosis and other tissues may be 
occurring. Interestingly all the A d5/I9p  viruses are cleared from  the blood very 
rapidly as no virus could be detected in any o f the blood samples taken ju st one hour 
after vector adm inistration. The total am ount o f  virus detectable by Taqm an from all 
organs exam ined appears to be greatly reduced for the Ad5/19p-CNEl and Ad5/19p- 
CQE com pared to A d5/19p, w ith only 0.1%  and 0.002%  o f  the total amount o f 
unm odified virus detected. In contrast to this, the total am ount o f  Ad5/19p-CAP 
detected w as 92%  o f  the control virus. A lthough the viruses m ay have been 
retargeted to other tissues that were not analysed in this biodistribution study, these 
findings suggest that insertion o f  the CNH and CQE peptides into the Ad5/19p 
background appears to create viruses that are very unstable in vivo as they are quickly 
cleared from  the body.
Interestingly, the in vivo results appear to show  conflicting results to the in vitro 
results. In vitro um nodified Ad5/19p produced only very low levels o f  transduction in 
all cell lines tested and A d5/19p-CQ E gave the highest level o f  transduction in 5 o f 
the 6 cell lines. W hereas in vivo A d5/19p-CQE was virtually undetectable and 
Ad5/19p virus was detected at the highest level. As the in vitro results suggest a 
degree o f  non-specific cellular uptake o f  the peptide-m odified viruses, in vivo this 
same m echanism  m ay be resulting in the very rapid clearance o f  the peptide-m odified 
viruses. The stability o f  A d5/19p in vivo has not previously been assessed, however 
Ad5 has been show n to have a half-life o f  less than 3 m inutes in m ice (Alem any et al., 
2000, Koizumi et a l ,  2003, Sakurai et a l ,  2003), m ainly due to the rapid uptake and 
degradation o f the virus by Kupffer cells (Lieber et a l ,  1997, W olff et a l ,  1997,
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W orgall et a l ,  1997a). It is possible that Ad5/19p viruses may also be cleared by this 
mechanism.
Overall these results suggest that the peptide-m odified Ad5/19p vectors do not 
specifically transduce vascular cells or areas o f  atherosclerotic vasculature. As the 
peptides have been show n to function in other vector platform s, it m ay be possible to 
improve the retargeting o f  A d5/19p by inserting the peptides into a different region o f 
the fiber laiob protein. The HI loop is norm ally used for targeting A d5 viruses as it 
forms a flexible loop and it is one o f  the m ost exposed regions o f  the fiber protein 
(Xia et a l ,  1994), so peptide insertion can be tolerated and the inserted peptide is 
accessible for binding to potential receptors (Ki'asnyldi et a l ,  1998). The peptides 
have also been inserted into the HI loop o f the A d l9 p  fiber, but the A d l9 p  fiber 
structure (Burm eister et a l ,  2004) shows that the HI loop m ay not be the most 
suitable position for peptide insertion and that the FG loop is m ore exposed so may 
provide a m ore efficient insertion site (Figure 3.19). How ever there is no structural 
evidence that shows w hether the fiber can tolerate insertions at this site, so this 
requires further investigation. Although, it has been dem onstrated that peptides can 
be successfully incorporated into the less flexible CD and IJ loops o f  Ad5 fiber larob 
(Lord et a l , 2006). Insertion o f  an RGD peptide into these 3 loops show ed that the HI 
loop and CD loop m odified viruses bound to integrins with a sim ilar efficiency but the 
IJ loop m odified virus bound w ith slower association and faster dissociation rates as 
the virus was only able to bind one integrin m olecule per fiber trim er whereas the 
other viruses were able to bind three m olecules per fiber trimer. This study highlights 
the fact that the peptide insertion site has an im portant role in determ ining the 
efficiency o f retargeting.
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Figure 3.19 Structure o f Ad fiber proteins. A. Ad5 B. A d l9p  (Burmeister et a l, 
2004).
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3 .3 3 .4  AAV2 based vectors
The basic transduction profiles o f the AAV2 vectors show that AA V2-CN H seems to 
target vascular cells w hereas AAV2-CAP was the only peptide-m odified virus 
(excluding the A dK O l S* viruses) that did not give higher transduction levels than the 
control virus in all vascular cell types tested. AA V2-CAP transduction was only 
higher than control virus in  RG E and IP -IB  cells. As in other vector backgrounds the 
CAP peptide has been shown to be capable o f  m ediating enlianced transduction o f 
vascular cells, further w ork was carried out to investigate the inefficiency o f AAV2- 
CAP.
Infection o f the m ouse endothelial cells in the presence o f  the proteasom e inhibitors 
MG 132 and LnLL showed significant enliancement o f the transduction o f both 
control AA V2-RC and A A V2-CA P, w hereas AA V2-CN H w as less affected. This 
suggests that A A V 2-CN H  m ight use an alternative m echanism  for trafficking to the 
nucleus that reduces virus degradation by the ubiquitin-proteasom e pathway and 
therefore increases transgene expression. W liereas AAV2-CAP m ay be entering cells 
but producing lim ited transgene expression due to degradation o f  the virus before it 
reaches the nucleus. O ther vascular cell targeted AAV2 vectors have also shown 
altered trafficking m echanism s, for example, the sm ooth m uscle cell targeting AAV2- 
EYH is unaffected by the proteasom e (W ork el a l ,  2004a), and the EC targeted 
AAV2-SIG showed increased transduction in the presence o f bafilom ycin h i  an 
inliibitor o f  endosom al acidification that reduces wild type AAV2 transduction 
(Nicklin et a l ,  2001a). These dem onstrate not only the im portance o f  the initial 
receptor binding interaction, but also the effect o f  capsid m odifications on the later 
stages o f transduction.
Despite the insertion o f  the peptides into the HSPG binding site o f  the AAV2 capsid, 
binding o f the viruses to heparin columns and heparin com petition experiments in 
vitro suggest that the ability o f  the viruses to bind HSPG and utilise it as a receptor 
has not been ablated. Recent studies have shown that the nature o f the m utations 
made and peptides inserted into the heparin binding dom ain at residue 587 affect 
whether heparin binding is m aintained or ablated. Binding is due to an electrostatic 
interaction betw een positively charged residues in the heparin binding site and 
negatively charged HSPG (Xie et a l , 2002), so the charge o f  the inserted peptide is
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thought to be an im portant determ inant o f  whether heparin binding is maintained 
(Opie et a l ,  2003, K ern et a l ,  2003, Perabo et a l ,  2006b, W ork et a l ,  2006). 
Characterisation o f an AAV2 library with random  7-mer peptides inserted after 
residue 587 suggests that positively charged peptides do not prevent the form ation o f 
an HSPG binding site w hereas negatively charged and neutral peptides ablate PI SPG 
binding (Perabo et a l ,  2006b) (See chapter 5). This is supported by results using 
other targeted viruses, for example, the insertion o f  a SMC targeting peptide with 3 
positively charged residues (EYHHYNK) m aintained heparin binding (W ork et a l ,  
2004a), w hereas the insertion o f the uncharged endothelial cell targeting peptide 
SIGYPLP ablated binding to heparin (Nicklin et a l ,  2001a). Both the CAP 
(CAPGPSKSC) and CNH (CNH RY M QM C) peptides have a net positive charge as 
they contain 1 and 2 basic amino acids respectively. M odeling to predict the 
conform ation o f  the peptides within the AAV2 capsid, suggests w ays in which the 
heparin binding site could be form ed with and without the form ation o f  a disulphide 
bond betw een the 2 cysteine residues o f the peptides (Figure 3.20). This may enable 
both o f these AAV2 vectors to m aintain an ability to bind heparin despite the 
disruption o f the original binding site in the capsid. The CQE peptide 
(CQEPTRLKC) also has a net positive charge, so although it was not tested in the 
AAV2 background, it can be predicted that it would also produce a vector with some 
ability to bind FI SPG.
To further enhance the detargeting o f  these vectors, the peptide insertion could have 
been com bined w ith m aking 3 point m utations (the A3 vector) in the heparin binding 
site (R585A, N 587A  and R588A ) that have been shown to decrease vector binding to 
HSPG (W u et a l ,  2000, Perabo et al., 2006b). Based on the m odel o f how  peptides 
restore HSPG binding (Perabo et al., 2006b), it can be speculated that m aking these 
additional m utations in com bination w ith peptide insertion w ould prevent HSPG 
binding. There are also other residues in the capsid that are thought to contribute to 
HSPG binding. Structural and m utational analysis o f AAV2 capsid indicates that 
amino acids R484 and K532 m ay also form part o f the heparin binding site (Opie et 
a l ,  2003) Kern, 2003 #5214}. The m utations R484A and K 532A  cause a partial 
decrease in heparin binding, but cause a greater decrease in transduction than 
expected, so they are thought to be im portant for a later stage in the infection process 
(Opie et a l ,  2003, K ern et a l ,  2003). To try and overcom e the
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Figure 3.20 Possible structures formed by the insertion of plaque targeting 
peptides after residue 587 of the AAV2 capsid. A. CNH peptide B. CAP peptide. 
Residues potentially involved in forming a heparin binding site are highlighted in red 
and possible disulphide bonds are shown in blue.
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partial ablation o f  H SPG  binding seen by inserting peptides in the 580-590 region, Shi 
et a l  (Shi et a l ,  2006) have sim ultaneously inserted the integrin targeting RGD4C 
peptide after residues 520 and 584. They showed that the double insertion had no 
inlribitory effect on capsid form ation and caused complete inhibition o f heparin 
binding and retargeting to cell lines expressing integrins (Shi et a l ,  2006). But, this 
peptide has a net negative charge, so detargeting may be easier to achieve. With 
further developm ent it m ay be possible to improve the detargeting o f AA V2-CN H and 
AAV2-CAP and produce m ore efficient and specifically targeted vectors.
Peptide com petition experim ents failed to demonstrate that the infectivity o f  the 
peptide-m odified AAV2 viruses is due to a specific interaction betw een the inserted 
peptide and the target cell as the presence o f  com peting peptide had no specific effect 
on virus transduction. One possible explanation for this is that the synthetic peptides 
are produced in a linear conform ation whereas the peptides were identified from a 
constrained phage library where the peptides are flanlced by cystine residues that form 
a di-sulphide bond. Therefore, the structural conform ation form ed by the peptides in 
the context o f  the phage and viral backbone is likely to be different from  the structure 
o f  the synthetic peptides. The synthetic peptides m ay therefore not have the same 
affinity for the corresponding receptor. Instead o f using synthetic peptides to try and 
block virus transduction, it may have been more successful if  the original phage 
containing the peptides were used as they have been shown to bind to the receptors 
and are more likely to contain the peptide in a similar conform ation to that in the 
virus. H ow ever in previous studies variable results have also been seen with this 
m ethod as the extent to w hieh the secondary structure o f the peptide ehanges in the 
phage and viral backgroim d is peptide dependent. For example, for 2 peptide- 
m odified A dK O l vectors targeted to ECs competitive inhibition was seen for only 
one o f  the viruses (Nicklin et a l ,  2004).
Despite the possible inefficiency o f  AA V2-CA P in vitro, in vivo both AAV2-CAP 
and AA V2-CN H seem  to be retargeted to the EG A and aorta o f  ApoE-/- mice with 
atherosclerosis and com pared to AAV2-RC they were detargeted from  all other 
tissues examined. The in vitro results m ay not accurately reflect the in vivo results as 
in vitro levels o f receptor expression on healthy cell lines in tissue culture are likely to 
differ from  that seen in vivo.
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The biodistribution pattern o f AAV2-CAP and AA V2-CN H show  different results to 
that seen w ith the Ad5/19p form  o f  the vectors. W hereas both the A A V 2 vectors gave 
10- 100-fold increase in transduction o f  both the BCA and aorta, w ith the Ad5/19p 
viruses CAP show ed only a small increase (3.5-fold) in the BCA  and there was 
actually a decrease seen w ith Ad5/19p-CNH. Also, the detargeting o f Ad5/19p-CAP 
from other tissues was not as com plete as that seen with AA V 2-CA P as higher levels 
o f the virus was also detected in the spleen and muscle. These results highlight the 
importance o f both the platform  vector and peptide in determ ining the tropism  o f the 
virus.
The in vivo results therefore suggest that both AA V2-CAP and A A V 2-CN H  provide 
vectors that are detargeted from  the native AAV2 tropism  and retargeted to areas o f 
the vasculature in m ice w ith atherosclerosis. The lack o f  retargeting o f  AAV2-CAP 
detected in m ice fed a norm al diet (that are thought to not develop atherosclerosis) 
suggests the vector is selectively targeting atherosclerotic plaques and not healthy 
vasculature. The study in healthy m ice is due to be repeated w ith the AAV2-CNP1 
vector to m ore precisely determ ine its selectivity. IHC is also being perform ed to 
determine which regions o f  the plaque or surrounding vasculature are transduced by 
the vectors. W ith further w ork these AAV2 based vectors m ay be developed into 
vectors for atherosclerotic plaque targeted gene therapy.
3.3.4 Determ ining w hether M T l-M M P  acts as the receptor for CNH  modified  
viruses
Although one o f  the m ain advantages o f biopanning is that it can be used to identify 
targeting peptides without the requirem ent for prior Imowledge o f a specific 
m olecular target, this has created problem s with the further developm ent and 
characterisation o f  the peptides used in targeting viral vectors. In m ost published 
examples where peptides have been used to retarget viral vectors for gene therapy, 
there has been very little attem pt to elucidate the novel receptor that the virus is 
utilising. Identifying the receptors for these vectors m ay be advantageous in the 
developm ent o f the vector by providing additional inform ation about the tropism  and 
specificity o f the vector and may highlight any potential problem s w ith species
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specificity o f  the vector. It w ould also be advantageous for developing an accurate 
safety profile o f  m odified viruses.
As the CNH peptide has hom ology to T1MP2 (Liu et a l ,  2003), it was thought that 
M T l-M M P  could act as a receptor for the CNH m odified viruses. In vitro results 
suggest A A V 2-CN H  and A dK O l-C N H  bind M T l-M M P, and for AA V2-CN H this 
was confirm ed by SPR. However, both the SPR results and in vitro infections with 
Ad5/19p-CN H  suggest that although the virus has increased transduction compared to 
unm odified A d5/19p it is unlikely to be caused by the virus using M T l-M M P as a 
receptor. The SPR results show Ad5/19p-CNH does not bind M T l-M M P. This could 
be because in the A d5/19p background the CNH peptide m ight form  an altered 
conform ation that has low er affinity for M T l-M M P, or it could be due to the peptide 
being less well exposed on the surface o f the virus capsid, m aking it inaccessible to 
receptor binding. This is in agreem ent w ith the transduction data that showed there 
was no difference in the transduction o f HT1080 cells and HT1080 cells over­
expressing M T l-M M P.
The CNH peptide is hom ologous to a region o f  the N -term inus o f  TIM P2, which 
spans 2 a-helices (helices II and 111). This region has high hom ology betw een hum an 
and bovine TIM P2 and hum an TIM P -3 and -4, but it is not conserved in T lM Pl 
(Fernandez-Catalan et a l ,  1998). According to the crystal structure o f  the M T l- 
M M P :TIM P2 complex, this region o f  T1MP2 does not form any direct contact with 
M T l-M M P (Fernandez-C atalan et a l ,  1998, Lee et al., 2004a) (Figure 3.21) (Liu et 
a l ,  2003). The critical residues for T1MP2 binding to M T l-M M P are 4 residues at the 
N-term inus, the AB-loop and the CD- and EF-connecting loops (Lee et a l ,  2004a), so 
it is not Imown how  CNH peptide m ay be binding to M T l-M M P, therefore the exact 
nature o f the interaction requires further investigation.
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Region o f  homology to CNH peptide (C terminal 
o f  helix 2 and N  terminal helix 3)
Figure 3.21 Ribbon diagram  o f M M P-TIM P complex. M Tl-M M P is shown in 
yellow  and TIMP2 in orange (Fernandez-Catalan et a l,  1998). The region with 
homology to CNH peptide is marked.
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3,3.5 Sum m ary
The 3 atherosclerotic plaque targeting peptides CAP, CNH and CQE have been 
successful incorporated into the capsid o f viral vectors A dK O l, A dK O lS * , Ad5/19p 
and AAV2. A lthough there are noticeable differences in the in vitro transduction 
profiles o f  the peptides in the different platform  vectors, the results suggest that the 
peptides are able to m ediate virus transduction o f  vascular cells. As an exception to 
this, in the A dK O lS* background only low levels o f transduction were detectable 
both with the um nodified virus and all 3 peptide viruses, suggesting that in some way 
the viruses all had significantly reduced efficiency o f  infection. It is therefore 
unlikely that the A dK O lS* background will provide a useful platform  for any gene 
therapy vector as the level o f  transgene expression achieved is too low  to have any 
therapeutic effect.
In vitro, the A d5/19p peptide-m odified viruses did give significantly higher levels o f 
transduction o f  the vascular cells, but this was also seen in H eLa cells, which suggests 
that the increase m ay not sim ply be due to peptide:receptor interaction and peptide 
incorporation m ay have activated non-specific viral uptake. In vivo Taqm an data 
suggests that A d5/19p-CN H  and A d5/19p-CQE were cleared from  the body very 
quickly as only very low  levels o f virus could be detected in any o f  the tissues tested. 
Ad5/19p-CAP w hich generally gave the lowest levels o f transduction o f  the 3 peptide- 
m odified viruses in vitro  was detectable in vivo and did dem onstrate some degree o f 
retargeting to the BCA, but also to other organs such as the spleen.
The m ost prom ising results were achieved with the AA V2-CA P and AAV2-CNH. 
The in vitro results were particularly good for AAV2-CNH, which produced enhanced 
transduction o f all the vascular cells, but not HeLa cells. The results also suggest it 
may traffic to the nucleus via a pathway which avoids degradation by the ubiquitin- 
proteasome pathway. The in vivo results with both AA V2-CA P and AAV2-CNP1 
were very encouraging, as they suggest the native tropism  o f  the virus has been 
greatly reduced and the viruses have been retargeted to areas o f  the vasculature where 
atherosclerosis is know n to occur. However, for both AA V2-CA P and AAV2-CNH 
some ability to bind heparin has been m aintained, although by incorporation o f further 
detargeting m utations it may be possible to reduce this and produce efficiently 
retargeted vectors.
174
Chapter 4:
Phage Display to Identify Peptides 
That Target Unstable 
Atherosclerotic Plaques
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4.1 Introduction
Rupture o f unstable atherosclerotic plaques is one o f the major causes o f mortality due to 
CVD (Falk et a l ,  1995). Although there are several treatments available for 
atherosclerosis e.g. statins, there is currently a lack o f treatments which aim to directly 
stabilise rupture prone plaques by altering their composition. Gene delivery could 
potentially be used to stabilise vulnerable atherosclerotic plaques and thereby prevent 
plaque rupture, if a vector that can selectively target unstable plaques can be developed. 
For this to be possible, molecules expressed at a high level on the surface o f unstable 
plaques need to be identified and exploited as receptors for novel vectors.
4,1.1 M olecular characterisation of atherosclerotic plaques
Unstable plaques have been well characterised at the cellular level, but at the molecular 
level they are less well understood. There are few molecular markers that are known to 
be expressed at a high level, selectively on unstable atherosclerotic plaques. There have 
been several microarray and proteomics studies carried out to try and improve this 
knowledge, however the majority o f studies have compared plaques with healthy 
vasculature (Seo et a l ,  2004, M artinet et a l ,  2003, Duran et a l ,  2002) and not 
specifically focused on unstable plaques. A recent study, however, has investigated the 
gene expression profile o f unstable and stable plaques from the same patient and 
identified many genes that have upregulated expression levels in unstable plaques 
(Papaspyridonos et al., 2006). Some o f these have previously been associated with 
plaque rupture e.g. M M Pl and MMP9 whilst others such as legumain (possibly involved 
in controlling matrix degradation) and vinculin (involved in attaching act in filaments to 
the plasma membrane) have no previous association (Papaspyridonos et a l ,  2006). In 
another study genetic profiling o f stable and ruptured human atherosclerotic plaques 
found peri lip in was expressed in 80% o f ruptured human plaques but not in any stable 
plaques. It is involved in lipid hydrolysis and may have a role in increasing the size o f 
the lipid core (Faber et a l ,  2001). A further study has also been carried out using an 
ApoE-/- mouse model o f atherosclerosis. Proteomic and metabolomic analysis o f aortas 
from 10 week, 12 month and 18 month old ApoE-/- mice was used to look at changes that
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occur in different stages o f plaque development (Mayr et a l ,  2005). Many changes in 
immune activation, oxidative stress and energy metabolism were identified (Mayr ei a l ,
2005).
Although these studies have provided further information about the disease, their 
relevance for developing gene therapy vectors targeted to unstable plaques is limited. To 
target a gene therapy vector to unstable atherosclerotic plaques, the vector needs to bind 
efficiently to a receptor that is expressed at a relatively high level on the plaque surface 
and this expression must be selective. Many o f the proteins identified in the studies 
described above are intracellular so could not be used as receptors for vectors as they 
would not be accessible for binding. Also, the proteins are not exclusively expressed in 
plaques but are also found in other tissues so may not provide the required level of 
specificity.
4.1.2.1 Phage display
Biopanning with a phage display library provides a method of identifying peptides that 
bind to a specific target without any prior knowledge o f either the target receptor or the 
targeting ligand. Since complete molecular profiling o f atherosclerotic plaques has not 
yet been performed, biopanning is likely to be the most effective way to identify potential 
atherosclerotic plaque specific receptors.
4.1.2.2 Phage libraries
There are 2 types o f phage that are commonly used for phage display, M l 3 and T7. Ml 3 
is a single-stranded filamentous DNA bacteriophage. It enters bacteria by binding to the 
F pi lus, then uncoats and its DNA is converted to a double stranded form, so that DNA 
replication can occur. From each infected cell about 200 copies o f the phage are 
produced. When M l3 phage is released from the bacterium it does not kill the cell, so 
M13 plaques are areas o f reduced growth and not clear areas due to lysis o f the bacteria. 
M l3 is a very stable phage and can survive temperatures as high as 55°C and pH as low 
as 3. The M13 phage capsid consists o f about 2700 copies o f the major coat-protein 
pV lll and about 3-5 copies o f the minor protein p ill. In most M 13-based libraries the
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peptides are inserted into the minor coat protein gene III protein (g3p) so that the peptides 
are displayed on the surface o f the phage without significantly affecting its ability to 
infect E.coli.
T7 is a double stranded DNA, lytic phage. Like M l3 phage T7 can withstand harsh 
conditions such as extremes o f temperature. Proteins o f up to 1200 amino acids can be 
displayed on the phage capsid using the low or mid copy number display systems (0.1-15 
copies per phage) and peptides up to 50 amino acids long can be displayed in the high 
copy number system (415 copies per phage) (Novagen, 2002).
Phage libraries normally contain peptides that are between 6 and 15 amino acids long. 
They can be in a linear conformation or they can be flanked by cysteine residues that 
form a disulphide bond under physiologically conditions, which forces the peptides into a 
constrained conformation. The configuration o f linear peptides can be affected by the 
surrounding amino acids in the phage capsid to a greater degree than constrained 
peptides. Constrained peptides are thought to more closely represent the configuration of 
the peptides when they are inserted into viral vectors as both termini o f the peptides will 
be bound to residues in the capsid. For example, peptides inserted into the HI loop of 
Ad vectors are constrained at both the N and C terminus, whereas peptides in filamentous 
phage libraries are constrained at only the C terminus.
Originally phage display used M13 based libraries but T7 libraries are becoming more 
common as they have several advantages over M l3 phage. T7 phage replicate faster than 
M l3 phage, so plaques form in 3 hours and cultures lyse within 1-2 hours whereas 
plaques take 10-12 hours to form with M l3 phage.
A recent study used a bioinformatics approach to compare the diversity o f  12-mer and 7- 
mer libraries o f T7 and M13 phage. It was found that the T7 libraries had a higher 
diversity (up to 14-fold higher for a 12-mer library) and fewer amino acid biases in their 
peptide composition (Krumpe et a l ,  2006). The restricted diversity o f M l3 libraries is in 
part due to the peptides having to be compatible with the phage assembly, secretion and
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infection process. T7 phage are not secreted through the host cell membrane so do not 
have to be compatible with the bacterial cell membrane secretory complex, therefore a 
larger range o f  peptides should be compatible with the phage biology (Krumpe et a l ,
2006). M l3 libraries have also been shown to have an amino acid bias caused by some 
peptides reducing the efficiency o f phage assembly and infection whereas other peptides 
seem to have a selective advantage (Rodi et a l ,  2002).
One potential problem with in vivo biopanning with T7 phage is that it has been shown in 
mice to be rapidly removed from the blood due to an immune response against the phage 
(Srivastava et a l ,  2004). Just 5 minutes after systemic administration into C57/B16 mice 
less than 50% o f phage remains detectable in the blood and after 1 hour this is reduced to 
less than 1% (Srivastava et a l ,  2004). Using immunocompromised strains o f mice it was 
demonstrated that this neutralising effect is mediated mainly by B-cells (Srivastava et a l ,  
2004). This rapid neutralisation o f phage may reduce the efficiency o f biopanning as it 
might prevent potential targeting phage reaching the tissue o f interest. However this 
means that any phage identified are likely to be highly efficient and stable in vivo.
4.1.3 Vascular targeted phage display
There are many examples o f studies where in vitro phage display has been used to 
identify vascular targeting peptides. If the molecular target is known then biopanning can 
be carried out on either an immobilised form o f  the protein or cells overexpressing the 
protein. For example, White et a l  (White et a l ,  2005) carried out phage display on 
endothelial cell protein C receptor (EPCR) as it is known to be expressed at relatively 
high levels on the vascular endothelium o f arteries and veins, so could potentially be a 
good target receptor for endothelium targeted gene therapy. Cells that do not express 
EPCR were transfected with an EPCR plasmid so that it was over-expressed. Negative 
selection steps were carried out on untransfected cell lines to remove phage that bound to 
naturally occurring receptors and then biopanning was carried out to select EPCR binding 
phage. Several targeting motifs were identified which had homology to functionally 
significant proteins such as an MMP (White et a l ,  2005).
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If no receptor is known then in vitro biopanning can be performed on a target cell type 
such as cardiomyocytes (McGuire et a l ,  2004), to identify both the targeting ligand and 
potential receptors. To increase the efficiency o f in vitro biopanning a pre-clearing step 
on another cell type can be used. For example, preclearing steps using vascular SMC, 
HepG2 and peripheral blood mononuclear cells was used to create a restricted library for 
biopanning on human umbilical vein ECs, which identified the endothelial cell targeting 
peptide SIGYPLP (Nicklin et a l ,  2000). Similar preclearing steps on HepG2 and 
peripheral blood mononuclear cells were used to identify peptides that target human 
saphenous vein SMC (W ork et a l ,  2004a).
4.1.4 Phage display targeting atherosclerosis
In vitro biopanning has also been performed to identify phage that bind to molecules 
Icnown to be expressed in atherosclerosis. For example, biopanning has been carried out 
on cells overexpressing lectin-like oxidized LDL receptor (LOX-1) (W hite et a l ,  2000). 
LOX-1 is a receptor for oxidized LDL that is expressed on endothelial cells, SMC, 
monocytes and macrophages. Its expression is up regulated by ox-LDL, angiotensin 11, 
endothelin, cytokines and shear stress, so it is found in high levels in atherosclerotic 
plaques (Mehta et a l ,  2006). It has also been found to be expressed on platelets and has 
a role in platelet activation and thrombus formation (Chen et a l ,  2001). Its expression is 
upregulated from the early stages o f plaque development so it may be a useful target for 
gene therapy to prevent plaque development.
Phage display has also been performed on immobilised murine P-selectin, which is 
expressed on the surface o f both early and advanced plaques (M olenaar et a l ,  2003). 
After 10 rounds o f  biopanning one peptide was found in more than 80% of phage 
sequenced. This peptide was found to be highly specific for murine P-selectin as its 
binding was found to be 100-fold higher than binding to either E-selectin or human P- 
selectin (Molenaar et al., 2003). Due to the high species specificity o f the isolated 
peptide it is unlikely to be useful for developing clinically relevant gene therapy vectors.
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All these examples o f in vitro biopanning are targeting potential receptors expressed in 
the early stages o f atherosclerotic development and not more advanced plaques. Further 
studies are required to determine their selectivity for atherosclerotic vasculature in vivo.
Several groups have performed in vivo phage display to identify plaque-targeting 
peptides. The first study used a 12-mer constrained library in LDLR-/- mice (Houston et 
al., 2001). For the first round of biopanning mice received 1 x 10'° pfu phage and in 
rounds 2 and 3 mice received 1 x 10  ^ pfu phage. After round 1 only 250 phage were 
picked and amplified for the next round and after round 2 this was reduced to just 100 
phage. The low dose used and the severe restriction o f the library diversity after one 
round of biopanning will have limited the results o f this study. Also, only one mouse was 
used for each round o f the biopanning. The study identified 10 peptides, one o f which 
(CLVEAYPGL-Stop-VRSC) was then investigated further. IHC performed on frozen 
sections o f plaques incubated with the selected phage showed the phage mainly bound to 
the plaque, although some was localised to the surrounding endothelium. When this was 
repeated using vasculature from a healthy C57/B16 mouse no phage binding was 
detected. However, when the phage was administered system! call y high levels o f phage 
were found to have bound to the liver, spleen, kidney and lung as well as the vasculature. 
Therefore there is some question about the specificity o f the selected phage. The 
biopanning may have been improved by using a predose o f non-peptide expressing 
phage, to reduce the chances o f identifying a phage that binds to non-specific receptors. 
Also, due to the variability in the extent o f disease in different mice in all models o f 
atherosclerosis, it may have been better if more than one mouse was used at each round. 
In this study there was no attempt to determine what the potential receptor for the 
selected peptide could be,
Liu et al. (Liu et al., 2003) carried out biopanning with a T7 7-mer constrained library in 
fat fed ApoE-/- mice to identify phage that bound to plaques in the aorta (Liu et al., 
2003). A predose o f  UV irradiated phage was administered 30 minutes before injection 
o f the phage library. After 4 rounds o f biopanning several consensus motifs were 
identified and some o f these were found to have homology to proteins associated with
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atherosclerosis e.g. TIM P2 (Liu et al., 2003) (See chapter 3). Further work showed one 
of the selected phage also targeted plaques isolated from humans (Liu et al., 2003).
Recently another group have performed biopanning in ApoE-/- mice to identify 
atherosclerotic plaque targeted peptides (Kelly et al., 2006). 3 rounds o f biopanning 
using an M l 3 7-mer linear library were carried out. The aim o f the study was to identify 
peptides that could be used for targeted imaging techniques so the biopanning was 
designed to identify phage that were efficiently internalised into cells. To achieve this 
phage bound to the vessel surface were removed by an acidic glycine wash before the 
cells were lysed and internalised phage were isolated. After 3 rounds o f panning, 96 
phage were sequenced and very few repeated sequences were found, so peptides were 
divided into 30 different groups based on common motifs found within the peptides. 
Two groups were said to have homology to proteins associated with atherosclerosis. One 
o f these peptide motifs was said to have homology to Very Late Antigen-4 (VLA-4), a 
ligand for VCAM-1, however only 2 out o f the 7 amino acids were the same and the 
other 5 amino acids were not conservative differences (VHPKQHR peptide homologous 
to VNPGAIY). The peptide was shown to bind to murine coronary artery endothelial 
cells, and its uptake could be inhibited by soluble VCAM-1. Further in vivo testing is 
required to determine the specificity o f this peptide.
Previously the same group had performed four rounds o f biopanning on mouse 
endothelium under physiological flow conditions and identified another peptide that was 
thought to bind to VCAM-1 (CVHSPNKKC) (Kelly et a l ,  2005). For plaque imaging 
studies the peptide was conjugated to a magnetofluorescent nanoparticle to enhance the 
accumulation o f the nanoparticle in endothelial cells to improve target to background 
ratios (Kelly et a l ,  2005). The complex was shown to rapidly internalise into murine 
cardiac endothelial cells by binding to VCAM-1. It was also found to accumulate in areas 
o f atherosclerosis in ApoE-/- mice. But, because a constrained peptide was used, only 4 
peptides could be attached to each nanoparticle, therefore to increase this they attempted 
to identify a linear peptide to use instead (Kelly et a l ,  2006). VCAM-1 is expressed on 
the endothelium under inflammatory conditions and has been detected in athero-prone
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areas before any visible atherosclerosis has developed (Cybulsky and Gimbrone, 1991), 
so it could be used as a marker o f early atherosclerotic development. However VCAM-1 
is expressed by cells other than ECs (Minami and Aird, 2005) so may not provide a 
highly specific target.
Although there has been some success in identifying peptides that target to 
atherosclerotic plaques using in vivo biopanning, none o f the studies have focused on 
identifying peptides that specifically target advanced plaques. Following identification of 
plaque targeting peptides none o f the groups have shown that systemic administration of 
the targeted phage results in a high level o f specific binding to areas o f atherosclerosis.
4.1.5 Aims
The aim of this chapter was to use in vivo phage display to identify peptides that target to 
unstable atherosclerotic plaques. This should provide more information about the 
molecular composition o f plaques by identifying proteins that are expressed on the plaque 
surface and identify peptides that can be incorporated into the capsid o f viral vectors to 
produce an atherosclerotic plaque targeted vector which could be used as a biological tool 
and as a potential therapy.
183
4.2 Results
4.2.1 Determining the diversity of the T7 library
Constrained (CX8C) and linear (X8) T7 phage libraries with random 8-mer peptides 
displayed at the C-terminal o f the phage capsid protein lOB were used in this study (gifts 
from E. Ruoslahti, Burnham Institute, CA, USA). Both libraries and non-recombinant 
(NR) control phage without a peptide insertion were amplified using the standard liquid 
culture method and the phage samples were purified by PEG precipitation. To examine 
the diversity o f the libraries, individual plaques were picked then the peptide insertion 
region was amplified by PGR and sequenced. 49 and 58 phage peptides from the X8 and 
CX8C libraries respectively were sequenced. All were found to contain different 
peptides (sequences not shown). Within these peptides there were 14 that were not 8- 
mers but had inserts o f between 5 and 11 amino acids long. There were also 36 peptides 
that encoded stop codons (sequences not shown).
Analysis o f the amino acid diversity showed the peptides contained approximately the 
expected amounts o f the majority o f amino acids (Figure 4.1). The results suggest that 
amino acids D and R were over-represented in the linear library where as K and T were 
under-represented. In the constrained library C and N were over-represented and P, Q 
and R were under-represented. Based on the amino acid distribution o f the 2 libraries the 
diversities o f the linear and constrained libraries were calculated to be 9.06 x 10  ^and 2.20 
X 10^ ,  respectively.
4.2.2 UV irradiation o f control phage
Following systemic injection phage naturally accumulate in the liver and spleen due to 
uptake by the reticulo-endothelial system (RES) (Clackson and Lowman, 2004). To 
prevent a large proportion o f the library being taken up by the RES, ‘control’ phage that 
have no inserted peptide can be pre-injected to block these non-specific binding sites and 
saturate the RES before the library phage are administered. In these experiments NR 
phage inactivated by UV irradiation was used as a ‘predose’. The inactivation is required 
to prevent the control phage from being able to replicate and therefore affect the titering
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results. A timecourse experiment was performed to determine the level o f irradiation 
required to completely inactivate the N R phage (Figure 4.2). This showed that 9 hours 
UV irradiation was sufficient to render the phage replication deficient.
4.2.3 In vivo biopanning
In vivo biopanning to identify peptides that target unstable atheroselerotic plaques was 
performed using ApoE-/- mice on a C57/B16/129SvJ background fed a high fat Western 
diet for 10 weeks. These animals have been shown to develop unstable plaques, as after 
8 weeks o f fat feeding over 60% o f mice have plaques that appear to have ruptured 
(Johnson et a l ,  2005b). This model was chosen as it is one o f the most reliable models 
o f spontaneous plaque rupture and has many of the features o f the human disease.
Five different biopanning protocols were used (Table 4.1). In experiment 1, 
approximately 400 individual phage plaques were picked, sequenced and amplified at 
each round. Individual amplification o f phage was used to try and reduce the potential 
bias created by individual peptides causing a sequence specific reduction in the efficiency 
of phage replication (Pasqualini and Ruoslahti, 1996). However, the majority o f the 
biopanning was performed using bulk amplification o f the phage directly from the tissue 
lysate so that the amplification process did not artificially limit the diversity o f the phage 
used in subsequent rounds. The number o f mice used for each round was between 3-5 
depending on availability (Table 4.2). Although in many published biopanning 
experiments only one animal is used per round (Pasqualini and Ruoslahti, 1996, A rap et 
al., 2002b, Arap et a l ,  2002a, Kolonin et a l ,  2001, Hoffman et a l ,  2004, Laakkonen et 
a l ,  2002), for this work it was thought using several animals would produce more 
consistent results as there is some variation on the degree o f atherosclerosis and plaque 
instability in this model.
At each round o f biopanning the amount o f phage recovered from the BCA was 
calculated (Figure 4.3). In all 5 biopanning experiments the amount o f phage recovered 
was higher in the final round compared to the first round, although this increase was only 
significant for protocols 2 and 5 (Figure 4.3). As it was not possible to use the same dose
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Figure 4.2 Effect o f U V  irradiation on phage titre. Aliquots o f  phage were 
irradiated in  the UV Stratalinker (Stratagene) using 120 m J for betw een 0-12 lioui's. 
A t three hour intervals phage w ere titred to determ ine the am ount o f  infectious 
phage rem aining.
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Protocol Round 1 Round 2 Round 3 Round 4
1. X8 picked + predose 4 4 3 --
2. X8 + predose 5 3 4 3
3. X8 no predose 5 3 4 4
4. CX8C + predose 5 3 4 4
5. CX8C no predose 5 3 4 4
Table 4.2 The number o f animals used in each round of biopanning. From the age of
8 weeks all animals were fed a high fat diet containing 21% beef lard supplemented with 
0.15% cholesterol for 10 weeks before being used in the study.
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of phage for all rounds, the amount o f phage recovered was calculated as a percentage of 
the total dose received (Figure 4.4). In 3 o f the 4 biopanning experiments where bulk 
amplification o f the libraries was used, a decrease in the amount o f phage in the BCAs 
was seen over the first three rounds and then an increase was seen in the last round. As a 
control, the amount o f phage in a non-target organ was also determined. The kidney was 
chosen for this as it is a highly vascularised tissue that has previously been used as a 
target for in vivo biopanning in mice and has been shown to express unique molecular 
markers (Pasqualini and Ruoslahti, 1996) that should be distinct from those upregulated 
in atherosclerotic BCAs. For experiments 2, 4 and 5 a decrease in the amount o f phage in 
the kidney was seen from rounds 1 to 4 and by the final round there was no detectable 
phage (Figure 4.5). In the other two experiments there was a slight increase in the 
amount o f phage recovered. In experiment 3 this was not significant and the amount of 
phage detected was lower than that found in the BCA.
4.2.4 Sequencing o f phage recovered from the BCA
Analysis o f the sequencing results from experiment 1 showed the library diversity was 
reduced as biopanning progressed (Table 4.3). After just one round there were very few 
repeated peptides. In the second round the number increased, but the majority o f repeated 
peptides still had an occurrence o f 1% or less. By the third round there were fewer 
repeated peptides, but they made up a larger percentage o f the sequences. O f particular 
interest was the LSVISS peptide as this was found in 19.4% o f phage sequenced.
After rounds 1, 3 and 4 o f biopanning with the bulk amplified libraries, phage samples 
were picked and sequenced to monitor the progress o f the biopanning. After 1 round of 
panning between 150-200 peptides from the X8 and CX8C pools were sequenced and no 
repeated sequences were found in any o f the experiments (data not shown). Round 2 was 
not sequenced as it was thought it would still be too early to detect any targeting motifs 
within the peptide pool. After the third round of biopanning, sequencing showed that 
there were several repeated peptides within the libraries, suggesting that the library was 
becoming enriched in phage targeting the BCA, but some diversity still remained (Table 
4.4). There was one peptide (CFGEGAEQSC) found in both CX8C biopanning
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Figure 4.3 Average litres o f phage recovered from  the BCAs at each round o f  
biopanning. A. Protocol 1. X8 picked phage, B. Protocols 2 and 3. X8 bulk am plified 
phage, C. Protocol 4 and 5. CX8C bulk am plified phage. p <0.05 vs round 1
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% O ccm  i encc Round 3
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4.2
2.1
2,8
19.4
1.42.8
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1.4
Table 4.3 Sequences o f peptides from phage identified more than once from  
biopanning protocol 1. (X8 library with predose using individually picked phage).
From rounds one, two and three 379, 404 and 144 phage peptides were sequenced 
respectively. Peptides recovered from more than one biopanning experiments are 
highlighted in bold. * = stop codon ^94
A.
Peptide %  Occurrence Round 3 from 153 peptides % Occurrence Round 4 From 142 peptides
*AHVNVNT 1.3 -
*G LSSM T N - 1.4
* T S L S N I D - 1.4
AWMANKDF - 1.4
FNLIM AQS - 1.4
FYDMESVN - 2.1
G N L C V Q *! - 1.4
H P I I G L S Y - 2.8
LALQLGRD - 1.4LSVISS - 2.8
L V * F I S S S - 2.1
P L Y V E I D E 1.3 -
PSFDSGMN 1.3 -
PSSV D N T G - 2.8
SCVTV M *F 2.0 -
SVTRHIMK - 1.4
TLFKRGNQ 1.3 -
V N K P IH V F - 2.1
V S I A N N R L - 4.2
V SN S Y Y T R - 3.5
YM R *R SF F - 2.1
B.
Peptide % Occurrence Round 3 
From 137 peptides
% Occurrence Round 4 
From 118 peptides
* R M T S S I I - 2,5
A N D Y S L * ! - 1.7
AVRHDYK* - 1.7
F * S L L K K L 1.5 -
F F L * A K T F - 1.7
F GD D LV SS 1,5 -
F I S V R V L S - 2.5
FNSRRSMH - 1.7
G M EW IK M - 1.7
H R G IF SN Q 3.4
IH R L F L T R - 1.7
P SFDSGM N - 6.8
Q D H F P IV N - 8.5
R I V R T * H F - -
SCVTV M *F - 3.4
T Y S Q K *F Y - 1.7
YTWHAPVK - 1.7
YVTMKHHP - 3.4
Table 4.4 Sequences o f peptides from phage identified more than once from the 
biopanning using the bulk amplification protocol. A. 2. X8 + predose. B. 3. X8 no
predose. C. 4. CX8C + predose (overleaf). D. 5. CX8C no predose (overleaf). * = stop 
codon. Peptides recovered from more than one biopanning experiments are highlighted in 
bold.
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c.
Peptide % Occurrence Round 3 
From 170 peptides
% Occurrence Round 4 
From 243 peptides
C*C*RVTNTC 0.8
C*GRSRVRIC - 0.8
C*IEANSLRC - 1.2
C*NFHRTLNC - 0.8
CADYCG*HRC - 0.8
CAPSMNILPC - 0.8
CCVAQVD^GC 1.2 -
CDASLWDYTC - 0.8
CDGSVTVRFC - 0.8
CE*GSADFFG - 0.8
CGANHAITEC - 1.2
CGIYNRDATC - 0.8
CHFEVLQNLC 0.8
CHHSTGNKSC 1.2 -
CHQSTGNKSC - 0.8
CIRTAHM*MC - 1.2
CKSKLVDDTC - 0.8
CN**RNYLC - 0.8
CPNGVLYVGC 1.2 1.2
CQLYKERFSC - 0.8
CQM*VVSSC - 0.8
GRNDTHSWSC 1.7 1.6
CSFKAWHSTC - 1.2
CSGWK*RNC - 0.8
CSLNTTDYSC - 0.8
CSNSLL*PNMC - 1.6
CSQDVYIDQC - 0.8
CSVAQVD*GG - 1.6
CTÏRSISDVC 1.7 -
CTRWGVGAPC - 0.8
C T S *L N Y T Y C - 1.2
CTVTPGYNDC - 0.8
, 9 6
D,
Peptide %  Occurrence Round 3 
From 140 peptides
%  Occurrence Round 4 
From 421 peptides
CAAARVIFRC - 0.7
CFDLLTNLPC - 0.5
CFSIRK KTSC - 0.5
CFYLSMDKTC - 0.5
CGANHAITEC 1.4 -
CGDYQTRKVC - 0.5
CGGIQSKADC - 0.7
CGHGSLHSTC - 0.5
CGIYNRDATC - 0.5
CGPHNLWDTC - 0.5
CGTGSDNNYC 1.4 0.7
CHIMMWSEC - 0.5
CHVDRLD*YV - 0.5
CHYNATLTLC - 0.5
CKGILVG*SELAV - 0.5
CKLELNDL*C - 0.5
CLRDILV - 0.5
CLYSGKPHLC 1.4 -
CMLNLWDSNC - 0.5
CNTSLSMNNSC - 0.7
CNYRDPTHRC - 0.5
CPASKRNGLC - 0.7
CPNGVLYVGC - 0.5
C Q IT*D FTSC - 0.7
CRADANVYHC 1.4 -
CRSAKTDD*C - 0.5
CSLKKSLDPC - 0.5
CSRGAYSAPC - 0.5
CTMRDTFKIC - 0.5
CTS*LNYTYC - 0.5
CWLEK*TPHC - 0.5
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experiments, After 4 rounds o f biopanning there were more repeated peptides, but in 
most cases the percentage occurrence o f these remained relatively low (Table 4.4). The 
results showed that the peptide pools from both CX8C biopanning experiments remained 
more diverse than those from the X8 biopanning (Table 4.4), Interestingly there were 
several peptides that were found to be repeated in more than one library. LSVISS, the 
most commonly occurring peptide from the individually amplified biopanning was also 
one o f the more frequently occurring peptides from experiment 2. The peptides 
CGIYNRDATC, CPNGVLYVGC and CTS*LNYTYC were also found in both CX8C 
biopanning experiments.
38 peptides isolated from the BCA o f mice fed a normal diet that received the X8 library, 
were found to share no common sequences with the peptides isolated from round 4 o f the 
biopanning with the fat fed mice (data not shown).
4.2.5 BLAST searching peptides for homology to known proteins
To try and provide more information about the identified consensus motifs, BLAST 
searching for homologous proteins was performed. By searching for short nearly exact 
protein matches from the order Rodentia some homologous proteins were identified 
(Table 4.5). Interestingly many o f the peptides have homology to proteins that have roles 
in inflammation, cholesterol metabolism or thrombus formation, so are associated with 
atherosclerosis.
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4.2.6 Developing a protocol for testing the targeting capacity of individual phage 
populations
Some of the most frequently occurring phage from the final round o f biopanning were 
chosen for further testing to analyse their specificity for atherosclerotic plaques in more 
detail. High titre populations o f individual phage were amplified for systemic 
administration into ApoE-/- mice so their biodistribution profile could be determined. 
Initially the peptide CPNGVLYVGC (CPN) that was identified from both the CX8C 
biopanning experiments was tested both with and without a predose o f UV irradiated NR 
phage (Figure 4.6). The results showed that a 55-fold higher level o f phage was detected 
in the BCA when no predose was used and that the ratio o f phage recovered from the 
blood:BCA and liver:BCA were 4.3 and 2.5 fold higher when the predose was used, 
suggesting that the results without the predose were more favorable. Therefore it was 
decided to test all the homogeneous phage without administering a predose.
4.2.7 Analysis o f the biodistribution of individual phage populations
To enable a relatively large number o f phage to be tested rapidly, the individual phage 
were each tested in two ApoE-/- mice on a C57/B16 background and an average titre for 
each tissue was calculated. The titres from the peptide-modified phage were compared to 
that o f 6 mice that received NR phage (Figure 4.7). The results showed that only 2 o f 
the peptide modified phage (CPN and CQI) had higher levels o f phage in the BCA than 
mice that received NR phage, and for the majority o f the phage tested, higher levels were 
found in the liver compared to NR phage.
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l.OxlO** 
1.0x10’® 
1.0x10® 
1.0x10» 
^ 1.0x107 
.2 1.0x10®
ÛÛI  1.0x10^ 
1.0x10^ 
1.0x10^ 
1.0x102 
1.0x10’ 
1.0x10®
CD Blood 
■  BCA 
n  Liver 
n  Kidney
CPN + predose CPN
Figure 4.6 Comparing biodistribution profiles of phage administered with and 
without a predose. ApoE-/- mice received either a predose o f  1 x 10” pfu UV  
irradiated phage followed by 1 x 10’® pfu o f  phage displaying the peptide 
CPNGVLYVGC or 1 x 10” pfh o f  phage displaying the peptide CPNGVLYVGC. 
n= 2 mice per group.
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4.3 Discussion
Biopanning with linear and constrained T7 phage display libraries was performed in an 
ApoE-/- mouse model o f atherosclerotic plaque rupture to identify peptides that 
selectively target unstable plaques. Five different protocols were used and from each o f 
these a pool o f  plaque-targeted peptides was identified. BLAST searching o f commonly 
occurring peptide motifs identified some with homology to proteins known to be 
involved in plaque development whereas for other peptides no homologous protein could 
be found.
4.3.1 Analysis o f original phage libraries
It was decided to perform the biopanning with both linear and constrained T7 based 8- 
mer libraries. Eight-mer libraries were chosen as they have a large diversity but the 
peptides are not so long that they significantly impair the rate o f phage growth (Clackson 
and Lowman, 2004). Two libraries were used to increase the likelihood of identifying 
targeting peptides, as in some cases linear and constrained peptides with the same 
sequence have been shown to have different affinities for the same receptor (Koivunen et 
a l ,  1993). The T7 system was chosen instead o f  M l 3 phage as the T7 libraries have been 
shown to have a wider diversity and less positional amino acid bias than M l3 phage 
libraries (Krumpe et a l ,  2006), so may be more effective in biopanning experiments. 
The T7Selectl0-3b library displays 5-15 copies o f the peptide on the surface o f the phage 
caps id at the C-terminal o f the lOB capsid protein. Higher and lower copy number 
libraries are available but this system was used so enough copies o f the peptide are 
displayed on the surface o f the phage without inhibiting production o f the phage. 
Libraries with higher copy numbers can cause problems with translation o f the modified 
capsid protein if the E.coli producing the phage do not contain sufficient copies o f the 
tRNA molecules required for rarer codons (Krumpe et a l ,  2006).
In vivo biopanning has commonly been used to identify phage that bind to larger target 
tissues such as the heart (Zhang et a l ,  2005). Targeting o f unstable atherosclerotic 
plaques is technically more difficult. Although the mouse model used in this study is one
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of the most reliable and accurate models o f atherosclerosis, it has been shown that 
unstable plaques are only found in about 60% of animals and that there is some variation 
in the degree o f atherosclerosis seen in the BCA of the mice (Johnson et a l ,  2005b). At 
the time o f dissection it was possible to see that the majority o f animals had developed 
atherosclerosis in the BCA, but the extent o f this varied between mice and without 
carrying out histology it is impossible to determine which mice had developed unstable 
plaques. As the whole o f the BCA is required for phage extraction it is impossible to use 
the tissue for both histology and biopanning. Also, it is not possible to ju st isolate phage 
that are binding to the plaques, phage binding to the surrounding healthier vasculature 
will also have been isolated and amplified. To try and reduce the effect o f plaque 
variability in the model, a minimum o f 3 mice was used for each round o f  biopanning. 
The biopanning may also have been improved if initially an ex vivo negative selection 
step had been carried out on healthy vasculature to reduce the possibility o f recovering 
phage that bind to healthy areas o f the BCA.
Analysis o f the amino acid composition o f the libraries suggests that some amino acids 
may be over or under-represented but this could be because only a relative small number 
o f peptides (about 50 for each library) were used in this analysis. Sequencing also 
showed that both libraries contained many peptides that were not o f the expected length. 
The error could have occurred during construction o f the DNA libraries or translation o f 
the capsid protein, but it is unlikely to have had a significant affect on the biopanning 
results.
Based on the diversities o f the libraries (both approximately 1 x 10^) it was thought that 
there was no advantage o f using one library over the other.
4,3.2 B iopanning results
For all 5 biopanning experiments, the overall increase in the amount o f phage recovered 
from the BCA in the final round compared to round 1 suggests that a pool of BCA 
targeted phage have been identified. In the majority o f experiments there was a decrease 
in the amount o f phage in the BCA from rounds 1-3 as phage that do not bind
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atherosclerotic plaques were sequentially depleted from the library to enable 
amplification o f a pool o f targeted phage. When individual phage were picked and 
amplified (protocol 1) an increase in the amount o f phage in the BCA was seen at every 
round probably because the diversity o f the library was reduced more rapidly using this 
protocol. A similar increase in recoveries was reported by Houston et a l  (Houston et a l ,  
2001) who performed biopanning to identify plaque-targeting peptides and picked 
individual phage for amplification at each round.
After four rounds o f biopanning with the bulk amplified libraries (protocols 2-5), there 
was no significant increase in the amount o f phage recovered from the kidney and in 3 o f 
the 4 experiments there was no phage recoverable from the fourth round. These results 
suggest that the phage pools have not become enriched in phage that target the 
vasculature o f tissues other than the BCA, suggesting they may be specific for areas of 
atherosclerosis. However, only one non-target tissue has been investigated, so to confirm 
this it would be necessary to analyse the amount o f phage accumulating in other non­
target tissues. This pattern o f results has previously been demonstrated in a number o f in 
vivo biopanning experiments (Rajotte et a l ,  1998, Work et a l ,  2006), for example, a 
study to identify brain targeting peptides reported an increase in the amount o f phage 
recovered from the brain and a decrease in the amount recovered from the heart, kidney 
and lung (W ork et a l , 2006).
The results also show that the amount o f phage found in the BCA is dose dependent as 
comparing the results from with and without a predose show that where a ten fold higher 
dose was received there is approximately a 10-fold increase in the amount o f phage 
detected. This suggests that the tissue has not been saturated with phage and that there 
were still further binding sites available.
4.3.3 A nalysis o f peptide sequences
Using protocol 1, where individual phages were amplified, by the 3"^  ^ round there were 
several peptides found at a relatively high frequency. The titering results also suggested 
there was no further enrichment o f the phage pool between rounds 2 and 3 so it was
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decided that for this experiment 3 rounds o f biopanning had produced a pool o f peptides 
with increased selectivity for the atherosclerotic BCA.
After four rounds o f biopanning with the bulk amplified libraries (protocols 2-5) there 
were many repeated peptides found, but the percentage occurrence o f these remained 
relatively low. The BCA titres had not yet reached a plateau, suggesting the library could 
have been further enriched for targeting peptides. There were few peptides repeated in 
the 3'^ '^  round that were also found repeated in the 4^ '^  round, suggesting that analysing 
results based on these low percentage frequencies (1-2%) is not very reliable. Performing 
additional rounds o f biopanning to further reduce the diversity o f the library may have 
made the identification o f targeting peptides easier. However, the identification o f the 
same peptides from the different biopanning reactions is encouraging as it suggests the 
results are reproducible and therefore it is more likely that these peptides have a high 
specificity for the BCA. O f particular interest is the peptide LSVISS as it occurred at a 
relatively high frequency in protocol 1 and was also one o f the most common peptides 
from protocol 2. The selectivity o f this peptide requires further analysis as it might not 
have been selected for ju st based on its ability to bind the BCA. Some peptides have a 
negative effect on the growth rate o f the phage (Clackson and Lowman, 2004). As 
LSVISS is a 6-mer peptide in an 8-mer library and only contains small-uncharged amino 
acids it may have less o f an effect on the rate o f phage growth, so the amplified peptide 
pools could have contained more copies o f this phage than others. A growth time course 
experiment is required to determine if this could be the case.
None o f the peptides sequenced from the BCA o f the fat fed mice were the same as those 
sequenced from the BCA o f mice fed a normal diet (that do not develop atherosclerosis. 
This suggests the peptides from the fat fed mice are plaque specific and not just BCA 
specific. However, the sequences from the normal mice were obtained after just one 
round o f biopanning, so their specificity for the BCA might not be reliable at this early 
stage. This is highlighted by the results in the fat fed mice that showed the phage 
recovery decreased after the first round, suggesting that some non-specific phage had
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been present. It is important that full biopanning is performed in healthy mice so the 
peptides can be more accurately compared.
The sequencing results showed that the targeted pools contained many phage that 
encoded for peptides containing stop codons. Other biopanning experiments have also 
identified peptides with stop codons (Houston et a i ,  2001, Goldman et a l ,  2000). It is 
thought that these phage can actually have a growth advantage over other phage (Houston 
et a l ,  2001). Several explanations for how they occur have been proposed. It may be 
that a truncated protein is produced, or translational read-through might occur (Goldman 
et a l ,  2000). Also under some conditions the stop codon UAG is translated as glutamine 
and UGA as selenocysteine (Bock et a l ,  \99 \) .  It has also been shown that a +1 or -1 
frameshift can occur to enable translation to continue past a stop codon (Goldman et a l ,  
2000). One problem with the T7-103b library is that in some cases the phage may not 
actually display the peptide encoded by the phage genome. The T7 capsid contains a 
total o f 5-15 copies o f the lOB and lOA capsid proteins, normally lOB makes up about 
10% of the capsid protein but this can vary (Condron et a l ,  1991). Phage can be 
assembled with only 1OA, so the peptide encoded for by the 1 OB gene may not always be 
expressed (Novagen, 2002).
4.3.4 Comparing the different biopanning protocols
Based on the number o f peptides identified and their frequency suggests there was no 
advantage gained by using the predose. However using a predose enabled the use o f a 
lower dose o f the phage library, which was advantageous as it was difficult to achieve 
purified stocks o f the required titre. Further testing o f the individual peptides inserted 
into viral vectors is also required to determine whether using the predose increased the 
specificity o f the identified phage by blocking binding to non-specific receptors.
After 4 rounds o f biopanning both pools o f constrained peptides remained more diverse 
than the linear pools, possibly because o f the slightly higher diversity o f  the initial CX8C 
library. The results suggest that there was no advantage in using either the X8 or CX8C 
library.
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Restricting the library by amplifying individual phage at each round has produced fewer 
peptide sequences that occurred at a higher frequency and it provided a quicker method 
that required less animals. However, artificially reducing the diversity o f the library may 
potentially remove peptides with a higher specificity, particularly after just one round 
where the diversity remained high.
In summary, the biopanning profiles and sequencing results suggest that some potential 
plaque-targeting peptides have been identified. Further testing o f the individual peptides 
incorporated into viral vectors is required to determine whether peptides identified from 
one o f the biopanning protocols have a higher degree o f specificity for the plaques.
4.3.5 Analysis of BLAST results
The results o f the BLAST searching identified several peptides that have homology to 
proteins that might have a role in atherosclerosis. Two peptides (QIFLFEIG and 
SIESSSKR) were found to have homology to ApoB, the main apolipoprotein component 
o f chylomicrons and LDL. ApoB binds to LDLR to mediate uptake o f  LDL into tissues 
and is found at high levels within human plaques (Martinet et a l ,  2003). O f particular 
interest is the peptide SIESSSKR as this is homologous to amino acids located near the 
LDLR binding domain (Figure 4.8) and near to a mutation that increases the risk o f 
atherosclerosis development. The R3527 to Q 3527 mutation occurs in familial defective 
apoB-100 (FOB 100) that results in hypercholesterolemia (Innerarity et a l ,  1987). It 
causes a conformational change that reduces its affinity to LDL-R to 5-10% of wild type 
levels as the arginine residue is thought to stabilise 2 clusters o f basic amino acids that 
are required for binding to LDLR (Vrablik et a l ,  2001).
There were also many peptides with homology to proteins involved in the inflammatory 
response. For example, 2 peptides (LSTVKTYE and CTS^LNYTYC) with homology to 
the leukocyte adhesion protein (32 were identified. This protein forms a receptor that 
binds to many molecules known to be expressed on the surface o f plaques. A recent study 
also found leukocyte adhesion protein (32 expression is upregulated in unstable plaques
21
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3121 anldflnipl tipemrlpyt iittpplkdf slwektglke flkttkqsfd Isvkaqykkn 
3181 khrhsitnpl avlcefisqs iksfdrhfek nrnnaldfvt ksynetkikf dkykaekshd 
3241 elprtfqipg ytvpvvnvev spftiem saf gyvfpkavsm psfsilgsdv rvpsytlilp 
3301 slelpvlhvp rnlklslpdf kelctishif ipamgnityd fstkssvitl ntnaelfnqs 
3361 divahllsss ssvidalqyk legttrltrk rglklatals Isnkfvegsh nstvslttkn 
3421 mevsvakttk aeipilrm nf kqelngntks kptvsssm ef kydfhssmly stakgavdhk 
3481 Islesltsyf siesstkgdv kgsvlsreys gtiaseanty Inskstrssv klqgtskidd
3541 iwnlevkenf ageatlqriy slwehstknh Iqleglfftn gehtskatle Ispwqmsalv
B N-terminus
C-terminus
Figure 4.8 ApoB-100. A. Part of the protein sequence of ApoB-100 {Law, 1990 #6150}. 
The C-terminus of the ApoB LDL receptor binding domain is shown in green and the 
region to which the peptide SIESSSKR is homologous is shown in red. The R3 5 2 7  o Q3527 
mutation (shown in blue) occurs in familial defective apoB-100 (FOB 100) (Innerarity et 
al,  1987). Rgggg to € 3 5 5 3  (shown in blue) also reduces the affinity of ApoB to LDL receptor 
resulting in subjects developing hypercholesterolemia (Pullinger et al,  1999). B. 
Secondary structure of ApoB-100 imposed onto low resolution model of the protein (from 
(Johs et al,  2006)). The LDLR binding residues and the region of the peptide homology is 
located in the P2  domain.
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compared to stable plaques (Papaspyridonos et a l ,  2006). Integrin p2 is the common 
subunit o f many leukocyte integrins including complement receptor 2 (CR2), CR4 and 
leukocyte function-associated antigen-1 (LFA-1). It can be expressed on the surface o f 
monocytes, T-cells, macrophages, neutrophils and dendritic cells and is involved in 
binding to cell adhesion molecules such as intercellular adhesion molecules (ICAMs), 
extracellular matrix proteins including fibronectin and complement protein 3B. Integrin 
(32 also binds LDL receptor-related protein (LRP) to enable leukocyte adhesion to the 
vascular endothelium during the inflammatory response involved in plaque development 
(Spijkers et a l ,  2005). The peptide LSTVKYTE has homology to an exposed region o f 
the I domain o f the protein (Figure 4.9), which is thought to play a critical role in ligand 
binding and heterodimer formation (Xiong and Zhang, 2001).
One o f the few peptides that produced positive results when tested as an individual phage 
population (CQHDFTSC) was found to have homology to TIMP4. TIM P4 has been 
associated with the inflammatory response in cardiovascular disease (Koskivirta et a l ,  
2006, Dollery et a l ,  1999, Li et a l ,  1999). In healthy arteries it has been found in medial 
SMC and in advanced plaques it has been found to co-localise with macrophages in areas 
surrounding the necrotic core (Koskivirta et a l ,  2006). Its expression is upregulated in 
inflammatory cardiovascular disorders as it is produced by lymphocytes, mast cells, 
monocytes and macrophages (Koskivirta et a l ,  2006). TIMP4 inhibits all known MMPs 
(Koskivirta et a l ,  2006) and it may also have a role in apoptosis. It has been shown to 
inhibit rat aortic SMC migration and induce apoptosis in vitro (Guo et a l ,  2004). In vivo, 
TIMP4 overexpression was shown to reduce neointima formation and increase SMC 
apoptosis in balloon injured rat carotid arteries (Guo et a l ,  2004). The TIMP2 
homologous peptide CNHRYM QM C (Liu et a l ,  2003) appears to be a promising 
atherosclerotic plaque targeting peptide (Chapter 3) and from these preliminary studies 
this TIMP4 homologous peptide also seems to have potential.
Interestingly a peptide with homology to P-selectin was identified. P-selectin is 
expressed on the surface o f both platelets and endothelial cells and acts as a receptor for 
leukocyte binding (Vestweber and Blanks, 1999). It is upregulated on the endothelium in
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Figure 4.9 Diagram of the pj I-Bke domain model. View of the top of the domain. 
The peptide LSTVKTYE is homologous to a  helix 5. Adapted from (Huang et ai,  
2000).
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atherosclerosis (Johnson Tidey et al., 1994, Molenaar et a l ,  2003). It has a key role in 
plaque development and progression as P-selectin-deficient mice develop significantly 
reduced atherosclerosis (Dong et a l ,  2000, Johnson et al., 1997). P-selectin is also found 
at higher levels in the blood as disease progresses (Blann and McCollum, 1998, Ridker et 
a l ,  2001). As its expression is increased on the endothelium, it is more likely that this 
biopanning would have identified a peptide that binds to P-selectin rather than a 
homologue o f P-selectin. However, the ligand for P-selectin, sialyl-Lewis^ 
carbohydrates has been reported to be expressed on the endothelium, although its role 
here is unlcnown (Munro, 1993).
Many o f the protein homologues identified have a role in wound healing and blood 
clotting, so could be expressed at a higher level in unstable plaques that have undergone 
previous silent ruptures. Therefore these peptides may have a higher specificity for 
unstable rather than stable plaques. This is o f particular interest, as silent ruptures have 
been shown to be a key feature o f the plaques produced in the mouse model used in this 
study (Johnson et a l ,  2005b). One o f the peptides (YVTMKHHP) has homology to 
FGF15, which has not been linked to atherosclerosis but has a role in cardiac 
development (Vincentz JW, 2005). However, other isoforms o f FGF are known to be 
expressed in atherosclerotic plaques (Brogi et a l ,  1993). They have a role in smooth 
muscle cell, proliferation, migration and proteoglycan synthesis (Tan et a l ,  1989). 
Another peptide (FISVRLS) has homology to fibronectin, which is a known component 
o f atherosclerotic plaques and its expression has been shown to be upregulated in 
advanced plaques (Hiltunen et a l ,  2002). It is a chemoattractant for several cell types 
that play a role in the wound healing process, including fibroblasts, endothelial cells and 
macrophages. It also generates a scaffold that allows attachment o f other extracellular 
matrix com ponents.
One o f the peptides (VSIANNRL) was found to have homology to the extracellular 
matrix protein laminin. The 37/67 kDa laminin receptor (LamR) has recently been 
identified as the receptor for cellular attachment o f AAV8 and might have a role in the 
infection pathway of AAV2, 3 and 9 (Akache et a l ,  2006). LamR is expressed in many
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tissues including the heart and liver and is upregulated in many cancers, so any virus or 
phage that uses it as a receptor is likely to have a broad trop ism (Sobel, 1993). Several 
other viruses including Dengue virus and Sindbis virus also use LamR as a receptor 
(Thepparit and Smith, 2004, Wang et a l ,  1992).
Another peptide (C*1EANSLRC) was found to have homology to platelet-activating 
factor acetylhydrolase (PAF-AH) which has been linked to atherosclerosis. It is produced 
by macrophages, mast cells and activated platelets (Karabina and Ninio, 2006). Secreted 
PAF-AH is mainly found associated with LDL (Stafforini et ah, 1987). PAF-AH has an 
anti-atherogenic effect as it degrades PAF (a potent proinflammatory phospholipid 
molecule generated by leukocytes, myeloid cells, platelets, mast cells, and endothelial 
cells) and PAF-like molecules produced by LDL oxidation and platelet activation and so 
reduces the migration o f leukocytes into the vessel wall (Lee et a l ,  1999). But, the 
products o f PAF-AH mediated degradation may have an adverse effect on the vessel wall 
(Karabina and Ninio, 2006). However, it has been shown to protect against 
atherosclerosis development in several animaLmodels (Quarack et a l ,  2001, Turunen et 
a l ,  2004). In another study in LDLR-/- mice over-expressing ApoB-100 suggested PAF- 
AH has a proatherogenic role as the mice developed large lesions and were found to have 
elevated levels o f  PAF-AH (Singh et a l ,  2004). PAF-AH was thought to be upregulated 
by the high levels o f LDL present (Singh et a l ,  2004). So as yet it is not known whether 
PAF-AH is pro- or anti- atherogenic or may just be a marker for atherosclerosis 
(Karabina and Ninio, 2006).
Some o f the proteins identified by the BLAST searching have no connection to 
atherosclerosis and may have ju st been identified randomly based on the probability o f a 
short peptide sequence existing in a protein. Interestingly the breast cancer susceptibility 
gene BRCA2 that has not been linked to atherosclerosis was found to have homology to 
two o f the peptides. However BRCA2 is a nuclear protein involved in DNA repair so it 
is unlikely that it binds to anything expressed on the surface o f atherosclerotic plaques. 
This highlights a limitation o f using BLAST searches alone to identify receptors for 
peptide motifs. However in combination with frequency analysis and screening of
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populations o f individual phage it can be used to provide additional information about 
identified peptides and their potential receptors, which can be investigated further.
Some peptides were also found to have homology to hypothetical proteins and proteins 
with no known function, so these may actually have some relevance.
A major problem with BLAST searching short peptide sequences is that in many cases 
the binding site o f the natural ligand for a receptor is not a linear peptide sequence but is 
discontinuous (i.e. formed when the protein is folded correctly). As such BLAST 
searching primary amino acid sequences does not produce definitive results, but can 
indicate potential homologues that require further investigation to validate them. Due to 
this and the fact that the BLAST database is incomplete, for many peptides no homology 
to any known protein is identified.
4.3.6 Analysis of biodistribution profiles of individual phage populations
The initial work with the CPNG peptide suggested that the best way to test the targeting 
capacity o f the individual phage was to administer the phage without a predose as this 
produced more favorable ratios o f phage in the blood: BCA and liver:BCA. This method 
was also chosen because it would provide a more rigorous testing o f the specificity o f the 
phage as any phage without a high specificity for the plaques could still be taken up by 
the RES.
The results showed that for the majority o f the phage tested, compared to N R phage there 
was no targeting to the BCA, but there was actually an increase in the amount o f phage 
accumulating in the liver. Although phage with the peptides CPN and QIT were found to 
have higher levels in the BCA, there was also a higher level in the liver, so the peptides 
may not bind to receptors specific to atherosclerotic plaques. It would be interesting to 
carry out IHC on the BCA o f mice receiving the homogeneous phage to determine more 
precisely if the phage in the BCA were binding to the plaques or to the surrounding 
healthier vessel.
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One problem with this experiment is that the method used (without a predose) was 
chosen on the basis o f  initial results with one o f the phage (CPN), which happens to be 
one o f  the few phage that did seem to have some degree o f targeting to the BCA. For 
other phage using a predose m ay have given better results as it would have reduced 
uptake o f  phage by the RES so it might have been possible to see targeting to the BCA.
Another problem with this study was that the biopanning was performed in ApoE-/- mice 
on a C57/B16/129SvJ background that have been shown to develop unstable plaques 
(Johnson et a l ,  2005b), whereas due to time constraints the individual phage were tested 
in ApoE-/- mice on a C57/B16 which have been shown to develop advanced plaques (See 
section 3.3.1). I f  the peptides are highly selective for unstable plaques then they are 
unlikely to target advanced plaques.
4.3.7 Summary
The biopanning profiles from the BCA and kidney and the sequencing results suggest 
that the biopanning has successfully reduced the diversity o f  the original libraries and 
produced pools o f BCA targeted peptides. The BLAST search results have shown 
several o f  the peptides have homology to proteins known to be involved in 
atherosclerosis suggesting some interesting, potential plaque targeting peptides have been 
identified. However, analysis o f  the peptides using individual phage populations, in most 
cases failed to demonstrate targeting to atherosclerotic plaques. Further testing o f  some 
o f  the more promising candidates based on frequency and the BLAST searching results is 
required. It is necessary to analyse the biodistribution profiles o f  the individual phage in 
ApoE-/- mice on a C57/B16/129SvJ background and perform detailed IHC to determine 
whether the phage are binding to atherosclerotic plaques or surrounding vasculature. 
Alternatively synthetic peptides labeled with fliiorescein-5~isoth iocyanate (FITC) could 
be used to analyse the targeting capacity o f  individual peptides. Ultimately, engineering 
o f the peptides into viral vectors would enable the targeting capacity o f  the peptides to be 
fully examined.
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Chapter 5: 
Development and Characterisation 
of an AAV2 Based Peptide Library
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5.1 Introduction
AAV2 is a promising vector for gene therapy as it causes no known human disease, is 
minimally immunogenic and can produce sustained transgene expression (Monahan and 
Samulski, 2000a). It may therefore be particularly good for treating chronic conditions 
such as atherosclerosis where long-term transgene expression may be beneficial. 
However due to the natural hepato-tropism o f the virus and sequestration in the 
extracellular matrix o f ECs (Pajusola et al., 2002), it provides poor transduction of 
vascular cells following both local and systemic administration (Richter et al., 2000, 
White et a l ,  2004, M aeda et a l ,  1997, Nicklin et a l ,  2001a). To use AAV2 as a vector 
for applications to atherosclerosis it needs to be both detargeted from its native tropism 
and retargeted to atherosclerotic plaques to produce a more efficient and useful vector. 
The most effective way o f doing this is thought to be via the incorporation o f targeting 
peptides into the HSPG binding site o f the AAV2 capsid (commonly after amino acid 
587). This can both redirect the virus to an alternative receptor and potentially block it’s 
binding to HSPG (Girod et a l ,  1999). This has been demonstrated with some success for 
targeting AAV2 to vascular cells both in vitro and in vivo (Nicklin et a l ,  2001a, Work et 
a l ,  2006, W ork et a l ,  2004a, White et a l ,  2004).
The most commonly used method to identify targeting peptides is phage display (see 
chapter 4). When no prior knowledge o f a target receptor is available biopanning with a 
phage library is an efficient way o f identifying peptides that can be used to target viral 
vectors to a particular tissue or cell type. Although there are many successful examples 
of this, two main problems have been encountered with this procedure. N ot all peptides 
identified by phage display can be incorporated into viral vectors as peptide insertion can 
affect the ability o f the capsid to assemble (Wickham et a l ,  1997, Hong and Engler, 
1996). For example, when 10 transferrin targeting peptides identified by phage display 
were inserted into the HI loop o f Ad5 only 2 o f the peptides had no detrimental effect on 
Ad production, 4 caused a reduction in the titre o f the virus and 4 prevented amplification 
o f the virus (Xia et a l ,  2000). From our experience approximately 50% o f identified 
peptides can be successfully incorporated into viral vectors. Changing the physical
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context in which the peptide is displayed from the phage to the virus may cause 
alterations in the 3D conformation o f the peptide that can alter the affinity o f the peptide 
for its receptor. For example the LSNFHSS peptide identified by phage display as 
targeting EC, did not improve A d5 transduction o f ECs when it was displayed in the HI 
loop (Nicklin et a i ,  2001c). The peptide GETRAPL was identified by phage display for 
targeting to SMC, but when inserted into both the Ad5 and AAV2 capsid it did not 
improve transduction o f these cells compared to unmodified control virus (Work et a l ,  
2004a).
One recent attempt to overcome the problems encountered when inserting peptides into 
Ad5 vectors has involved the creation o f a context-specific phage library. It has the H 
and I sheets o f the adenovirus knob inserted into the p ill protein o f filamentous 
bacteriophage, with a library o f 12-mer peptides inserted into the same position where 
they would be displayed in the HI loop (Ghosh and Barry, 2005). This library was used 
to identify a muscle targeting peptide and when the corresponding Ad5 virus was tested it 
was shown to be a functional and muscle-specific vector (Ghosh and Barry, 2005). 
Although this overcomes the problem o f context specificity and in this case it was 
successful, it still doesn’t overcome the problem that the identified peptide may inhibit 
virus assembly and function.
An alternative approach developed to produce targeted AAV vectors has completely 
removed the need to use phage by producing peptide-modified libraries o f AAV2 vectors 
(Perabo et a l ,  2003, M uller et a l ,  2003). The libraries were made by inserting random 
oligonucleotides encoding 7 amino acids into a plasmid encoding the AAV genome to 
create a plasmid library. Perabo et a l  (Perabo et a l ,  2003) then produced the viral 
library by co-transfecting the plasmid library with an adenovirus helper plasmid. This 
created a library with random 7-mer peptides inserted after amino acid 587, which had a 
diversity o f 4 x 10^ modified virus particles. It was used for in vitro biopanning to 
identify viruses targeted to M-07e (a human megakaryocytic cell line) cells and M e d  
cells (derived from B-cell chronic lymphocytic leukaemia cells) (Perabo et a l ,  2003). 
Three o f the four viruses identified from the screening showed significantly increased
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transduction o f the target cells, independently o f HSPG binding (Perabo et a l ,  2003). 
However, as with all biopanning on cells, peptides that mediate binding to a ubiquitously 
expressed protein can be identified. Two of the peptides identified contained an RGD 
m otif so they are likely to bind integrins (Perabo et a l ,  2003, Pasqualini et a l ,  1995).
Muller et a l  (Muller et a l ,  2003) used a two-step system to produce a viral library from 
the plasmid library. The first step packaged the library genomes into chimeric caps ids of 
both wild type and mutant capsids by transfecting 293T cells with the plasmid library, 
plasmid encoding wild type capsid and a helper adenovirus plasmid. The resulting 
shuttle virus library was then infected into 293T cells with a helper Ad virus to produce 
the virus library (Muller et a l ,  2003). This 2-step protocol was used to try and avoid 
producing virions displaying more than one peptide, which could be produced by a cell 
being transfected by more than one plasmid from the library. However using this method 
results in the library containing wild type AAV2 (Waterkamp et a l ,  2006). The resulting 
library had an estimated diversity o f 1 x 10  ^ random 7-mer peptides inserted after residue 
587 (Muller et a l ,  2003). Biopanning performed on HCAEC identified several targeted 
viruses that were shown to function in vitro and targeted the heart in vivo (Muller et a l ,  
2003). These studies are proof o f concept showing that in vitro biopanning with AAV2 
based libraries can be used to identify specifically targeted viruses that can efficiently, 
bind, internalise and translocate to the nucleus in the target cell type. In both cases, in 
vitro the viruses had a high degree o f selectivity for target cell types that are normally 
poorly transduced by AAV2 and their transduction was shown to be mediated by the 
inserted peptides. Further work is needed to determine their efficacy in vivo. It is 
important to note that the diversity o f the AAV libraries is several logs lower than that 
typically found in phage libraries, so the chance o f identifying targeting peptides is 
therefore reduced. However, these studies have shown that the diversities are still high 
enough to enable identification o f  viruses targeted to different cell types.
AAV2 based libraries have also been used to identify mutants with higher resistance to 
the most commonly occurring neutralising antibodies (Perabo et al., 2006a, Maheshri et 
a l ,  2006). Both groups used error prone PGR of the cap gene to create a library of
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AAV2 mutants, which was then used in directed evolution experiments to identify 
antibody resistant virions. Perabo et al. biopanned on HeLa cells in the presence o f a 
pool o f human sera known to contain AAV2 neutralising antibodies. The most 
commonly identified point mutations were R459G, R459K and N551D (Perabo et a l ,  
2006a). These residues and 73% of the less frequently occurring mutations are all 
located in the same region o f the capsid, suggesting that an antigenic epitope had been 
identified (Perabo et a l ,  2006a). Maheshri et al. (Maheshri et a l ,  2006) performed 
biopanning in the presence o f rabbit anti-AAV2 neutralising sera. This identified 
mutations N587I and T716A for enabling antibody-evasion. These mutations may be 
part o f several different antibody binding epitopes that may all require mutating to 
provide a vector, which evades antibody neutralisation in the majority o f the human 
population due to the diversity o f antibodies known to exist.
5.1.1 Aims
The main aims o f this chapter were to use the AAV2 library created by Perabo et al. 
(Perabo et a/., 2003) to:
1. Develop and optimise protocols for biopanning with the AAV library both in vitro 
and in vivo.
2. Further characterise the library and the effect o f peptide insertions on the 
infectivity o f the virus to study the basic biology o f AAV2, to enable better vector 
development.
3. Identify peptide modified AAV2 vectors that target endothelial cells and 
atherosclerotic plaques, by performing in vitro and in vivo biopanning in a mouse 
model o f atherosclerosis.
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5.2 Results
5.2.1 Estimation of the diversity of the AAV libraiy
The library contains AAV2 virions with a random 7-mer peptide inserted into the virus 
capsid at position 587. There is no accurate way o f assessing the true diversity o f the 
library, although it has been estimated to contain 4 x 1 0 ^  different peptides based on the 
ligation efficiency o f the random oligonucleotides into the plasmid used to create the 
library and the efficiency o f transfection during the packaging reaction (Perabo et a l ,  
2003). To try and confirm that the diversity o f the plasmid library was maintained in the 
virus library, the peptide-containing region o f the virus library was PCR amplified, 
cloned and sequenced. Two pools o f the library from different synthesis reactions were 
used. From pool A 84 peptide sequences were obtained and o f these 13 sequences 
occurred more than once (Table 5.1). From pool B, 1 o f 34 peptides occurred twice. 
None o f the peptides were found in both pool A and B, suggesting the peptide repetition 
may be due to sequence bias created by the PCR. Statistical analysis o f the peptide 
sequences based on the frequency o f amino acids occurring in different positions within 
the peptides calculates that the library has a diversity o f 5 x 10^ different peptides.
The oligonucleotides encoding the peptides were synthesised randomly, so all codons 
were possible. This means their will be some bias in the frequency o f amino acids as 
some are encoded by 6 different codons whereas others are encoded by only 1 codon. 
Analysis o f the occurrence o f each amino acid within the peptides showed that the library 
contains a higher than expected number o f alanine (A), aspartic acid (D), glycine (G) and 
proline (P) (Figure 5.1). The library had fewer than expected phenylalanine (F), 
isoleucine (I), lysine (K), asparagine (N) and tryptophan (Y) residues. Several peptides 
containing stop codons were also identified (Figure 5.1).
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Pool A Pool B
AADLLGP PW AQRLP AE-Stop-DARS
AGRDYSL QATGCHR (2) AFSGS-Stop-Y
ALADSLT RLTLSCI AQGYPEG (2)
ALGPRSL RPFCQLY CGLSPDL
ALRSTSP RSRARAG CSEAPM R
ALVARVN RWPDQRA DQDQLSG
APRLSSS SEARXRA DRRHTHA
AQELRGH SEVQRSH DSHRGHS
CATAANL SGSDPAD (2) ERGDPGV
CDSRLRR SHSRSRA GAEWAVR
DMA VERA (3) SLAHSAT GLPRNLS
DQTYPTE SMMHRLR GRSEPDS
DSQPLRW  (4) SPLPPDP (3) GTQSLAS
DSRSADR SRGKPIT GYPRHSE
DTAAYLG Stop-W LRPHS (2) HSSRPIS
EAGLTVD (2) TPSGRSG (2) IVRRLVR
EGGEPDD TRL"Stop“QDR LGAT-Stop-RS
ELGRSDK (2) TRSGATD MMTRLGE
EQLSLRE VPKPGSP RASCGGA
ERSPPTH VSSNAVS RATTPR
FGPGHVV VSVSAAA RCAAVPA
FHRAESG WATADQI RGRAGSD
GATAGFY YEDGFFIQ RRRIATA
GNCHETP YLVGRCQ RTQLVPC
GRLGVVT YQDGGTA (3) SCLQLRA
HLTSPRS (5) SEAPEGI
IDTLGRA (2) SELGAFE
MIVPRSC SGPTMKA
NLGPAM S SIAPGPS
NRPTPTR (2) SQHSDGD
PEAARQQ SR-Stop-PRPV
PGCHLSA SYSLPQR
PLGPAAA
PPPKPTY
PRAPLHT
PSALSNM
PTCRRPP
PWAHRLA
VLRSPGA
T able  5.1 Pep tide sequences from  the  com plete AAV librai*y. Positively charged peptides 
are shown in red and negatively charged peptides are in green. For peptides that occurred more 
than once, the number o f  copies is indicated in parenthesis.
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g  Expected frequency 
□  AAV library frequency
14
12
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bI K
A C D E F G H I  K L M N P Q R S  T V W Y  Stop
Am ino A cid
Figure 5.1 Amino acid composition of peptides from the complete AAV library. 118
peptides were sequenced from  the com plete A A V  library and com pared to  the expected 
am ino acid fr equency based on all codons occurring at the sam e rate. A lanine (A), Cysteine 
(C), A spartic acid (D), G lutam ic acid (E), Phenylalanine (F), G lycine (G), H istidine (H), 
Isoleucine (I), Lysine (K), Leucine (L), M ethionine (M), A sparagine (N), Proline (P), 
G lutam ine (Q), A rginine (R), Serine, (S), Threonine (T), V aline (V), Tryptophan (W ), 
Tyrosine (Y).
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Analysis o f the peptides to determine whether any amino acids occur more or less 
frequently at a specific position within the peptide indicated that for most amino acids 
there was no positional specificity. The exceptions to this are that acidic amino acids 
were more commonly found at the N- and C-termini o f the peptides (positions 1 and 7) 
and bulky amino acids were generally found in positions 1 and 2 (Figure 5.2).
5.2.2.1 In  vitro b iopann ing  w ith  the AAV lib ra ry
In vitro biopanning was performed on RGE cells to identify endothelial cell-targeted 
viruses and on HeLa cells as a control, to confirm that different peptide containing 
viruses can be selected for on different cell types. Taqman analysis o f the amount of 
virus in cell media, pellet and supernatant samples from all six rounds o f biopanning 
shows a similar pattern o f results was obtained with all 3 cell fractions (Figure 5.3). The 
results from the RGE cell samples show an increase in the Ct values over the first three 
rounds, indicating the amount o f virus present has been reduced (Figure 5.3A). Over the 
last three rounds there was an increase in the amount o f virus detected (Figure 5.3A). 
With HeLa cells a decrease in the amount o f virus was also seen over the first three 
rounds but there was no consistent increase seen in the latter rounds (Figure 5.3B).
HeLa cell samples from rounds 4, 5 and 6 were then used as templates for sequencing of 
the peptide-containing region o f the AAV2 capsid (Figure 5.4). From the mixed 
sequencing trace in the peptide insertion site, it is clear that even after 6 rounds of 
biopanning, the cell samples still contained a mixed pool o f viruses, although the 
diversity was greatly reduced from the starting library. PCR analysis o f  the RGE cell 
samples from round 6 indicated that the population o f viruses contained viruses both with 
and without a peptide (Figure 5.5A), whereas the HeLa cell samples only contained 
viruses with an inserted peptide (Figure 5.5B). As a consensus sequence had not been 
reached after 6 rounds o f  biopanning, the peptide-encoding region o f the virus capsids 
was amplified by PCR and TA cloned, so individual peptide sequences could be 
obtained.
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A. Small non polar B. Uncharged Polar
C. Basic D. Acidic
Amino acid position
CZl 1
2
CZ3 3
CZl 4
5
EZD 6
7
E. Bulky
Figure 5.2 Analysis of the amino acid composition of 118 peptides sequenced from 
the virus library. A. Small non-polar amino acids (A, G, I, L, M, P and V). B. 
Uncharged polar amino acids (S, T, N, Q and C). C. Basic amino acids (R, K and H). 
D. Acidic amino acids (D, E). E. Bulky amino acids (F, W, Y)
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A. RGE cells
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Biopanning Round
B. HeLa
Media 
■*—Cell pellet
Cell supernatant
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25 
 ^20 
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Biopanning Round
Figure 5.3 Real time PCR results from in vitro biopanning with the AAV library.
Samples of cell media, pellet and supernatant were isolated from each round of 
biopanning and used as a template for Taqman real time PCR. A. RGE cells. B. HeLa 
cells. To detect the amount of virus in each sample The cycle threshold (Ct) value is the 
number of PCR cycles required before a significant amount of PCR product above 
background level has been produced.
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peptide encoding region
259
c g g c c g c c v n n v n n  v n  
A A A K K
69 279  289
aj ynnv n n v n n v n n g c g g c g c g c c a a g c  ^  
K K K K  A A R  Q
C G G C C G C C C ,  G G A T C i ^ G  
C C C  C C  A T C c
: C C  C C  A T C C
.A/\J /VI
? j 3 Y T J C S G G G G G - G C G G C G C G C C A A G C
C C C C A A C
C C C C a  A C
.V ra  V
reference
sequence
Figure 5.4 Sequence analysis of HeLa biopanning samples. Two sequencing 
traces of the peptide insertion region of viruses in cell samples from round 6  of 
biopanning on HeLa cells.
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A. RGE cells
400bp
300bp
M P S pi
B. HeLa cells
400bp
300bp
Figure 5.5 PCR analysis of AAV library biopanning samples. Agarose gel 
electrophoresis of the PCR products of the peptide containing region of the virus library from 
round 6 of biopanning on A. RGE cells and B. HeLa cells. The PCR product from AAV 
library virions containing a peptide is 330 bp where as for wild type AAV without a peptide it 
is 309 bp. Cell media (M), Cell pellet (P), Cell supernatant (S) and a plasmid positive control 
(pi) (containing no peptide)
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5.2.2.2 Analysis of peptide sequences from biopanning on RGE cells
As the PCR results suggested the majority o f viruses from the RGE cell samples 
contained viruses that had no peptide insertion. From 55 sequences, only 4 were found to 
contain a peptide (ARSTLSH, SIRGTGG, SQVRATT and SSGTPSR) and these shared 
no consensus motif.
5.2.2.3 Analysis of peptide sequences from biopanning on HeLa cells
Sequencing o f the peptide insertion region o f 2 PCR products from round 6 of the 
biopanning in HeLa cells produced 95 sequences containing 27 different peptides (Table
5.2). Sequencing results identified several consensus motifs that might enable specific 
targeting o f HeLa cells. The most commonly occurring peptide motifs (e.g. ASSPRPS 
which was in 30% o f the peptides) were found in the 2 independent PCRs. BLAST 
searching the peptide ASSPRPS did not identify homology to any relevant proteins. One 
commonly occurring m otif SIR^/qT'^/a was found in 3 peptides from the HeLa 
biopanning and I in the RGL biopanning. This was the only peptide identified from both 
biopanning experiments suggesting it might bind a receptor found on both cell types.
Interestingly, 84% o f the different peptides sequenced from the HeLa cell biopanning had 
an overall positive charge, 16% were neutral and none were negatively charged (Table
5.2). This is in contrast to the peptides sequenced from the full library that were 46% 
positive, 32% neutral and 22% negative (Table 5.1). Further analysis o f the peptide 
sequences from round 6 has identified several features o f the HeLa selected population of 
peptides that are different from the composition o f peptides in the full library (Figure 
5.6). The HeLa targeted peptides contain lower levels o f the large amino acids F, W and 
Y than the original library (p<0.05), suggesting that as well as inhibiting capsid formation 
they may also reduce virus infectivity, however due to the low level seen in both libraries 
it is difficult to draw any conclusions from this. The percentage occurrence o f basic 
amino acids was not altered from the original library, but within the HeLa targeted pool 
they were commonly found in positions 5 and 7, where as in the original library they 
were evenly distributed (Figure 5.6B). There is a significant reduction (p<0.05) in the
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Pool A
Positive Neutral
ASSPRPS ATSTMGG
GASNPAR DSAVKQT
GRRDSPV (5)
GSAVKQT
SIRATGG (9)
Pool B
Positive Neutral
AAGSPVR LDPDSRR
ALTPPRV TGTAGVA (2)
ANGPLPR
ASSPRPS (27)
ATSTMGG
ATSTRAP
GNPLSTR (3)
GRRDSPV (5)
GSAVKQT (6 )
NRGTTNA (2)
NTPIQAR
NTPTQAR (4)
QHGSAPR
SAPVPTR (4)
SIRATAR
SIRGTGG (8 )
SVAPRGP
SYSPPVR
TLIPPGR
TNPPRTT
TPAPGSK (2)
VNPDSRR
Table 5.2 Peptide sequences from round 5 of biopanning on HeLa cells. The sequences are 
from 2 PCRs (pool A and B) and are divided on the basis of the overall charge of the peptides 
(there were no negative peptides). Positively charged amino acids are shown in red and 
negatively charged amino acids are in green. For peptides that occurred more than once, the 
number of copies is indicated in parenthesis.
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□ AAV library 
■ HeLa selected peptides
I i.Q
A C D E F G H I  K L M N P Q R S  T V W Y  Stop
Amino acid
Amino acid position
B. Basic C. Acidic □ 1
■ 2
□ 3
□ 4
■ 5
□ 6
■ 7
Figure 5.6 Analysis of the amino acid composition of peptides sequenced from 
round 6 of biopanning on HeLa cells. A. Frequency of amino acids within the 
peptides. B. Position of basic amino acids within the peptides. C. Position of Acidic 
amino acids within peptides. Small non-polar amino acids (A, G, 1, L, M, P and V). 
Uncharged polar amino acids (S, T, N, Q and C). Basic amino acids (R, K and H). 
Acidic amino acids (D, E). Bulky amino acids (F, W, Y)
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amount o f acidic amino acids (D and E) found in the HeLa targeted peptides and they are 
only found at residues 1, 2 and 4 (Figure 5.6C). There were no positional effects seen 
with any o f the other amino acid groups (data not shown).
These results and the previously published example (Perabo et a l ,  2003) suggest that the 
AAV library can be used for in vitro biopanning as several consensus peptides that might 
target HeLa cells were identified, and the pool o f targeted peptides had different features 
from the original library, indicating that some selection had occurred that required further 
investigation.
5.2.3 Influence of peptide insertion on heparin binding
One o f the main problems encountered when trying to develop peptide-targeted AAV2 
vectors is that in some cases HSPG binding can be maintained, despite the insertion of 
the peptide into a region o f the capsid that is known to form the major HSPG binding site. 
However, the level o f this binding varies depending on the peptide (White et a l ,  2004, 
Grifman et a l ,  2001), and it has been noted that in many cases where HSPG binding is 
maintained, the inserted peptides are positively charged (W ork et a l ,  2006, Work et a l ,  
2004a). Previously biopanning with the AAV library identified 4 targeted viruses, of 
these 1 was positively charged (RSNAVVP) and still bound heparin whereas the other 3 
peptides had no charge and their transduction was independent o f heparin (Perabo et a l ,  
2003). So, the library contains both HSPG binding-dependent and independent viruses. 
For a virus to be targeted to a cell type with a high degree o f selectivity it is important 
that the ability o f the virus to bind HSPG is ablated, so the library was separated into 
pools o f HSPG binding and non-binding viruses (based on their affinity for a heparin 
column) for further biopanning experiments.
The binding library (Table 5.3) and 2 pools o f the non-binding library were sequenced 
(Table 5.4). No peptides were found in both libraries, suggesting the library had been 
successfully divided. From the binding library 63 different peptide sequences were 
obtained and o f these 4 occurred twice (Table 5.3). More repetition was seen in the non­
binding library sequencing, with 10/55 and 12/40 repeated peptides from pools A and B
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Positive peptides N eu tra l peptides
ANSSPGR ADAQTRl
APASAHV SSGHQSA DNAPTTR
APPRSVN (2) STAQGVR ESARQAQ
ASRASGA (2) SVRPSSG ESLGSGR
ASSGGLK TATNSSK GADVSTK
ATRGVPS (2) TIAPRAT RRDSNPE
GAHDGVR TPQPPNR SGELRGS
GGRPQIV TPSAKPS SGSDRDR
GHGLPYV TQAQLQR TNDGAVR
GRDM APR TRKSPER VEAARTS
GSICAVGS TTLNPPR
GSPKPPG TTSGNRL
GTAPRTS TVRGSAS
GTSAKGV (2) VTAHPTR
GTVSGIR
GVKREAG
ÏGVSTRH
KLDPTPR
KLDQMRP
LPPHHTV
NATSGPR
NÏRQPTG
NRGSTVT
PDPARGK
FLHNRTS
PNTNPAR
PSVPQAR
PTSGAPK
QTGTTVR
RAGSATW
RASAHPS
RASAHRS
RDRPVVS
RGAQQGA
RGHGGGE
RGTTPPV
RSNSPSR
SGYHARE
SQRLPHP
SRALGTS
T able  5.3 P ep tide sequences from  the  h ep a rin  b inding  lib ra ry . The sequences are 
divided on the basis o f the overall charge o f the peptides. Positively charged amino acids 
are shown in red and negatively charged amino acids are in green. For peptides that 
occurred more than once, the number o f  copies is indicated in parenthesis.
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A.
B.
Positive Neutral Negative
AAHTAPP AAVSVSA APDSAGA
DLRSIRT ATGPTTL APTDTDD
GSPKPPG ATPPQQP ARADDLE
HTPGGAP DHGSVAT ASESPPP
RSSSSEK DPPPRLQ DGDDGPA (2)
RTEHLQH DSHRPDQ DSSPPGV
SHAAQPT FGSTTGG EAGGGAV (3)
SHGEWTR GAGLGTI (2) ERDRGDV (2)
THSNSQR GDHLTGM GNDADER
VMPARLQ GENQARS GTDQTPA (2)
GHDNGPV PDVTELY
GNPPTGM (6) PESEVPM
GSPAGPN PNGGDSV (2)
LPADVLH PSDPSPT
LPAGTLQ RDEPPGM
NVHSDRD SAPRDDQ
PPSATTS (2) SCQQSDC
TGGTAST (4) SGDSLLG
TPTGNAG SSLSLES
TQPGSTG TAASTEC
TTTSRES TRETDSN 
TSQDGVT 
VREIIGD 
VRENTGD (2)
Positive Neutral Negative
AAHTAPP APPEQTH AMSDAPV
APHPGPG CAARSDL DLPSDRD (4)
APEIPGPS (2) DHGRAEP DSHSPDQ
GVKR-stop-AG DRSPPAT ERDRGDV (2)
IFCGTR-stop GNPPTGM (5) GDGGSAG
LPTGHVQ GSPAGPN TSEEQPV (2)
PPTSVPR LGAAGPV (2) PECDVTL
SHGEWTR NQTAREA PESEVPM (2)
PGGSSCS RDEPPGM
PHGVSDS (2) SGDRTSE
PPSATTS SGDSLLG (3)
SAPTTAP SSLSLES
SSSGPSG STFPADG
TGGTAST (4) TRADDPP (2)
TLPPNTS VADPTFV (2)
VFETSTS
VSEVNDV
Table 5.4 Peptide sequences from 2 pools of the non-binding libraiy (A and B). The sequences 
are divided on the basis o f  the overall charge o f  the peptides. Positively charged amino acids are 
shov/n in red and negatively charged amino acids are in green. For peptides that occurred more than 
once, the number o f  copies is indicated in parenthesis. Peptides that were found in both non-binding 
pools are shown in bold.
237
(Table 5.4). There were also twelve sequences found in both independent sequencing 
reactions o f the non-binding library (Table 5.4).
The overall charge o f the peptides (Table 5.5) suggested that charge does have an effect 
on the ability o f the virus to bind heparin. The majority o f peptides from the binding 
library were positively charged, with the remainder being neutral. All the binding 
peptides with a net neutral charge contained positively charged residues. The non­
binding library was depleted o f positively charged peptides and contained a higher 
percentage o f negatively charged peptides. Analysis o f the amino acid composition of 
the libraries (Figure 5.7) shows that the major differences between the non-binding and 
binding peptides were the levels o f R, K, D and E residues.
Investigating the positions o f amino acids within the peptides shows that in the heparin 
binding pool, 41% o f the peptides have a positively charged residue at their C-terminal 
(Figure 5.8). Whereas for the AAV library and non-binding library it is only 15% (Figure
5.2) and 10% respectively (Figure 5.9). In the non-binding library basic amino acids are 
most commonly found at position 2 whereas in the binding library this is where the 
fewest are seen. There were no other major differences between the libraries in terms of 
the position o f amino acids within.
5.2.4 In vitro characterisation of the non-binding and binding libraries
To characterise the non-binding and binding library pools, experiments were performed 
on FlepG2, and FISVEC. The transduction o f the HSPG binding and non-binding pools 
was compared to that o f control viruses AAV2-RC (wild type AAV2 capsid) and A3, a 
triple mutant (R585A, N587A and R588A) known not to bind HSPG (Wu et a l ,  2000). 
In both cell types a similar profile was observed, with AAV2-RC and the binding library 
producing higher levels o f transduction than A3 and the non-binding library (Figure 
5.10). Interestingly although heparin binding has been ablated in the triple mutant A3, it 
is still able to transduce cells, all be it at a much lower level than AAV2-RC. The 
experiments were repeated (M Ol 1000) in the presence o f soluble heparin (Figure 5.11). 
This confirmed that AAV2-RC and the binding library use HSPG as a primary receptor
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Positive Neutral Negative
AAV lib 46% 32% 22%
Non-binding 
library pool A
18% 38% 44%
Non-binding 
libraiy pool B
19% 38% 43%
Binding
libraiy
84% 16% 0
Table 5.5 Summary of the net charges of the peptides sequenced from the complete, 
non-binding and binding libraries.
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■ Non-binding library
□ Binding library
Mi
A C D E F G H I  K L M N P Q R S  T V W Y  Stop
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Figure 5.7 Comparison of the amino acid composition of peptides sequenced from 
the complete, non-binding and binding libraries. Small non-polar amino acids (A, G, 
I, L, M, P and V). Uncharged polar amino acids (S, T, N, Q and C). Basic amino acids 
(R, K and H). Acidic amino acids (D, E). Bulky amino acids (F, W, Y)
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A. Small non-polar B. Uncharged polar
C. Basic D. Acidic
• n
E. Bulky
Amino acid position
□ 1
■ 2
□ 3
□ 4
■ 5
□ 6
fB 7
Figure 5.8 Analysis of the peptide composition of peptides sequenced from the 
binding library. A. Small non-polar amino acids (A, G, I, L, M, P and V). B. 
Uncharged polar amino acids (S, T, N, Q and C). C. Basic amino acids (R, K and H). 
D. Acidic amino acids (D, E). E. Bulky amino acids (F, W, Y)
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A. Small non-polar B. Uncharged polar
C. Basic D. Acidic Amino acid position
E. Bulky
W Ê H
w
□ 1
■ 2
□ 3
□ 4
■ 5
□ 6
■ 7
Figure 5.9 Analysis of the peptide composition of peptides sequenced from the 
non-binding library. A. Small non-polar amino acids (A, G, I, L, M, P and V). B. 
Uncharged polar amino acids (S, T, N, Q and C). C. Basic amino acids (R, K and 
H). D. Acidic amino acids (D, E). E. Bulky amino acids (F, W, Y)
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1x10' 
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M OI o f AAV
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Figure 5.10 In vitro analysis o f A A V  libraries. Transduction o f  AAV2-RC, 
binding libraiy, A3 and non-binding library in A. HepG2 cells and B. HSVECs. 
Cells were co-infected with A A V  MOIs o f  100, 1000 and 10000 and wild type Ad 
M Ol 1 and 10 for HepG2 cells and HSVECs respectively. 72 houi’s post infection a 
p-gal. assay was performed using cell lysates and results were normalised to the 
total protein content. *p<0.05 vs AAV2-RC
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A.
II'
■ No heparin 
□ + heparin
B.
AAV2-RC Binding 
libraiy
Non-biding
library
.ag  8.0x104
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Figure 5.11 A ffect o f heparin on in vitro transduction. Comparing the transduction 
of AAV2-RC, binding library, A3 and non-binding library in A. HepG2 cells and B. 
HSVECs with and without the presence of 10 lU heparin. Cells were co-infected 
with AAV MOI 1000 and wild type Ad MOI 1 and 10 for HepG2 cells and HSVECs 
respectively. 72 hours post infection a (3-gal. assay was caiiied out on cell lysates and 
results were normalised to the total protein content. *p<0.05 vs + heparin
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as there was a significant decrease in transduction in the presence o f heparin, whereas the 
infection o f A3 and the non-binding library was not affected by the presence o f heparin, 
suggesting the use o f alternative receptors for cell binding and internalisation.
5.2.5.1 In vitro biopaiining with the non-binding library
Although the diversity o f  the non-binding library was reduced from the original library, 
the initial results suggested that it could provide a useful novel tool for biopanning to 
identify cell specific viruses that do not interact with HSPG. Biopanning was therefore 
performed on venous and arterial primary endothelial cells HSVEC and HCAEC to 
compare viruses that target to different vascular beds and HeLa cells as a control. Five 
rounds o f biopanning were performed, with cell samples taken at each round and used for 
real time PCR to monitor the course o f the biopanning (Figure 5.12). Surprisingly, the 
profiles show a general trend for a reduction in the amount o f AAV present at each 
round.
5.2.5.2 HeLa targeting peptides from the non-binding library
Sequencing o f the PCR amplified peptide-eneoding region from round 5 o f the 
biopanning showed only 14/57 (25%) of inserts sequenced contained a peptide. From the 
24 hour infection, none o f the sequences contained peptides, but only a small sample 
number was tested. This is in contrast to the results from the biopanning with the full 
library where they all contained peptides. The 14 peptide sequences consisted o f 5 
different peptides, none o f which were identified by the biopanning with the full library 
or were found in the sequeneing o f the non-binding library (Table 5.6). Despite so few 
sequences being identified, there are some interesting points to note. All the peptides are 
positively charged, and all have a positively charged residue in the 7^ '’ position. This is 
despite the non-binding library containing a reduced amount o f positively charged 
peptides and only 10% o f peptides within the library having a positively charged 7^ ’^ 
residue.
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Figure 5.12 Taqman to detect the number of virus particles in cell samples from 
biopanning with the non-binding library. A. HeLa B. HSVEC and C. HCAEC. The 
concentration o f  DNA extracted from the HCAEC cell pellets was not high enough to use in 
the Taqman assay.
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NSAQGPR (5) 
TSGVAGR (2) 
GRASIQK 
TNVPSPR (5) 
ASTGLPR
T able  5.6 Pep tide sequences from  ro u n d  5 o f b iopanning  on H eL a cells w ith  the  non­
binding  lib ra ry  using a 3 h o u r infection tim e. Positively charged amino acids are shown 
in red and negatively charged amino acids are in green. For peptides that occurred more 
than once, the number o f  copies is indicated in parenthesis. There were also 34 sequences 
that contained no targeting peptide.
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5.2.5.3 EC targeting peptides
Biopanning on HSVECs identified 12 and 14 targeting peptides from the 3 hour and 24 
hour infections respectively, some o f which were found repeatedly (Table 5.7A and 
5.7B). Biopanning on HCAEC identified 3 peptides that were also found in the 
biopanning on HSVEC (Table 5.7). The most commonly identified peptide from the 
HSVEC biopanning SNSVARP, was identified in both screens and in the HCAEC screen 
(Table 5.7). The m otif SNSV^/y is also found in other peptides. The 2"^ most frequent 
peptide was YNSTQRD, and another commonly occurring m otif TAREA were found in 
both HCAEC and HSVEC biopanning. BLAST searching identified no homology to any 
proteins o f interest. As with the HeLa biopanning, viruses with no peptide were also 
identified, and they occurred more commonly in the experiment where a 24 hour 
infection was used. None o f the peptides identified in any o f the endothelial cell 
biopanning experiments were also found in any o f  the biopanning experiments on HeLa 
cells.
5.2.6 In vivo biopanning with the complete AAV library
Whilst the initial in vitro work with the non-binding library was being performed, and as 
the in vitro biopanning suggested that the AAV2 library can be used to identify viruses 
targeted to a particular cell type, methods were developed for in vivo biopanning with the 
complete AAV library. Although the ultimate aim o f this work is to identify 
atherosclerotic plaque targeting viruses, initial in vivo experiments were designed to 
compare the biodistribution profiles o f AAV2-RC and the library and to develop 
protocols for in vivo biopanning by focusing on identifying viruses which target the 
theoretically technically simpler targets, the heart and liver. Comparing the 
biodistribution o f the AAV library with control wild type AAV in ApoEV- mice shows 
that the peptide library has altered trop ism in vivo (Figure 5,13). A lower level o f the 
library was detected in all tissues examined except the heart. The most significant 
difference seen was in the blood, where 80% of the library was found compared to 
approximately 30% o f  the wild type AAV. In other tissues the greatest reduction was 
seen in the liver and spleen.
248
A.
Positive N eu tra l Negative
ISAGRTG (3) GENQARS (4) YNSVDRD
FIA WARP (3) GNPPTGM
SNSNVRD (2) NQTAREA (4)
SNSVARP (54) PTGDVRT
SNSVVRQ THTAREA
YNSTQRD (47)
and 13 insertless clones
B .
Positive N eu tra l Negative
APHPGPG ADNVARP GNSTPED
ASSGGLK GNPPTGM  (2) SAPRDDQ
LQTRARP PAGSSSG SGDSLLG (3)
RTPNSSP TNAELPH SIPDGTV
SNSVARL
SNSVARP (12)
and 12 insertless clones
C ,
Positive N eu tra l Negative
SNSVARP NQTAREA (79)
and 1 insertless clone
D .
Positive N eu tra l Negative
GENQARS (14)
and 13 insertless clones
Table 5.7 P ep tide sequences from  ro u n d  5 o f b iopanning  w ith the  non-b inding  lib ra ry , A.
HSVEC using a 3 hour infection time, B. HSVEC using a 24 hour infection time, C. HCAEC using a 
3 hour infection time and D. HCAEC using a 24 hour infection time. The sequences are divided on 
the basis o f the overall charge o f the peptides. Positively charged amino acids are shown in red and 
negatively charged amino acids are in green. For peptides that occurred more than once, the number 
o f copies is indicated in parenthesis.
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Figure 5.13 I n  vivo biodistribution o f A A V 2-R C  and th e  com plete AA V  libraiy .
A poE-/- m ice received 4 x 10'* gp o f  virus by tail vein injection. 24 hours post infusion 
organs w ere harvested, D N A  w as extiacted and used as a  tem plate for Taqm an real-tim e 
PC R to detect the num ber o f  virions in each sample. A. B iodistributuion o f  AAV2-RC 
and A A V  library B . A m ount o f  virus detected in  each tissue as a percentage o f the total 
am ount detected. n=4 per group. *p<0.05 vs AA V2-RC
250
Sequencing o f the peptides isolated from the liver and heart (Table 5.8) showed that as 
expected, after just one round o f biopanning no consensus motifs could be identified. 
Interestingly the overall charge o f the peptides found in the liver has approximately the 
same percentage o f positive and negatively charged peptides as the full library (Table 
5.8A), whereas the heart had an increased amount o f neutrally charged peptides and a 
decrease in the amount o f positively charged peptides (Table 5.8B). Eight percent of 
viruses found in the liver had no peptide whereas all viruses sequenced from the heart 
samples contained peptides.
A second round o f biopanning was carried out using pools o f viruses synthesised from 
those isolated in round 1. Comparing the Taqman results o f the heart and liver from 
round 2, show that both biopanning screens had similar biodistribution profiles, although 
the heart and liver pools did have slightly higher amount o f virus in their target organs 
(Figure 5,14). The only significant differences between the 2 experiments is the liver 
pool o f viruses had about 7-fold more virus detected in the spleen, and with the heart pool 
of virus there was more than a 300-fold increase in the amount o f virus remaining in the 
blood. To compare the Taqman results from rounds 1 and 2 the amount o f virus detected 
in each tissue has been calculated as a percentage o f the total amount o f virus detected, as 
different doses were used at rounds 1 and 2 so they cannot be directly compared. The 
second round o f liver targeted biopanning produced a higher percentage o f virus in all 
tissues except the blood, with the biggest increase seen in the liver and spleen (Figure 
5.15A). The results from the heart pool were less encouraging, as there was an increase 
in the amount o f virus found in the blood, and a decrease in that found in every other 
tissue (Figure 5.15B). Sequencing o f peptides isolated from round 2 o f the heart 
biopanning identified 5 peptides that occurred twice (Table 5.9). None o f the peptides 
sequenced in round 2 were also found in round 1.
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A. Liver
Positive Neutral Negative
GISRTVM NTVGGDR RDEPLPD
RHWARRA DHGRDPN GEAAG
PTRGVPT PHGIDPA DPSALSG
Stop-SCWWMR AAPTTPT DCTLGSS
APLHPAS VAi:SARP SEGQLAS
g a q q g h s RPAQVEW GAPPDAS
PTALVKL ADATPRM PTFNSMC
DRLHEGR CSEGGHS DSPDPGD
RRAPHLP SSPTTPT VYPALES
GSLSGSH PSGLPGA PPGGDVP
RPPASQS PRTITTP ALWGFDD
LQRPTRG GAPDRFV CDSNPGD
SVPRQTG HPMPSDP DYDPVGS
MLAGRT PPPPGAL GDGGPGQ
ACQPRTP PPPSLGN TATPDDG
SLSHCPA PTSQLWT DDSPRPQ
LLRAAAR PSLLQPP TQVGEAT
SRATGPC LCCAPGA NQLAEAP
VRRSC-Stop-L VYPSACG EITGADP
ISPHLER DLHDRSW DPDVGSC
PPGFVRA WPRLDPG NGTTGDP
HHRRAGS LSEWPSV
HSAPKSS ADRTPDV
CATPRCT
PVCGHAR
GARLPP
HWPHALR
DPSAPRR
TTSFPHP
Stop-WAPRTA
NRASRNC
SAIRAAS
APPLSPH
WACPSHC
HCCAPGA
RSRWHSS
KATQLRV
KEPRLER
TWLRDRA
RSSLRDY
YNMRTPA
KATQVRE
NSAATPR
RSSLHNY
Table 5.8 Peptide sequences from round 1 o f biopanning with the AAV library in ApoE-/- 
mice. A. Peptides isolated form the liver, B. (shown overleaf) Peptides isolated from the heart. The 
sequences are divided on the basis o f  the overall charge o f  the peptides. Positively charged amino 
acids are shown in red and negatively charged amino acids are in green. All peptides shown were 
found once.
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B. H eart
Positive Neutral Negative
GKSPLVA ASSHTLD YCSPGEC
RYPGLTC ITAPPLA TDLLPYA
SALRNPC GHPPGQD CIAEWIS
HVPRRTN DLSHATA CLPDLWA
RPGALLA PMYDSGR GSNPDAL
ADTRPTR PCSSPPT CAPDPDN
ANGCRYH VPERPPG
ISARQPA GPSPAAV
RPVCGLD
GSGGSSA
GLVALTA
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Figure 5.14 Biodistributiiiou o f viruses after 2 rounds o f  biopanning for heart and  
liver targeted peptides. ApoE-A m ice received 2 x 10'* gp o f  virus by tail vein 
injection. 24 hours post infusion organs w ere harvested, DN A was extracted and used as 
a  tem plate for Taqm an real-tim e PC R to detect the num ber o f  virions in each sample. 
n=3 per group.
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Figure 5.15: Com parison o f the biodistribution o f viruses from  round 1 and 2 o f  
biopanning w ith  the com plete A A V  library. A. Liver targeted biopanning. B. H eatt 
targeted biopanning
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Neutral
Stop-APERGG
EGDRRWG
GAISSSA
LL-Stop-TVAG
P-Stop-GAPAS
PGVVDQR
SLSGPER
SLSQALA
SPMAGLA
Negative
DSEDPRA 
GDSDDQR 
QSGADCA (2) 
QSGGADA 
QWDGPGG
Positive
Stop-RLLCRR 
AAR-Stop-QCR 
AGDAAQR 
GLLRP-Stop-C 
GPRGRWC (2)
GQSAGLR 
GRLPP-Stop-G 
HPGGFCR 
HRAQERG 
LAGRALR (2)
LGGIRIR 
LHVGRS-Stop 
LL-Stop-TVAR (2)
PQRAPHG 
PRGLFAR 
PRPELRR 
PWGGPRG 
QHRHLRG (2)
QQLRESR
RCDLQQR
RFGEWPR
RGCECVR
RGFRRQR
RLNRGCR
RPAHRRA
RPGHRER
RPRLVGR
RRDFRRR
RRHRPGG
SARSRFR
SFCRRGR
SG-Stop-LAAR
SGYWRHG
SLSRPLA
SPTSPRG
SRWQV-Stop-R
SVWRRGR
VSRR-Stop-QR
YFSCCWR
YRSCRLR
Table 5.9 Peptide sequences from round 2 o f the heart biopanning with the AAV library
in ApoE-/- mice. The sequences are divided on the basis o f  the overall charge o f  the peptides.
Positively charged amino acids are shown in red and negatively charged amino acids are in
green. The occurrence o f  repeated peptides is shown in parenthesis.
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In round 1 no viruses without peptides were found in the heart, but in round 2, 8% o f the 
sequences had no peptide insertion. Further analysis of the sequences shows that the type 
of peptides found in the heart at round 2 were very different from R I, as the percentage 
o f positively charged viruses more than doubled (Table 5.10) and o f  these 69% had an R 
residue at position 7, which is characteristic o f heparin binding. Also, in round 1 no 
peptides containing stop codons were identified where as in round 2 there were several.
5.2.7 Comparing the non-binding and binding libraries in vivo 
C57/B16 mice received 4 x 10  ^ gp o f either the binding library, non-binding library, 
AAV2-RC or A3 viruses (expressing the lac Z  reporter gene) via tail vein injection. 24 
hours post injection mice were sacrificed. DNA was extracted from tissues and used as a 
template for Taqman real-time PCR. As expected, the AAV2-RC and binding library 
have a very similar profile with the majority o f the viruses being found in the liver and 
spleen (Figure 5,16). The amount o f A3 and non-binding library found in the liver and 
spleen was reduced compared to both AAV2-RC and the binding library.
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Positive Neutral Negative No peptide
AAV library 46% 32% 22% 0%
Heart R l 32% 42% 24% 0%
Liver R l 46% 22% 24% 8%
Heart R2 69% 14% 9% 8%
Table 5.10 Summary of the net charge o f peptides isolated from in vivo biopanning with the 
complete AAV library in ApoE-/- mice.
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□  A3
CD Non-binding library 
S  AAV2-RC  
H  Binding library
2  1x10'*
F IxlO^
BCA aorta heart lung liver kidney spleen muscle brain carotid blood
Figure 5.16 In vivo biodistribution of AAV libraries. C57/B16 mice received 4 x 1 0 *  
gp o f  A3, non-binding library, AAV2-RC or binding library. 24 hours after systemic 
administration DNA was extracted from tissues and used as a template for real-time PCR 
to detect the number o f  virions in each sample. n=4 per group.
259
5.3 Discussion
Not enough is known about AAV2 biology and its cellular interactions to develop 
specific cell targeted vectors by rational design, although phage display has successfully 
identified some retargeting peptides without a positive charge that have been shown to 
alter AAV2 tropism (White et a l ,  2004, Work et a l ,  2006). Recent structural (Xie et a l ,  
2002) and mutational studies (Kern et a l ,  2003, Opie et a l ,  2003, Girod et a l ,  1999) 
have provided some information about the AAV2 process o f infection that has enabled 
the development o f  an AAV2 based library that can be used to identify cell type specific 
viruses by biopanning (Perabo et a l ,  2003). The work in this chapter has used an AAV2 
library to try to identify endothelial cell targeting peptides and developed methods for 
biopanning with the library in vivo. Analysis o f the library has also provided more 
information about how peptide insertion affects HSPG binding o f the vectors.
5.3.1 Composition of the AAV libraiy
The diversity o f peptide libraries is an important determinant in how successful a 
biopanning experiment can be, as libraries with a lower diversity are less likely to contain 
peptides with a high affinity for the target. Sequencing o f the peptide-containing region 
o f PCR products from the AAV library did identify repeated sequences within just a 
small number o f samples, indicating that the library diversity may be relatively low. 
However, this may not actually be the case as repeated peptides were only found in 
sequences from the same PCR product and not from different PCRs. Therefore the 
repeated peptides may be due to problems with the method used to obtain the sequences. 
To clone the peptides, the insert region was amplified by 40 cycles o f PCR, and this may 
have introduced some sequence bias. Due to the exponential nature o f the reaction any 
inserts that were amplified in the initial cycles would have been present in significantly 
higher numbers than other peptides and so are more likely to be repeatedly amplified in 
subsequent rounds o f PCR. Consequently, the cloned peptides may not be a true 
representation o f the library diversity. The bias in the PCR is random, so comparing 
results from different PCRs should provide a better representation o f the diversity. There 
is no way to directly sequence the peptides from the virus library. Alternatively the 
plasmid library can be sequenced directly without the requirement for PCR from a pool
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of peptides, but this still would not show if the diversity seen in the plasmid library is 
maintained at the virus level. There is likely to be some decrease in diversity from the 
plasmid library to the virus library as it is possible that not all peptides present in the 
plasmid library will be capable o f being packaged into the AAV capsid, as some peptide 
sequences may form a structure that is not compatible with the structure o f the 
surrounding amino acids in the virus capsid.
Statistical analysis based on the sequencing results estimates the library has a diversity of 
5 x 1 0 ^  different peptides, which is about 10 fold higher than the original estimation 
(Perabo et a l ,  2003). Both calculations are only estimates so this degree o f difference 
between the two values is to be expected. However, both estimates predict the AAV 
library has a diversity several logs lower than that produced by standard phage libraries 
which can display about 1 x 10^different peptides (Hajitou et a l ,  2006).
Analysis o f amino acid composition o f the peptides showed large amino acids were 
possibly under-represented in the library whereas small uncharged peptides were over­
represented. This could be because the larger amino acids are more likely to cause a 
significant alteration in the structure o f the AAV capsid and therefore will be less well 
tolerated and might prevent capsid assembly. Pro line was also found to be over­
represented in the library, this could be because it can introduce kinks into proteins and 
this may enable easier incorporation o f  the peptide into the capsid (Perabo et a l ,  2006b). 
Peptides containing stop codons could have occurred due to read through o f the stop 
codons enabling translation o f the full AAV capsid, but it is more likely to be due to a 
problem with the packaging method used to synthesise the library. The library is 
produced by transfection o f cells with a plasmid encoding the capsid gene. If cells 
become transfected with more than one plasmid then this could result in chimeric virions 
expressing more than one peptide in their capsid and therefore uncoupling o f the 
genotype from the phenotype. The sequencing results obtained in this study generally 
agree with an analysis carried out on another pool o f the library (Perabo et a l ,  2006b).
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The positional specificity o f acidic and bulky amino acids within the peptides may be 
because in these positions their incorporation may be better tolerated by the capsid 
structure. Restrictions such as these may reduce the variability seen in peptide 
sequences, so may reduce the effectiveness o f the library for biopanning. However it has 
been shown that phage libraries also show some bias in amino acid composition and 
distribution within peptides. For example, a 12-mer M l3 library has been shown to have 
an over-representation o f threonine and proline residues, an under-representation o f 
cysteine, arganine, valine and glycine and positional bias with a reduction in arginine 
residues and an increase in asparagine at the N-terminus and a decrease in acidic residues 
at the C-terminus (Krumpe ei a l ,  2006). This demonstrates that amino acid bias is not 
unique to the AAV library so it is not disadvantageous to use the AAV library instead o f 
a phage library for biopanning.
Although the diversity o f  the library is significantly less than standard phage libraries, it 
was decided to use the AAV2 library for biopanning as it has several advantages over 
using phage-based libraries. The AAV library enables identification o f the peptide in the 
correct context, so there are not problems with possible loss o f targeting capacity as has 
been seen when some peptides identified by phage display have been incorporated into 
viral vectors. Some peptides identified by phage display can inhibit viral capsid 
assembly when inserted into the virus capsid, for example, in one study producing 
peptide modified Ad vectors, it was found that 2 out o f 6 peptides could not be 
incorporated into the capsid o f an Ad vector (Wickham et a l ,  1997). Using the AAV 
library, it is not possible to identify peptides that prevent capsid assembly. Also, unlike 
phage libraries the AAV library can also be used to select for viruses that most efficiently 
complete all stages o f  the infection process and not just binding to the cell surface. 
Another disadvantage o f phage libraries is that different peptides have different effects on 
the rate o f phage growth, so false positive results can occur when biopanning with phage 
libraries as the screening may just identify a peptide that has no inhibitory effect on the 
phage replication (Pasqualini and Ruoslahti, 1996).
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5.3.2 In vitro biopanning with the AAV library
The Taqman profile o f  the RGE biopanning is typical o f a successful biopanning 
experiment, with a decrease in the amount o f virus present over the first three rounds as 
viruses with a low infectivity for RGE cells are removed, and then an increase in the 
amount o f  virus in the later rounds as the more efficiently infective viruses are selected 
and amplified by replication in the target cells. However, biopanning on HeLa cells did 
not produce an enrichment in the number o f targeted viruses. This could be because 
HeLa cells are a cancer cell line that us transcriptionally very active, so will express a 
large range o f surface proteins that could potentially act as receptors, so more rounds o f 
biopanning may be required to see further enrichment o f targeted viruses. This is 
supported by the sequencing results o f the HeLa targeted peptides that showed there were 
still a large number o f different peptides present.
5.3.2.1 Analysis o f peptide sequences from biopanning on RGE cells
The majority o f viruses isolated from round 6 o f biopanning in RGE cells contained no 
inserted peptide. The insertless virus could have come from contamination at some stage 
during the biopanning process or may have been produced during library production. 
Muller et al. (Muller et a l ,  2003) also detected insertless AAV in the first two rounds of 
biopanning with an AAV2 based library on HCAEC, but by the 3"^  round it was no 
longer present. They suggest that AAV2 without peptides could have occurred due to 
recombination events that led to packaging o f wild type cap genes into the shuttle capsids 
during production o f the library transfer shuttle vectors, but it was undetectable after 2 
rounds as wild type AAV2 poorly infects HCAEC (Muller et a l ,  2003). If there was a 
low level o f AAV with wild type cap gene in the original library then this would be 
selected for by biopanning on RGE cells as they are highly perm issive to wild type 
AAV2 (See chapter 3) so will probably replicate more efficiently than the peptide 
modified viruses. As no viruses without peptides were found when the library was 
sequenced it seems that the biopanning has selected for them. The four peptides that 
were present after the six rounds o f biopanning may have some specificity for RGE cells, 
but this would require further work to determine.
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S.3.2.2 Analysis o f peptide sequences from biopanning on HeLa cells
Several repeated peptides were identified from the biopanning on HeLa cells and as some 
were found in independent PCRs this suggests their repeated occurrence is not due to bias 
in the PCR and that they were actually present at a higher level by round 6 o f the 
biopanning. None o f the peptides isolated from the 6'*^  round o f biopanning were also 
sequenced in the original library pools. Although some diversity remained in the HeLa 
targeted pool o f peptides after 6 rounds, the biopanning has identified some consensus 
motifs that may enhance virus transduction o f the cell line. The m otif SIRGTGG was 
identified from both the RGE and HeLa cell biopanning suggesting the peptide may have 
some cross specificity and bind to a receptor expressed on both cell lines. As cell lines 
and not primary cells were used in this work it is likely they will have a lot o f molecular 
similarities.
5.3.3 Characterisation of heparin binding and non-binding peptides
The sequencing results suggest the non-binding library has a lower diversity than the 
binding library implying that peptides that enable heparin binding are more common in 
the library, so might be more compatible with insertion into the AAV capsid than non­
binding peptides, as they are likely to cause a smaller alteration in the capsid structure. 
Therefore to find specifically targeted peptides that do not interact with heparin, the non­
binding library may be better to use for biopanning than the full library, as heparin 
binding viruses seem to be more common than non-binders.
Analysis o f the overall charge o f peptides isolated from the 2 libraries suggest that 
positively charged peptides enable the formation o f a heparin binding site whereas 
negatively charged peptides block the ability o f the virus to bind heparin. This supports 
previous findings, but it has not previously been demonstrated with such a large number 
o f peptides. The difference in overall charge o f the peptides is due to the over 
representation o f E and D amino acids in the non-binding library and under­
representation o f K and R. There is no difference in the number o f H residues in the non­
binding and binding libraries, but H could be considered a neutral amino acid as it has a 
low pKa value. If  IT is considered a neutral amino acid then the effect o f charge o f the
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peptide becomes even more pronounced, with less than 10% of the peptides in the non­
binding library having a positive charge, while the binding library contains no negatively 
charged peptides.
This data supports the evidence from structural (Xie et a l ,  2002) and mutational studies 
(Kern et a l ,  2003) that suggest the interaction between HSPG and AAV2 is due to 
electrostatic interactions o f the positively charged amino acids in the virus heparin 
binding site and negatively charged HSPG. Based on the features o f the peptides found 
in the two libraries a model o f how peptide insertion can either maintain or ablate the 
ability o f  AAV2 to bind heparin can be proposed (Figure 5.17). Figure 5 .17A shows the 
HSPG binding site found in wild type AAV2. Inserted positively charged peptides may 
form a heparin binding site in combination with existing capsid R residues (Figure 5.I7B) 
or a new HSPG binding site could be formed independently without any major 
interactions with existing capsid residues (Figure 5.17C). The peptide sequences suggest 
a positively charged residue at position 7 is particularly good at enabling reconstruction 
of the heparin binding site. As the position o f the positively charged residue seems to 
effect HSPG binding this suggests that receptor binding is in part mediated by the amino 
acids in the virus capsid (Figure 5.I7D ). A positive charged amino acid at position 7 in 
this library is separated from R588 by 2 amino acids, which most closely resembles the 
wild type situation involving R585 and R588. The SMC targeting peptide EYHHYNK 
that was inserted into AAV2 in the same way as the library peptides also retains a strong 
heparin dependency, so supports the observations in this study (Work et a l ,  2004a). In 
the non-binding library positively charged amino acids were most commonly found in 
position 2, which is the furthest position form both R585 and R588, so it cannot facilitate 
the formation o f a heparin binding site. Neutral and negatively charged peptides may 
prevent the formation o f an HSPG binding site (Figure 5.17E) by preventing an 
interaetion between R585 and R588 from occurring.
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Figure 5.17 Schematic diagrams of the AAV2 HSPG binding site. A. Wild type 
A AV2, AAV library virions which bind heparin (B, C and D) and E. AAV library 
virions which do not bind heparin. (Perabo et a i ,  2006b)
5.3.4 In vitro characterisation of the non-binding and binding libraries
In vitro transduction assays using the 2 library pools on HSVEC and HepG2s showed that 
the library had been correctly split to produce the non-binding and binding libraries as 
they produced similar infectivity profiles to the A3 and AAV2-RC viruses respectively. 
The non-binding library and A3 virus were still able to transduce both eell lines, 
suggesting that although HSPG is the main receptor for AAV2, other receptors can also 
be used independently. In both cell types the level o f transduction measured from AAV2- 
RC in the presence o f heparin is equivalent to A3, indicating that this is the level of 
transduction achievable independent o f virus:HSPG interaction.
5.3.4.1 Analysis o f HeLa targeting peptides identified from the non-binding library
Despite the lack o f enrichment seen by the Taqman profiles, the sequencing results show 
consensus targeting peptides have been identified. Biopanning with both the full library 
and the non-binding library suggests the infection o f HeLa cells seems to be most 
efficient when the peptides are positively charged and have a positively charged 7'*^  
residue, which are also the characteristics o f peptides which mediate binding to HSPG. 
HeLa cells are known to express HSPG (Pinon et a l ,  2003), so this may be the receptor 
the viruses are using. Due to the method used to split the AAV library into the non­
binding and binding pools, it is possible that there could be a low level o f heparin binding 
viruses (including wild type AAV) in the non-binding pool. Despite this low level, it 
does seem that particularly in the HeLa cell biopanning, these heparin binding viruses 
have been selected for. The high level o f viruses without peptides identified by this 
biopanning could be because the non-binding library is depleted in this type o f peptide, 
so the insertless AAV may more efficient at infecting HeLa than the majority o f viruses 
in the non-binding library. These results suggest that AAV2 has evolved to be highly 
efficient at binding HSPG to infect cells so any alterations we make to this may be 
reducing its overall transduction efficiency and therefore the selection pressure selects for 
the few remaining heparin binding viruses, including both wild type virus and peptides 
which bind to HSPG and most closely mimic the natural AAV capsid structure and 
infection mechanism. One possible way o f overcoming this could be to carry out the first
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round of biopanning in the presence o f soluble heparin to remove any remaining HSPG 
binders. Alternatively, the library could be produced on the A3 background, which 
should reduce the ability o f the viruses to bind heparin even if they contain a positively 
charged peptide.
5.3 4.2 Analysis o f EC targeting peptides
EC gene expression varies between different vascular beds as in different tissues the EC 
are exposed to different environments e.g. varying oxygen concentrations in the blood 
and are required to carry out different functions depending on their location (Minami and 
Aird, 2005, Lacorre et a l ,  2004, Aird, 2004). Despite using arterial and venous 
endothelial cells, there were some peptides that were identified from biopanning on both 
cell types (but not HeLa cells) suggesting that they may be EC specific. Identification of 
the same peptides from different screens shows its occurrence was not due to the random 
bias in the PCR reaction. Although some peptides were identified from both EC cell 
types, others were unique to one cell type, demonstrating there are molecular differences 
between these 2 vascular beds. Comparing the HSVEC targeting peptides from this work 
with those identified by biopanning on HSVEC using an M l3 linear library o f 7-mer 
peptides (L. Work, unpublished) has identified some similarities. From the phage 
biopanning, 90 different peptides were each found once, and several o f these contain 
motifs found in the non-binding library HSVEC biopanning (Table 5.11). The most 
commonly occurring similarity has homology to SNSVARP, which suggests the 
(SV)ARP m otif may be important. This m otif has also been found in peptides isolated 
form biopanning with a M13 phage 12-mer library on Human umbilical vein endothelial 
cells (HUVEC)s. The most commonly occurring peptide from that screen was 
M SLTTPPAVARP and the m otif YARP was also found in another peptide (White et al., 
2004). This suggests the m otif may target a receptor found on endothelial cells from a 
range o f vascular beds. Comparing the results o f the HSVEC biopanning with results 
from biopanning with an AAV2 library on HCAEC also shows some similarity in motifs 
identified (Muller et a l ,  2003). In 2 independent screens the tri-peptide m otif NSV was 
identified (Muller et a l ,  2003), which was also found in the most commonly identified 
HSVEC peptide and in the HCAEC screen in this study.
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Figure 5.16 In vivo biodistribution o f  AAV libraries. C57/B16 mice received 4 x 1 0 *  
gp o f  A3, non-binding library, AAV2-RC or binding library. 24 hours after systemic 
administration DNA was extracted from tissues and used as a template for real-time PCR 
to detect the number o f  virions in each sample. n=4 per group.
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Interestingly the peptide GENQARS that was found in both the HSVEC and HCAEC 
biopanning has also been identified from biopanning with the complete AAV2 library on 
M ecl cells (a human cell line derived from B-cell chronic lymphocytic leukemia (B- 
CLL) (Perabo et a l ,  2003). Further worked showed the virus infected primary leukemia 
cells from B-CLL patients significantly better than wild type AAV2 and that the 
transduction is heparin independent and can be competed by soluble peptide (Perabo et 
al., 2003). It also transduces HeLa and CO-115 (human colon carcinoma) cells at an 
equivalent level to wild type AAV2 (Perabo et a l ,  2003). Therefore these cell lines may 
have a common receptor to which GENQARS binds. As GENQARS has been identified 
from biopanning on 3 different cell types it may be a particularly efficient virus in the 
later stages o f transduction. Identification o f a peptide known to mediate infection 
independently o f heparin acts as proof o f concept as it shows a heparin independent virus 
has been isolated from the non-binding library.
From all 3 cell types, most information was gained from the 3 hour infection time rather 
than 24 hours. For HeLa and HCAEC more viruses without peptides were identified in 
the 24 hour screen and for HSVEC more consensus motifs could be identified from the 3 
hour screen. This could be because a shorter infection time will only select for the most 
efficient viruses for binding and internalisation, so the less specific viruses which bind to 
a receptor which is expressed at a lower level or bind with a lower affinity are more 
likely to be removed.
The presence o f wild type AAV2 in the library does seem to have reduced the number of 
targeting peptides identified from some of the screens. However it seems to be due to the 
wild type capsid infecting the cells more efficiently than the majority o f the peptide 
modified viruses, so in these cases the identification o f more, but less efficient viruses 
may not actually be advantageous. Waterkamp et a l  (Waterkamp et a l ,  2006) have 
altered the way they produce their AAV library to eliminate any wild type AAV2 
contamination. To avoid homologous recombination between wild type and library 
genomes a synthetic cap gene containing alternative codons was used to produce the
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library (Waterkamp et a l ,  2006). In vitro biopanning experiments comparing the 
contaminated and wild type free library showed targeting peptides could be identified 
from both libraries, although some o f the selected peptides identified using the new 
library seemed to have a better degree o f cell specificity than those identified with the 
original library (W aterkamp et a l ,  2006).
5.3.5 In vivo biopanniiig with the complete AAV libraiy
Comparing the biodistribution o f the AAV library with AAV2-RC showed that insertion 
of peptides into the capsid o f AAV does alter the trop ism of the virus as the majority of 
the AAV library was found to still be circulating in the blood 24 hours after vector 
administration indicating that the majority o f the library virions did not have a strong 
affinity for any accessible receptor, so they remained in the blood. Peptide insertion 
seems to prolong the amount o f time the virus can remain in the blood before being 
cleared from the body or infect a tissue such as the liver. Increased levels o f virus in the 
blood have been found with other peptide modified AAV2 vectors (W hite et a l ,  2004). 
Higher levels o f the library were detected in the heart, and interestingly an HSPG 
detargeted virus with the mutations R585E and R484E has also been found 
predominantly in the heart suggesting that a secondary receptor for AAV2 may be 
expressed at high levels in the heart (Kern et a l ,  2003, Müller et a l ,  2006). Also, several 
wild type viruses were found in the liver, but not in the heart. This supports previous 
studies that have shown that wild type AAV does not have an efficient trop ism for the 
heart after systemic administration (Muller et a l ,  2006, White et a l ,  2004, Work et a l,  
2006).
After 2 rounds o f biopanning the biodistribution o f the pool o f viruses from the liver 
biopanning suggest that the biopanning may have selected viruses that are efficiently 
taken up by the reticulo-endothelial system as higher levels o f the virus were found in the 
liver, spleen and lungs. The biodistribution profile o f the heart pool o f viruses suggests 
the pool mainly contains detargeted virus as their was a large increase in the amount o f 
virus found in the blood, suggesting viruses that target other tissues have been removed 
in the first round o f biopanning. Some repeated peptides were isolated from the heart
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suggesting that there was some reduction in the diversity o f the library and a degree of 
enrichment for heart targeting peptides had occurred. However, the majority o f peptides 
isolated in round 2 had features typical o f peptides that bind HSPG (a net positive charge 
and a positively charged 7*^'^  residue). The Taqman profile did not show any enrichment 
for viruses targeted to the heart, the amount o f virus without a peptide had increased and 
the majority o f  peptides identified contained features typical o f peptides that bind 
heparin, so it was decided not to continue with this biopanning. Instead, the possibility of 
using the non-binding library for in vivo biopanning was investigated.
5.3.6 Comparing the non-binding and binding libraries in vivo
Comparing the libraries with AAV2-RC and A3 in vivo showed similar results to the in 
vitro comparison, as similar biodistribution profiles were achieved with AAV2-RC and 
the binding library and the A3 virus and non-binding library. This suggests that the 
majority o f virions in the binding library use HSPG as a receptor. Reduced amounts of 
the non-binding library were found in the liver and spleen suggesting that HSPG binding 
ablation does detarget the virus from its native tropism, as has previously been seen with 
other HSPG mutants (Kern et a l ,  2003) and targeted viruses modified with HSPG 
independent peptides (W hite et a l ,  2004, Work et a l ,  2006). Ablation o f HSPG binding 
seems to reduce the overall infectivity o f the virus as more A3 and non-binding viruses 
were found in the blood than the other 2 viruses. The increase with the non-binding 
library was not as great as that seen with A3 as the inserted peptides may be enabling 
virus to use alternative receptors and so restores some of the virus infectivity.
These results suggest that in vivo biopanning with the non-binding library may provide a 
way o f identifying viruses which are detargeted from the natural tropism o f AAV2 and 
retargeted to specific tissues o f interest.
5.3.7 Summary
The work in this chapter has focused on characterising the AAV library and developing 
methods for effectively using the library for both in vitro and in vivo biopanning. It has 
demonstrated that using the complete AAV library it is difficult to identify peptides that
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ablate HSPG binding, as these seem to be both more compatible with the AAV structure 
and more efficient at m ediating infection, so the biopanning process actually selects for 
these viruses. Biopanning with the HSPG non-binding library seems to have been more 
successful and has identified 4 potential endothelial cell targeted AAV2 vectors 
containing the peptides GENQARS, SNSVARP, YNSTQRD and NQTAREA which may 
infect cells independently o f an interaction with HSPG. These vectors are currently being 
synthesised so their selectivity for endothelial cells both in vitro and in vivo and their 
ability to bind heparin can be further investigated.
The complete AAV library was used to develop methods for in vivo biopanning. After 2 
rounds o f biopanning, sequencing results suggest that it may be possible to identify 
consensus sequences after 3-4 rounds, but to avoid the identification o f heparin binding 
peptides it is likely that viruses with better selectivity will be identified using the non­
binding library.
Work carried out with the full AAV library and the non-binding and binding library 
supports previous studies that have indicated that insertion o f positively charged peptides 
into the heparin binding site in the AAV2 capsid is able to maintain some degree o f 
heparin binding. In the case o f the library used for this work, a positively charged residue 
at position 7 within the peptide seems to be particularly efficient at restoring heparin 
binding ability. This positional affect highlights one o f the advantages o f using the 
AAV2 library instead o f phage, as it shows the context specificity o f the peptide is 
important as the heparin binding site must be formed by the peptide and existing capsid 
residues for the position o f the charged residue to be important. As well as providing 
information about peptides which enable targeting o f particular cell types/tissues, the 
information gathered in this chapter will enable a more accurate prediction o f which 
peptides identified by phage display can be successfully incorporated into the AAV 
capsid to produce functional viruses which do not interact with heparin
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6.1
General Discussion
274
The initial optimism surrounding the potential to use gene therapy to treat a wide range of 
diseases receeded following a number o f negative clinical trials and treatments that 
resulted in serious adverse effects. However, improvements in the understanding o f the 
mechanisms involved in successful gene delivery and vector optimisation have 
regenerated interest in this field. Cardiovascular gene therapy is an advancing area as the 
knowledge o f both the disease and gene therapy vectors is improving. Following many 
successful studies in animal disease models over 100 clinical trials have now been 
undertaken (http://www.wiley.co.ulVwileychi/genmed/clinical/) for diseases such as 
ischemia and vein graft failure (Alexander et a l ,  2005, Losordo et al., 2002). However, 
further advancements in vectors are still required for clinical gene therapy for CVD to be 
realised.
Gene therapy vectors are ideally required to be non-toxic, non-immunogenic, stable in 
blood and producible on a large scale. Ideally a vector to treat atherosclerosis would 
provide a high level o f transgene expression specifically in the atherosclerotic plaque 
following systemic administration o f the vector. Highly localised gene expression 
reduces the likelihood o f vector toxicity, reduces the possibility o f adverse affects due to 
gene expression in non-target tissues and reduces the dose o f the vector required. As 
atherosclerosis is a chronic condition long-term transgene expression may be required for 
a treatment to be effective.
The aim o f this study was to develop atherosclerotic plaque targeted viral vectors using 
three different approaches:
1. Previously identified plaque targeting peptides were inserted into Ad and AAV 
vectors to test their targeting capacity and compare the efficiency o f different 
vector platforms.
2. In vivo phage display was performed to identify peptides that target unstable 
atherosclerotic plaques.
3. Biopanning with the AAV library was used to identify EC targeting peptides and 
further develop the use o f this technology.
275
6.1 Atherosclerotic plaque targeted viral vectors
The previously identified plaque targeting peptides CAP, CNH and CQE were inserted 
into the capsid o f Ad and AAV based vectors to compare the targeting capacity o f the 
vectors both in vitro and in vivo in a mouse model o f atherosclerosis. Initial testing of 
AdK Ol vectors suggested they had a tropism for vascular cells in vitro. Incorporation o f 
the peptides into the CAR and HSPG detargeted vector A dK O lS* produced vectors that 
inefficiently infected all cell types tested. These results, in combination with results from 
other studies that have failed to demonstrate retargeting o f A dK O lS* vectors (Bayo- 
Puxan et a l ,  2006) (A. Kritz, in press) suggest that the platform vector is defective. 
Although it remains to be proven exactly why the KOIS* mutation produces an 
inefficient vector, based on this evidence it is unlikely that the KO IS* platform can be 
efficiently targeted to any cell type.
Insertion o f the CAP, CQE and CNH peptides into the fiber o f the Ad5/19p vector 
significantly increased the transduction o f all cell types tested in vitro, suggesting that 
peptide insertion caused non-specific cellular uptake o f the vectors. In vivo results 
showed the peptide-targeted vectors were inefficient and not selective for the vasculature. 
The lack o f specificity o f the Ad5/19p vectors may be due to the position into which the 
targeting peptides were inserted. The peptides may not be sufficiently exposed on the 
capsid surface or the conformation that the peptides form in the A d l9p  fiber might not 
enable receptor binding.
The most promising results were achieved with the vectors AAV2-CNH and AAV2- 
CAP, which were found to have an increased tropism for the BCA and aorta o f 
atherosclerotic mice. The lack o f retargeting o f AAV2-CAP in healthy mice suggests this 
vector is selectively targeted to plaques and not just vascular targeted. 
Immunohistochemistry to identify what cell types are infected by the viruses and a 
biodistribution study o f AAV2-CNH in healthy mice will be performed to provide more 
detailed information about the selectivity o f the vectors and their likely effectiveness as 
plaque targeted gene therapy vectors. Ultimately the most important test o f the vectors
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will be to determine whether the vectors expressing a therapeutic gene can produce levels 
o f transgene expression that result in a therapeutic effect in the ApoE-/- mouse model. 
There are a number o f genes that could potentially have a therapeutic effect if they were 
delivered to atherosclerotic plaques. For example, TIMP2 is thought to inhibit the 
migration o f macrophages and reduce smooth muscle cell apoptosis in plaques (Johnson 
et a l ,  2006), therefore it is a promising candidate gene for a treatment aiming to stabilise 
vulnerable plaques. Also, targeted delivery o f anti-inflammatory cytokines such as IE -10 
or TGFp could reduce the inflammatory component o f plaque progression and thereby 
stabalise plaques. Systemic over-expression o f these cytokines has previously been 
shown to slow the progression o f atherosclerosis in mouse models o f the disease (Liu et 
a l ,  2005, Yoshioka et a l ,  2004, Li et a l ,  2006).
Although the biodistribution studies showed the peptide-modified AAV vectors target the 
vasculature compared to untargeted AAV2, there was still a significant amount o f the 
vector found in non-target organs such as the liver and spleen. To improve this, further 
modifications could be made to the capsid. In vitro experiments showed that both 
AAV2-CAP and AAV2-CNH are still able to bind heparin, which may be why the 
detargeting was not more efficient. If  the vectors were produced on the A3 background, 
which has additional mutations that reduce heparin binding (Wu et al., 2000), then the 
specificity o f the vectors may be increased. Ultimately, these transdiictionally targeted 
vectors could also be combined with transcriptional targeting to increase their specificity. 
The expression cassette used in the vectors in this study contained a CM V promoter, 
which is active in a wide range o f cell types. To increase the specificity o f these vectors 
EC or SMC specific promoters such as flt-1 (Nicklin et a l ,  2001b) or SM -22a (Moessler 
et a l ,  1996) could be used. If  the vectors are found to be vascular-specific rather than 
specific for atherosclerotic plaques then hypoxic response elements (Modlich et a l ,  2000, 
Houston et a l ,  1999) could be used to increase the specificity o f the vectors.
It is advantageous that the most promising results were achieved with the AAV based 
vectors as they can produce long term transgene expression so are more likely to provide 
an effective form o f treatment for atherosclerosis. For Ad to be a useful vector in this
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situation, targeting peptides could be engineered into HdAds, which have been shown to 
provide effective gene therapy o f atherosclerosis for over 2.5 years in ApoE-/- mice (Kim 
et a l ,  2001).
As it has been proposed that the CAP peptide binds Grp78 (Liu et a l ,  2003), which is 
thought to be upregulated in a number o f diseases (Shin et a l ,  2003, Asplin et a l ,  2000), 
it would be interesting to test the targeting capacity o f the CAP modified vectors in 
models o f cancer as other putative Grp78 binding peptides have been characterised in 
melanoma, prostate and breast cancer xenograft models (Arap et al., 2004). It would also 
be interesting to compare the plaque targeting efficiency o f these other Grp78 binding 
peptides (Kim et a l ,  2006, Blond-Elguindi et a l ,  1993) in ApoE-/- mice.
6.2 Identification of peptides targeted to unstable plaques
Although biopanning has previously been performed in mouse models o f atherosclerosis 
(Houston et a l ,  2001, Liu et a l ,  2003, Kelly et a l ,  2006) no studies have focused on 
targeting o f advanced, unstable plaques, which are responsible for the majority o f deaths 
due to atherosclerosis (Falk et a l ,  1995, Davies, 1996). To identify peptides that target 
unstable plaques, biopanning was performed in ApoE-/- mice on a C57/B16/129SvJ 
background fed a high fat Western diet. This diet has previously been shown to lead to 
the development o f  rupture-prone plaques in approximately 60% o f mice (Johnson et a l, 
2005b). The amount o f phage recovered from the BCA and kidney at each round of 
biopanning suggests that pools o f peptides specific for the BCA of atherosclerotic mice 
were produced. BLAST searching the peptides that occurred at the highest frequency 
identified peptides with homology to many proteins known to be involved in 
atherosclerosis. Particularly encouraging was the identification o f  peptides with 
homology to proteins involved in thrombus formation, which suggests they may have a 
higher degree o f specificity for unstable plaques that have undergone previously silent 
rupture.
To further examine the targeting capacity o f the identified peptides they could be 
incorporated into viral vectors. Based on the comparison o f the vectors with the CAP,
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CNH and CQE peptides it seems that AAV2 vectors would provide the best platform for 
this. Candidate peptides should be chosen based on the frequency with which they were 
identified from the biopanning and the BLAST search results. The work with the AAV 
library also suggests that positively charged peptides would produce a less effectively 
detargeted vector, so should be avoided. Based on these criteria some of the peptides 
which should be investigated further include LSVISS, CSNSLL*PNMC, 
CTS*LNYTYC, CQIT*DFTSC and QIFLFEIG.
In addition to providing a tool for targeting gene therapy vectors, peptides that target 
unstable plaques could also be used for the development o f molecular imaging probes for 
non-invasive imaging techniques to aid the detection o f vulnerable plaques. Although 
there have been some advances in identifying unstable plaques, there is still a 
requirement for the development o f a non-invasive diagnostic system which can 
accurately predict the presence o f unstable plaques in patients as 30-50% o f people of 
people with severe atherosclerosis have no symptoms until they suffer a heart attack, 
which in many cases can result in death (Morteza et a l ,  2006).
One example o f this used probes that target VCAM-1, which is expressed on the 
endothelium from the early stages o f atherosclerosis (liyama et al., 1999, Davies et a l ,  
1993). Radiolabelled VCAM-1 antibodies have been used for imaging VCAM-1 
expression but the target to background ratio remained low, limiting their efficiency for 
in vivo cardiovascular imaging (Kelly et a l ,  2005). A VCAM-1 binding peptide 
identified by phage display was combined with a magnetofluorescent nanoparticle to 
produce an imaging agent (Kelly et a l ,  2005). Using fluorescence microscopy this was 
found to colocalise with VCAM-1 expressing cells in atherosclerotic lesions o f ApoE-/- 
mice (Kelly et a l ,  2005). For this procedure linear peptides were found to be more 
effective than constrained peptides as a larger number o f linear peptides can be attached 
to each nanoparticle and so they provide more efficient targeting (Kelly et a l ,  2006).
Targeting peptides have also been used to enhance magnetic resonance imaging (MRl). 
To enhance the quality o f M Rl scans, contrast agents containing the paramagnetic
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material gadolinium combined with a targeting moiety can be used. For example, 
Dirksen et a l  (Dirksen et a l ,  2005) developed a contrast agent by combining an atom of 
gadolinium, avidin and the cyclic peptide cNGR, which binds CD 13 (an enzyme 
overexpressed in growing blood vessels) enabling angiogenic blood vessels involved in 
cancer development to be viewed. The peptides identified in this study have the potential 
to be utilised in similar systems to specifically diagnose unstable plaques.
6.3 Development o f the AAV library
The work with the AAV library has focused on developing the technology so that the 
library can be efficiently utilised for both in vivo and in vitro biopanning. In the process, 
several EC targeting viruses have been identified from the in vitro biopanning. 
Populations o f the individual viruses require further testing. Virus binding to heparin 
columns will be analysed to confirm they are unable to bind heparin and in vitro and in 
vivo studies will be performed to determine the tropism of these viruses.
Biopanning with the AAV2 library proved to be more o f a challenge than originally 
anticipated as the biopanning process seems to select for the low level o f  wild type AAV 
present in the library and peptide-modified viruses that bind heparin. This suggests 
AAV2 is highly evolved to very efficiently use HSPG as a receptor and any changes 
made to the virus reduce its efficiency. Biopanning with the heparin non-binding library 
helped to overcome this problem but further improvements could still be made. If the 
library was produced on the detargeted A3 background this would reduce the likelihood 
o f the peptide insertion being able to maintain the HSPG binding site. In vitro 
biopanning could also be performed in the presence of heparin to block the transduction 
o f heparin binding viruses. Although the procedures involved are technically 
challenging, the methods developed for in vivo biopanning can now be utilised with the 
heparin non-binding library in ApoE-/- mice to identify plaque specific vectors that do 
not bind HSPG.
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This work has also provided more information about which targeting peptides produce 
more efficient detargeting o f AAV. This is important to further the development of 
vectors targeted via peptides identified by phage display.
6.4 Summai*y
The work presented in this thesis has made progress towards the development of 
atherosclerotic plaque targeted vectors and has provided further characterisation o f Ad 
and AAV platform vectors which can be applied to the development o f vectors targeted 
to other cell types. The plaque targeted vectors may also be used to provide more 
information about the molecular mechanisms o f the disease by using the vectors to over­
express genes specifically in plaques. Further work aimed at characterising the most 
promising vectors, first at the level o f reporter gene expression but ultimately by testing 
therapeutic transgene expression is required to prove whether significant gains can be 
made in treatment.
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